{"add": {"doc": {"field": [{"@name": "docid", "#text": "BR-TU.10568"}, {"@name": "filename", "#text": "15709_ve_Isabella_Hirako_IRR_2016.pdf"}, {"@name": "filetype", "#text": "PDF"}, {"@name": "text", "#text": "Minist\u00e9rio da Sa\u00fade Funda\u00e7\u00e3o Oswaldo Cruz Centro de Pesquisas Ren\u00e9 Rachou Programa de P\u00f3s-Gradua\u00e7\u00e3o em Ci\u00eancias da Sa\u00fade\nO sistema imune inato na patog\u00eanese da mal\u00e1ria\npor\nIsabella Cristina Hirako\nBelo Horizonte 2016\nTESE DCS - CPqRR\nI.C.HIRAKO\n2016\nIsabella Cristina Hirako\nO sistema imune inato na patog\u00eanese da mal\u00e1ria\nTese apresentada ao Programa de P\u00f3s-gradua\u00e7\u00e3o em Ci\u00eancias da Sa\u00fade do Centro de Pesquisas Ren\u00e9 Rachou, como requisito parcial para obten\u00e7\u00e3o do t\u00edtulo de Doutor em Ci\u00eancias - \u00e1rea de concentra\u00e7\u00e3o Biologia Celular e Molecular.\nOrienta\u00e7\u00e3o: Dr. Ricardo Tostes Gazzinelli\nBelo Horizonte 2016\nCataloga\u00e7\u00e3o-na-fonte\nRede de Bibliotecas da FIOCRUZ Biblioteca do CPqRR\nSegemar Oliveira Magalh\u00e3es CRB/6 1975\nH668s 2016\tHirako, Isabella Cristina. 0 sistema imune inato na patog\u00eanese da mal\u00e1ria / Isabella Cristina Hirako. - Belo Horizonte, 2016. xvii, 115 f: il.: 210 x 297 mm. Bibliografia: 121 - 127 Tese (doutorado) - Tese para obten\u00e7\u00e3o do t\u00edtulo de Doutor(a) em Ci\u00eancias pelo Programa de P\u00f3s-Gradua\u00e7\u00e3o em Ci\u00eancias da Sa\u00fade do Centro de Pesquisas Ren\u00e9 Rachou. \u00c1rea de concentra\u00e7\u00e3o: Biologia Celular e Molecular. 1. Mal\u00e1ria/imunologia 2. Plasmodium/gen\u00e9tica 3. Imunidade Inata/imunologia 1. T\u00edtulo. II. Gazzinelli, Ricardo Tostes (Orienta\u00e7\u00e3o). CDD - 22. ed. - 616.936 2\nIsabella Cristina Hirako\nO sistema imune inato na patog\u00eanese da mal\u00e1ria\nTese apresentada ao Programa de P\u00f3s gradua\u00e7\u00e3o em Ci\u00eancias da Sa\u00fade do Centro de Pesquisas Ren\u00e9 Rachou, como requisito parcial \u00e0 obten\u00e7\u00e3o do t\u00edtulo de Doutor em Ci\u00eancias - \u00e1rea de concentra\u00e7\u00e3o Biologia Celular e Molecular Banca Examinadora:\nProf. Dr. Ricardo Tostes Gazzinelli (CPqRR/FIOCRUZ) Presidente\nProf. Dra. Andrea Teixeira de Carvalho (CPqRR/FIOCRUZ) Titular\nProf. Dr. Marco Ant\u00f4nio Silva Campos (CPqRR/FIOCRUZ) Titular\nProf. Dra. Karina Ramalho Bortoluci (UNIFESP) Titular\nProf. Dr. Ricardo Toshio Fujiwara (UFMG) Titular\nProf. Dr. Alexandre de Magalh\u00e3es Vieira Machado (CPqRR/FIOCRUZ) Suplente\nTese defendida e aprovada em Belo Horizonte, 18/05/2016\nDedico estes trabalhos\nao meu orientador Prof. Dr. Ricardo Gazzinelli\nAGRADECIMENTOS\nAgrade\u00e7o primeiramente a Deus, por me guiar pelos obst\u00e1culos, me mantendo firme e fortalecida. Obrigada pelos muitos sinais enviados.\nAos meus pais, a quem devo meu car\u00e1ter e disciplina ao trabalho, e ao meu irm\u00e3o por todo amor e momentos de divers\u00e3o. Muito obrigada por voc\u00eas existirem em minha vida.\nAo meu namorado pela presen\u00e7a amorosa. Elaborar uma tese ao lado de um companheiro deste quilate \u00e9 um presente. Obrigada por tornar a minha vida mais completa e realizada.\nMeu profundo agradecimento ao professor orientador Dr. Ricardo Gazzinelli pela confian\u00e7a e incentivo. Obrigada por me transmitir grandes e valiosos ensinamentos de imunologia e de vida.\nAo professor. Dr. Andrew Luster por ter me recebido gentilmente em seu laborat\u00f3rio. Obrigada pela oportunidade de trabalhar no Massachusetts General Hospital (Harvard Medical School).\nAos meus colaboradores, colegas de trabalho e t\u00e9cnicos de laborat\u00f3rio pela agrad\u00e1vel conviv\u00eancia.\nRESUMO\nOs imunocomplexos (ICs) s\u00e3o encontrados na circula\u00e7\u00e3o de pacientes com inflama\u00e7\u00e3o, seja ela est\u00e9ril ou causada por infec\u00e7\u00f5es. O presente trabalho demonstra que pacientes com mal\u00e1ria apresentam elevados n\u00edveis de anticorpos circulantes anti-DNA, bem como ICs contendo DNA do parasito. A ativa\u00e7\u00e3o de mon\u00f3citos por ICs resultou na forma\u00e7\u00e3o de specks de inflamassomas contendo NLRP3, NLRP12 ou AIM2, ativa\u00e7\u00e3o de caspase 1 e libera\u00e7\u00e3o de IL-ip ativa. As c\u00e9lulas monocucleares do sangue perif\u00e9rico estimuladas com ICs produzem grandes quantidades de IL-1 p e TNFa e, no entanto, baixos n\u00edveis de IL-10. A principal fonte de citocinas pr\u00f3-inflamat\u00f3rias em pacientes de fase aguda da mal\u00e1ria \u00e9 a subpopula\u00e7\u00e3o de mon\u00f3citos CD14+, que expressa o receptor FcyRIIIA (CD16). Os mon\u00f3citos de pacientes em fase de convalesc\u00eancia apresentam um fen\u00f3tipo anti-inflamat\u00f3rio e, quando estimulados com ICs, produzem elevados n\u00edveis de IL-10 e baixos n\u00edveis de TNFa e IL-ip. Portanto, dependendo do status de ativa\u00e7\u00e3o do mon\u00f3cito, os ICs podem estimular ou modular a produ\u00e7\u00e3o de citocinas pr\u00f3-inflamat\u00f3rias, atuando como um importante imunoregulador durante a mal\u00e1ria.\nOs mon\u00f3citos (MOs), macr\u00f3fagos e c\u00e9lulas dendr\u00edticas (DCs) s\u00e3o popula\u00e7\u00f5es de c\u00e9lulas heterog\u00eaneas que t\u00eam papel crucial na repara\u00e7\u00e3o de tecidos, detec\u00e7\u00e3o de presen\u00e7a de microrganismos invasivos, iniciando respostas imunit\u00e1rias protetoras. Estudos recentes definiram novos marcadores que permitem a distin\u00e7\u00e3o entre mon\u00f3citos inflamat\u00f3rios de c\u00e9lulas dendr\u00edticas derivadas de mon\u00f3citos (MO-DCs), no entanto, a contribui\u00e7\u00e3o destas c\u00e9lulas para neuroinflama\u00e7\u00e3o durante a MCE n\u00e3o foi\navaliada. Neste trabalho, observamos que a infec\u00e7\u00e3o por Plasmodium berghei ANKA (PbA) promove a diferencia\u00e7\u00e3o de mon\u00f3citos inflamat\u00f3rios espl\u00e9nicos e DCs convencionais por c\u00e9lulas dendr\u00edticas derivadas de mon\u00f3citos (MO-DCs), que s\u00e3o CD11c+CD11b+F4/80+DC-SIGN+Ly6C+. Estas c\u00e9lulas respondem a IFNy sendo a principal fonte de CXCL9 e CXCL10. Al\u00e9m disso, c\u00e9lulas MO-DCs expressando CXCL9/10 emergem no c\u00e9rebro via CCR5 dependente, coincidindo com o influxo de c\u00e9lulas T CD8+ e o desenvolvimento da s\u00edndrome neuropatol\u00f3gica letal. Assim, nossos dados fornecem evid\u00eancias de que as MO-DCs induzidas pela infec\u00e7\u00e3o com PbA desempenham um papel central nas respostas imunes, mediando o desenvolvimento de MCE. De acordo com nossos resultados, ap\u00f3s a diferencia\u00e7\u00e3o, MO-DCs, que expressam CXCL9 e CXCL10, tem um papel importante na ativa\u00e7\u00e3o de c\u00e9lulas T CD4+ e T CD8+ no ba\u00e7o e tamb\u00e9m migram para o SNC dependente de CCR5, onde atraem e ativam c\u00e9lulas T CD8+, levando ao desenvolvimento de MCE.\nPalavras-chave: Imunologia, Imunidade Inata, Mal\u00e1ria\nABSTRACT\nImmunocomplexes (ICs) are found in the circulation of patients undergoing either infectious or sterile systemic inflammation. Here, we report that malaria patients display high levels of circulating anti-DNA antibodies, as well as ICs containing parasite DNA. Monocyte activation with malaria-induced ICs resulted in formation of NLRP3-, NLRP12- or AIM2-inflammasome specks, caspase-1 activation, and release of IL-ip. Upon stimulation with ICs malaria-primed peripheral blood mononuclear cells secrete bulk amounts of IL-1 p and TNFa, but low IL-10 levels. The main source of pro-inflammatory cytokines in acutely infected malaria patients is a subset of CD14+ monocytes that express the FcyRIIIA receptor (CD16). Intriguingly, in convalescent malaria patients, monocytes shifted back to an anti-inflammatory phenotype, and upon IC stimulation produced high levels of IL-10, but low levels of TNFa and IL-1 p. Hence, depending on the status of monocyte activation, ICs may promote or dampen the production of pro-inflammatory cytokines, and thus act as important immune-regulators during malaria.\nMonocytes (MOs), macrophages and dendritic cells (DCs) are heterogeneous cell populations that have critical role in tissue repair, sensing presence of invasive microorganisms and initiating protective immune responses. Recent studies have defined new markers that allows the distinction of inflammatory monocytes from monocyte derived dendritic cells (MO-DCs), however the contribution of these cells to neuroinflammation during ECM have not been explored. Here we show that infection with Plasmodium berghei ANKA (PbA) promotes replacement of splenic inflammatory\nmonocytes and conventional DCs by monocyte-derived dendritic cells (MO-DCs), which are CD11c+CD11b+F4/80+DC-SIGN+Ly6c+. These cells are highly responsive to IFNy being a main source of CXCL9 as well as CXCL10. Importantly, the CXCL9/10 MO-DCs emerge in the brain in a CCR5-dependent manner, coinciding with CD8+ T cell influx and development of the lethal neuropathological syndrome. Thus, we provide evidences that the MO-DCs induced by PbA infection play a central role in initiating immune responses and mediating the development of experimental cerebral malaria (ECM). Taken together, we would like to demonstrate that after differentiation, the CXCL9/10 MO-DCs not only have an important role in activating both CD4+ T and CD8+ T cells in the spleen, but also migrate to the CNS in a CCR5-dependent manner, where they attract/activate CD8+T cell leading to the development of ECM.\nKey-words: Immunology, Innate Immunity, Malaria\nLISTA DE FIGURAS\nFigura 1. Personalidades infectadas com Plasmodium ao longo da vida..........................19\nFigura 2. Pa\u00edses com transmiss\u00e3o cont\u00ednua de mal\u00e1ria (2013)..................................24\nFigura 3. Mapa de risco da mal\u00e1ria por munic\u00edpio, Brasil (2013)..............................25\nFigura 4. Ciclo de vida de Plasmodium infectantes ao homem...................................28\nFigura 5. Principais eventos na patog\u00eanese da mal\u00e1ria........................................29\nFigura 6. Aumento de IgM espec\u00edfico para AMA-1 em plasma de pacientes durante a fase aguda da mal\u00e1ria por P.vivax..................................................71\nFigura 7. Altos n\u00edveis de citocinas pr\u00f3-inflamat\u00f3rias e IL-10 no plasma de pacientes durante a fase aguda da mal\u00e1ria..........................................72\nFigura 8. Soro de pacientes infectados com P. falciparum ou P. vivax apresentam elevados n\u00edveis de imunocomplexos (ICs)...........................................74\nFigura 9. N\u00edveis elevados de anticorpos anti-DNA de fita dupla durante a fase aguda de mal\u00e1ria por P. vivax e P. falciparum.........................................75\nFigura 10. Elevados n\u00edveis de DNA humano e do parasito em plasma e imunocomplexos (ICs) de pacientes com mal\u00e1ria por P. vivax...................................77\nFigura 11. Assinatura de genes da fam\u00edlia NF-kB em mon\u00f3citos estimulados com o ICs........................................................................78\nFigura 12. E6446, um antagonista de TLR7 e TLR9, bloqueia\na atividade estimulat\u00f3ria de ICs em mon\u00f3citos................................................81\nFigura 13. Mon\u00f3citos s\u00e3o as principais fontes de citocinas\nem c\u00e9lulas monoucleares de sangue perif\u00e9rico (CMSPs) ap\u00f3s est\u00edmulo com imunocomplexos (iCs) purificados de pacientes com mal\u00e1ria..................82\nFigura 14. ICs purificados de pacientes com mal\u00e1ria por P. vivax\nativam caspase-1 e induzem a produ\u00e7\u00e3o de elevados n\u00edveis da citocina\npirog\u00e9nica IL-1 p em mon\u00f3citos humanos.......................................................83\nFigura 15. Plataformas de inflamassoma contendo NLRP12, NLRP3 e AIM2 s\u00e3o formados ap\u00f3s est\u00edmulo com ICs em mon\u00f3citos..............................................84\nFigura 16. ICs purificados induzem elevados n\u00edveis de citocinas pr\u00f3-inflamat\u00f3rias por mon\u00f3citos CD14+ CD16+ em pacientes com mal\u00e1ria.........................85\nFigura 17. Diferencia\u00e7\u00e3o de MO-DCs no ba\u00e7o (F4/80+CD11b+DCSIGN+MHCIIhighCD11c+Ly6C+) de animais infectados com PbA......................88\nFigura 18. Express\u00e3o de CXCL9 e CXCL10 por MO-DCs\nde animais infectados com PbA................................................................90\nFigura 19. Aumento da frequ\u00eancia de MO-DCs no c\u00e9rebro de animais infectados com PbA.....................................................92\nFigura 21. Tratamento com E6446 inibe a express\u00e3o de IFNy\npor linf\u00f3citos T bem como de CXCL9 e CXCL10 em MO-DCs......................................97\nFigura 22. Express\u00e3o de quimiocinas e o surgimento de c\u00e9lulas hematopoi\u00e9ticas CD45high para o SNC de animais infectados com\nPbA \u00e9 dependente de IFNy...................................................................99\nFigura 23. Aumento da resist\u00eancia de animais CCR5-/- ao desenvolvimento da MCE............102\nFigura 24. Migra\u00e7\u00e3o de c\u00e9lulas MO-DCs para o SNC de animais infectados\ncom PbA \u00e9 dependente de CCR5..............................................................103\nFigura 25. Ativa\u00e7\u00e3o de receptores da imunidade inata por hemozo\u00edna (Hz)\nou imunocomplexo (ICs).....................................................................109\nFigura 26. C\u00e9lulas dendr\u00edticas derivadas de mon\u00f3citos (MO-DCs)\nna mal\u00e1ria cerebral experimental...........................................................118\nLISTA DE QUADROS\nQuadro 1. Sintomas cl\u00ednicos e par\u00e2metros laboratoriais de pacientes infectados\ncom P. vivax......................................................................................46\nQuadro 2. Sintomas cl\u00ednicos e par\u00e2metros laboratoriais de pacientes infectados com P. falciparum.................................................................................47\nQuadro 3. Primers utilizados nas rea\u00e7\u00f5es de PCR para detec\u00e7\u00e3o dos genes\nCCND e Plasmodium esp\u00e9cie espec\u00edfica..............................................................52\nQuadro 4. Especifica\u00e7\u00f5es dos anticorpos utilizados no ensaio de imunofluoresc\u00eancia com microscopia confocal..........................................................................56\nQuadro 5. Primers utilizados nas rea\u00e7\u00f5es de PCR para detec\u00e7\u00e3o dos genes\nCXCL9, CXCL10, CCL3, CCL4, IFNy, CD8, CCL2, CCL5, p2-microglobulina e GAPDH...........................................................................................67\nQuadro 6. Genes com a express\u00e3o aumentada em mon\u00f3citos estimulados com ICs........................79\nAIM2\nAMA-1 APCs BSA CBA CCND cDNA cGAS CMSPs CpG CSFE\nDAMPs\nDCs DDT DNA ECL EDTA iMOs IRF g GAPDH\nGPI HRP ICs ICAM1 IFNy ig IL\nITAM\nITIM\nLES LPS MAVS MCE MDA5\nMOs MO-DCs mRNA MyD88\nNK NLR NLRC4\nNLRP\nNS\nAusente em melanoma 2 (Absent in melanoma 2)\nAnt\u00edgeno de membrana apical 1 (Apical merozoite antigen-1)\nC\u00e9lulas apresentadoras de ant\u00edgeno (Antigens presenting cells)\nAlbumina de soro bovino (Bovine serum albumin)\nCitometria com esferas (Cytometric bead array)\nC\u00edclico DI (Cyclic D1)\nDNA complementar\nGMP-AMP c\u00edclico sintase (Cyclic GMP-AMP synthase)\nC\u00e9lulas mononucleares de sangue perif\u00e9rico\nCitosina fosfato guanina (cytosine phosphate guanine)\nCorante fluorescente carboxifluoresce\u00edna sucinimidil ester (Carboxy fluorescein succinimidyl ester)\nPadr\u00f5es moleculares associados a danos (Danger associated molecular patterns)\nC\u00e9lulas dendr\u00edticas (Dendritic cells)\nDicloro-Difenil-Tricloroetano\n\u00c1cido desoxirribonucleico (Desoxyribonucleic acid)\nSubstrato quimioluminescente (Enhanced chemiluminescence)\n\u00c1cido etileno diamino tetrac\u00e9tico (Ethylenediaminetetraacetic acid)\nMon\u00f3citos inflamat\u00f3rios (Inflammatory monocytes)\nFator regulador do interferon (Interferon regulatory fator)\nAcelera\u00e7\u00e3o da gravidade (=9,8m/s2)\nGliceralde\u00eddo 3 fosfato desidrogenase (Glyceraldehyde 3 phosphate dehydrogenase) glicosilfosfatidilinositol\nHorseradish peroxidase\nImunocomplexos\nMol\u00e9cula de ades\u00e3o intercelular 1 (Intercellular adhesion molecule1)\nInterferon-Y\nImunoglobulina\nInterleucina\nSequ\u00eancia\tde\tativa\u00e7\u00e3o\tdo\timunoreceptor\tbaseado\tem\ttirosina\n(Immunoreceptor tyrosilne-based activation motif)\nSequ\u00eancia\tde\tativa\u00e7\u00e3o\tdo\timunoreceptor\tbaseado\tem\ttirosina\n(Immunoreceptor tyrosilne-based inhibition motif)\nL\u00fapus eritematoso sist\u00eamico\nLipopolissacar\u00eddeo\nSinaliza\u00e7\u00e3o mitocondrial antiviral (Mitochondrial anti-viral signaling protein) Mal\u00e1ria cerebral experimental\nProte\u00edna associada \u00e0 diferencia\u00e7\u00e3o do melanoma 5 (Melanoma differentiation-associated protein 5)\nMon\u00f3citos\nC\u00e9lulas dendr\u00edticas derivadas de mon\u00f3citos (Monocyte-derived dendritic cells) RNA mensageiro\nFator 88 de diferencia\u00e7\u00e3o miel\u00f3ide (Myeloid differentiation primary response gene 88)\nExterminadoras naturais (Natural killer)\nReceptor do tipo NOD (NOD-like receptor)\nReceptor da fam\u00edlia dos NLRs contendo o dom\u00ednio card (Card domaincontaining protein 4)\nReceptor da fam\u00edlia dos NLRs contendo o dom\u00ednio pyrin (NACHT, LRR and\nPYD domains-conteining protein)\nN\u00e3o significante\nOCT OMS PAMPs\tMeio \u00f3timo de temperatura de corte (Optimum cutting temperature) Organiza\u00e7\u00e3o mundial da sa\u00fade Padr\u00f5es moleculares associados a pat\u00f3genos (Pathogen associated molecular patterns)\nPBS PBS-T PCR PECAM1\tTamp\u00e3o fosfato salino (Phosphate buffered saline) Tamp\u00e3o fosfato salino com tween (Phosphate buffered saline - Tween) Rea\u00e7\u00e3o em cadeia da polimerase (Polimerase chain reaction) Mol\u00e9cula de ades\u00e3o de c\u00e9lula endotelial e plaqueta 1 (Platelet endothelial cell adhesion molecule 1)\nPfEMPI\tProte\u00edna de membrane do eritr\u00f3cito 1 de Plasmodium falciparum (Plasmodium falciparum erythrocyte membrane protein 1)\npH PLP PPRs\tPotencial de hidrog\u00eanio Paraformalde\u00eddo lisina periodato Receptores de reconhecimento de padr\u00f5es (Pathogen recognition receptor)\nRIG-I RNA rpm SBF SDS-PAGE\tReceptores do tipo RLR (RIG-I-like receptor) \u00c1cido ribonucleico (Ribonucleic acid) Rota\u00e7\u00f5es por minuto Soro bovino fetal Dodecil sulfato de s\u00f3dio em gel de poliacrilamida (Sodium dodecyl sulfate polyacrylamide gel)\nSNC SNP STING TBM TLR TNFa VR WT\tSistema nervoso central Polimorfismo de nucleot\u00eddeo \u00fanico (Single nucleotide polymorphism) Estimulador de genes para IFN (Stimulator of interferon genes) Tetrametilbenzidina Receptor do tipo Toll (Toll-like receptor) Fator de necrose tumoral-a (Tumor necrosis factor- a) Valores de refer\u00eancia Animal selvagem (Wild type)\nC ug Eq/mL p,g/mL p,L p,M cm g g/dL g/mL M mA mg mL m/m3 nm UI/mL v\tCent\u00edgrados Equivalentes de gamablobulina agregada por mililitro Microgramas por mililitro Microlitro Micromolar Cent\u00edmetros Acelera\u00e7\u00e3o da gravidade (=9,8m/s2) Gramas por decilitro Gramas por microlitro Molar Miliampere Miligrama Mililitro Mil\u00edmetro c\u00fabico Nan\u00f4metro Unidade internacional por mililitro Volts\nSUM\u00c1RIO\n1\tINTRODU\u00c7\u00c3O E JUSTIFICATIVA...............................................................18\n1.1\tA hist\u00f3ria da pesquisa mal\u00e1ria.................................................19\n1.2\tEpidemiologia..................................................................22\n1.3\tAgente etiol\u00f3gico e ciclo biol\u00f3gico da mal\u00e1ria.................................26\n1.4\tA patog\u00eanese da mal\u00e1ria........................................................28\n1.5\tA imunidade inata e a fisiopatologia da mal\u00e1ria................................32\n1.5.1\tPapel de receptores da imunidade\tinata\tna mal\u00e1ria...................32\n1.5.2\tModelo murino da mal\u00e1ria cerebral.....................................35\n2\tJUSTIFICATIVA GERAL......................................................................38\n3\tOBJETIVOS................................................................................40\n3.1\tMal\u00e1ria........................................................................41\n3.1.1\tObjetivo geral................................................................41\n3.1.2\tObjetivos espec\u00edficos.........................................................41\n3.2\tModelo murino da mal\u00e1ria cerebral.............................................41\n3.2.1\tObjetivo geral................................................................41\n3.2.2\tObjetivos espec\u00edficos.........................................................41\n4\tMETODOLOGIA..............................................................................43\n4.1\tMal\u00e1ria........................................................................44\n4.1.1\tPaciente......................................................................44\n4.1.1.1\tCaracter\u00edsticas e proced\u00eancia da\tamostra.............................44\n4.1.1.2\tAspectos \u00e9ticos da pesquisa.........................................44\n4.1.1.3\tIndiv\u00edduos da pesquisa..............................................44\n4.1.1.4\tCaracteriza\u00e7\u00e3o cl\u00ednica e laboratorial\tdos\tpacientes.................45\n4.1.2\tDetermina\u00e7\u00e3o da parasitemia...................................................47\n4.1.3\tQuantifica\u00e7\u00e3o de imunocomplexos (ICs).........................................47\n4.1.4\tELISA para anticorpos anti-DNA................................................49\n4.1.5\tELISA para ant\u00edgeno espec\u00edfico................................................50\n4.1.6\tPurifica\u00e7\u00e3o de ICs............................................................50\n4.1.7\tExtra\u00e7\u00e3o de DNA...............................................................48\n4.1.8\tPCR em Tempo Real.............................................................51\n4.1.9\tObten\u00e7\u00e3o das c\u00e9lulas mononucleares do sangue perif\u00e9rico (CMSP) e\nprepara\u00e7\u00e3o de mon\u00f3citos humanos.....................................................52\n4.1.10\tDetec\u00e7\u00e3o de citocinas........................................................53\n4.1.11\tWestern blot para caspase-1..................................................55\n4.1.12\tImunofluoresc\u00eancia com microscopia confocal..................................55\n4.1.13\tDetec\u00e7\u00e3o de mRNA e an\u00e1lise de express\u00e3o g\u00eanica por nanostring\n(Nanostring Technologies)...........................................................58\n4.1.14\tAn\u00e1lise estat\u00edstica..........................................................59\n4.2\tModelo murino da mal\u00e1ria cerebral..............................................59\n4.2.1\tAnimais.......................................................................59\n4.2.2\tInfec\u00e7\u00e3o......................................................................60\n4.2.3\tCitometria de fluxo...........................................................60\n4.2.4\tEnsaio de fagocitose por citometria de fluxo..................................61\n4.2.5\tPurifica\u00e7\u00e3o por citometria....................................................62\n4.2.6\tMicroscopia eletr\u00f4nica de varredura...........................................62\n4.2.7\tConfocal......................................................................63\n4.2.8\tMigra\u00e7\u00e3o de c\u00e9lulas dendr\u00edticas enriquecidas..................................63\n4.2.9\tDetec\u00e7\u00e3o de citocinas.........................................................64\n4.2.10\tExtra\u00e7\u00e3o de RNA..............................................................64\n4.2.11\tS\u00edntese do DNA complementar..................................................65\n4.2.12\tPCR em Tempo Real........................................................66\n4.2.13\tDetec\u00e7\u00e3o de mRNA e an\u00e1lise de express\u00e3o g\u00eanica por nanostring\n(Nanostring Technologies).......................................................67\n4.2.14\tDroga e tratamento......................................................67\n4.2.15\tMicroscopia intravital..................................................68\n4.2.16\tAn\u00e1lise estat\u00edstica.....................................................69\n5\tRESULTADOS.........................................................................70\n5.1\tMal\u00e1ria....................................................................71\n5.1.1\tProdu\u00e7\u00e3o de IgG e IgM durante a mal\u00e1ria..................................71\n5.1.2\tAltos n\u00edveis de citocinas pr\u00f3-inflamat\u00f3rias circulantes no plasma\nde pacientes com mal\u00e1ria.......................................................72\n5.1.3\tAumento dos n\u00edveis de ICs durante a m\u00e1laria..............................73\n5.1.4\tAumento de anticorpos anti-DNA durante a m\u00e1laria.........................74\n5.1.5\tPresen\u00e7a de DNA de P. vivax em ICs.......................................76\n5.1.6\tMon\u00f3citos estimulados com ICs apresentam uma assinatura de\ngenes induzida pelo fator de transcri\u00e7\u00e3o NF-kB..................................77\n5.1.7\tICs purificados de pacientes com mal\u00e1ria induzem a produ\u00e7\u00e3o\nde citocinas por mon\u00f3citos.....................................................79\n5.1.8\tA exposi\u00e7\u00e3o pr\u00e9via ao IFNy aumenta a produ\u00e7\u00e3o de citocinas\ninduzidas por ICs...............................................................81\n5.1.9\tICs purificados de pacientes com mal\u00e1ria induzem a ativa\u00e7\u00e3o\nde caspase-1 em mon\u00f3citos.......................................................82\n5.1.10\tForma\u00e7\u00e3o da plataforma de inflamassomas em mon\u00f3citos\nestimulados com ICs de pacientes com mal\u00e1ria...................................84\n5.1.11\tICs induzem a produ\u00e7\u00e3o de elevados n\u00edveis de citocinas\npr\u00f3-inflamat\u00f3rias por mon\u00f3citos.................................................85\n5.2\tModelo murino da mal\u00e1ria cerebral.........................................86\n5.2.1\tA infec\u00e7\u00e3o por Plasmodium induz a presen\u00e7a de c\u00e9lulas MO-DCs..............86\n5.2.2\tA mal\u00e1ria induz a express\u00e3o de CCR5+CXCL9+CXCL10+ em MO-DCs...............89\n5.2.3\tC\u00e9lulas MO-DCs CCR5+CXCL9+CXCL10+ s\u00e3o encontradas\nno sistema nervoso central de animais infectados com PbA........................91\n5.2.4\tIFNy induz a express\u00e3o de CXCL9 e CXCL10 em MO-DCs........................93\n5.2.5 TLRs induzem a express\u00e3o de CXCL9 e CXCL10 em MO-DCs......................95\n5.2.6\tO recrutamento de MO-DCs para o SNC em animais infectados\ncom PbA \u00e9 dependente de IFNy....................................................98\n5.2.7\tO recrutamento de MO-DCs para o SNC em animais infectados\ncom PbA \u00e9 dependente de\tCCR5..................................................100\n6\tDISCUSS\u00c3O.........................................................................104\n6.1\tPapel dos ICs na ativa\u00e7\u00e3o das c\u00e9lulas do sistema imune inato..............106\n6.2\tPapel de mon\u00f3citos e\tDCs\tdurante a mal\u00e1ria...............................113\n7\tCONCLUS\u00c3O.........................................................................119\nREFER\u00caNCIAS..........................................................................121\nANEXOS...............................................................................128\nAnexo 1: \u201cDNA-containing immunocomplexes promote inflammasome assembly\nand release of pyrogenic cytokines by CD14+CD16+CD64highCD32low inflammatory monocytes from mal\u00e1ria patients\u201d........................................................129\nAnexo 2: \u201cSplenic differentiation and emergence of CCR5+CXCL9+CXCL10+ monocyte-derived dendritic cells in the brain during cerebral malaria\"........148\nAnexo 3: Carta confirma\u00e7\u00e3o \u201cHarvard Medical School\".............................181\n1 INTRODU\u00c7\u00c3O E JUSTIFICATIVA\n1\tINTRODU\u00c7\u00c3O\n1.1\tA hist\u00f3ria da pesquisa na mal\u00e1ria\nDesde a antiguidade a mal\u00e1ria \u00e9 um dos principais flagelos da humanidade.\nOriginada provavelmente no continente africano, acompanhou o processo migrat\u00f3rio do ser humano por diversas regi\u00f5es ao longo dos tempos1.\nFigura 1. Personalidades infectadas com Plasmodium ao longo da vida.\n\n\n\n\n\nOs primeiros registros de mal\u00e1ria foram encontrados em escritos chineses e eg\u00edpcios de 3 mil anos a.C.. Textos religiosos e m\u00e9dicos da antiguidade relacionavam febres agudas como puni\u00e7\u00e3o dos Deuses e a presen\u00e7a de maus esp\u00edritos. Hip\u00f3crates, na Gr\u00e9cia antiga, foi o primeiro a descartar supersti\u00e7\u00f5es, descrevendo de forma clara a periodicidade da febre (paroxismo) al\u00e9m de atribuir a esplenomegalia ao diagn\u00f3stico cl\u00ednico da mal\u00e1ria1,2. Posteriormente, no s\u00e9culo II d.C., ocorreram epidemias em diversas \u00e1reas da Europa. Os romanos relacionaram a \u00e1gua parada dos p\u00e2ntanos que cercavam o imp\u00e9rio romano com a presen\u00e7a de\nfebres agudas durante os meses de ver\u00e3o. Estas febres foram inicialmente chamadas de mal air - do italiano, mau ar - pois acreditava-se que a causa da doen\u00e7a estava relacionada com o ar insalubre de determinadas regi\u00f5es pantanosas2,3. Sendo assim, engenheiros romanos projetaram grandes sistemas de drenagem no intuito de eliminar a causa da mal\u00e1ria. Ap\u00f3s a queda do imp\u00e9rio romano e a destrui\u00e7\u00e3o dos sistemas de drenagem de \u00e1gua, os b\u00e1rbaros se tornaram as principais v\u00edtimas da mal\u00e1ria. Grande parte do seu ex\u00e9rcito n\u00e3o resistiu a doen\u00e7a. No s\u00e9culo XVI, a mal\u00e1ria \u00e9 disseminada ao novo mundo por meio das grandes navega\u00e7\u00f5es, ou seja, viagens de colonizadores espanh\u00f3is e portugueses2.\nEm 1880, Charles Laveran, foi a primeira pessoa a encontrar parasitos no sangue de pacientes infectados com mal\u00e1ria. Durante seus trabalhos na Arg\u00e9lia, ele observou formas sangu\u00edneas do parasito que se desenvolviam no interior de gl\u00f3bulos vermelhos humanos4. Por essa grande descoberta, Laveran foi agraciado com o Premio Nobel de medicina em 19075. A partir dai, o modo de transmiss\u00e3o e o ciclo do parasita foram esclarecidos at\u00e9 o final do s\u00e9culo XIX4. Em 1886, Camillo Golgi tamb\u00e9m elucidou o ciclo do agente da mal\u00e1ria, o Plasmodium, nos gl\u00f3bulos vermelhos, e a coincidencia temporal entre os calafrios e a febre recorrentes com a ruptura e a libera\u00e7\u00e3o de parasitos na corrente sangu\u00ednea. Com isso, ele formulou uma hip\u00f3tese sobre a toxina na patogenese da mal\u00e1ria, demonstrando que a febre de forma c\u00edclica segue o ciclo de desenvolvimento do parasito no sangue, sugerindo que era consequente da libera\u00e7\u00e3o de uma toxina de origem do parasito, liberada pelo amadurecimento destes nas c\u00e9lulas vermelhas3,6.\nEste conhecimento sobre a febre induzida pela mal\u00e1ria foi aplicado por um professor de psiquiatria e neurologia em Viena, Julius Wagner-Jauregg, desenvolvendo um m\u00e9todo para o tratamento de demencia paral\u00edtica (est\u00e1gio\navan\u00e7ado de neuros\u00edfilis) por inocula\u00e7\u00e3o de parasitos da mal\u00e1ria. Ele observou que individuos que desenvolviam febres altas poderiam ser curados da s\u00edfilis3,7. Deste modo, de 1917 a meados dos anos 1940, a mal\u00e1ria induzida pelo parasito menos agressivo, Plasmodium vivax, foi usada como tratamento para a s\u00edfilis terci\u00e1ria uma vez que produzia febres altas e prolongadas (uma forma de piroterapia). Isso foi considerado um risco aceit\u00e1vel porque a mal\u00e1ria poderia ser tratada posteriormente com quinino, o qual estava dispon\u00edvel naquele momento7. Por este estudo, Jauregg foi agraciado com o pr\u00eamio Nobel em medicina em 19278.\nEm 1897, Ronald Ross, um oficial brit\u00e2nico no servi\u00e7o m\u00e9dico indiano, foi o primeiro a demonstrar que os parasitos da mal\u00e1ria podem ser transmitidos de pacientes infectados para mosquitos. Ele encontrou formas do parasito da mal\u00e1ria no interior de um mosquito que havia se alimentado em um portador da doen\u00e7a. Al\u00e9m disso, ele sugeriu que a transmiss\u00e3o do parasito para humanos ocorria atrav\u00e9s da picada do mosquito. Assim, a forma de transmiss\u00e3o da mal\u00e1ria foi resolvido3,4. Por sua descoberta, Ross foi agraciado com o pr\u00eamio Nobel de medicina em 19029. Em 1942, Pa\u00fal M\u00fcller, um qu\u00edmico que trabalhava no desenvolvimento de v\u00e1rios produtos qu\u00edmicos para combater insetos agr\u00edculas, desenvolveu o inseticida DDT (Dicloro-Difenil-Tricloroetano) de grande atividade inseticida, poder residual e baixo custo. O DDT foi tamb\u00e9m usado para combater mosquitos transmissores da mal\u00e1ria em v\u00e1rias partes da Europa tanto durante quanto ap\u00f3s a guerra, salvando milhares de vidas3,4. M\u00fcller tamb\u00e9m foi agraciado com o pr\u00eamio Nobel de medicina em 194810.\nNo s\u00e9culo XVII, os padres jesu\u00edstas observaram que os ind\u00edgenas da Am\u00e9rica utilizavam cascas de \u00e1rvores nativas para curar doen\u00e7as febris. Esta planta foi denominada Cinchona em 1735, e em 1820, o seu princ\u00edpio ativo foi isolado, o\nquinino. Com as dificuldades no fornecimento do quinino durante a I Guerra Mundial, pesquisadores alem\u00e3es foram estimulados a desenvolver antimal\u00e1ricos sint\u00e9ticos, culminando na produ\u00e7\u00e3o de pamaquina (1924), mepacrina (1930) e cloroquina (1934)1,3. Ainda na busca de potenciais f\u00e1rmacos contra a mal\u00e1ria devido a resist\u00eancia de parasitos as drogas, Youyou Tu isolou um composto ativo a partir da artemisia annua em 1972, sintetizando o derivado mais potente, dihidroartemisinina, em 197311. Pela descoberta da artemisinina, uma terapia para a mal\u00e1ria que salvou milh\u00f5es de pessoas no mundo, especialmente nos pa\u00edses em desenvolvimento, Youyou Tu recebeu o pr\u00eamio Nobel em medicina em 201512.\nO aumento de fundos designados ao controle da mal\u00e1ria, a estabilidade econ\u00f4mica e a melhoria no sistema p\u00fablico de sa\u00fade s\u00e3o fatores importantes que contribuem para uma redu\u00e7\u00e3o na taxa de incid\u00eancia da mal\u00e1ria. Contudo, o financiamento para o controle da doen\u00e7a n\u00e3o \u00e9 o \u00fanico desafio. Em diversas regi\u00f5es, o sistema p\u00fablico de sa\u00fade ainda se encontra em precariedade, sendo incapaz de integrar ao plano de controle global da doen\u00e7a. Al\u00e9m disso, n\u00e3o h\u00e1 ferramentas adequadas dispon\u00edveis e suficientes para monitorar o plano de a\u00e7\u00e3o global contra a mal\u00e1ria13.\n1.2\tEpidemiologia\nA mal\u00e1ria \u00e9 uma doen\u00e7a infecciosa de grande import\u00e2ncia no mundo. Est\u00e1 classificada como uma das maiores endemias, sendo um grande obst\u00e1culo para o avan\u00e7o de comunidades e na\u00e7\u00f5es menos desenvolvidas14. Atualmente, o impacto global referente aos danos sociais e econ\u00f4micos causados pela mal\u00e1ria \u00e9 extenso e representa um dos maiores problemas de sa\u00fade p\u00fablica nas \u00e1reas tropicais e subtropicais do mundo14,15. Segundo a Organiza\u00e7\u00e3o Mundial de Sa\u00fade (OMS 2015),\n1.2\tbilh\u00f5es de indiv\u00edduos habitam \u00e1reas de risco e, em m\u00e9dia, 214 milh\u00f5es de novos casos ocorrem anualmente. Al\u00e9m disso, aproximadamente 438 mil mortes s\u00e3o contabilizadas anualmente, principalmente de crian\u00e7as com menos de cinco anos de idade. Al\u00e9m das crian\u00e7as, as gestantes tamb\u00e9m constituem um grupo de alto risco de mortalidade por mal\u00e1ria. A cada ano, estima-se que aproximadamente 55 milh\u00f5es de gesta\u00e7\u00f5es ocorrem em \u00e1reas de risco a transmiss\u00e3o de Plasmodium falciparum, na \u00c1frica sub saariana, com aproximadamente 10 mil mortes maternas14.\nA distribui\u00e7\u00e3o de casos de mal\u00e1ria depende de v\u00e1rios fatores que influenciam na din\u00e2mica de transmiss\u00e3o. A grande maioria dos casos letais da mal\u00e1ria ocorrem na \u00c1frica sub saariana, e s\u00e3o causados pelo P. falciparum. Esta esp\u00e9cie do parasito \u00e9 respons\u00e1vel por 90% dos casos mais graves da mal\u00e1ria no mundo, atingindo principalmente a \u00c1frica14. No continente africano, a mal\u00e1ria \u00e9 fundamentalmente domiciliar, atingindo principalmente crian\u00e7as com menos de cinco anos de idade. Portanto, o uso de redes de prote\u00e7\u00e3o vem sido empregado para o controle do vetor e evitar a transmiss\u00e3o do parasito. Baseado em dados de pesquisas domiciliares e relat\u00f3rios de programa nacional de controle da mal\u00e1ria, a propor\u00e7\u00e3o da popula\u00e7\u00e3o que dorme utilizando as redes de prote\u00e7\u00e3o tem aumentado acentuadamente na \u00c1frica sub saariana. Estima-se que no ano de 2000, menos de 2% da popula\u00e7\u00e3o fazia o uso das redes de prote\u00e7\u00e3o. Em 2015, esse n\u00famero aumentou para 55%. A propor\u00e7\u00e3o de crian\u00e7as menores de cinco anos que faz o uso das redes de prote\u00e7\u00e3o aumentou para 68% em 201514.\nO P. vivax \u00e9 a esp\u00e9cie predominante na \u00c1sia e Am\u00e9ricas, onde ocorrem 9% e 1% dos casos de mal\u00e1ria, respectivamente. Mesmo considerada uma esp\u00e9cie mais benigna, \u00e9 respons\u00e1vel por grandes perdas econ\u00f4micas e problemas sociais14,15,16.\nFigura 2. Pa\u00edses com transmiss\u00e3o cont\u00ednua de mal\u00e1ria (2013).\nNo Brasil, no ano de 2015 foram relatados 139.354 casos de mal\u00e1ria, sendo que mais de 99% dos casos ocorreram na Regi\u00e3o Amaz\u00f4nica, composta pelos estados do Acre, Amazonas, Amap\u00e1, Maranh\u00e3o, Mato Grosso, Par\u00e1, Rond\u00f4nia, Roraima e Tocantins, compreendendo 807 munic\u00edpios15. A esp\u00e9cie predominante \u00e9 o P. vivax em 82% dos casos, embora no per\u00edodo de 2011 a 2013, tenha ocorrido um aumento na propor\u00e7\u00e3o de mal\u00e1ria por P. falciparum de 13% para 18%. Este aumento \u00e9 preocupante, visto que a mal\u00e1ria causada por P. falciparum \u00e9 a respons\u00e1vel pela grande maioria das formas graves e \u00f3bitos15,16. Ademais, a mal\u00e1ria no Brasil \u00e9 considerada uma doen\u00e7a de car\u00e1ter ocupacional que afeta principalmente adultos que fazem parte de migra\u00e7\u00f5es desordenadas e ocupa\u00e7\u00e3o de \u00e1reas rurais16. Atividades relacionadas a garimpos de ouro e outros minerais, assentamentos agr\u00edcolas, explora\u00e7\u00e3o de madeiras e atividades agropecu\u00e1rias contribuem para a maior ocorr\u00eancia de casos da doen\u00e7a17.\nFigura 3. Mapa de risco da mal\u00e1ria por minic\u00edpio, Brasil (2013).\nNas popula\u00e7\u00f5es amaz\u00f4nicas a associa\u00e7\u00e3o entre atividades ocupacionais e o risco de mal\u00e1ria aponta para uma g\u00eanese multifatorial, que envolve mudan\u00e7as clim\u00e1ticas e movimentos migrat\u00f3rios, ocupa\u00e7\u00e3o do solo irregular, desmatamentos resultantes de reforma agr\u00e1ria, avan\u00e7os na agricultura, constru\u00e7\u00e3o de represas e dificuldade de acesso aos servi\u00e7os de sa\u00fade17. Desta forma, faz-se necess\u00e1rio o envolvimento incondicional do segmento governamental e da iniciativa privada em conjunto, pois aproveitar o impulso politico e financeiro sem precedentes implica numa melhor coordena\u00e7\u00e3o global. Esta atitude reflexiva de ambas as partes deve contribuir para a criatividade nas estrat\u00e9gias da ci\u00eancia e sa\u00fade de um modo geral, resultando na sustentabilidade e inova\u00e7\u00e3o em prol do controle e da erradica\u00e7\u00e3o da mal\u00e1ria13.\n1.3\tAgente etiol\u00f3gico e ciclo biol\u00f3gico da mal\u00e1ria\nA mal\u00e1ria \u00e9 uma doen\u00e7a infecciosa causada por um protozo\u00e1rio, pertencente ao filo Apicomplexa, fam\u00edlia Plasmodiidae e g\u00eanero Plasmodium. Atualmente, s\u00e3o conhecidas cerca de 150 esp\u00e9cies causadoras de mal\u00e1ria em diferentes hospedeiros vertebrados. Destas, principalmente quatro esp\u00e9cies parasitam o homem: P. falciparum, P. vivax, P. malarie e P. ovale18.\nA infec\u00e7\u00e3o pelo P. falciparum \u00e9 a mais grave, uma vez que estes par\u00e1sitos invadem hem\u00e1cias em qualquer fase evolutiva (eritr\u00f3citos e reticul\u00f3citos). O tempo de incuba\u00e7\u00e3o \u00e9 curto, por volta de seis dias, causando mal\u00e1ria maligna com paroxismo de 24 horas, podendo haver crises di\u00e1rias. O P. vivax n\u00e3o causa doen\u00e7a mortal, J\u00e1 que estes s\u00f3 invadem hem\u00e1cias Jovens (reticul\u00f3citos). O periodo de incuba\u00e7\u00e3o \u00e9 de cerca de oito dias com crises parox\u00edsticas a cada 48 horas. O P. malarie n\u00e3o causa doen\u00e7a aguda fatal infectando somente hem\u00e1cias envelhecidas. O seu per\u00edodo de incuba\u00e7\u00e3o \u00e9 de aproximadamente 15 dias. O paroxismo \u00e9 de 72 horas e a doen\u00e7a \u00e9 considerada benigna quart\u00e3. O P. ovale, n\u00e3o causa doen\u00e7a mortal uma vez que s\u00f3 infecta reticul\u00f3citos. O seu per\u00edodo de incuba\u00e7\u00e3o \u00e9 de cerca\n18 de 15 dias, causando mal\u00e1ria benigna terci\u00e1ria, com paroxismo de 48 horas18.\nO ciclo de vida do parasito no hospedeiro vertebrado se inicia pela inocula\u00e7\u00e3o de esporozo\u00edtos, formas infectantes do Plasmodium, atrav\u00e9s da picada do mosquito f\u00eamea do g\u00eanero Anopheles (Figura 4). Ap\u00f3s ser inoculada na derme humana, formas alongadas e m\u00f3veis do Plasmodium, os esporozo\u00edtos, movimentam-se rapidamente acessando a corrente sangu\u00ednea. Posteriormente, essas formas invadem os hepat\u00f3citos iniciando o ciclo hep\u00e1tico da infec\u00e7\u00e3o. Nos hepat\u00f3citos, ocorre a esquizogonia, um ciclo assexuado de reprodu\u00e7\u00e3o, em que os esporozo\u00edtos se desenvolvem e originam os esquizontes, os quais amadurecem e liberam por\nvolta de 40 mil merozo\u00edtos na corrente sangu\u00ednea. Em algumas esp\u00e9cies de Plasmodium (P. ovale e P. vivax), o esquizonte hep\u00e1tico pode permanecer em estado latente, em forma de hipnozo\u00edto. Essas formas podem ser reativadas, levando a reca\u00eddas de epis\u00f3dios agudos da mal\u00e1ria. Os merozo\u00edtos liberados na circula\u00e7\u00e3o, por sua vez, invadem as hem\u00e1cias e iniciam nova esquizogonia, transformando-se em trofozo\u00edtos que amadurecem e se dividem, gerando os esquizontes. Os esquizontes amadurecidos rompem os eritr\u00f3citos e liberam aproximadamente dois mil merozo\u00edtos que invadem novos eritr\u00f3citos, iniciando um novo ciclo replicativo, ou se diferenciando em gamet\u00f3citos macho e f\u00eamea. Estes gamet\u00f3citos, quando ingeridos pelo mosquito Anopheles no repasto sangu\u00edneo, iniciam um ciclo sexuado no intestino do mosquito, com a fus\u00e3o dos gametas para forma\u00e7\u00e3o dos oocinetos que penetram na parede intestinal e geram oocistos. Por sua vez, os oocistos se dividem por esporogonia, originando milhares de esporozo\u00edtos que chegam \u00e0 gl\u00e2ndula salivar do mosquito. Quando o mosquito, carregando esporozo\u00edtos nas gl\u00e2ndulas salivares, se alimentar novamente, ir\u00e1 infectar outros hospedeiros humanos, fechando assim o ciclo do parasito, que \u00e9 altamente esp\u00e9cie espec\u00edfico18,19.\na Infec\u00e7\u00e3o\nCiclo Assexuado\nb Esporozo\u00edtos\nMerozo\u00edtos\nGamet\u00f3citos\nTransmiss\u00e3o para o mosquito\nFigura 4. Ciclo de vida de Plasmodium infectantes ao homem. a, F\u00eameas infectadas injetam a forma de esporozo\u00edto do parasito num hospedeiro humano. b, Esporozo\u00edtos s\u00e3o transportados na corrente sangu\u00ednea para as c\u00e9lulas do f\u00edgado, onde proliferam-se assexuadamente, e, em seguida, como merozo\u00edtos, invadem os gl\u00f3bulos vermelhos. c, Ciclo assexuado dentro das c\u00e9lulas vermelhas do sangue, fase de manifesta\u00e7\u00e3o cl\u00ednica da doen\u00e7a, seguido pela produ\u00e7\u00e3o de gamet\u00f3citos macho e f\u00eamea. d, estes s\u00e3o transmitidos de volta para um mosquito durante o repasto sangu\u00edneo, onde se fundem para formar oocistos que dividem para criar esporozo\u00edtos. Estes migram para as gl\u00e1ndulas salivares, iniciando-se assim novamente o ciclo. (Renaud, F; Michalakis, Y. Nature. 2009; 46: 298300).\n1.4\tA patog\u00eanese da mal\u00e1ria\nA patog\u00eanese da mal\u00e1ria \u00e9 multifatorial. As manifesta\u00e7\u00f5es cl\u00ednicas variam de infec\u00e7\u00e3o assintom\u00e1tica em indiv\u00edduo imune a complica\u00e7\u00f5es graves e dependem de aspectos como a gen\u00e9tica do parasito e hospedeiro, exposi\u00e7\u00e3o pr\u00e9via a infec\u00e7\u00e3o, idade, fatores nutricionais, geogr\u00e1ficos e s\u00f3cio econ\u00f4micos. Os sinais e sintomas mais comuns da mal\u00e1ria, em indiv\u00edduos n\u00e3o imunes, como febre (paroxismo), n\u00e1usea, dor de cabe\u00e7a, iniciam-se entre sete a 15 dias ap\u00f3s a infec\u00e7\u00e3o, com a ruptura dos esquizontes eritroc\u00edticos e s\u00e3o caracter\u00edsticos de resposta inflamat\u00f3ria sist\u00eamica, com altos n\u00edveis de citocinas pr\u00f3-inflamat\u00f3rias circulantes20,21. A ativa\u00e7\u00e3o de c\u00e9lulas do sistema imune e consequentemente a inflama\u00e7\u00e3o sist\u00eamica podem\nlevar a manifesta\u00e7\u00f5es cl\u00ednicas graves, como anemia, acidose metab\u00f3lica, mal\u00e1ria cerebral, hipoglicemia, dist\u00farbios respirat\u00f3rios e insufici\u00eancia de m\u00faltiplos \u00f3rg\u00e3os. As manifesta\u00e7\u00f5es cl\u00ednicas em infec\u00e7\u00f5es causadas por P. falciparum, se n\u00e3o tratadas, podem evoluir levando a letalidade. Crian\u00e7as com mal\u00e1ria grave apresentam quadros de anemia aguda, icter\u00edcia, estresse respirat\u00f3rio devido a acidose metab\u00f3lica e mal\u00e1ria cerebral20. O P. vivax invade preferencialmente reticul\u00f3citos\n(eritr\u00f3citos jovens) contribuindo para cargas parasit\u00e1rias mais baixas al\u00e9m de uma menor destrui\u00e7\u00e3o de eritr\u00f3citos totais. No caso da infec\u00e7\u00e3o por este parasito, a forma\u00e7\u00e3o de knobs (protuber\u00e2ncias na superf\u00edcie de eritr\u00f3citos) n\u00e3o ocorre, sugerindo sua capacidade limitada de ader\u00eancia ao endot\u00e9lio vascular. Assim, n\u00e3o ocorrendo a obstru\u00e7\u00e3o de capilares de importantes \u00f3rg\u00e3os, a ocorr\u00eancia da mal\u00e1ria cerebral e placent\u00e1ria \u00e9 apenas espor\u00e1dica22.\nA patog\u00eanese da mal\u00e1ria resulta de tr\u00eas eventos principais fisiopatol\u00f3gicos: a\nresposta inflamat\u00f3ria excessiva, destrui\u00e7\u00e3o de c\u00e9lulas vermelhas do sangue e ades\u00e3o de eritr\u00f3citos infectados \u00e0s veias capilares20,23.\nS\u00edndromes:\nAnemia\nRegula\u00e7\u00e3o negativa da eritropoiese\ncerebral, _placent\u00e1ria_e respirat\u00f3ria\nSequestramento de parasitos\nExpress\u00e3o de mol\u00e9culas de ades\u00e3o\nS\u00edndrome de Sepse\nCitocinas Pr\u00f3-inflamat\u00f3rias\nFigura 5. Principais eventos na patog\u00eanese da mal\u00e1ria. A inflama\u00e7\u00e3o sist\u00eamica \u00e9 um evento central nas s\u00edndromes associadas a mal\u00e1ria.\nEsses eventos est\u00e3o associados e s\u00e3o respons\u00e1veis pelas principais s\u00edndromes relacionadas a mal\u00e1ria: a inflama\u00e7\u00e3o sist\u00eamica, anemia bem como a mal\u00e1ria cerebral e placent\u00e1ria20. O balan\u00e7o entre respostas pr\u00f3 e anti-inflamat\u00f3rias contra o parasito \u00e9 critico para se ter prote\u00e7\u00e3o cl\u00ednica, ou seja, pouca ativa\u00e7\u00e3o imune pode n\u00e3o inibir o crescimento do parasito, enquanto a ativa\u00e7\u00e3o exacerbada pode levar \u00e0 imunopatologia24.\nUma vez que o crescimento do parasito \u00e9 sincronizado, pode-se dizer que a libera\u00e7\u00e3o de citocinas pirog\u00e9nicas \u00e9 c\u00edclica. As citocinas pr\u00f3-inflamat\u00f3rias s\u00e3o importantes mediadores inflamat\u00f3rios durante a mal\u00e1ria20,23. A \u201ctempestade de citocinas\u201d, tamb\u00e9m conhecida como hipercitocinemia, \u00e9 a grande respons\u00e1vel pela febre alta, fadiga extrema e n\u00e1useas. A patologia da mal\u00e1ria est\u00e1 intrinsecamente ligada a produ\u00e7\u00e3o descontrolada de mediadores pr\u00f3-inflamat\u00f3rios, resultando em um quadro de inflama\u00e7\u00e3o sistemica. A libera\u00e7\u00e3o maci\u00e7a de citocinas vasoativas, hipovolemia e a redu\u00e7\u00e3o da viscosidade sangu\u00ednea contribuem para quadros de sepse durante a mal\u00e1ria. No entanto, estes sinais s\u00e3o inespec\u00edficos da mal\u00e1ria, podendo ser encontrados em outras infec\u00e7\u00f5es. Uma desregula\u00e7\u00e3o no equil\u00edbrio da produ\u00e7\u00e3o de citocinas pro-inflamat\u00f3rias pode tamb\u00e9m culminar em quadros de encefalopatia. Al\u00e9m disso, observa-se um efeito inibit\u00f3rio da eritropoese, por meio do aumento no padr\u00e3o de produ\u00e7\u00e3o de citocinas pr\u00f3-inflamat\u00f3rias, agravando a anemia em est\u00e1gios avan\u00e7ados da doen\u00e7a25,26,27.\nTr\u00eas tipos de mecanismos (n\u00e3o excludentes) explicam o desenvolvimento de uma anemia, de forma n\u00e3o relacionada com o grau de parasitemia, no curso da mal\u00e1ria: o aumento da destrui\u00e7\u00e3o de hem\u00e1cias pelo parasita, remo\u00e7\u00e3o de eritr\u00f3citos infectados ou alterados por c\u00e9lulas fagoc\u00edticas e o d\u00e9ficit na reposi\u00e7\u00e3o de novos eritr\u00f3citos. A destrui\u00e7\u00e3o de c\u00e9lulas vermelhas do sangue corresponde \u00e0 uma fase\nintra-eritroc\u00edtica onde parasitos digerem a hemoglobina, produzindo metab\u00f3litos potencialmente t\u00f3xicos, refletindo em quadros severos de anemia. Al\u00e9m disto, durante o hiper-esplenismo observado na mal\u00e1ria, h\u00e1 remo\u00e7\u00e3o por c\u00e9lulas fagoc\u00edticas de eritr\u00f3citos parasitados. Al\u00e9m disso, a reduzida capacidade e deformidade mesmo de eritr\u00f3citos n\u00e3o parasitados durante a mal\u00e1ria, leva a um aumento na ingest\u00e3o por fag\u00f3citos. Al\u00e9m da hem\u00f3lise de eritr\u00f3citos infectados, h\u00e1 a disfun\u00e7\u00e3o da medula \u00f3ssea com diseritropoiese, que persiste por algumas semanas ap\u00f3s a infec\u00e7\u00e3o aguda, causando uma baixa quantidade de reticul\u00f3citos. Os mecanismos do hospedeiro respons\u00e1veis pela supress\u00e3o da eritropoese podem envolver uma resposta imune excessiva ou continua. Algumas citocinas pr\u00f3-inflamat\u00f3rias como TNFa, IFNy e MIF inibem a eritropoese28,29,30.\nOutro evento chave na fisiopatologia da mal\u00e1ria \u00e9 o seq\u00fcestro de hem\u00e1cias parasitadas em diferentes \u00f3rg\u00e3os, incluindo os pulm\u00f5es, c\u00e9rebro, f\u00edgado, rins e placenta. Citocinas circulantes, como TNFa e IFNy ou componentes liberados na ruptura de hem\u00e1cias infectadas, levam a um aumento da express\u00e3o de mol\u00e9culas de ades\u00e3o por c\u00e9lulas endoteliais, tais como CD36, ICAM1 (do ingl\u00eas, intercellular adhesion molecule 1), PECAM1 (do ingl\u00eas, platelet endothelial cell adhesion molecule 1), receptor do complemento 1, sulfato de heparan e sulfato de condroitina A. Consequentemente, PfEMPI (do ingl\u00eas, Plasmodium falciparum erythrocyte membrane protein 1) se ligam a essas mol\u00e9culas de ades\u00e3o que est\u00e3o distribu\u00eddas entre diferentes \u00f3rg\u00e3os e tecidos do hospedeiro. Essa intera\u00e7\u00e3o entre mol\u00e9culas do parasito (PfEMP1) e mol\u00e9culas de ades\u00e3o do hospedeiro \u00e9 o principal determinante do tropismo do parasito em tecidos e patogenicidade31,32. Por exemplo, CD36 e ICAM1 s\u00e3o importante para o sequestramento de parasitos no c\u00e9rebro enquanto o sulfato de heparan e sulfato de condroitina A s\u00e3o os principais receptores para os\n33 eritrocitos infectados na placenta33. A liga\u00e7\u00e3o de hem\u00e1cias infectadas a c\u00e9lulas endoteliais leva a obstru\u00e7\u00e3o da microvasculatura, disfun\u00e7\u00e3o endotelial, edema e extravasamento de leuc\u00f3citos para tecidos. O sequestro de parasitas e estes processos de inflama\u00e7\u00e3o tecidual s\u00e3o, pelo menos em parte, respons\u00e1veis pela s\u00edndrome do estresse respirat\u00f3rio, mal\u00e1ria cerebral e mal\u00e1ria gestacional30,32,33.\nEm regi\u00f5es end\u00eamicas de mal\u00e1ria, constata-se o desenvolvimento gradativo de imunidade e diminui\u00e7\u00e3o das manifesta\u00e7\u00f5es cl\u00ednicas em indiv\u00edduos com m\u00faltiplas infec\u00e7\u00f5es progressas. A aquisi\u00e7\u00e3o deste tipo de prote\u00e7\u00e3o natural \u00e9 dependente principalmente da exposi\u00e7\u00e3o do indiv\u00edduo ao parasito, da exposi\u00e7\u00e3o a variantes antig\u00eanicos m\u00faltiplos do Plasmodium, bem como da matura\u00e7\u00e3o do sistema imunol\u00f3gico21,31. Altas parasitemias com sinais e sintomas cl\u00ednicos da doen\u00e7a s\u00e3o comuns em crian\u00e7as com menos de cinco anos de idade. Com o avan\u00e7o da idade e a reincid\u00eancia de infec\u00e7\u00f5es diferentes, mecanismos da imunidade inata e adaptativa participam do controle de altas parasitemias e dos sintomas cl\u00ednicos. No entanto podem n\u00e3o eliminar completamente a infec\u00e7\u00e3o, o que leva \u00e0 persist\u00eancia de baixas parasitemias por longos per\u00edodos, mantendo alta preval\u00eancia de indiv\u00edduos\n21 assintom\u00e1ticos e altas taxas de transmiss\u00e3o do parasito21.\n1.5\tA imunidade inata e a fisiopatologia da mal\u00e1ria\n1.5.1\tPapel de receptores da imunidade inata na mal\u00e1ria\nEstruturas microbianas conhecidas como padr\u00f5es moleculares associados a pat\u00f3genos (PAMPs, do ingl\u00eas, Pathogen Associated Molecular Patterns) s\u00e3o detectadas por receptores de reconhecimento de PAMPs (PRR, do ingl\u00eas, PAMP recognition receptors)34. Os receptores do tipo Toll (TLRs, do ingl\u00eas, Toll Like Receptors) detectam PAMPs na membrana dos endossomas ou na superf\u00edcie celular35, enquanto receptores do tipo RIG-I (RLRs, do ingl\u00eas, RIG-I Like\nReceptors)3 e do tipo NOD (NLRs, do ingl\u00eas, NOD Like Receptors) s\u00e3o encontrados no citosol . A ativa\u00e7\u00e3o de PRRs desencadeia vias de sinaliza\u00e7\u00f5es diferentes, culminando na elimina\u00e7\u00e3o do pat\u00f3geno. No entanto, a ativa\u00e7\u00e3o excessiva pode ser delet\u00e9ria, causando inflama\u00e7\u00e3o sist\u00eamica34. Al\u00e9m disso, padr\u00f5es moleculares associados a danos teciduais (DAMPs, do ingl\u00eas, Damage Associated Molecular Patterns) que s\u00e3o componentes end\u00f3genos liberados por c\u00e9lulas em situa\u00e7\u00f5es de estresse, dano ou morte, tamb\u00e9m s\u00e3o capazes de ativar PRRs e inflamassomas, independente da infec\u00e7\u00e3o. Existem evid\u00eancias que os DAMPs podem tamb\u00e9m ter um importante papel na inflama\u00e7\u00e3o sist\u00eamica e patog\u00eanese da mal\u00e1ria37,38.\nA inflama\u00e7\u00e3o sist\u00eamica \u00e9 um evento central nas diversas s\u00edndromes associadas \u00e0 mal\u00e1ria. \u00c9 causada pela ativa\u00e7\u00e3o excessiva da imunidade inata e, basicamente induzida por mediadores pr\u00f3-inflamat\u00f3rios, principalmente por citocinas pr\u00f3-inflamat\u00f3rias26. Para isso, compreender os mecanismos pelos quais componentes end\u00f3genos (\u00e1cido \u00farico, microves\u00edculas e o grupamento heme)38,39,40, assim como do parasito (mol\u00e9culas GPI, hemozo\u00edna e \u00e1cidos nucl\u00e9icos)36,41,42, liberados durante a infec\u00e7\u00e3o, ativam c\u00e9lulas da imunidade inata \u00e9 de grande import\u00e2ncia.\nAs citocinas pr\u00f3-inflamat\u00f3rias s\u00e3o produzidas como resultado do reconhecimento direto de elementos do Plasmodium por PRRs. Mol\u00e9culas de glicosilfosfatidilinositol (GPI, do ingl\u00eas, glycosylphosphatiylinositol), hemozo\u00edna ligada ao DNA e \u00e1cidos nucl\u00e9icos derivados de Plasmodium t\u00eam sido postuladas como grandes respons\u00e1veis pela indu\u00e7\u00e3o da produ\u00e7\u00e3o de citocinas pr\u00f3-inflamat\u00f3rias durante a fase aguda da mal\u00e1ria41,42.\nforma de sobreviv\u00eancia, o Plasmodium utiliza enzimas (plasmepsinas) que clivam a hemoglobina em pept\u00eddeos menores, amino\u00e1cidos, e o heme que \u00e9 polimerizado, resultando na forma\u00e7\u00e3o de cristais de hemozo\u00edna no vac\u00faolo parasit\u00f3foro. Estudos in vitro evidenciam que a hemozo\u00edna \u00e9 capaz de ativar mon\u00f3citos e macr\u00f3fagos, e estes passam a produzir citocinas pr\u00f3-inflamat\u00f3rias tais como TNFa e IL-ip. A hemozo\u00edna derivada de P. falciparum ligada a \u00e1cidos nucl\u00e9icos do parasito \u00e9 internalizada para o fagolisossomo, onde posteriormente ativa receptores da imunidade inata tanto no endossoma quanto no citoplasma das c\u00e9lulas. Deste modo, a hemozo\u00edna tem sido classificada como um componente chave do parasito na ativa\u00e7\u00e3o da imunidade inata durante a mal\u00e1ria42.\n\u00c1cidos nucl\u00e9icos derivados de parasitos inicialmente ligados a hemozo\u00edna, tamb\u00e9m s\u00e3o importantes estimuladores da resposta imune inata. Uma vez que se encontram no fagolisossomo, os motivos estimulat\u00f3rios CpG do DNA do Plasmodium ativam TLR9. A fagocitose de eritr\u00f3citos infectados tamb\u00e9m resulta na ativa\u00e7\u00e3o de TLR9, como consequ\u00eancia da libera\u00e7\u00e3o de DNA por meio da destrui\u00e7\u00e3o do parasito. Caso o DNA do parasito seja liberado no citosol, ap\u00f3s a ruptura do fagolisossomo, causada por cristais de hemozo\u00edna, este \u00e9 capaz de induzir a forma\u00e7\u00e3o do inflamassoma AIM2 (do ingl\u00e9s, absent in melanoma 2), que \u00e9 respons\u00e1vel pela ativa\u00e7\u00e3o de caspase-1, clivagem de pr\u00f3-IL-1 p e libera\u00e7\u00e3o de IL-1 p. Ademais, o DNA tamb\u00e9m induz a produ\u00e7\u00e3o de IFN do tipo I de forma independente de TLRs, atrav\u00e9s da ativa\u00e7\u00e3o de cGAS (do ingl\u00eas, cyclic GMP-AMP synthase)42,43.\nPor outro lado, o \u00e1cido \u00farico, um produto do metabolismo das purinas, \u00e9 liberado de c\u00e9lulas mortas em forma de cristais de urato em grandes quantidades durante a mal\u00e1ria. S\u00e3o internalizados por fagolisossomos onde contribuem para a ativa\u00e7\u00e3o de NLRP3 e a resposta inflamat\u00f3ria durante a mal\u00e1ria. Microves\u00edculas com\n1.5.2\tModelo murino da mal\u00e1ria cerebral\nComo descrito na sess\u00e3o anterior, a inflama\u00e7\u00e3o sist\u00eamica \u00e9 um importante componente da patog\u00eanese da mal\u00e1ria. Para tal, o modelo murino tem sido de grande valia para o melhor entendimento dos estudos mecan\u00edsticos sobre o papel da imunidade inata na indu\u00e7\u00e3o desta inflama\u00e7\u00e3o sist\u00eamica e patog\u00eanese da mal\u00e1ria. Existem tr\u00eas esp\u00e9cies principais que infectam naturalmente roedores e s\u00e3o utilizadas nestes modelos: P. yoelli, P. chabaudi e P. berghei.\nA infec\u00e7\u00e3o com P. yoelii 17XL (cepa letal), P. yoelii 17XNL (cepa n\u00e3o-letal) assim como o P. chabaudi (cepa n\u00e3o letal) s\u00e3o utilizadas para a avalia\u00e7\u00e3o de vacinas experimentais e processos imunol\u00f3gicos que controlam a parasitemia. J\u00e1 a infec\u00e7\u00e3o com o P. berghei ANKA (PbA) \u00e9 um bom modelo para se estudar a mal\u00e1ria cerebral. Consiste em uma s\u00edndrome neurol\u00f3gica, ocorrendo de seis a 12 dias ap\u00f3s a infec\u00e7\u00e3o, com mortalidade de cerca de 90%. A parasitemia no momento da morte \u00e9 relativamente baixa. As manifesta\u00e7\u00f5es neurol\u00f3gicas incluem p\u00ealo arrepiado, postura arqueada, desequil\u00edbrio, paralisia dos membros, convuls\u00f5es e coma. Os 10% dos animais que sobrevivem a mal\u00e1ria cerebral experimental (MCE), morrem nas pr\u00f3ximas tr\u00eas a quatro semanas, com anemia grave e parasitemia elevada, sem sinais neurol\u00f3gicos54.\nANKA quando comparado com animais WT. A resist\u00eancia destes animais foi associada a uma menor produ\u00e7\u00e3o de IL-12 no soro. Com isso, a inj\u00faria hep\u00e1tica, caracter\u00edstica da doen\u00e7a, n\u00e3o foi observada devido a uma defici\u00eancia na resposta do tipo Thl. Al\u00e9m disso, animais IL-12-/- tamb\u00e9m se mostraram resistentes \u00e0 MCE na infec\u00e7\u00e3o por PbA55,56.\nOs TLRs ensossomais tamb\u00e9m s\u00e3o de grande import\u00e2ncia no desenvolvimento da MCE. Animais infectados com PbA e tratados com o composto E6446 (antagonista de TLR7/9), produziram n\u00edveis de citocinas pro-inflamat\u00f3rias significativamente menores que animais tratados com ve\u00edculo. Os animais tratados com o composto n\u00e3o apresentaram sintomas neurol\u00f3gicos tampouco les\u00f5es\n57\ncerebrais, mostrando-se resistentes57. Estudos demonstram que a hemozoina natural \u00e9 capaz de ativar mon\u00f3citos e macr\u00f3fagos murinos, induzindo tamb\u00e9m a produ\u00e7\u00e3o de citocinas pr\u00f3-inflamat\u00f3rias como TNFa e IL-1 p via TLR9. A hemozo\u00edna sint\u00e9tica associada a oligonucleot\u00eddeos contendo motivos CpG n\u00e3o metilados tamb\u00e9m ativa TLR9 em c\u00e9lulas dendr\u00edticas (DCs, do ingl\u00eas, dendritic cells) e macr\u00f3fagos de camundongos e induz a forma\u00e7\u00e3o do inflamassoma NLRP3 e AIM2, resultando na libera\u00e7\u00e3o de IL-1 p por macr\u00f3fagos42,43.\nConsistente com dados em humanos, DNA derivado do parasito no citosol de c\u00e9lulas do hospedeiro, \u00e9 capaz de induzir a forma\u00e7\u00e3o do inflamassoma AIM2, em consequ\u00eancia da ativa\u00e7\u00e3o de TLRs, e a produ\u00e7\u00e3o de IFN do tipo I via ativa\u00e7\u00e3o de cGAS e do adaptador STING (do ingl\u00eas, stimulator of interferon genes). Ainda, o RNA derivado de PbA pode ativar receptores das c\u00e9lulas do hospedeiro. A invas\u00e3o de hepat\u00f3citos por esporozo\u00edtos induz a produ\u00e7\u00e3o de IFN do tipo I via MDA5 (do ingl\u00eas, melanoma differentiation-associated protein 5) atrav\u00e9s de MAVS (do ingl\u00eas, mitochondrial antiviral-signaling protein) e fatores de transcri\u00e7\u00e3o como IRF3 (do\nDurante a mal\u00e1ria, a fagocitose de eritr\u00f3citos infectados ocorre principalmente na polpa vermelha e na zona marginal do ba\u00e7o. Nestes locais, observa-se popula\u00e7\u00f5es heterog\u00eaneas de c\u00e9lulas fagoc\u00edticas, formada por macr\u00f3fagos e DCs. Os eritr\u00f3citos infectados ou merozo\u00edtos s\u00e3o fagocitados de forma precoce logo ap\u00f3s a infec\u00e7\u00e3o. Este processo auxilia no controle de parasitos no sangue e na indu\u00e7\u00e3o das respostas imunes que s\u00e3o observadas na fase aguda da infec\u00e7\u00e3o. O aumento na produ\u00e7\u00e3o de citocinas pr\u00f3-inflamat\u00f3rias \u00e9 um resultado da ativa\u00e7\u00e3o direta de fag\u00f3citos que tem papel central nos processos patol\u00f3gicos30,60.\nEstas popula\u00e7\u00f5es tem um papel cr\u00edtico no controle das infec\u00e7\u00f5es, identificando a presen\u00e7a de microrganismos invasores e iniciando respostas imunes protetoras. Contudo, as subpopula\u00e7\u00f5es de c\u00e9lulas t\u00eam fun\u00e7\u00f5es sobrepostas. DCs s\u00e3o eficientes c\u00e9lulas apresentadoras de ant\u00edgenos (APCs, do ingl\u00eas, antigen presenting cells) para c\u00e9lulas T, ao passo que os macr\u00f3fagos atuam principalmente como fonte de citocinas pr\u00f3-inflamat\u00f3rias e c\u00e9lulas fagoc\u00edticas que destroem com efic\u00e1cia os agentes patog\u00eanicos. Mon\u00f3citos (MOs) s\u00e3o c\u00e9lulas menos especializadas que contribuem, de um modo geral, para a produ\u00e7\u00e3o de citocinas inflamat\u00f3rias, mediadores pr\u00f3 inflamat\u00f3rios, anti-microbianos e s\u00e3o os principais progenitores para DCs e macr\u00f3fagos61,62.\nDCs, mon\u00f3citos e macr\u00f3fagos tem um papel de grande import\u00e2ncia na resist\u00eancia do hospedeiro durante a infec\u00e7\u00e3o por Plasmodium, no modelo murino. Durante a mal\u00e1ria, DCs miel\u00f3ides s\u00e3o ativadas atrav\u00e9s de TLRs, principalmente\nTLR9, servindo como fonte importante de IL-12. Com isso, a IL-12 ativa c\u00e9lulas NK que produzir\u00e3o IFNy, promovendo a diferencia\u00e7\u00e3o de linf\u00f3citos Thl, respons\u00e1vel pela imunidade protetora, controlando a infec\u00e7\u00e3o por Plasmodium spp20,63.\nEm roedores, mon\u00f3citos inflamat\u00f3rios (CCR2+Ly6C+F4/80+), bem como DCs s\u00e3o importantes fontes de citocinas inflamat\u00f3rias, esp\u00e9cies reativas de oxig\u00eanio e \u00f3xido n\u00edtrico que destroem efetivamente c\u00e9lulas com eritr\u00f3citos infectados contendo Plasmodium fagocitados. Da mesma forma, DCs tamb\u00e9m contribuem para a patog\u00eanese da mal\u00e1ria em roedores. Al\u00e9m disso, DCs tamb\u00e9m s\u00e3o necess\u00e1rias para o desenvolvimento de MCE64,65.\nUm subtipo de c\u00e9lulas monoc\u00edticas Ly6C+ tem um papel cr\u00edtico no recrutamento de c\u00e9lulas T CD8+ para o sistema nervoso central (SNC) resultando no desenvolvimento MCE. Por\u00e9m, estudos recentes definiram v\u00e1rios marcadores que permitem a distin\u00e7\u00e3o de iMOs de DCs derivadas de mon\u00f3citos (MO-DCs). No entanto, o papel da MO-DCs na neuroinflama\u00e7\u00e3o durante MCE n\u00e3o foi explorado. Portanto, na segunda parte desta tese estudamos o papel de MO-DCs no desenvolvimento da inflama\u00e7\u00e3o no SNC e MCE.\n2\tJUSTIFICATIVA GERAL\nA mal\u00e1ria representa um dos principais problemas de sa\u00fade p\u00fablica no mundo em desenvolvimento, tanto em termos de morbidade como de mortalidade. O ac\u00famulo de conhecimento na \u00e1rea leva um consenso de que uma resposta exacerbada do sistema imune inato tem um importante papel na patog\u00eanese da mal\u00e1ria. Acredita-se que a ativa\u00e7\u00e3o de c\u00e9lulas do sistema imune e consequentemente a inflama\u00e7\u00e3o sist\u00eamica \u00e9 a base das manifesta\u00e7\u00f5es cl\u00ednicas graves da mal\u00e1ria. A inflama\u00e7\u00e3o sist\u00eamica e a febre durante a fase aguda da mal\u00e1ria\n\u00e9 uma consequ\u00eancia da produ\u00e7\u00e3o de citocinas por fag\u00f3citos ativados atrav\u00e9s de TLRs, NLRs e receptores citos\u00f3licos que reconhecem \u00e1cidos nucl\u00e9icos deste protozo\u00e1rio. Com isso, \u00e9 importante investigar o mecanismo pelo qual o DNA e o RNA do parasito se tornam acess\u00edveis a receptores presentes nos endossomas e citoplasma e ativam os fag\u00f3citos durante a mal\u00e1ria. Al\u00e9m disso, tendo em vista a import\u00e2ncia de fag\u00f3citos durante a infec\u00e7\u00e3o pelo Plasmodium, torna-se importante caracterizar e identificar o mecanismo pelo qual estas c\u00e9lulas promovem a inflama\u00e7\u00e3o e letalidade durante a mal\u00e1ria.\nAcreditamos que os estudos realizados durante esta tese, proporcionar\u00e3o novos conhecimentos acerca dos mecanismos respons\u00e1veis pela patog\u00eanese e neuroinflama\u00e7\u00e3o causada pela infec\u00e7\u00e3o com o Plasmodium, abrindo portas para novas interven\u00e7\u00f5es terap\u00eauticas na mal\u00e1ria.\n3\tOBJETIVOS\n3\tOBJETIVOS\n3.1\tMal\u00e1ria\n3.1.1\tObjetivo geral\nAvaliar a atividade pr\u00f3-inflamat\u00f3ria de ICs na ativa\u00e7\u00e3o de receptores da imunidade inata durante a mal\u00e1ria.\n3.1.2\tObjetivos espec\u00edficos\nDeterminar se ICs s\u00e3o fatores imunoestimulat\u00f3rios via receptores de DNA/RNA, como TLRs, NLRs e outros receptores citos\u00f3licos.\nDeterminar a resposta celular \u00e0 ICs, bem como as principais fontes celulares de citocinas em c\u00e9lulas mononucleares do sangue perif\u00e9rico (CMSPs) de indiv\u00edduos saud\u00e1veis ou com mal\u00e1ria.\nAvaliar a import\u00e2ncia de ICs e diferentes receptores Fcy (CD64, CD16, CD32) na ativa\u00e7\u00e3o de c\u00e9lulas de indiv\u00edduos saud\u00e1veis e pacientes com mal\u00e1ria.\nAvaliar o impacto dos ICs na forma\u00e7\u00e3o dos inflamassomos em c\u00e9lulas derivadas CMSPs de pacientes com mal\u00e1ria.\n3.2\tModelo murino da mal\u00e1ria cerebral\n3.2.1\tObjetivo geral\nInvestigar o papel de MO-DCs no desenvolvimento da MCE.\n3.2.2\tObjetivos espec\u00edficos\nCaracterizar c\u00e9lulas MO-DCs quanto ao fen\u00f3tipo, propriedades morfol\u00f3gicas e express\u00e3o g\u00eanica durante a infec\u00e7\u00e3o com PbA.\nDeterminar a express\u00e3o de quimiocinas e receptores de quimiocinas em c\u00e9lulas MO-\nDCs durante a infec\u00e7\u00e3o por PbA.\nAvaliar a migra\u00e7\u00e3o de c\u00e9lulas MO-DCs no SNC na infec\u00e7\u00e3o por PbA.\n4\tMETODOLOGIA\n4\tMETODOLOGIA\n4.1\tMal\u00e1ria\n4.1.1\tPaciente\n4.1.1.1\tCaracter\u00edsticas e proced\u00eancia da amostra\nEste estudo foi conduzido no Centro de Pesquisas Ren\u00e9 Rachou (CPqRR) -Funda\u00e7\u00e3o Oswaldo Cruz, Belo Horizonte (MG) e Centro de Pesquisa em Medicina Tropical (CEPEM), Porto Velho (RO). Foram estudadas amostras de sangue colhidas de indiv\u00edduos residentes em Porto Velho (RO), regi\u00e3o end\u00eamica de mal\u00e1ria.\n4.1.1.2\tAspectos \u00e9ticos da pesquisa\nOs estudos envolvendo pacientes infectados e doadores saud\u00e1veis foram aprovados pelo Centro de Pesquisas Ren\u00e9 Rachou (CPqRR) - Funda\u00e7\u00e3o Oswaldo Cruz (CEP-CPqRR 2004), Comit\u00ea de \u00c9tica Nacional do Minist\u00e9rio da Sa\u00fade (CONEP, n\u00famero do protocolo 15652), Comit\u00ea \u00c9tico em Experimentos com Humanos do Centro de Pesquisa em Medicina Tropical (CEP-CEPEM 095/2009) e tamb\u00e9m pelo Conselho de Pesquisa Institucional da Universidade de Massachusetts (IRB-UMMS 10268).\n4.1.1.3\tIndiv\u00edduos da pesquisa\nOs crit\u00e9rios de inclus\u00e3o para pacientes com mal\u00e1ria aguda foram: positividade para P. vivax ou P. falciparum em esfrega\u00e7os sangu\u00edneos e presen\u00e7a de sintomas cl\u00ednicos da doen\u00e7a como febre, calafrio, cefaleia, mialgia, n\u00e1usea e v\u00f4mito. Foram inclu\u00eddos indiv\u00edduos com idade entre 18 a 60 anos.\no acompanhamento, mulheres gr\u00e1vidas, necessidade de interna\u00e7\u00e3o e apresentar doen\u00e7as cr\u00f4nicas ou autoimunes. No tratamento antimal\u00e1rico para pacientes infectados por P. vivax foi utilizado cloroquina (150 mg) associado a primaquina (15 mg) por sete dias. J\u00e1 o tratamento para pacientes infectados com P. falciparum foi utilizado artemether (20 mg) associado a lumefantrina (120 mg) e primaquina (45 mg) por tr\u00eas dias. Pacientes que aceitaram participar do estudo doaram 100 mL de sangue total, que foram coletados em tubos sem anticoagulantes, heparinizados ou EDTA, antes e ap\u00f3s 30-45 dias de tratamento quimioter\u00e1pico. O mesmo procedimento de coleta foi adotado para doadores saud\u00e1veis da regi\u00e3o end\u00eamica e fora da regi\u00e3o end\u00eamica. O sangue foi usado como fonte de c\u00e9lulas mononucleares de sangue perif\u00e9rico (CMSPs), plasma e soro.\n4.1.1.2\tCaracteriza\u00e7\u00e3o cl\u00ednica e laboratorial dos pacientes\nNo presente estudo foram inclu\u00eddos 80 pacientes infectados com P. vivax, 32 pacientes infectados com P. falciparum e 30 doadores saud\u00e1veis. Os quadros tr\u00eas e quatro apresentam a distribui\u00e7\u00e3o do n\u00famero de indiv\u00edduos por sexo, idade, epis\u00f3dios de mal\u00e1ria, parasitemia, sintomas cl\u00ednicos e par\u00e2metros hematol\u00f3gicos de pacientes infectados com P. vivax e P. falciparum, respectivamente.\nQuadro 1. Sintomas cl\u00ednicos e par\u00e2metros laboratoriais de pacientes infectados com P. vivax\nPaciente\n1\n2\n3\n4\n5\n6\n7\n8\n9\n10\n11\n12\n13\n14\n15\n16\n17\n18\n19\n20\n21\n22\n23\n24\n25\n26\n27\n28\n29\n30\n31\n32\n33\n34\n35\n36\n37\n38\n39\n40\n41\n42\n43\n44\n45\n46\n47\n48\n49\n50\n51\n52\n53\n54\n55\n56\n57\n58\n59\n60\n61\n62\n63\n64\n65\n66\n67\n68\n69\n70\n71\n72\n73\n74\n75\n76\n77\n78\n79\n80\nDiagn\u00f3stico\nP. P.\nP.\nP. P.\nP.\nP.\nP.\nP.\nP.\nP.\nP.\nP.\nP.\nP.\nP.\nP.\nP.\nP.\nP.\nP.\nP.\nP.\nP.\nP.\nP.\nP.\nP.\nP.\nP.\nP.\nP.\nP.\nP.\nP.\nP.\nP.\nP.\nP.\nP.\nP.\nP.\nP.\nP.\nP.\nP.\nP.\nP.\nP.\nP.\nP.\nP.\nP.\nP.\nP.\nP.\nP.\nP.\nP.\nP.\nP.\nP.\nP.\nP.\nP.\nP.\nP.\nP.\nP.\nP.\nP.\nP.\nP.\nP.\nP.\nP.\nP.\nP.\nP.\nP.\nvivax vivax vivax vivax vivax vivax vivax vivax vivax vivax vivax vivax vivax vivax vivax vivax vivax vivax vivax vivax vivax vivax vivax vivax vivax vivax vivax vivax vivax vivax vivax vivax vivax vivax vivax vivax vivax vivax vivax vivax vivax vivax vivax vivax vivax vivax vivax vivax vivax vivax vivax vivax vivax vivax vivax vivax vivax vivax vivax vivax vivax vivax vivax vivax vivax vivax vivax vivax vivax vivax vivax vivax vivax vivax vivax vivax vivax vivax vivax vivax\nPpaoa \u00a1temia\tTemperatraa (\u00b0C)\tEpisodiss de Mal\u00e1ria\tCalafaio\tCafal\u00e9ia\tMiaigig\tSintomas\t\t\t\t\t\t\tPlaquetas x 103/mm3\t\n\t\t\t\t\t\tN\u00e1usse\tLeuc\u00f3citos x 103/mm3\t\tHem\u00e1cias x 106/mm3 VR: 4.4 a 6\t\tHemoglobina g/dL\t\t\t\n\t\t\t\t\t\t\tVR: 5000 a Antes do Tratamento\t10000\t\t\tVR: 13. Antes do Tratamento\t4 a 17\tVR: Antes do Tratamento\t150\n\t\t\t\t\t\t\t\tAp\u00f3s o Tratamento\tAntes do Tratamento\tAp\u00f3s o Tratamento\t\tAp\u00f3s o Tratamento\t\tAp\u00f3s o Tratamento\n\tN\u00e3o\t4\tSim\tSim\tSim\tN\u00e3o\t3.8\t4.1\t4.1\t4.78\t12.2\t13.9\t75\t\n(+)\t37\u00b0C\t\tN\u00e3o\tSim\tN\u00e3o\tN\u00e3o\t5.8\t7.3\t4.05\t2.83\t12\t9.7\t190\t80\n(+++)\t39.5\u00b0C\t20\tN\u00e3o\tSim\tSim\tN\u00e3o\t3.7\t5.6\t4.09\t4.47\t11.2\t12.9\t106\t\n\t38\u00b0C\t3\tSim\tSim\tSim\tN\u00e3o\t5.4\t3.8\t4.78\t4.73\t13.9\t14.4\t130\t\n\t37\u00b0C\t6\tN\u00e3o\tN\u00e3o\tSim\tN\u00e3o\t5.9\t5.3\t4.99\t5.17\t13.7\t14.7\t91\t\n(++)\t36.2\u00b0C\t10 a 12\tSim\tSim\tSim\tSim\t4.3\t4.7\t4.42\t4.45\t12.7\t13.3\t63\t63\n(++)\t\t2\tSim\tSim\tSim\tSim\t4.8\t9.8\t5.02\t4.88\t13.8\t14.5\t40\t\n(++)\t37\u00b0C\t0\tSim\tSim\tSim\tSim\t3.7\t6.5\t4.67\t4.6\t11.8\t12.9\t78\t\n(++)\t37\u00b0C\t10\tSim\tSim\tSim\tSim\t5.5\t7.3\t3.56\t4.51\t10.1\t12.6\t\t237\n(+)\t38\u00b0C\t8\tN\u00e3o\tSim\tN\u00e3o\tSim\t4.1\t7.3\t4.55\t5.07\t13.9\t15.5\t207\t277\n\t\t\t\t\t\t\t3\t6.6\t4.81\t5.2\t13\t15.3\t\t180\n(++)\t38.5\u00b0C\t2\tSim\tSim\tSim\tN\u00e3o\t3.1\t6.6\t4.21\t5.2\t12\t15.3\t\t180\n(++)\t36\u00b0C\t6\tSim\tSim\tSim\tN\u00e3o\t7.2\t8\t5.61\t5.36\t14\t13.5\t\t211\n(1/2)\t37\u00b0C\t0\t\tSim\tSim\tN\u00e3o\t3.1\t5.4\t4.93\t5.16\t13.9\t14.6\t\t267\n(+++)\t38\u00b0C\t5\tN\u00e3o\tSim\tSim\tN\u00e3o\t6.5\t5.7\t5.26\t4.6\t12.6\t12.2\t104\t220\n(1/2)\t37.5\u00b0C\t30\tSim\tSim\tSim\tN\u00e3o\t8.2\t\t4.99\t\t14.8\t\t\t\n(++)\t37\u00b0C\t20\tSim\tN\u00e3o\tSim\tN\u00e3o\t3.6\t5.6\t4.86\t4.93\t13.5\t14.9\t97\t180\n(++)\t37\u00b0C\t11\tSim\tSim\tSim\tSim\t4.6\t5.6\t5.04\t4.98\t15\t13.9\t108\t182\n\t37\u00b0C\t3\tN\u00e3o\tN\u00e3o\tN\u00e3o\tN\u00e3o\t7.1\t8.8\t5.05\t5.56\t13.8\t15.6\t57\t321\n(+)\t38.2\u00b0C\t1\tSim\tSim\tSim\tSim\t6.5\t8.1\t4.43\t4.81\t12.5\t14.3\t88\t200\n(+)\t38.9\u00b0C\t8\tSim\tSim\tN\u00e3o\tN\u00e3o\t5\t5.3\t5.61\t5.3\t13.8\t14.1\t91\t190\n(+)\t36\u00b0C\t1\tSim\tSim\tSim\tSim\t5\t5.9\t4.5\t4.78\t14\t14.4\t129\t200\n(+)\t37.6\u00b0C\t1\tSim\tSim\tSim\tN\u00e3o\t4.2\t\t4.88\t\t15.5\t\t89\t\n(++)\t36\u00b0C\t5\tSim\tSim\tSim\tSim\t6.8\t6.4\t4.88\t5.35\t13.1\t14.2\t138\t305\n(+)\t37.4\u00b0C\tmais de 10\tSim\tSim\tSim\tSim\t4.6\t4\t4.66\t4.71\t14.2\t13.7\t96\t188\n(++)\t37\u00b0C\t5\tSim\tN\u00e3o\tSim\tSim\t6.1\t5\t4.7\t4.82\t14.2\t14\t112\t121\n(+++)\t39\u00b0C\t0\tSim\tSim\tSim\tSim\t9.5\t6.1\t4.4\t5.28\t12.1\t14.8\t94\t135\n+\t37.4\u00b0C\t6\tSim\tSim\tSim\tSim\t7.7\t7\t4.45\t4.53\t13.8\t13.3\t120\t171\n(+++)\t\t4\tSim\tSim\tSim\tSim\t6.3\t\t5.25\t\t13.8\t\t74\t\n(++)\t41\u00b0C\t0\tSim\tSim\tSim\tSim\t3.3\t\t4.16\t\t12.4\t\t\t\n(++)\t37.7\u00b0C\t5\tSim\tN\u00e3o\tSim\tN\u00e3o\t4.7\t6.5\t4.98\t5.54\t14.4\t15.5\t41\t\n(+)\t38.7\u00b0C\tmais de 10\tN\u00e3o\tSim\tSim\tN\u00e3o\t7.6\t\t4.38\t\t12.8\t\t150\t\n(+)\t\tmais de 10\tSim\tSim\tSim\tSim\t5.1\t8\t4.31\t4.51\t13.1\t13.6\t151\t249\n(+)\t38.5\u00b0C\t3\tN\u00e3o\tN\u00e3o\tSim\tN\u00e3o\t6.9\t6.9\t5.29\t5.29\t16.1\t16.6\t107\t107\n(+)\t38\u00b0C\t0\tSim\tSim\tSim\tN\u00e3o\t4.8\t\t4.83\t\t13.2\t\t124\t\n(++)\t37\u00b0C\t2\tN\u00e3o\tSim\tSim\tN\u00e3o\t6.9\t5.5\t4.82\t5.14\t14.3\t15.8\t\t189\n(++)\t38.7\u00b0C\t0\tSim\tSim\tSim\tSim\t4\t6.9\t5.24\t5.82\t13.6\t15.9\t52\t238\n(++)\t39.5\u00b0C\t4\tSim\tSim\tSim\tN\u00e3o\t5.1\t4.9\t4.42\t5.35\t13.3\t17.4\t\t195\n(+)\t36.5\u00b0C\t0\tSim\tSim\tSim\tN\u00e3o\t2.5\t\t4.84\t\t13.6\t\t30\t\n(++)\t\t2\tSim\tSim\tSim\tN\u00e3o\t5.3\t6.5\t5.36\t5.41\t14.8\t14.4\t148\t261\n(+)\t36.5\u00b0C\t10\tSim\tSim\tSim\tSim\t5.5\t\t5.09\t\t13.2\t\t53\t\n(+)\t36.6\u00b0C\t\tSim\tSim\tSim\tN\u00e3o\t2\t3.8\t3.6\t4.63\t11.1\t14.7\t44\t101\n(++)\t39.2\u00b0C\t4\tsim\tsim\tsim\tsim\t3.4\t\t2.62\t\t6.7\t\t220\t\n(++)\t36.4\u00b0C\t2\tsim\tsim\tsim\tsim\t6.6\t\t4.25\t\t11.7\t\t75\t\n(+)\t36.5\u00b0C\t3\tsim\tN\u00e3o\tsim\tsim\t5.2\t\t5.36\t\t14.1\t\t153\t\n(+++)\t37\u00b0C\t0\tSim\tSim\tSim\tSim\t3.3\t\t3.93\t\t11.8\t\t29\t\n(+++)\t35.2\u00b0C\t1\tn\u00e3o\tN\u00e3o\tsim\tn\u00e3o\t5.5\t\t4.35\t\t13.2\t\t112\t\n\t38.6\u00b0C\t5\tsim\tsim\tsim\tn\u00e3o\t4.1\t\t4.89\t\t14.2\t\t179\t\n(++)\t37.2\u00b0C\t3\tsim\tsim\tsim\tsim\t4.1\t\t5.03\t\t14.6\t\t132\t\n(++)\t\t3\tsim\tSim\tSim\tSim\t4.2\t\t6.19\t\t17.7\t\t61\t\n(++)\t\t4\t\tsim\tsim\tN\u00e3o\t\t\t\t\t\t\t\t\n(+)\t36.7\u00b0C\t3\tsim\tsim\tsim\tsim\t6.8\t\t4.86\t\t14.6\t\t235\t\n(++)\t38.1\u00b0C\t2\tN\u00e3o\tSim\tN\u00e3o\tN\u00e3o\t7.8\t\t5.5\t\t15.9\t\t171\t\n(+)\t38.2\u00b0C\t1\tSim\tSim\tSim\tSim\t2.4\t\t3.7\t\t10.7\t\t50\t\n(1/2)\t38.7\u00b0C\t15\tSim\tSim\tSim\tN\u00e3o\t6.8\t\t4.7\t\t13.2\t\t140\t\n(++)\t37.6\u00b0C\t21\tN\u00e3o\tN\u00e3o\tN\u00e3o\tN\u00e3o\t4.2\t\t4.37\t\t13.3\t\t109\t\n(+)\t37.5\u00b0C\t37\tSim\tN\u00e3o\tN\u00e3o\tN\u00e3o\t9.1\t\t4.19\t\t10.5\t\t144\t\n(+++)\t37.5\u00b0C\t1\tSim\tSim\tSim\tSim\t6.2\t\t4.33\t\t12\t\t150\t\n(+++)\t37.6\u00b0C\t30\tSim\tSim\tSim\tN\u00e3o\t6.6\t\t5.2\t\t11.7\t\t164\t\n\t\t30\tSim\tN\u00e3o\tSim\tSim\t5.5\t8.7\t4.44\t4.52\t12.9\t13.1\t113\t193\n\t39,2\u00b0C\t0\tSim\tSim\tSim\tSim\t3.4\t4.6\t3.69\t3.77\t10.7\t11.6\t42\t191\n\t\t10\tSim\tSim\tSim\tSim\t5\t7.1\t3.61\t4.68\t10.4\t14.1\t51\t159\n\t38,5\u00b0C\t2\tSim\tSim\tSim\tSim\t6\t6\t4.44\t4.77\t13.4\t14.5\t66\t189\n\t39,8\u00b0C\t3\tSim\tN\u00e3o\tSim\tN\u00e3o\t5.2\t5.2\t5.27\t5.05\t13.8\t13.3\t86\t170\n\t37,2\u00b0C\t10\tSim\tSim\tSim\tN\u00e3o\t5.8\t5\t4.85\t4.5\t14.7\t13.8\t131\t125\n\t\t5\tN\u00e3o\tSim\tSim\tSim\t6.1\t4.3\t4.88\t4.54\t13.8\t13.1\t202\t179\n\t\t15\tN\u00e3o\tSim\tSim\tSim\t6.6\t7.6\t5.45\t4.9\t15.9\t14\t180\t278\n\t37,2\u00b0C\t2\tSim\tSim\tSim\tSim\t6.6\t6.5\t4.32\t4\t13.5\t12\t171\t229\n\t39\u00b0C\t5\tSim\tSim\tSim\tSim\t8.2\t8\t5.36\t4.4\t15.1\t12\t93\t224\n\t39,7\u00b0C\t1\tSim\tSim\tSim\tSim\t2.9\t6.5\t3.80\t4.4\t11\t13\t98\t262\n(++)\t38.8\u00b0C\t1\tsim\tsim\tsim\tsim\t8\t6.9\t4.73\t5.4\t13.4\t14\t111\t253\n(++)\t36.9\u00b0C\t7\tsim\tsim\tsim\tn\u00e3o\t5\t8\t5\t4.96\t14\t14,10\t90\t143\n(+)\t37.5\u00b0C\t4\tsim\tsim\tsim\tsim\t4\t6.8\t5.16\t5.18\t15.1\t14,50\t186\t353\n(++)\t36.1\u00b0C\t1\tn\u00e3o\tsim\tsim\tsim\t3\t6.2\t5.25\t5.16\t14.3\t14,10\t135\t254\n(++)\t36\u00b0C\t8\tsim\tsim\tsim\tsim\t5\t6.4\t5.66\t5.66\t14.5\t13,9\t85\t157\n(+)\t36.1\u00b0C\t1\tsim\tsim\tsim\tsim\t4\t4.4\t4.6\t4.6\t13.1\t13.1\t119\t119\n(++)\t36.2\u00b0C\t10\tn\u00e3o\tsim\tsim\tn\u00e3o\t5\t7.6\t4.7\t4.81\t13.2\t14,4\t189\t309\n(+++)\t36.4\u00b0C\t10\tsim\tsim\tn\u00e3o\tn\u00e3o\t8\t\t5\t\t13.3\t\t150\t\n(1/2)\t35.5\u00b0C\t1\tsim\tsim\tsim\tsim\t2\t2.3\t5.75\t5.75\t\t16\t\t110\n(++)\t37.5\u00b0C\t0\tsim\tsim\tsim\tsim\t4\t5.2\t5.09\t4.36\t13.2\t11,3\t154\t284\nQuadro 2. Sintomas cl\u00ednicos e par\u00e2metros laboratoriais de pacientes infectados com P. falciparum\nPaciente\n1\n2\n3\n4\n5\n6\n7\n8\n9\n10\n11\n12\n13\n14\n15\n16\n17\n18\n19\n20\n21\n22\n23\n24\n25\n26\n27\n28\n29\n30\n31\n32\nDiagn\u00f3stico\nP. falciparum P. falciparum P. falciparum P. falciparum P. falciparum P. falciparum P. falciparum P. falciparum P. falciparum P. falciparum P falciparum P. falciparum P. falciparum P. falciparum P falciparum P. falciparum P. falciparum P. falciparum P. falciparum P. falciparum P. falciparum P. falciparum P. falciparum P. falciparum P. falciparum P. falciparum P. falciparum P. falciparum P. falciparum P. falciparum P falciparum P. falciparum\nHemoglobina g/dL\nVR: 13.4 a 17\nHem\u00e1cias x 106/mm3\nVR: 4.4 a 6\nLeuc\u00f3citos x 103/mm3\nVR: 5000 a 10000\nPaaaaiiemia\t\tde Mal\u00e1ria\tCalafaio\tCafaieia\tMiaigia\tNa\u00e1sse\tAntes do Tratamento\tAp\u00f3s o Tratamento\tAntes do Tratamento\tAp\u00f3s o Tratamento\tAntes do Tratamento\tAp\u00f3s o Tratamento\tAntes do Tratamento\tAp\u00f3s o Tratamento\n(1/2)\t37\u00b0C\t\tSim\tSim\tN\u00e3o\tSim\t3. 9\t9.3\t5.29\t5.13\t15.3\t14.9\t\t149\n+\t36\u00b0C\t\tN\u00e3o\tN\u00e3o\tN\u00e3o\tN\u00e3o\t5.3\t5.8\t4.28\t4.23\t13\t13\t\t166\n++\t37\u00b0C\t\tSim\tSim\tSim\tN\u00e3o\t5.8\t7\t5.49\t4.69\t15.4\t13.9\t\t193\n\t\t\t\t\t\t\t4.3\t6.6\t4.59\t3.77\t13.6\t11.3\t91\t206\n+\t37\u00b0C\t\tSim\tN\u00e3o\tSim\tN\u00e3o\t2.6\t5.8\t5.04\t4.77\t15.1\t14.1\t48\t201\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\n(++)\t40\u00b0C\t11\tSim\tSim\tSim\tN\u00e3o\t8\t\t4.79\t\t14.7\t\t182\t\n(+)\t36.5\u00b0C\tMais de 30\tN\u00e3o\tSim\tSim\tN\u00e3o\t5.4\t7.7\t4.08\t4.1\t11.6\t12.3\t155\t199\n(++)\t38.5\u00b0C\t\tN\u00e3o\tSim\tSim\tN\u00e3o\t4.6\t\t3.7\t4.75\t10.3\t\t150\t\n(++)\t36.4\u00b0C\t10\tSim\tSim\tSim\tSim\t5.5\t11.2\t4.93\t4.75\t13.8\t13.7\t173\t286\n(++)\t39\u00b0C\t0\tSim\tSim\tSim\tSim\t5.5\t8.1\t4.6\t4.99\t13.7\t15.3\t60\t167\n(++)\t36.5\u00b0C\t\tSim\tSim\tSim\tN\u00e3o\t4.2\t\t4.9\t\t15.3\t16.3\t151\t\n(+)\t36.5\u00b0C\t13\tSim\tSim\tSim\tSim\t\t6.4\t\t5\t\t16.3\t\t201\n(++)\t36.5\u00b0C\t0\tSim\tSim\tSim\tSim\t3.1\t\t4.5\t\t12.7\t\t60\t\n\t36.5\u00b0C\tMais de 10\tSim\tSim\tSim\tN\u00e3o\t5\t6.5\t4.74\t4.67\t13\t14.3\t80\t157\n\t36.5\u00b0C\tMais de 10\tSim\tSim\tSim\tSim\t.6\t8.1\t5.28\t4.97\t15\t14.9\t95\t250\n(+)\t39\u00b0C\t\tSim\tSim\tSim\tSim\t6.8\t.4\t5.35\t5.6\t15.2\t17.3\t86\t150\n(++)\t38.5\u00b0C\t3\tSim\tSim\tSim\tSim\t6.3\t7.1\t4.89\t4.64\t14.1\t13.3\t155\t206\n\t\t10\t\t\t\t\t5\t7.8\t4.4\t4.55\t13\t13.7\t113\t243\n(++)\t\t10\t\t\t\t\t\t4.5\t\t4.83\t\t13.3\t\t98\n(++)\t36.4\u00b0C\t\tSim\tSim\tSim\tN\u00e3o\t4.2\t4.6\t4.3\t5.19\t12\t16\t192\t187\n(+)\t36\u00b0C\t\tSim\tSim\tSim\tSim\t5.7\t.3\t4.63\t4.41\t13.7\t13.3\t113\t243\n(+)\t36.4\u00b0C\t3\tSim\tSim\tSim\tSim\t4.7\t7.2\t4.89\t4.6\t14.9\t14.7\t68\t201\n(+)\t36.7\u00b0C\t1\tSim\tN\u00e3o\tN\u00e3o\tN\u00e3o\t4.2\t5.\t4.32\t4.81\t13.3\t13.6\t152\t226\n(+)\t37.3\u00b0C\t20\tSim\tSim\tSim\tN\u00e3o\t5.\t\t5.17\t\t14.1\t\t\t\n\t36.5\u00b0C\t1\tSim\tSim\tSim\tN\u00e3o\t5.3\t8\t4.09\t4.66\t12.7\t14.7\t218\t184\n(+)\t39\u00b0C\t1\tSim\tN\u00e3o\tSim\tN\u00e3o\t6.4\t4.7\t5.1\t5.46\t14.1\t13.5\t224\t300\n(+)\t37.4\u00b0C\t10\tN\u00e3o\tSim\tSim\tN\u00e3o\t6.3\t6.8\t4.81\t4.72\t13.4\t14.7\t191\t261\n(++)\t38\u00b0C\t3\tSim\tSim\tSim\tN\u00e3o\t6\t6.6\t5.06\t4.8\t14\t15.1\t214\t243\n(+)\t37.5\u00b0C\t20\tSim\tSim\tSim\tSim\t5.5\t7.3\t5.32\t4.58\t15\t14.6\t150\t297\n(+)\t38.8\u00b0C\t0\tSim\tSim\tSim\tN\u00e3o\t3.3\t5.4\t5.13\t4.74\t15.1\t14.1\t109\t170\n(+)\t\t2\tSim\tSim\tSim\tSim\t3.2\t\t4.69\t\t14\t\t150\t\n4.1.2\tDetermina\u00e7\u00e3o da parasitemia\nA determina\u00e7\u00e3o da parasitemia foi realizada por meio de gota espessa de sangue corado com Giemsa e a contagem, de acordo com o n\u00famero de cruzes preconizado pelo Minist\u00e9rio da Sa\u00fade18.\n4.1.3\tQuantifica\u00e7\u00e3o de imunocomplexos (ICs)\nOs ICs foram quantificados em soro de pacientes e doadores saud\u00e1veis, utilizando o kit imuno enzim\u00e1tico MicroVue CIC-Clq (Quidel, CA), de acordo com as recomenda\u00e7\u00f5es do fabricante. Este imunoensaio enzim\u00e1tico baseia-se\nno princ\u00edpio de que os ICs de amostras ir\u00e3o ligar-se a prote\u00edna humana purificada Clq aderida a placa. Primeiramente, cada padr\u00e3o e controle foi reconstitu\u00eddo com 2 mL de reagente hidratante por 15 minutos e as amostras de soro foram dilu\u00eddas 1:50 com diluente de amostras do complemento. Foram adicionados 300 uL de solu\u00e7\u00e3o de lavagem em cada po\u00e7o, revestido com Clq, da placa e incubado por 20 minutos \u00e0 temperatura ambiente. Ap\u00f3s o per\u00edodo de incuba\u00e7\u00e3o, o l\u00edquido foi removido e as amostras, padr\u00f5es e controles foram adicionados em seus respectivos po\u00e7os, seguido de uma incuba\u00e7\u00e3o de uma hora (no intuito de que os ICs possam se ligar ao Clq, formando complexos com os po\u00e7os do microensaio revestidos com Clq) \u00e0 temperatura ambiente. Posteriormente, a placa foi lavada cinco vezes com solu\u00e7\u00e3o de lavagem (fornecida pelo kit) e 50 uL do conjugado ICs-Clq (anti-IgG humana conjugada a peroxidase HRP) foram adicionados, seguido de uma incuba\u00e7\u00e3o por 30 minutos \u00e0 temperatura ambiente. O ciclo de lavagem foi repetido e adicionados 100 uL de solu\u00e7\u00e3o de substrato. O anticorpo conjugado a HRP reagiu com o substrato cromog\u00eanico formando uma cor verde. A placa foi incubada por 30 minutos e ap\u00f3s este per\u00edodo, a rea\u00e7\u00e3o foi parada com 50 uL de solu\u00e7\u00e3o de paragem. A leitura da densidade \u00f3tica foi feita a 405 nm em leitor de ELISA EIA Multi-Well Reader. Todas as amostras foram analisadas em duplicata. Os resultados foram obtidos por meio da curva padr\u00e3o e expressos como equivalentes de gamaglobulina humana t\u00e9rmicamente agregada por mL (^g Eq/mL).\n4.1.4\tELISA para anticorpos anti-DNA\nPlacas de 96 po\u00e7os Corning Inc. (NY, NY) foram sensibilizadas overnight a 37\u00b0C com 100 ^g/mL de DNA bovino, 25 ^L/po\u00e7o Sigma-Aldrich (St. Louis, MO), previamente filtrado, utilizando filtros 0,45 ^M Milipore (Alemanha) para remover fita simples de DNA. As placas foram bloqueadas com soro bovino fetal 3%, dilu\u00eddo em PBS (50 ^l/po\u00e7o), seguido pela incuba\u00e7\u00e3o de 25 ^l/po\u00e7o de amostras (dilu\u00eddas 1:50 para DNA de fita dupla e 1:100 para DNA de fita simples). Anticorpos anti-DNA fita dupla IgG+ e IgM+ foram detectados usando fosfatase alcalina e anticorpos marcados com anti-IgG ou anti- IgM humano respectivamente (dilui\u00e7\u00e3o 1:1000), Southern Biotechnology (Birmingham, AL). As placas foram lavadas com PBS-tween 0,05% entre incuba\u00e7\u00f5es. Foram adicionados 50 ^l/po\u00e7o de substrato (Sigma-Aldrich, St. Louis, MO) e a leitura foi feita em 405 nm, usando o leitor de placa Victor (Perkin Elmer, Waltham, MA). Todas as incuba\u00e7\u00f5es foram feitas a 37\u00b0C, por uma hora e 30 minutos. Para a determina\u00e7\u00e3o de anticorpos anti-DNA de fita simples, placas foram sensibilizadas com 25 ^g/mL de DNA de fita simples.\n4.1.5\tELISA para ant\u00edgeno espec\u00edfico\nOs n\u00edveis de IgG e IgM ant\u00edgeno espec\u00edfico foram determinados por ELISA. Placas NUNC\u00ae Maxisorp foram sensibilizadas overnight a 37\u00b0C com ant\u00edgeno espec\u00edfico AMA-1 (do ingl\u00eas, Apical Merozoite Antigen-1) 1 ^g/mL em PBS. Ap\u00f3s incuba\u00e7\u00e3o, as placas foram lavadas com tamp\u00e3o de lavagem PBS-Tween 0.01% (PBS-T) e bloqueadas com leite desnatado (Molico, lote: 5087046031 0754) a 5% em PBS-T por uma hora a 37\u00b0C. Ap\u00f3s ciclos de cinco lavagens com PBS-T, as amostras de plasma foram dilu\u00eddas em leite 3% (1:50 IgG e 1:30 IgM), adicionadas em duplicata aos po\u00e7os e incubadas por uma hora a 37\u00b0C. Um novo ciclo de\nlavagens foi realizado, adicionando-se o conjugado biotinilado anti-lgG ou anti-lgM humano dilu\u00eddo em leite desnatado 3%. Ap\u00f3s incuba\u00e7\u00e3o por uma hora a 37\u00b0C, as placas foram lavadas e adicionou-se streptavidina dilu\u00edda 3 mil vezes e, ap\u00f3s mais uma incuba\u00e7\u00e3o de uma hora, 100 uL da solu\u00e7\u00e3o cromog\u00eanica (TMB+H2O2) pronta para o uso. A rea\u00e7\u00e3o enzim\u00e1tica foi interrompida ap\u00f3s 20 minutos com a adi\u00e7\u00e3o de 50 uL de H2SO4 e a leitura foi realizada em leitor de ELISA EIA Multi-Well Reader a 450 nm.\n4.1.6\tPurifica\u00e7\u00e3o de ICs\nICs foram purificados de plasma de indiv\u00edduos por meio do kit de prote\u00edna A (Affi-Gel MAPS II). Todos os procedimentos foram feitos na capela de fluxo laminar, em temperatura ambiente. As amostras de plasma foram descongeladas (1 mL), homogeneizadas e dilu\u00eddas 1:1, usando um tamp\u00e3o filtrado de liga\u00e7\u00e3o pH= 9,0 (fornecido pelo kit Affi-Gel MAPS II). Numa coluna (Econo-Column chromatography -1 x 10 cm) foi inserido 1 mL de prote\u00edna A agarose Affi-Gel e equilibrada com cinco volumes de tamp\u00e3o de liga\u00e7\u00e3o. A amostra dilu\u00edda foi aplicada na coluna e lavada duas vezes com 15 volumes de tamp\u00e3o de liga\u00e7\u00e3o. IgGs foram elu\u00eddas com cinco volumes de tamp\u00e3o de elui\u00e7\u00e3o pH= 3,0 (fornecido pelo kit) e rapidamente neutralizadas com 1 M trizma base pH= 9,0. A quantifica\u00e7\u00e3o da prote\u00edna foi feita atrav\u00e9s de espectrofotometria. A concentra\u00e7\u00e3o foi determinada levando-se em conta que 1 mg/mL produz absorv\u00e2ncia a 280 nm.\n4.1.7\tExtra\u00e7\u00e3o de DNA\ncada tubo falcon (Corning Inc, NY, NY) foram adicionados 800 uL de Buffer ACL e 100 uL de proteinase K do kit. Ap\u00f3s homogeneiza\u00e7\u00e3o por 30 segundos em vortex, as amostras foram incubadas em banho maria a 60\u00b0C, durante 30 minutos. Ap\u00f3s esse per\u00edodo, adicionaram-se a cada tubo 1,8 mL de Buffer ACB (fornecido pela QIAgen, Holanda), seguido de uma homogeneiza\u00e7\u00e3o e incuba\u00e7\u00e3o por cinco minutos no gelo. A solu\u00e7\u00e3o resultante foi transferida para o dispositivo da coluna QIAamp DNA e passada por meio de v\u00e1cuo. O dispositivo com a coluna foi removido do tubo e recolocado em um novo tubo. Foram adicionados 600 uL de Buffer ACW ao dispositivo com a coluna, que foram passados a v\u00e1cuo novamente. O procedimento foi repetido com 750 uL de Buffer ACW 2. Em seguida, foram adicionados 200 uL de etanol absoluto (Milipore, Alemanha) e o procedimento foi realizado pela \u00faltima vez. A coluna foi centrifugada a 20.000 g por tr\u00eas minutos para que o excesso de etanol fosse retirado. Posteriormente, a coluna foi colocada no termobloco (Eppendorff, Alemanha) a 56\u00b0 C por 10 minutos. O DNA extra\u00eddo da coluna foi elu\u00eddo pela adi\u00e7\u00e3o de 80 uL de Buffer AE (fornecido pelo fabricante) em uma centrifuga\u00e7\u00e3o de 20.000 g por um minuto. A quantidade e a pureza do DNA foram determinadas por densidade \u00f3ptica em espectrofot\u00f4metro (NanoDrop\u00ae ND-1000 UV-Vis). As leituras a 260 nm e 280 nm, respectivamente, serviram como par\u00e1metro na estimativa do grau de contamina\u00e7\u00e3o do \u00e1cido nucl\u00e9ico com prote\u00ednas. Os valores considerados satisfat\u00f3rios foram aqueles entre 1,8 a 2,0. As amostras foram armazenadas a -20\u00b0C.\n4.1.8\tPCR em Tempo Real\nespec\u00edfica de sequ\u00eancia do gene SSUrRNA (18S do rRNA). Os oligonucleotideos utilizados na rea\u00e7\u00e3o de PCR est\u00e3o presentes no quadro 3. As rea\u00e7\u00f5es de PCR foram realizadas em triplicata, incluindo controles negativos, em placas de 96 po\u00e7os usando o reagente SYBR-Green PCR Master Mix (Applied Biosystems, Foster City, CA USA), equipamento 7500 rfv e analisadas no software 7500 v2.0.5. 1 de DNA foi adicionado \u00e0 mistura de PCR contendo 0,15 ^L de cada oligonucleotideo (100 ^M) CCND ou P. vivax e 10 p,L Sybr green PCR Core Reagents (Applied Biosystems). O volume foi completado para 20 ^L com \u00e1gua destilada est\u00e9ril. Foi realizada uma desnatura\u00e7\u00e3o inicial a 95o C por 10 minutos, seguido de 40 ciclos (95OC por 15 segundos, 60oC por 60 segundos) e uma extens\u00e3o final a 60oC por um minuto. Uma curva padr\u00e3o foi constru\u00edda por meio de dilui\u00e7\u00f5es entre 101 to 107 em triplicata.\nQuadro 3. Oligonucleot\u00eddeos utilizados nas rea\u00e7\u00f5es de PCR para detec\u00e7\u00e3o dos genes CCND humano e ribossomal do Plasmodium esp\u00e9cie espec\u00edfica\nOligonucleot\u00eddeos\tFoward (5'\t3')\tReverse (5'\t3')\nCCND\tGCTCCTGGTGAACAAGCTCAA\tTTG GAGAGGAAGTG TTCAATGAAA\nP. vivax\tACGATCAGATACCGTCGTCGTAAT\tCAATCTAAGAATAAACTCCGAAGAGAAA\nP. falciparum\tTTAAACTGGTTTGAACCAAATATAT T\tACACAATGAACTTATGACTACCCGTC\n4.1.9\tObten\u00e7\u00e3o das c\u00e9lulas mononucleares do sangue perif\u00e9rico (CMSPs) e prepara\u00e7\u00e3o de mon\u00f3citos humanos\nCerca de 100 mL de sangue heparinizado de pacientes ou doadores saud\u00e1veis foi coletado em tubos de coleta a v\u00e1cuo e heparinizados. O material foi dilu\u00eddo 1:1 em solu\u00e7\u00e3o salina (PBS). A seguir, 15 mL de Ficoll-Paque (densidade 1,078 g/mL) (GE-Healthcare) foram depositados no fundo do tubo (Falcon), e o\nmaterial dilu\u00eddo com PBS (15 mL) foi lentamente sobreposto acima do Ficoll-Paque. Os tubos foram centrifugados por 15 minutos a 800 x g, \u00e0 temperatura ambiente. A interface de c\u00e9lulas mononucleares foi obtida, lavada duas vezes com meio RPMI (Gibco, CA) completo, contendo penicilina (100 UI/mL), streptomicina (100 ^g/mL) e 10% soro fetal bovino Gibco (Carlsbad, CA) por cinco minutos a 1800rpm, \u00e0 temperatura ambiente. Ap\u00f3s a centrifuga\u00e7\u00e3o, o sedimento obtido foi dilu\u00eddo em 1 mL de meio RPMI, as c\u00e9lulas foram contadas em c\u00e2mara de Neubauer e adicionadas na concentra\u00e7\u00e3o de 3 x 105 CMSPs por po\u00e7o, em placas de 96 po\u00e7os. As culturas de c\u00e9lulas foram incubadas em estufa (Thermo, MA) a 37\u00b0C em atmosfera de 5% CO2. As c\u00e9lulas foram sensibilizadas ou n\u00e3o com IFNy (200 ng/ml) (BD) overnight e posteriormente, estimuladas com ICs (15-120 ^g) ou LPS (100 ng/mL) por 24 horas. Em alguns experimentos, as c\u00e9lulas foram tratadas com o composto E6446, antagonista de TLR7/9 (dois e 20 micro molar) ou E5564, antagonista de TLR4 (3 ^g/ml) por tr\u00eas horas antes do est\u00edmulo com ICs. C\u00e9lulas CD14+ foram purificadas por meio do kit EasySep, sele\u00e7\u00e3o negativa para c\u00e9lulas humanas, de acordo com o protocolo do fabricante Stemcell (Canada), marcadas com anti-CD14 (APC, clone: 61D3, e-Bioscience) (San Diego, CA) e anti-CD16 (PE, clone: 3G8, BD) (Franklin Lakes, NJ) e a pureza foi verificada por citometria de fluxo Fortessa (BD) e analisadas com o software FlowJo vers\u00e3o 10.0.8.\n4.1.10\tDetec\u00e7\u00e3o de citocinas\nOs n\u00edveis de TNFa, IL-1 p e IL-10 humano foram avaliados em sobrenadantes de CMSPs, ap\u00f3s 24 horas de est\u00edmulo com ICs em cultura. Os sobrenadantes foram armazenados a - 20\u00b0C at\u00e9 o momento do uso. O kit cytometric beads array CBA (BD Becton-Dickinson, cat: 560485) foi usado nesse estudo para a quantifica\u00e7\u00e3o de\ncitocinas em uma mesma amostra. Popula\u00e7\u00f5es de esferas com distintos tamanhos s\u00e3o conjugadas com um anticorpo de captura espec\u00edfico para cada citocina. As esferas foram misturadas para formar o CBA e lidas nos canais FL3 e FL2 do cit\u00f4metro de fluxo FACScan (BD). As popula\u00e7\u00f5es de esferas foram visualizadas de acordo com as suas respectivas intensidades de fluoresc\u00eancia: da menos brilhante para a mais brilhante. No CBA, as esferas de captura das citocinas s\u00e3o misturadas com o anticorpo de detec\u00e7\u00e3o conjugado com o fluorocromo PE, e depois incubadas com as amostras para formar o ensaio \"sandu\u00edche\". As placas para aquisi\u00e7\u00e3o foram preparadas com: 25 uL de amostra, 25 uL da mistura de esferas e 14 uL do reagente de detec\u00e7\u00e3o PE (Cytokine PE Detection Reagent /1 vial, 4 mL). O mesmo procedimento foi realizado para a obten\u00e7\u00e3o da curva-padr\u00e3o. As placas foram homogeneizadas e incubadas por duas horas, em temperatura ambiente, protegido da luz. A seguir, as amostras foram transferidas das placas para tubos de citometria de fluxo. Os resultados foram gerados em gr\u00e1ficos e tabelas utilizando-se o software FCAP vers\u00e3o 3.0 (BD).\nOs n\u00edveis de IL-ip tamb\u00e9m foram determinados por ELISA (R&amp;D System). Placas NUNC\u00ae Maxisorp foram sensibilizadas overnight com anticorpo anti-ILip (200 ng/mL) dilu\u00eddo em PBS 1% BSA. Ap\u00f3s incuba\u00e7\u00e3o overnight em temperatura ambiente, as placas foram lavadas com tamp\u00e3o de lavagem PBS-Tween 0.01% (PBS-T) e bloqueadas com 200 uL de leite desnatado (Moli\u00e7o, lote: 5087046031 0754) a 5% em PBS-T por duas horas a 37\u00b0C. Ap\u00f3s um ciclos de quatro lavagens com PBS-T, os sobrenadantes foram adicionados em duplicata aos po\u00e7os e incubados overnight a 4\u00b0C. Um novo ciclo de lavagens foi realizado, adicionando-se o conjugado anti-IgG humano dilu\u00eddo \u00e0 PBS-T. Ap\u00f3s incuba\u00e7\u00e3o por uma hora a 37\u00b0C as placas foram lavadas e adicionou-se 100 uL da solu\u00e7\u00e3o cromog\u00eanica\n(TMB+H2O2) pronta para o uso. A rea\u00e7\u00e3o enzim\u00e1tica foi interrompida ap\u00f3s 15 minutos com a adi\u00e7\u00e3o de 50 de H2SO4 e a leitura foi realizada em leitor de ELISA EIA Multi-Well Reader a 450 nm.\n4.1.11\tWestern blot para caspase-1\nPara as an\u00e1lises por Western blot, foi adicionado 250 ^L de inibidor de protease Ripa (Sigma Aldrich, St. Louis, MO) acrescido do tamp\u00e3o de lise complete (Roche, Sui\u00e7a), conforme o fabricante, ao precipitado contendo 1 x 106 de CMSPs estimulados com ICs por 24 horas, a 37\u00b0C em atmosfera de 5% CO2. Ap\u00f3s 15 minutos no gelo, os lisados foram centrifugados a 13,000 g por 20 minutos a 4\u00b0C. Foi adicionado o tamp\u00e3o de amostra (dilu\u00eddo 1:5 em amostra) e aquecidas a 99\u00b0C por 10 minutos. Os sobrenadantes foram separados em um gel de acrilamida 15% SDS-PAGE a 100-150v e transferidos para membranas de nitrocelulose a 300 mA por duas horas, com todo o sistema no gelo. Foi adicionado a solu\u00e7\u00e3o de bloqueio (TBS tween 0,05%) com leite desnatado \u00e0 5% e incubado por uma hora em agita\u00e7\u00e3o. As membranas foram incubadas com anticorpo prim\u00e1rio (anti-caspase-1) dilu\u00eddo em TBS tween 0,05% com leite desnatado \u00e0 5% overnight a 4\u00b0C. Ap\u00f3s o per\u00edodo de incuba\u00e7\u00e3o, a membrana foi lavada tr\u00eas vezes por cinco minutos com PBS tween e o anticorpo secund\u00e1rio dilu\u00eddo em PBS tween 0,05% e leite desnatado \u00e0 5% foi adicionado e incubado por uma hora em agita\u00e7\u00e3o. Posteriormente a membrana foi reveladas com o anticorpo conjugado com HRP e ECL (Bucks, UK).\n4.1.12\tImunofluoresc\u00eancia com microscopia confocal\npositivos, foram utilizados est\u00edmulos com LPS (100 ng/mL) por tr\u00eas horas seguido de hemozo\u00edna sint\u00e9tica (150 ^g) por quatro horas e meia ou LPS (100 ng/ml) por tr\u00eas horas seguido de nigericina (10 ^M) por 30 minutos ou meio como controle negativo. Ap\u00f3s o per\u00edodo de est\u00edmulo, o sobrenadante foi coletado e as c\u00e9lulas foram lavadas com PBS. Posteriormente, o paraformalde\u00eddo 4% foi adicionado e as c\u00e9lulas foram fixadas numa incuba\u00e7\u00e3o de 20 minutos. Em seguida, as c\u00e9lulas foram lavadas com PBS e permeabilizadas com tamp\u00e3o de permeabiliza\u00e7\u00e3o (PBS + 0,3% Trit\u00f3n) por 20 minutos. O sobrenadante foi descartado e o tamp\u00e3o de incuba\u00e7\u00e3o (PBS + 3% SBF + 0,1% Trit\u00f3n) foi adicionado e incubado por mais 20 minutos. As c\u00e9lulas foram lavadas uma vez mais com o tamp\u00e3o de incuba\u00e7\u00e3o.\nAs imunofluoresc\u00eancias para os marcadores ASC, NLRP12, NLRP3, NLRC4 e AIM2 foram realizadas em mon\u00f3citos purificados e preparadas em l\u00e1minas. Os anticorpos e suas especifica\u00e7\u00f5es est\u00e3o mostrados na quadro 4.\nQuadro 4. Especifica\u00e7\u00f5es dos anticorpos utilizados no ensaio de imunofluoresc\u00eancia com microscopia confocal\nAnticorpos\tFluorocromo\tEspecifica\u00e7\u00f5es/Isotipo\tDilui\u00e7\u00e3o\nASC (Santa Cruz Biotechnology - SC-22514-R)\tN/C\tAnti-camundongo IgG\t1:350\nNLRP3 (Abeam - ab4207)\tN/C\tAnti-camundongo IgG\t1:350\nNLRP12 (Abeam - ab64928)\tN/C\tAnti-camundongo IgG\t1:350\nNLRC4 (Abeam - ab99860)\tN/C\tAnti-coelho IgG\t1:300\nAIM2 (Abeam - ab93015)\tN/C\tAnti-coelho IgG\t1:350\nTexas Red (Abeam - ab6800)\tA/S\tAnti-coelho IgG\t1:10.000\nTexas Red (Abeam - ab6883)\tA/S\tAnti-cabra IgG\t1:10.000\nFITC (Abeam - ab7057)\tA/S\tAnti-camundongo IgG\t1:30.000\nAs rea\u00e7\u00f5es de imunofluoresc\u00eancia foram feitas em mon\u00f3citos purificados e preparados como descrito previamente. Foram adicionados os anticorpos prim\u00e1rios, dilu\u00eddos em PBS, em volume final de 400 ^L. As c\u00e9lulas foram incubadas overnight a 40C e protegidas da luz. Foram realizadas tr\u00eas lavagens de 10 minutos em PBS e o anticorpo secund\u00e1rio foi adicionado. Ap\u00f3s uma hora de incuba\u00e7\u00e3o, foram realizadas tr\u00eas lavagens de 10 minutos com PBS e secagem das l\u00e2minas. As l\u00e2minas foram montadas com solu\u00e7\u00e3o de montagem (90% glicerol + 10% Tris HCL 1M) e armazenadas a 4oC, protegidas da luz por no m\u00e1ximo 48 horas, at\u00e9 que fosse realizada a aquisi\u00e7\u00e3o das imagens. Em l\u00e2minas separadas para cada est\u00edmulo, foram realizadas incuba\u00e7\u00f5es somente com anticorpos secund\u00e1rios, para descartar marca\u00e7\u00f5es inespec\u00edficas.\nAs imagens foram obtidas por microscopia confocal (Bio-Rad MRC 1024 laser scanning confcal) utilizando o programa Lasersharp 3.0, acoplado a um Microsc\u00f3pio Confocal Zeiss LSM 510, com objetiva de imers\u00e3o em oleo (63X). A luz emitida foi selecionada utilizando filtros 522/35 para FITC e 568 para Texas Red. Para visualizar as imagens de campo claro, utilizamos os filtros para a visualiza\u00e7\u00e3o do fluorocromo conjugado ao anticorpo utilizado.\nO processamento e an\u00e1lise das imagens foram realizados utilizando o programa ImageJ software. Foram capturados m\u00faltiplos campos para cada l\u00e2mina, utilizando-se comprimentos de onda espec\u00edficos para cada fluorocromo. A an\u00e1lise da express\u00e3o de cada marcador baseou-se na identifica\u00e7\u00e3o de cada fluorescencia FITC, Texas Red nos mon\u00f3citos purificados e estimulados. Para todas as amostras foram obtidas imagens de campo escuro e claro.\n4.1.13\tDetec\u00e7\u00e3o de mRNA e an\u00e1lise de express\u00e3o g\u00eanica por Nanostring (Nanostring Technologies)\nPara o experimento de express\u00e3o g\u00eanica, foram utilizados mon\u00f3citos purificados de doadores saud\u00e1veis estimulados com 60 ^g/mL de ICs por seis horas. As an\u00e1lises de express\u00e3o de mRNA foram realizadas atrav\u00e9s da metodologia do Nanostring Technologies que consiste em uma rea\u00e7\u00e3o n\u00e3o enzim\u00e1tica utilizando c\u00f3digos de barras de sondas fluorescentes (GEISS et al., 2008). Conjuntos de c\u00f3digos foram desenhados para detectar genes relacionados a resposta imune. Um total de IxIO4 c\u00e9lulas foram lisadas com tamp\u00e3o RLT (Qiagen) suplementado com p-Mercaptoetanol, e em seguida congeladas no freezer -80oC. Posteriormente, os lisados celulares, de tr\u00eas animais por grupo, foram hibridizados com sondas rep\u00f3rter e de captura por 16 horas a 65OC e depois foram colocados em uma plataforma onde ocorre a separa\u00e7\u00e3o magn\u00e9tica das sondas hibridizadas, lavagem para remover excessos de sondas e imobiliza\u00e7\u00e3o destas nos cartuchos. Por fim, a quantifica\u00e7\u00e3o foi realizada no analisador digital utilizando 600 campos para detec\u00e7\u00e3o das sondas hibridizadas.\nA an\u00e1lise dos dados gerados foi realizada utilizando um software do programa (nSolver). Estas an\u00e1lises consistem na normaliza\u00e7\u00e3o dos controles positivos para detectar pequenas varia\u00e7\u00f5es entre diferentes codesets, seguido de normaliza\u00e7\u00e3o com sete genes constitutivos, inclusos nos codesets, para avaliar diferen\u00e7as entre as amostras. A normaliza\u00e7\u00e3o foi feita com 14 genes constitutivos (housekeeping genes). Resultados normalizados foram representados como n\u00edveis relativos de mRNA. O aumento foi definido pela rela\u00e7\u00e3o do n\u00famero de c\u00f3pias de animais infectados por n\u00e3o infectados. Os heatmaps foram constru\u00eddos utilizando o programa\nMulti Experiment Viewer v 4.8. Diferen\u00e7as de express\u00e3o g\u00eanica foram consideradas estatisticamente significativas com p &lt;0,05 utilizando o teste t n\u00e3o pareado.\n4.1.14\tAn\u00e1lise estat\u00edstica\nTodas as an\u00e1lises estat\u00edsticas foram realizadas no programa Prism (GraphPad 6). Compara\u00e7\u00f5es entre dois grupos foram feitas pelo teste t student pareado ou n\u00e3o. Mann-Whitney teste foi usado para a an\u00e1lise n\u00e3o param\u00e9trica quando os dados n\u00e3o se encaixavam na distribui\u00e7\u00e3o Gaussiana. A compara\u00e7\u00e3o entre grupos experimentais foi feita utilizando-se o teste ANOVA (do ingl\u00eas, analysis of variance), seguida por an\u00e1lise de compara\u00e7\u00f5es m\u00faltiplas, segundo o m\u00e9todo de Tukey.!\n4.2\tNo modelo murino da mal\u00e1ria cerebral\n4.2.1\tAnimais\nForam utilizados camundongos f\u00eameas, com idade entre oito a 12 semanas, pesando de 20 a 28 g. Animais C57BL/6 foram fornecidos pelo biot\u00e9rio da Universidade Federal de Minas Gerais e pelos laborat\u00f3rios Jackson. Animais REX3 e REX3 IFNyR-/- foram desenvolvidos pelo Dr. Andrew D. Luster no Massachusetts General Hospital. Camundongos Great (IFNy GFP-reporter), CCR2-/-, CCR5-/- e IFNy-/- foram comprados dos laborat\u00f3rios Jackson e mantidos no biot\u00e9rio da Fiocruz. Durante todos os procedimentos, os animais foram acondicionados em microisoladores coletivos autoclavados, contendo no m\u00e1ximo cinco animais por microisolador, \u00e0 temperatura constante de 22\u00b0C, com suprimentos de \u00e1gua e alimento, alojados na Funda\u00e7\u00e3o Oswaldo Cruz ou Massachusetts General Hospital. Todas as pr\u00e1ticas utilizadas com animais foram aprovadas pelo MGH Subcommittee\non Research and Animal Care and Harvard Committee on Microbiological Safety (IACUC# 2005N000176); e pela Comiss\u00e3o de \u00c9tica para Experimenta\u00e7\u00e3o Animal da Fiocruz (CEUA# LW 15-14).\n4.2.2\tInfec\u00e7\u00e3o\nOs parasitos, conservados em nitrog\u00eanio l\u00edquido, foram descongelados e mantidos em camundongos C57BL/6 por at\u00e9 10 passagens. Para infec\u00e7\u00f5es experimentais, hem\u00e1cias infectadas com PbA foram coletadas dos animais com\n5\ntubos heparinizados e 1x105 hem\u00e1cias infectadas foram injetadas i.p. em animais na\u00edve. Estes animais foram observados diariamente e a parasitemia foi feita por meio de colora\u00e7\u00e3o com Giemsa em esfrega\u00e7os sangu\u00edneos. Sinais e sintomas de mal\u00e1ria cerebral foram observados por dois indiv\u00edduos usando par\u00e2metros como: arrepio, postura curvada, perda de reflexo, perda de equil\u00edbrio, coma e convuls\u00f5es. Animais que demonstraram defici\u00eancia nos par\u00e2metros ou morreram entre os dias sete e 12 ap\u00f3s infec\u00e7\u00e3o foram considerados como tendo MCE.\n4.2.3\tCitometria de Fluxo\nC\u00e9rebro de animais foram removidos ap\u00f3s perfus\u00e3o intracard\u00edaca com 30 mL de PBS, macerados e as c\u00e9lulas passadas por um filtro de 70 um e centrifugadas em percoll 45% por 30 min a 800 x g. O precipitado foi lavado e dilu\u00eddo 1:1 em PBS. Tais c\u00e9lulas foram contadas em uma c\u00e2mara de Neubauer e marcadas para a citometria de fluxo. Os ba\u00e7os foram removidos e macerados. As c\u00e9lulas foram passadas por um filtro de 70 ^m, as hem\u00e1cias foram lisadas com tamp\u00e3o de lise e os esplen\u00f3citos foram contados usando a c\u00e2mara de Neubauer. Para a citometria de fluxo, as c\u00e9lulas foram marcadas por 20 minutos em temperatura ambiente, com anticorpos\nespec\u00edficos para camundongos: CD11b (PE-Cy7, clone: M1/70, e-Bioscience), F4/80 (PE-Cy5, clone: BM8, e-Bioscience), CD11c (Alexa 700, clone: N418, e-Bioscience), MHC II (PE, clone: AF6-120.1, BD), DC-SIGN (APC e-fluor 660, clone: MMD3, eBioscience), Ly6C (e-fluor 450, clone: HK1.4, e-Biosciences), CD8 (APC Cy7, clone: 53-6.7, Biolegend) or (PerCP-Cy 5.5, clone: 53-6.7, e-Bioscience), CD3 (Percep Cy5.5, clone: 145-2C11, e-Bioscience), CD45 (V500, clone: 30-F11, BD), CD62L (PE-Cy7, clone: MEL-14, BD), CD44 (Pacific Blue, clone: IM7, Biolegend) CD4 (APC, clone: RM4-5, Biolegend), CD80 (FITC, clone: 16-10A1, BD), CD86 (FITC, clone: GL1, BD). Em animais REX3, a fluoresc\u00eancia end\u00f3gena RFP (CXCL9) e BFP (CXCL10) foram lidas em canais PE e Pacific Blue respectivamente. A citometria foi feita por meio do cit\u00f4metro Fortessa (Becton-Dickinson) e analisada com o software FlowJo vers\u00e3o 10.0.8.\n4.2.4 Ensaio de fagocitose por citometria de fluxo. Sangue (2 mL) de animais controles e infectados com PbA-GFP foi coletado em tubos heparinizados. A purifica\u00e7\u00e3o de hem\u00e1cias infectadas foi realizada de acordo com o manual do fabricante, utitilizando um kit de sele\u00e7\u00e3o positiva (Miltenyi Biotec, Bergisch Gladbach, DE). Hem\u00e1cias n\u00e3o infectadas foram utilizadas como controle negativo. A pureza foi determinada pela colora\u00e7\u00e3o Giemsa por meio de esfrega\u00e7os sangu\u00edneos.\n5\nEsplen\u00f3citos totais (5x105) de animais infectados (sexto dia) e controles foram 55\nincubados com hem\u00e1cias infectadas (5x105) ou n\u00e3o infectadas (5x105) por uma hora a 37\u00b0C (1:1). As c\u00e9lulas foram lavadas e marcadas com anticorpos espec\u00edficos para camundongos CD11b (PECy7, clone: M1/70, e-Bioscience), F4/80 (PE-Cy5, clone: BM8, e-Bioscience), CD11c (Alexa 700, clone: N418, e-Bioscience), MHC II (PE, clone: AF6-120, BD), DC-SIGN (APC e-fluor 660, clone: MMD3, e-Bioscience) e\nLy6C (e-fluor 450, clone: HK1.4, e-Bioscience) por 20 minutos a temperatura ambiente. A citometria de fluxo foi realizada usando o cit\u00f4metro Fortessa (Becton-Dickinson) e analizada utilizando o software FlowJo vers\u00e3o 10.0.8.\n4.2.5\tPurifica\u00e7\u00e3o por citometria\nBa\u00e7os de animais infectados C57BL/6 e IFNy-/- (sete dias ap\u00f3s infec\u00e7\u00e3o) foram coletados, macerados e os esplen\u00f3citos marcados com CDIIb (PE-Cy7, clone: MI/70, e-Bioscience), F4/80 (PE-Cy5, clone: BM8, e-Bioscience), CDIIc (Alexa 700, clone:N418, e-Bioscience), MHC II (PE, clone:AF6-120.1, BD), DC-SIGN (APC efluor 660, clone: N418, e-Bioscience) e submetidos a purifica\u00e7\u00e3o usando cell sorting ARIA (BD). Primeiramente, foi feito uma janela na popula\u00e7\u00e3o FSC-H/FSC-A, a fim de se excluir grumos celulares. Em seguida, uma janela na popula\u00e7\u00e3o duplo positiva para CD11b/F4/80 foi realizada e posteriormente, na popula\u00e7\u00e3o MHCII/DC-SIGNhigh. A separa\u00e7\u00e3o foi realizada de acordo com as popula\u00e7\u00f5es selecionadas anteriormente e as c\u00e9lulas foram coletadas em um novo tubo. As c\u00e9lulas purificadas foram confirmadas quanto a express\u00e3o de CD11c+ e ent\u00e3o congeladas em al\u00edquotas de 10 mil c\u00e9lulas para an\u00e1lise de express\u00e3o g\u00eanica usando a tecnologia Nanostring ou submetido a citospin para an\u00e1lise morfol\u00f3gica ou preparadas para microscopia eletronica de varredura.\n4.2.6\tMicroscopia eletr\u00f4nica de varredura\nAp\u00f3s a purifica\u00e7\u00e3o celular por citometria, MO-DCs foram fixadas em tamp\u00e3o 2.5% glutaldeido, 0.1 M, pH= 7.2, por seis horas, a 8\u00b0C. As c\u00e9lulas foram lavadas com a mesma solu\u00e7\u00e3o e fixadas numa mistura de 1% tetr\u00f3xido de \u00f3smio e 1.5% (p/v) ferrocianeto de pot\u00e1ssio, desidratadas gradualmente em etanol e embebecidas\nem Araldite 502. Os cortes foram corados com 2% acetato de uranila e citrato e a an\u00e1lise foi realizada usando um microsc\u00f3pio eletr\u00f4nico de varredura. (DSM 960 A).\n4.2.7\tConfocal\nBa\u00e7os foram coletados em tamp\u00e3o PLP (0.05 M tamp\u00e3o fosfato contendo 0.2 M L-lisina (pH= 7.4), 2 mg/mL NalO4 10 mg/mL paraformalde\u00eddo), fixado por cinco a 12 horas e desidratado em 30% sacarose e posteriormente embebido em OCT meio de congelamento (Sakura Fineteck). Cortes de 10 mm de tecido congelado foi feito em criostato (CM3050S, Leica). Estes cortes foram secos por duas horas, fixados com acetona por 10 minutos, reidratados, fixados com solu\u00e7\u00e3o de c\u00e1lcio-formalde\u00eddo e lavados com PBS. Em seguida, os cortes foram bloqueados com PBS contendo American Hamster ou Rat gamma globulina (100 ^g/mL), marcados com F4/80 (APC, clone: BM8, e-Bioscience) ou CDIIc (APC, clone: N418, e-Bioscience) e embebidos em solu\u00e7\u00e3o fixadora que evita foto degrada\u00e7\u00e3o. As imagens foram adquiridas em um microsc\u00f3pio confocal LSM510 (Carl Zeiss Mircoimaging).\n4.2.8\tMigra\u00e7\u00e3o de DCs enriquecidas\nEsplen\u00f3citos CD11b+CD11c+ de animais controles e infectados (seis dias ap\u00f3s infec\u00e7\u00e3o) foram purificados usando o kit de sele\u00e7\u00e3o positiva de acordo com o protocolo do fabricante (Miltenyi Biotec, Bergisch Gladbach, DE). As c\u00e9lulas foram marcadas com anti-CDIIb (PE-Cy7, clone: M1/70, e-Bioscience) e anti-CDIIc (Alexa 700, clone: N418, e-Bioscience), e a pureza avaliada por citometria de fluxo. C\u00e9lulas CD11b+CD11c+ foram resuspendidas 1x105 c\u00e9lulas/mL em meio RPMI completo (10% SBF). Para avaliar a capacidade migrat\u00f3ria de MO-DCs, foi utilizado uma placa transwell de 12 po\u00e7os (Corning, Amboise, FR) com membrana contendo\nporos de 5 um que evita a difus\u00e3o passiva, contudo permite a migra\u00e7\u00e3o ativa de DCs. Para cada condi\u00e7\u00e3o testada, c\u00e1maras inferiores do transwell foram preenchidas com 600 uL ou mais 0.1, 1 ou 10 ng/mL de CCL2 (Biolegend) ou/e CCL5 (e-Bioscience). As DCs (IxIO5 em lOO^L) foram depositadas na c\u00e1mara superior do transwell e a placa foi incubada por tr\u00eas horas a 37\u00b0C. As DCs que migraram foram coletadas da c\u00e1mara inferior e contadas por meio de uma c\u00e1mara de Neubauer. A contagem foi realizada duas vezes para avaliar a confiabilidade do m\u00e9todo. N\u00e3o foi encontrada varia\u00e7\u00e3o acima de 10% entre as duas contagens.\n4.2.9\tDetec\u00e7\u00e3o de citocina\nOs n\u00edveis de IFNy foram avaliados em soro de animais controle e infectados, em determinados dias ap\u00f3s a infec\u00e7\u00e3o. Os soros foram armazenados a -20\u00b0C at\u00e9 o momento do uso. O kit Cytometric Beads Array (CBA) (BD) foi usado nesse estudo para a quantifica\u00e7\u00e3o das citocinas em uma mesma amostra, como descrito anteriormente. Os resultados foram gerados em gr\u00e1ficos e tabelas utilizando-se o software FCAP vers\u00e3o 3.0 (BD).\n4.2.10\tExtra\u00e7\u00e3o de RNA\nBa\u00e7o e c\u00e9rebro de animais controle e infectado foram removidos ap\u00f3s perfus\u00e3o intracard\u00edaca com 50 mL de PBS est\u00e9ril. Foi adicionado 1 mL do reagente Trizol (mantido a 4\u00b0C) aos tecidos e, com aux\u00edlio de um macerador de tecidos, homogeneizou-se durante um min. Logo ap\u00f3s, as amostras foram mantidas por cinco minutos a temperatura ambiente para permitir a completa dissocia\u00e7\u00e3o dos complexos de nucleoprote\u00ednas. Foram adicionados 200 uL de clorof\u00f3rmio (1:5 v/v clorof\u00f3rmio; Trizol), homogeneizou-se por 15 segundos em equipamento tipo vortex\ne as amostras foram incubadas por tr\u00eas minutos em temperatura ambiente. Em seguida, as amostras foram centrifugadas a 12.000 g por 15 minutos a 4\u00b0C e o sobrenadante (fase aquosa) foi transferido para um novo tubo de 2 mL (o RNA total encontra-se exclusivamente nessa fase). Para a precipita\u00e7\u00e3o do RNA foram adicionados 500 uL de isopropanol (mantido a -20\u00b0C) (1:2 v/v, isopropanol e Trizol utilizado no inicio). Os tubos foram agitados cuidadosamente, por invers\u00e3o, durante dois minutos e mantidos a temperatura ambiente por 10 minutos. Ap\u00f3s este procedimento, as amostras foram centrifugadas a 12.000 g por 10 minutos a 4\u00b0C e o RNA precipitado, at\u00e9 ent\u00e3o invis\u00edvel, formou um sedimento gelatinoso no fundo do tubo (precipitado). O sobrenadante foi descartado e esse precipitado foi lavado com 1 mL de etanol 75% (1:1 v/v, etanol 75% e Trizol utilizado no inicio). As amostras foram centrifugadas a 7.500 g por cinco minutos a 4\u00b0C e o sobrenadante foi imediatamente descartado. O precipitado foi seco por cerca de 10 minutos a temperatura ambiente e depois eluido em 25 uL de \u00e1gua est\u00e9ril. O RNA isolado foi quantificado e, depois, estocado em -80\u00b0C.\n4.2.11\tS\u00edntese do DNA complementar\nO DNA complementar (cDNA) foi sintetizado a partir de RNA total. Primeiramente, 1 ug RNA total foi incubado com 2 uL de oligonucleotideo num volume final de 19,25 uL completado com \u00e1gua livre de DNAse e RNAse, a 70\u00b0C por oito minutos. A propor\u00e7\u00e3o de reagentes utilizada para a transcri\u00e7\u00e3o reversa foi: 5 uL de tamp\u00e3o RT 10X, 11 uL de MgCl, 1 uL d'NTP Mix (100 mM), 1,25 uL de transcriptase reversa Multiscribe RT (Applied Biosystems) e 12,5 uL de \u00e1gua livre de DNAse e RNAse, totalizando um volume final de 30,75 ^L. A rea\u00e7\u00e3o foi feita sob as seguintes condi\u00e7\u00f5es de ciclagem: incuba\u00e7\u00e3o dos reagentes por 10 minutos a 25\u00b0C,\naquecimento a 37\u00b0C por 120 minutos e 85\u00b0C por 5 minutos e resfriamento a 4\u00b0C. A efici\u00eancia da rea\u00e7\u00e3o de transcri\u00e7\u00e3o reversa foi considerada igual para todas as amostras. O cDNA obtido foi armazenado a -20\u00b0C at\u00e9 a realiza\u00e7\u00e3o da PCR em tempo real.\n4.2.12\tPCR em Tempo Real\nForam utilizados os oligonucleot\u00eddeos para CXCL9, CXCL10, IFNy, CD8, CCL2, CCL5, p2 microglobulina e GAPDH. Os oligonucleot\u00eddeos utilizados na rea\u00e7\u00e3o de PCR est\u00e3o presentes no quadro 5. As rea\u00e7\u00f5es de PCR foram realizadas em triplicata, incluindo controles negativos, em placas de 96 po\u00e7os usando o reagente SYBR-Green PCR Master Mix (Applied Biosystems, Foster City, CA USA), equipamento Realplex2 mastercycler (Eppendorf). Dois ^L de cDNA foi adicionado \u00e0 mistura de PCR contendo 1 ^L da mistura de cada oligonucleot\u00eddeo e 13 ^L Sybr green PCR Core Reagents (Applied Biosystems). O volume foi completado para 25 ^L com \u00e1gua destilada est\u00e9ril. Foi realizada uma desnatura\u00e7\u00e3o inicial a 95o C por 10 minutos, seguido de 40 ciclos (95OC por 15 segundos, 60oC por 60 segundos) e uma extens\u00e3o final a 60OC por um minuto. Todas as amostras foram normalizadas usando p2-microglobulina ou GAPDH.\nQuadro 5. Oligonucleot\u00eddeos utilizados nas rea\u00e7\u00f5es de PCR para detec\u00e7\u00e3o dos genes CXCL9, CXCL10, CCL3, CCL4, IFNy, CD8, CCL2, CCL5, p2-microglobulina e GAPDH\nOligonucleot\u00eddeos\tFoward (5'\t3')\tReverse (5'\t3')\nCXCL9\tAATGCACGATGCTCCTGCA\tAGGTCTTTGAGGGATTTGTAGTGG\nCXCL10\tGCCGTCATTTTCTGCCTCA\tCGTCCTTGCGAGAGGGATC\nCCL3\tCCAAGTCTTCTCAGCGCCAT\tTCCGGCTGTAGGAGAAGCAG\nCCL4\tTCTTGCTCGTGGCTGCCT\tGGGAGGGTCAGAGCCCA\nIFNy\tAACGCTACACACTGCATCTTGG\tGCCGTGGCAGTAACAGCC\nCD8\tGACGAAGCTGACTGTGGTTGA\tGCAGGCTGAGGGTGGTAAG\nCCL2\tTGGCTCAGCCAGATGCAGT\tTTGGGATCATCTTGCTGGTG\nCCL5\tCAAGTGCTCCAATCTTGCAGTC\tTTCTCTGGGTTGGCACACAC\np2-microglobulina\tCCGAACATACTGAACTGCTACGTAA\tCCCGTTCTTCAGCATTTGGA\nGAPDH\tGTGGTGAAGCAGGCATCTGA\tGGGAGTCACTGTTGAAGTCGC\n4.2.13\tDetec\u00e7\u00e3o de mRNA e an\u00e1lise de express\u00e3o g\u00eanica por Nanostring (Nanostring Technologies)\nPara o experimento de express\u00e3o g\u00eanica, foram utilizados MO-DCs purificados de animais C57BL/6 e IFNy - infectados com PbA. As an\u00e1lises de express\u00e3o de mRNA foram realizadas atrav\u00e9s da metodologia do Nanostring Technologies, como descrito anteriormente. Os heatmaps foram constru\u00eddos utilizando o programa Multi Experiment Viewer vers\u00e3o 4.8. Diferen\u00e7as de express\u00e3o g\u00eanica foram consideradas estatisticamente significativas com p &lt;0,05 utilizando o teste t Student n\u00e3o pareado.\n4.2.14\tDroga e tratamento\nO composto E6446 (antagonista de TLR7/9 - Eisai Pharmaceuticals) foi dissolvido em \u00e1gua e o animais foram tratados com 120 mg/Kg/dia come\u00e7ando do dia anterior a infec\u00e7\u00e3o at\u00e9 o terceiro dia ap\u00f3s a infec\u00e7\u00e3o, administrando 100 ^L por meio de gavagem diariamente. Animais tratados como ve\u00edculo (\u00e1gua) foram\nutilizados como controle.\n4.2.15\tMicroscop\u00eda intravital\nC\u00e9lulas CD11b+CD11c+ do ba\u00e7o foram purificadas como descrito pelo fabricante (MACS Miltenyi Biotec, CA), incubadas com CFSE (2 uM) durante oito minutos e lavadas. A vasculatura foi corada com anticorpo anti-CD31 (PE) (10 uL de uma solu\u00e7\u00e3o de estoque (0,2 mg / mL eBioscience, o clone 390). Os animais infectados (cinco dias ap\u00f3s a infec\u00e7\u00e3o) foram anestesiados via intraperitoneal (100 uL por animal) contendo ketamina (37,5 mg/mL, concentra\u00e7\u00e3o final) e xilazina (2,5 mg/mL, concentra\u00e7\u00e3o final). Ap\u00f3s anestesiados, as c\u00e9lulas e o anti-CD31 foram injetados via intravenosa e uma perfura\u00e7\u00e3o craniana (2x2 mm) foi feita acima do c\u00f3rtex parietal deixando a dura-m\u00e1ter intacta, permitindo a visualiza\u00e7\u00e3o da microvasculatura cerebral. O animal era imobilizado utilizando um surporte e c\u00e9lulas CD11b+ CD11c+ juntamente com o endot\u00e9lio foram observadas utilizando um microsc\u00f3pio confocal (Nikon, o Eclipse 50i, 20x lente objetiva) equipado com uma fonte de luz fluorescente (epi-ilumina\u00e7\u00e3o a 510-560 nm, usando um filtro de emiss\u00e3o de 590 nm). O n\u00famero de c\u00e9lulas que migraram foi determinado durante an\u00e1lise da reprodu\u00e7\u00e3o do video de 15 minutos de dura\u00e7\u00e3o. Em cada animal, um campo foi registado e analisado para determinar o n\u00famero total de c\u00e9lulas. An\u00e1lise de imagem quantitativa foi realizada usando o software Volocity vers\u00e3o 6.3. Os dados s\u00e3o representativos de quatro experimentos independentes.\n4.2.16\tAn\u00e1lise estat\u00edstica.\nTodas as an\u00e1lises estat\u00edsticas foram realizadas no programa Prism (GraphPad 6). Compara\u00e7\u00f5es entre dois grupos foram feitas pelo teste t Student. Mann-Whitney teste foi usado para a an\u00e1lise n\u00e3o param\u00e9trica quando os dados n\u00e3o se encaixavam na distribui\u00e7\u00e3o Gaussiana. A compara\u00e7\u00e3o entre grupos experimentais foi feita utilizando-se o teste ANOVA (do ingl\u00eas, analysis of variance), seguida por an\u00e1lise de compara\u00e7\u00f5es m\u00faltiplas, segundo o m\u00e9todo de Tukey. As curvas de sobreviv\u00eancia foram analisados pelo teste log-rank. O valor p &lt;0,05 foi considerado significativo. Todos os dados est\u00e3o representados como m\u00e9dia das amostras. Dados do gr\u00e1fico de barras mostram o desvio padr\u00e3o (SD).\n5\tRESULTADOS\n5\tRESULTADOS\n5.1\tMal\u00e1ria\n5.1.1\tProdu\u00e7\u00e3o de IgG e IgM durante a mal\u00e1ria\nForam determinados os n\u00edveis de anticorpos IgG e IgM espec\u00edficos para o ant\u00edgeno AMA-1 em plasma de pacientes com mal\u00e1ria (n= 18), durante a fase infec\u00e7\u00e3o com P. vivax e 30-45 dias ap\u00f3s o tratamento com anti-mal\u00e1ricos e cura parasitol\u00f3gica. Plasmas de doadores saud\u00e1veis foram utilizados como controle (Figura 6). Nenhuma diferen\u00e7a significantiva foi observada na produ\u00e7\u00e3o de anticorpos IgG entre pacientes com mal\u00e1ria e ap\u00f3s o tratamento. Al\u00e9m disso, amostras de pacientes na fase aguda da doen\u00e7a apresentaram altos n\u00edveis de anticorpos IgM contra AMA-1, seguindo de uma redu\u00e7\u00e3o destes ap\u00f3s o tratamento.\nIgG\nNS\n0.5-1\nIgM\np=0.0003\n1-2-1\n\n1.0-\nro o \u00a3Z \u25a0ro \u00a3 o&lt;/)\n<\n0.8-\n0.6-\n0.4-\n0.4-\n0.3-\u00f5 0.2-\u25a0ro 0.1- \u25a0 o 0.10-r R 0.08-&lt;0.06-\n0.04-\n0.02-\n\u2022 \u2022\u2022\n\u2022\u2022\u2022\u2022\n0.2-\n0.0-\n\u2666\n0.00\n\nFigura 6. Aumento de IgM espec\u00edfico para AMA-1 em plasma de pacientes durante a fase aguda da mal\u00e1ria por P. vivax. Os anticorpos IgG e IgM espec\u00edfos para AMA-1 foram detectados, por ELISA, em plasma de pacientes (n= 18) antes e ap\u00f3s o tratamento com anti-mal\u00e1ricos, bem como em plasma de doadores saud\u00e1veis. Diferen\u00e7as significativas est\u00e3o indicadas pelo valor de p determinado pelo test t Student.\n5.1.2\tAltos n\u00edveis de citocinas pr\u00f3-inflamat\u00f3rias circulantes no plasma de pacientes com mal\u00e1ria\nA partir de amostras de plasma de pacientes com mal\u00e1ria, infectados com P. vivax ou P. falciparum, foi feita uma an\u00e1lise no perfil e citocinas pr\u00f3-inflamat\u00f3rias produzidas durante a fase aguda e 30-45 dias ap\u00f3s o tratamento (Figura 7). Pacientes sintom\u00e1ticos, durante a fase aguda da infec\u00e7\u00e3o seja por P. vivax ou P.\nfalciparum apresentaram altos n\u00edveis de IL-8, IL-ip, IL-10 e IL-6 circulante. N\u00e3o\nobstante, observou-se uma diminui\u00e7\u00e3o na produ\u00e7\u00e3o destas citocinas pr\u00f3-inflamat\u00f3rias, assim como IL-10 (anti-inflamat\u00f3ria) em amostras de pacientes ap\u00f3s o tratamento com anti-mal\u00e1ricos.\nA\nB\nP. falciparum\nP. vivax\np=0.0353\np=0.1411\np<0.0001\n500-1\n400-\n1500-\n1000-\n500-\n\u2022 antes do tratamento O ap\u00f3s o tratamento\n10000-\t5000-\t400-\t\t50-\n8000-\t\u2022\t4000\t\\\t300-\t\t40-\n6000-\t\\\t= \\\t\u00a3\t3000- A \\\t0) \u25a0 \\\t0\t\\\t_l \\\t30 \u2022 \\ \u201c- 200-\tpg/mL\t30-\n4000-\tj\\\\\t2000\tIL-10\tIL-6\t20-\n\t\t\t\t\n2000-\t\u2022\t1000-\t\u2022 y\\\t100-\t\t10-\nFigura 7. Altos n\u00edveis de citocinas pr\u00f3-inflamat\u00f3rias e IL-10 no plasma de pacientes durante a fase aguda da mal\u00e1ria. As citocinas IL-8, IL-1 p, IL-10 e IL-6 foram medidas em plasma de pacientes Infectados por P. vivax (n= 56) (A) ou P. falciparum (n= 14) (B), durante a fase aguda (c\u00edrculos pretos) e 30-45 ap\u00f3s o tratamento (c\u00edrculos brancos). N\u00edveis de produ\u00e7\u00e3o das citocinas foram medidos por melo de CBA. Diferen\u00e7as significativas est\u00e3o indicadas pelo valor de p determinando test t Student pareado.\n5.1.3\tAumento dos n\u00edveis de ICs durante a m\u00e1laria\nO soro de pacientes com mal\u00e1ria causada pelo P. vivax ou P. falciparum foi capaz de induzir a produ\u00e7\u00e3o de TNFa em mon\u00f3citos humanos (Figura 8A). Esta indu\u00e7\u00e3o n\u00e3o foi observada quando utilizado o soro de doadores saud\u00e1veis. Dessa forma, hipotetizamos que ICs circulantes poderiam ser importantes fatores imuno estimulat\u00f3rios. De fato, detectamos elevados n\u00edveis de ICs em soro dos mesmos pacientes com mal\u00e1ria aguda (Figura 8B).\nOs n\u00edveis de ICs foram quantificados em soro de pacientes infectados por P. vivax (n= 25) antes e 30-45 dias ap\u00f3s o tratamento quimioter\u00e1pico, bem como em doadores saud\u00e1veis (n= 6) (Figura 8C). N\u00edveis elevados de ICs foram encontrados no soro de pacientes sintom\u00e1ticos durante a fase aguda da infec\u00e7\u00e3o por P. vivax (m\u00e9dia 16.1 ug mEq/mL), quando comparados com doadores saud\u00e1veis (m\u00e9dia s\n2.3\tug mEq/mL). Contudo, n\u00e3o houve correla\u00e7\u00e3o entre os n\u00edveis de ICs e a parasitemia dos pacientes. Os n\u00edveis de ICs no soro de pacientes tratados apresentaram n\u00edveis intermedi\u00e1rios e tamb\u00e9m diferiram significativamente quando comparados a pacientes antes do tratamento e doadores saud\u00e1veis.\n500-\n400-\n300-\np=0.0260\n----1\n100-r\n100-\nP=0.0256\nB P. vivax\n\u25a0 P. falciparum\nE\nLU\nO)\nO o\n50-\n40-\n30-\n20-\np=0.0027\ni------------1\np<0.0001\nI------------1\no N\u00e3o infectado C0> 200-300 (1/2+)\nO 300-500 (+) O 501-10,000 (++)\nO 10,001-100,000 (+++)\n10-\n\u2022\nFigura 8. Soro de pacientes infectados com P. falciparum ou P. vivax apresentam elevados n\u00edveis de imunocomplexos (ICs). A. Mon\u00f3citos de doadores saud\u00e1veis foram incubados individualmente com soro dilu\u00eddo 1:2 de pacientes infectados com mal\u00e1ria, sendo P. vivax (n=3) e P. falciparum (n=8) ou estimulados com 100ng/mL de LPS e a produ\u00e7\u00e3o de TNFa foi avaliada ap\u00f3s 24 horas por ELISA (gr\u00e1fico superior a esquerda). B. N\u00edveis de ICs foram quantificados nas mesmas amostras. C. ICs foram quantificados em soro de indiv\u00edduos infectados por P. vivax (n=25), antes e 30-45 dias ap\u00f3s o tratamento e em doadores saud\u00e1veis (n=6). Cores diferentes significam parasitemias diferentes. N\u00edveis de ICs foram quantificados utilizando o kit MicroVue CIC-Clq EIA (Quindel). Linhas horizontais indicam a m\u00e9dia de cada grupo. Diferen\u00e7as significantes est\u00e3o indicadas pelo valor de p por meio de test One-way ANOVA.\n5.1.4\tAumento de anticorpos anti-DNA durante a m\u00e1laria\nN\u00edveis significativamente elevados de anticorpos anti-DNA fita dupla (ds) tamb\u00e9m foram encontrados em soro de pacientes infectados por P. vivax (n= 52) ou P. falciparum (n= 25) (Figura 9). O soro de pacientes portadores de l\u00fapus (n= 19), bem como de doadores saud\u00e1veis (n= 28), foram utilizados como controles positivos e negativos, respectivamente. Os n\u00edveis de anticorpos anti-DNA de fita dupla IgG e IgM est\u00e3o significantemente elevados em soro de pacientes com mal\u00e1ria na fase aguda, tanto na infec\u00e7\u00e3o por P. vivax quanto por P. falciparum. Nenhuma diferen\u00e7a\nfoi observada nos n\u00edveis de anticorpos anti-DNA de fita simples. N\u00e3o obstante, os n\u00edveis de anticorpos anti-DNA de fita dupla persistiram por pelo menos 30-40 dias ap\u00f3s o tratamento (fase de convalesc\u00eancia) e cura parasitol\u00f3gica dos pacientes.\nanti dsDNA IgG 1:50\np<0.0004\np<0.0099\nanti dsDNA IgM 1:50\np<0.0001\nI-------------------------------------------------1\nNS\nFigura 9. N\u00edveis elevados de anticorpos anti-DNA de fita dupla durante a fase aguda de mal\u00e1ria por P. vivax e P. falciparum. Os n\u00edveis de anticorpos IgG e IgM anti-DNA de fita dupla IgG e IgM foram medidos por ELISA em soro de 58 pacientes com infecc\u00e7\u00e3o aguda da mal\u00e1ria por P. vivax (Pv) e 25 com P. falciparum (Pf) e na em fase de convalesc\u00eancia (conv) 30-45 dias ap\u00f3s terapia com antimal\u00e1ricos. Como controles negativo e positivo, foi utilizado soro de 28 doadores saud\u00e1veis e 19 pacientes portadores de L\u00fapus respectivamente. Diferen\u00e7as significantes s\u00e3o indicadas por valor de p usando o teste Mann Whitney.\n5.1.5\tPresen\u00e7a de DNA de P. vivax em ICs\nFoi detectada da presen\u00e7a de DNA em ICs. Estes n\u00edveis de DNA foram quantificados em ICs purificados de plasma de pacientes infectados por P. vivax por PCR em tempo real, utilizando oligonucleot\u00eddeos de sequ\u00eancia para o gene humano CYCLIN D1 (CCND) e P. vivax SSUrRNA (18S do rRNA). Foi observado um aumento dos n\u00edveis de DNA humano e do parasito em plasma de pacientes infectados com P. vivax antes do tratamento. O DNA circulante humano persistiu, ainda que em baixos n\u00edveis, enquanto o DNA do parasito foi praticamente eliminado da circula\u00e7\u00e3o ap\u00f3s a terapia com anti-mal\u00e1ricos (Figura 10A).\nDo mesmo modo, o DNA do parasito foi detectado em ICs de pacientes infectados por P. vivax, antes, e em n\u00edveis muito baixos, depois do tratamento (Figura 10B). Por outro lado, o DNA humano foi detectado em n\u00edveis muito baixos em ICs dos mesmos pacientes. Uma vez que a benzonase degrada todas as formas de DNA, este ensaio foi realizado para confirmar a presen\u00e7a de DNA em ICs oriundos de pacientes com mal\u00e1ria.\n* antes do tratamento O ap\u00f3s o tratamento A doador saud\u00e1vel\nFigura 10. Elevados n\u00edveis de DNA humano e do parasito em plasma e imunocomplexos (ICs) de pacientes com mal\u00e1ria causada pelo P. vivax. A. N\u00edveis de DNA circulante foram quantificados em plasma de pacientes infectados com P. vivax (n=24) antes e 30-45 dias ap\u00f3s o tratamento bem como em doadores saud\u00e1veis (n=5) atrav\u00e9s da amplifica\u00e7\u00e3o dos genes humano CYCLIN D1 (CCND) e P. vivax SSUrRNA (18S do rRNA). B. ICs de pacientes infectados por P. vivax (n=8) antes e 30-45 dias ap\u00f3s o tratamento bem como doadores saud\u00e1veis (n=5) foram purificados e utilizados para a amplifica\u00e7\u00e3o dos genes humano CCND e P. vivax SSUrRNA. C. Quantifica\u00e7\u00e3o de DNA total extra\u00eddo de ICs purificados de pacientes com mal\u00e1ria infectados por P. vivax (n=6) antes e ap\u00f3s o tratamento com benzonase. Diferen\u00e7as significativas est\u00e3o indicadas por valores de p utilizando test t Student pareado.\n5.1.6\tMon\u00f3citos estimulados com ICs apresentam uma assinatura de genes induzida pelo fator de transcri\u00e7\u00e3o NF-k B\nFoi avaliada a express\u00e3o de genes em mon\u00f3citos de quatro doadores saud\u00e1veis, estimulados com 60 ^g/mL de ICs por seis horas. De um total de 105 genes relacionados a respostas inflamat\u00f3rias presentes no codeset analisado, sete eram constitutivos e 98 eram genes relacionados a resposta imune inata. Os genes foram divididos em seis grupos: via de sinaliza\u00e7\u00e3o de receptores do tipo NOD, via de sinaliza\u00e7\u00e3o de receptores do tipo Toll, fam\u00edlia do NF-kB, citocinas e receptores de citocinas, quimiocinas e receptores de quimiocinas e genes estimulados por IFN. Os mon\u00f3citos expressaram um aumento na express\u00e3o de 27 genes diferencialmente expressos ap\u00f3s est\u00edmulo com ICs, com um valor de p &lt;0.05 e uma indu\u00e7\u00e3o maior\nVIA DE SINALIZA\u00c7\u00c3O DO TIPO NOD\n0.0 1.0 8.0\nESTIMULADOS POR IFN\nNLRC4\nNLRP3\nNLRC5\nCASP1\nCASP4\nASC\nCARD9\nNLRP12\nNLRP6\nVIA DE SINALIZA\u00c7\u00c3O NF-kB\n0.0 1.0 8.0\n<h\t<n\tm\t*\u2022\nQ\tQ\tQ\ta\nS\tB\tX\tEC\nA20\nNFKB2\nNFKB1 IKBKE REL\nNFKB1A\n0.0 1.0 8.0\nCITOCINAS E RECEPTORES DE\nCITOCINAS\nVIA DE SINALIZA\u00c7\u00c3O DO TIPO TOLL\nMOLECULAS DE ADES\u00c3O, QUIMIOCINAS, RECEPTORES DE QUIMIOCINAS\nICAM1\nCCL2\nCCL4\nCCL3\nCXCL10\nCCR1\nCXCL2\nCD18\nCCL5\nCCL8\nCCR2\nIL-1A\nIL-1B\nTNFA\nIL1RA\nTNFR1\nIFNGR2\nTGFB\nIL-8\nIL-15\nIL-18\nIFNAR1\nIL-13\nIFNA4\nIFNB\nIL-4\nIL-23A\nIL-6\nIL-12A\nIL-12B\nIFNG\nIL-33\nQ Q Q Q\nGBP1 RASGEF1B SOCS3 IDO1 IRF2 IRF8 IRF1\nDDX21\nIRF5 MXA\nDHX9\nPRDM1\nTREX1 DDX1\nSAMHD1\nDHX36\nSTAT1\nIFI16\nIFI30\nTAP1\nTAP 2 TRIM56 IFIT2 RSAD2 SOCS1\nLGP2\nIRF7 PYHIN1 MNDA DIABLO DDX58 IFIT1\nAIM2 CYP27B1\nFigura 11. Assinatura de genes da fam\u00edlia NF-kB em mon\u00f3citos estimulados com o ICs. Mon\u00f3citos de quatro doadores saud\u00e1veis foram purificados e estimulados com ICs (60p,g/mL) por 6 horas. A an\u00e1lise da express\u00e3o g\u00eanica foi realizada por meio da tecnologia Nanostring. Diferentes vias de sinaliza\u00e7\u00e3o est\u00e3o representadas nos heatmaps. Os dados foram normalizados utilizando genes constitutivos e o aumento da express\u00e3o do gene foi calculada em compara\u00e7\u00e3o com amostras n\u00e3o estimuladas do mesmo doador. Os heatmaps mostram genes diferencialmente expressos (linhas) para cada dador saud\u00e1vel (coluna) que diminu\u00edram (verde), foram inalterados (preto) ou tiveram express\u00e3o aumentada (vermelho). O quadro 6 fornecem o valor de p dos genes que apresentaram aumento significativo na express\u00e3o, determinado pelo teste t Student.\nQuadro 6 - Genes com a express\u00e3o aumentada em mon\u00f3citos estimulados com ICs. Asteriscos indicam diferen\u00e7as significativas, determinadas por teste t Student\nGene\tNome de Gene\tN\u00edvel de express\u00e3o\tEstat\u00edstica\nA20\tFator de necrose tumoral prote\u00edna 3 induzida por alfa\t5.03\t**\nCCL3\tQuimiocina (motivo C-C) ligando 3\t10.14\t**\nCCL4\tQuimiocina (motivo C-C) ligando 4\t9.69\t***\nCCL5\tQuimiocina (motivo C-C) ligando 5\t2.11\t**\nCCL8\tQuimiocina (motivo C-C) ligando 8\t5.14\t*\nCD80\tComplexo de diferencia\u00e7\u00e3o 80\t2.31\t*\nCXCL10\tQuimiocina (motivo C-X-C) ligando 10\t3.42\t*\nGBP1\tProte\u00edna 1 de liga\u00e7\u00e3o ao guanilato\t3.44\t*\nHCK\tCinase de c\u00e9lulas hematopoi\u00e9ticas\t2.29\t**\nICAM1\tMol\u00e9cula de ades\u00e3o intercelular 1\t3.98\t****\nIFNGR2\tReceptor de IFN gama 2\t2.71\t***\nIKBKE\tInibidor do fator nuclear kappa B\t22.24\t**\nIL18\tInterleucina 18\t3.87\t**\nIL1A\tInterleucina 1 alfa\t9.39\t**\nIL1B\tInterleucina 1 beta\t16.16\t****\nIL1RA\tReceptor para interleucina 1 alfa\t7.41\t*\nIL6\tInterleucina 6\t1.83\t***\nIL8\tInterleucina 8\t17.09\t****\nNFKB1\tFator nuclear kappa B 1\t2.50\t**\nNFKB2\tFator nuclear kappa B 2\t2.44\t**\nNFKBIA\tFator nuclear kappa B 1 alfa\t4.55\t***\nPSTPIP2\tIntera\u00e7\u00e3o de prolina-serina-treonina fosfatase a prote\u00edna 2\t2.08\t*\nPTGS2\tProstaglandina-endoperoxidase sintetase 2\t5.97\t**\nRASGEF1B\tFator de troca de nucleot\u00eddeos guanina associado ao dom\u00ednio Ras 1 B\t3.43\t*\nSOCS3\tSupressor da sinaliza\u00e7\u00e3o de citocina 3\t4.01\t***\nTLR2\tReceptor do tipo Toll 2\t7.80\t**\nTNFA\tFator de necrose tumoral alfa\t7.31\t\n5.1.7\tICs purificados de pacientes com mal\u00e1ria induzem a produ\u00e7\u00e3o de citocinas por mon\u00f3citos\nFoi analisada a capacidade de ICs purificados de plasma de pacientes infectados por P. vivax em induzir a produ\u00e7\u00e3o de citocinas por c\u00e9lulas mononucleares do sangue perif\u00e9rico (CMSPs) de doadores saud\u00e1veis. Utilizou-se diferentes concentra\u00e7\u00f5es de ICs purificados e n\u00edveis de o TNFa, IL-1 p e IL-10 foram avaliados em sobrenadantes de cultura de CMSPs, 24 horas ap\u00f3s o est\u00edmulo. Foi definido que 60 ug de ICs purificados \u00e9 a concentra\u00e7\u00e3o ideal para induzir a produ\u00e7\u00e3o de citocinas por CMSPs (Figura 12A). Essa concentra\u00e7\u00e3o foi utilizada em experimentos posteriores. A seguir, avaliamos se o DNA \u00e9 um componente importante para a atividade imunoestimulat\u00f3ria dos ICs. Para isso, foi utilizado o E6446 (antagonista de TLR7 e TLR9) um composto que se liga ao DNA e RNA no compartimento lisossomal, bloqueando a ativa\u00e7\u00e3o de TLR7, bem como TLR9\n(Figura 12B). Como controle, utilizou-se CMSPs tratados previamente por 3 horas com E5564 (2 ^g), um antagonista de TLR4, seguido de estimula\u00e7\u00e3o com LPS (100 ng/mL). O tratamento de CMSPs com E6446 (2 ^M) por 3 horas, seguido de est\u00edmulo com ICs, resultou na inibi\u00e7\u00e3o de 30-40% de IL-1 p. Uma concentra\u00e7\u00e3o maior do inibidor de DNA/RNA (20 ^M) foi necess\u00e1ria para inibir a produ\u00e7\u00e3o de 70% de TNFa e 90% de IL-1 p e IL-10. Experimentos controles utilizando E5564 (antagonista de TLR4) (1 ^g/mL) resultaram em 100% na inibi\u00e7\u00e3o de TNFa, IL-1 p e IL-10 ap\u00f3s est\u00edmulo com LPS. Essa inibi\u00e7\u00e3o n\u00e3o foi observada quando CMSPs foram previamente tratados com E5564 e estimulados com ICs. Estes dados sugerem que os fragmentos de DNA do parasito presentes nos ICs formados durante a mal\u00e1ria est\u00e3o diretamente envolvidos na ativa\u00e7\u00e3o celular do sistema imune inato.\nE6446\n2hM 20uM\nE5564\n1 pg/ml\nTNF-a\nIL1-P\nIL-10\n10000]\n\u00ed \u00a3\n10000]\n10000]\niu+..........I....I\nO\t20\t40\t60\nConcentra\u00e7\u00e3o de ICs\nr\nr\n1000]\n1000]\nf f 0\nFigura 12. E6446, um antagonista de TLR7 e TLR9, bloqueia a atividade estimulat\u00f3ria de ICs em mon\u00f3citos. A. CMSPs foram isolados de doadores saud\u00e1veis, estimulados com ICs em diferentes concentra\u00e7\u00f5es e os n\u00edveis de citocinas foram medidos ap\u00f3s 24 horas nos sobrenadantes da cultura celular. B. CMSPs foram tratados com E6446, antagonista de TLR7 e TLR9, (2p,M ou 20 p,M) ou E5564, um antagonista de TLR4 (2p,g/mL) por 2 horas antes do est\u00edmulo com 60 p,g/ml de ICs por 24 horas. Logo ap\u00f3s, n\u00edveis de citocinas foram medidos em sobrenadante. Barras representam porcentagem de inibi\u00e7\u00e3o da citocina em sobrenadantes. TNFa, IL-1 p e IL-10 foram medidos por meio de CBA (BD).\n5.1.8\tA exposi\u00e7\u00e3o pr\u00e9via ao IFNy aumenta a produ\u00e7\u00e3o de citocinas induzidas por ICs\nFoi avaliado o efeito da sensibiliza\u00e7\u00e3o pr\u00e9via com IFNy no perfil de citocinas produzidas por CMSPs de doadores saud\u00e1veis. A exposi\u00e7\u00e3o ao IFNy, seguido de est\u00edmulo de 24 horas com ICs purificados de plasma de pacientes com mal\u00e1ria, infectados por P. vivax ou P. falciparum, elevou a produ\u00e7\u00e3o de citocinas pr\u00f3-inflamat\u00f3rias, como IL-ip e TNFa. Em contraste, observou-se uma redu\u00e7\u00e3o na produ\u00e7\u00e3o de IL-10 quando comparado com os n\u00edveis de citocinas produzidas por c\u00e9lulas n\u00e3o sensibilizadas (Figura 13A). O mesmo perfil de produ\u00e7\u00e3o de citocinas pr\u00f3-inflamat\u00f3rias versus anti-inflamat\u00f3rias foi observado em mon\u00f3citos purificados (Figura 13B).\nA\nE\n\u25a1) Q.\na\nB\np=0.0287\nO N\u00e3o sensibilizado\nS en si b i l izad o (IFNy)\nMon\u00f3citos\nEnriquecidos\n10000q\nPBMCs com mon\u00f3citos depletados\nPBMCs\nP. vivax\tP. falciparum\n\t1000-\t\t\t\n\t800\u2019\t\t\t\n\u2022\t\t\t\t\no>\t600-\t\t\t\nQ. O\t400\t\t\t\n\t2CJ-\t\t1\t\n\t\t\t\t\n\tzx\u00b0\\O\tzx\u00b0\\O zx\u00b0\\O\taW # # # # # #\t\t\t\nFigura 13. Mon\u00f3citos s\u00e3o as principais fontes de citocinas em c\u00e9lulas mononucleares de sangue perif\u00e9rico (CMSPs) ap\u00f3s est\u00edmulo com imunocomplexos (ICs) purificados de pacientes com mal\u00e1ria. A. CMSPs foram isolados de doadores saud\u00e1veis, sensibilizadas (c\u00edrculos escuros) ou n\u00e3o (c\u00edrculos claros) com 100 ng de IFNg e estimulados com 60 mg/mL de ICs purificados de plasma de pacientes com mal\u00e1ria por P. vivax (gr\u00e1ficos a esquerda, n=12) ou P. falciparum (gr\u00e1ficos a direita, n=5) e os n\u00edveis de citocinas medidos em sobrenadante de cultura celular, 24 horas ap\u00f3s est\u00edmulo. B. Mon\u00f3citos CD14+ foram purificados de CMSPs de tr\u00eas doadores saud\u00e1veis por sele\u00e7\u00e3o positiva. Mon\u00f3citos purificados, CMSPs com mon\u00f3citos depletados e CMSPs totais foram sensibilizados ou n\u00e3o com IFNg (100 ng/mL) e estimulados com 60 mg/mL de ICs purificados de plasma de pacientes com mal\u00e1ria. TNFa, IL-1b and IL-10 foram medidos por CBA 24 horas ap\u00f3s est\u00edmulo com ICs. Diferen\u00e7as significativas est\u00e3o indicadas pelos valores de p utilizando teste t student pareado.\n5.1.9\tICs purificados de pacientes com mal\u00e1ria induzem a ativa\u00e7\u00e3o de caspase-1 em mon\u00f3citos\nUma vez observado que ICs induzem a produ\u00e7\u00e3o de IL-1 p, investigamos se estes eram capazes de promover a ativa\u00e7\u00e3o de caspase-1. Primeiramente, foi definida a principal fonte de IL-1 p em CMSPs, ap\u00f3s est\u00edmulo com ICs purificados de plasma de pacientes com mal\u00e1ria. Para tanto, foi utilizado CMSPs totais, CMSPs com mon\u00f3citos depletados (c\u00e9lulas CD14+) e mon\u00f3citos purificados. Os resultados mostram que, na popula\u00e7\u00e3o purificada, aproximadamente 95% das c\u00e9lulas s\u00e3o CD14+ e CD16- (Figura 14A painel esquerdo). Uma pequena popula\u00e7\u00e3o \u00e9 CD14+ CD16lo. Os resultados apresentados tamb\u00e9m mostram que mon\u00f3citos purificados\nMon\u00f3citos Enriquecidos (MO)\nDoador saud\u00e1vel\nICs\npro-casp-1\ncasp-1 (p10)\nPBMCs Totais\n10000n\n8000*\n6000-\n4000-\n2000-\nPBMCs com mon\u00f3citos depletados (MO/neg)\nlOOOOq\n8000-\n6000-\n4000-\n2000-\nMon\u00f3citos enriquecidos (MO)\n100001\n95.7%Z\n8000-\nt L C 0 -\n4000-\n*9*\n2CCC-\nICs2\nE\nO) Q.\n\u2022 W\u00bb M4\nCD16(PE)\nE\nD) Q.\n\u2022i\t___\u2014 -\n\u2022 II* M*\tW*\nCD 16 (PE)\n\u25a0 to4\nO\n\u00a3\nQ O\n0 103 10* 10* CD 16 (PE)\nMEIO ICs1\nControle\n12 12\n\u00bfd\n\nFigura 14. ICs purificados de pacientes com mal\u00e1ria causadas por P. vivax ativam caspase-1 e induzem a produ\u00e7\u00e3o de elevados n\u00edveis da citocina pirog\u00e9nica IL-1 p por mon\u00f3citos humanos. A. Pain\u00e9is da esquerda mostram a frequ\u00eancia de c\u00e9lulas CD14+ em CMSPs (gr\u00e1fico superior), CMSPs com mon\u00f3citos depletados (gr\u00e1fico do meio) e mon\u00f3citos purificados (gr\u00e1fico inferior). Nos pain\u00e9is da direita, CMSPs, CMSPs com mon\u00f3citos depletados e mon\u00f3citos purificados foram estimulados com ICs (60 p,g/ml) por 24 horas e IL-ip foi medida no sobrenadante de cultura celular por ELISA. B. Mon\u00f3citos purificados foram estimulados com 60 p,g/mL de ICs por 24 horas e as c\u00e9lulas foram lisadas por tamp\u00e3o RIPA e usadas para a detec\u00e7\u00e3o de pro-caspase-1 e forma ativa de caspase-1 (plO) por Western blot. Os presentes resultados s\u00e3o representativos de tr\u00eas diferentes doadores saud\u00e1veis.\n5.1.10\tForma\u00e7\u00e3o da plataforma de inflamassomas em mon\u00f3citos estimulados com ICs de pacientes com mal\u00e1ria\nPara saber se ICs promovem a forma\u00e7\u00e3o de inflamassomas, mon\u00f3citos de doadores saud\u00e1veis foram purificados e estimulados com ICs de pacientes com mal\u00e1ria, infectados por P. vivax. Foi observada a forma\u00e7\u00e3o de plataformas contendo NLRP12, AIM2 e NLRP3 (Figura 15A). Cerca de 10, 10 e 5% dos mon\u00f3citos expressam inflamassomas de AIM2, NLRP12 e NLRP3 respectivamente (Figura 15C). Contudo, nenhuma evid\u00eancia de forma\u00e7\u00e3o de inflamassoma contendo NLRC4 foi encontrada. Al\u00e9m disso, verificou-se a co-localiza\u00e7\u00e3o de mol\u00e9cula adaptadora ASC com o inflamassoma NLRP3 ou AIM2. O inflamassoma NLRP12 n\u00e3o foi associado a ASC, sugerindo que este se auto-oligomeriza (Figura 15B). Estes resultados vinculam a forma\u00e7\u00e3o de inflamassomos \u00e0 ativa\u00e7\u00e3o de caspase-1 e secre\u00e7\u00e3o de IL-1 p, um aspecto importante na atividade pr\u00f3-inflamat\u00f3ria dos ICs.\nA\nC\nFigura 15. Plataformas de inflamassoma contendo NLRP12, NLRP3 e AIM2 s\u00e3o formados ap\u00f3s est\u00edmulo com ICs em mon\u00f3citos. A. Detec\u00e7\u00e3o por an\u00e1lise confocal de inflamassomas contendo NLRP3 (em verde), NLRP12 (vermelho) e AIM2 (vermelho), em mon\u00f3citos CD14+ estimulados com 60 p,g de ICs por 24 horas. N\u00e3o foi observada rea\u00e7\u00e3o com anticorpos secund\u00e1rios, na aus\u00eancia de anticorpos prim\u00e1rios. B. ASC co-localiza com NLRP3 e AIM2 mas n\u00e3o com NLRP12. Ambos inflamassomas foram encontrados no citoplasma de mon\u00f3citos. C. O gr\u00e1fico de barra mostra a frequ\u00eancia de inflamasomas em mon\u00f3citos de doadores saud\u00e1veis, 24 horas ap\u00f3s est\u00edmulo com 60 p,g de ICs.\n5.1.11\tICs induzem a produ\u00e7\u00e3o de elevados n\u00edveis de citocinas pr\u00f3-inflamat\u00f3rias por mon\u00f3citos\nFoi utilizada a concentra\u00e7\u00e3o de 60 ^g/mL de ICs para estimular CMSPs de\npacientes com mal\u00e1ria, infectados com P. vivax antes e 30-40 dias ap\u00f3s o tratamento e cura parasitol\u00f3gica. O est\u00edmulo com ICs induziu a produ\u00e7\u00e3o de elevados n\u00edveis de citocinas pr\u00f3-inflamat\u00f3rias, TNFa e IL-1 p, e baixos n\u00edveis de IL-10 (Figura 16A) por mon\u00f3citos de pacientes infectados. A principal fonte de citocinas pr\u00f3-inflamat\u00f3rias eram as c\u00e9lulas CD14+ CD16+. Curiosamente, o perfil de\ncitocinas produzidas\npor mon\u00f3citos ap\u00f3s o tratamento mudou-se para anti\ninflamat\u00f3rio: produ\u00e7\u00e3o elevada de IL-10 e\nprodu\u00e7\u00e3o reduzida de IL-ip e TNFa\n(Figura 16B)\nFigura 16. ICs purificados induzem elevados n\u00edveis de citocinas pr\u00f3-inflamat\u00f3rias por mon\u00f3citos CD14+CD16+ de pacientes com mal\u00e1ria. A. CMSPs de pacientes com mal\u00e1ria infectados por P. vivax (n=7) antes e 30-45 dias ap\u00f3s o tratamento foram isolados e estimulados com 60 p,g/ml de ICs por 24 horas. As citocinas TNFa, IL-ip e IL-10 foram medidas nos sobrenadantes de cultura celular por CBA. B. An\u00e1lise por citometria mostra um aumento na frequ\u00eancia de c\u00e9lulas CD14+CD16+ em CMSPs de dois pacientes infectados por P. vivax antes e 30-45 dias ap\u00f3s o tratamento e cura parasitol\u00f3gica. CMSPs de pacientes foram estimulados com meio ou ICs purificados de diferentes pacientes por 24 horas e, posteriormente, realizada uma marca\u00e7\u00e3o intracelular para avaliar TNFa e IL-ip por citometria de fluxo. Diferen\u00e7as significantes est\u00e3o indicadas com valores de p utilizando teste t student pareado.\n5.2\tModelo murino da mal\u00e1ria cerebral\n5.2.1\tA infec\u00e7\u00e3o por Plasmodium induz a presen\u00e7a de c\u00e9lulas MO-DCs\nEstudos recentes demonstraram que os iMOs diferenciam em MO-DCs durante infec\u00e7\u00f5es microbianas in vivo86,87. Sendo assim, avaliamos a presen\u00e7a de MO-DCs\tdurante a infec\u00e7\u00e3o murina com\tPbA.\tC\u00e9lulas\nCD11c+MHCII+CD11b+F4/80+DC-SIGN+ foram avaliadas no ba\u00e7o de animais infectados, uma vez que este \u00e9 o principal org\u00e3o onde observa-se a intera\u00e7\u00e3o de fag\u00f3citos e hem\u00e1cias infectadas. Para isso, foi feita uma sele\u00e7\u00e3o na janela de c\u00e9lulas duplo positivas para CDIIb e F4/80 e posteriormente, na popula\u00e7\u00e3o MHCIIhighDC-SIGN+CD11c+. Os resultados apresentados na Figura 17A indicam que a frequ\u00eancia de MO-DCs na popula\u00e7\u00e3o total de CD11b+F4/80+ do ba\u00e7o aumentou de 18 a 74% quando comparamos os animais controles e infectados com PbA. Al\u00e9m disso, a intensidade de fluoresc\u00eancia m\u00e9dia (IFM) de DC-SIGN e MHCII em MO-DCs de animais infectados aumentou 3 vezes. Uma parte destas c\u00e9lulas tamb\u00e9m expressou n\u00edveis diferentes de Ly6C. Entretando, a porcentagem de c\u00e9lulas CD11b+F4/80+DC-SIGNintMHCII-CD11c-Ly6Chigh (iMOs) reduziu de 10 para 4,4% sugerindo que iMOs est\u00e3o se convertendo em MO-DCs. Nossas an\u00e1lises indicam que a frequ\u00eancia de CD11c+MHCIIhighDC-SIGN-Ly6c-, o que corresponde a c\u00e9lulas dendr\u00edticas convencionais (cDCs), diminuiu de 48% para 20% do total de CD11c+MHCIIhigh em animais controles e infectados respectivamente. Para melhor caracterizar MO-DCs, foi feita uma purifica\u00e7\u00e3o desta c\u00e9lulas em cit\u00f4metro de fluxo (95-99% de pureza em diferentes experimentos) (Figura 17B) seguida de uma colora\u00e7\u00e3o por Giemsa, onde observou-se hemozo\u00edna no interior das c\u00e9lulas ou an\u00e1lise por microscopia eletr\u00f4nica de varredura (Figura 17C). Para investigar a capacidade fagoc\u00edtica de MO-DCs, esplen\u00f3citos de animais controles e infectados foram incubados com hem\u00e1cias\n\u00a1nFecTaDas ou n\u00e3o com PbA-GFP. Por me\u00edo De c\u00edTomeTr\u00eda De Fluxo Foi visTo que MO-DCs Tem uma eIevaDa capac\u00edDaDe Fagoc\u00edT\u00edca quanDo comparamos esTas com \u00edMOs e MOs (Figura 17D). Al\u00e9M Disso, ao conTr\u00e1r\u00edo De MOs, MO-DCs apresenTou um aumenTo no n\u00edveI De CD80 e CD86 (Figura 17E), suger\u00ednDo que MO-DCs s\u00e3o c\u00e9IuIas apresenTaDoras De anT\u00edgeno aITamenTe eF\u00edc\u00edenTes.\nA\n4x106-|\n3x1Q6-\n'<D\n<1> \"O \"ra\nO\nO\n<1)\nE o z\n2x1Q6-\n5x105-> 4x105-T 3x105-|\n2x105-|J 1x105-\n8x105-|\n6x105-I\n4x1Q5- I\nN\u00e3o infectado\nCClulas CD11b+ F4/80+\nInfectado\nCD11b\n<1)\nE o\nInfectado N\u00e3o infectado\n2x106\n1x106\n0\nCD11b+\nF4/80+\n8000-1\t\t**\t\t4000-1\t**\t\n\t6000-\t\tI\t3000-\t\tX\nT\t\u25a0 S i. 4000-\t\t\tS 2000-\t\t\na\t1\t DC-SIGN o o T\t\t1\t\to o ll-DHIAl\t1\t\niMOs\nMOs\nCD11c+\n8000-\n6000\n3000-\n4000\n2000-\n2000\n1000-\n1.5X1006\n1.0X1006\n5.0X1005\n4000, CD80+\n0\nE o z.\nu 4x1005\n2x1005\n0 \u20225 l0\n3 e\n|\t| Controle + Hem\u00e1cia n\u00e3o infectada\nI I Controle + Hem\u00e1cia infectada\nInfectado 6\u00b0 dia + Hem\u00e1cia n\u00e3o infectada\nInfectado 6\u00b0 dia + Hem\u00e1cia infectada\n1\n\n\nB\n2x1Q5-\n0-\n1500\n1000\n500\n1.0x10o5\n5.0x10o4\n0.0\n0-\nMO-DCs\n0\n1.5x 1005\nIxIO6-\n\u2019\u25a0\u25a0II\n11\n\u00a1MOs\nCD11c+CD11b+ F4/80+DC-SIGN+MHC IIhigh\nGiemsa\tMicroscopia de varredura\n100\nCD86+\n1000-\n0-\n~ 2000-\nLL\n19\n<\n\u00a7\nD\n\n\niMOs i MOs\nFigura 17. Diferencia\u00e7\u00e3o de MO-DCs no ba\u00e7o (F4/80+CD11b+DC-SIGN+MHCIIhighCD11c+Ly6C+) de animais infectados com PbA. Ba\u00e7os foram coletados cinco dias ap\u00f3s a infec\u00e7\u00e3o com PbA. Resultados representativos da citometria de fluxo s\u00e3o mostrados a seguir. A. Primeira janela feita em esplen\u00f3citos F4/80+CD11b+ e posteriormente em c\u00e9lulas DC-SIGN+MHCIIhigh. C\u00e9lulas F4/80+CD11b+DC-SIGN+MHCIIhigh tamb\u00e9m foram avaliadas quanto a express\u00e3o de CDIIc e Ly6C. Gr\u00e1fico de barras correspondem o n\u00famero total de c\u00e9lulas (quatro animais por grupo). Os dados mostrados s\u00e3o representativos de cinco experimentos independentes. B. Ba\u00e7os foram coletados no sexto dia ap\u00f3s infec\u00e7\u00e3o com PbA. MO-DCs foram marcados com anticorpos anti-F4/80+CD11 b+DC-S IGN+MHCIIhigh, e posteriormente, submetidas a citometria de fluxo. Foi obtido aproximadamente 98.2% de c\u00e9lulas puras, os quais s\u00e3o tamb\u00e9m CD11c+. C. Esplen\u00f3citos foram marcados com anticorpos fluorescentes e as MO-DCs foram purificadas por citometria de fluxo e coradas com Giemsa ou analisadas por microscopia de varredura. D. Express\u00e3o de CDIIc e mol\u00e9culas co-estimulat\u00f3rias CD80 e CD86 na superf\u00edcie de MOs, iMOS e MO-DCs. E. Histogramas mostram resultados de IFM de esplen\u00f3citos de animais co ntroles (linh as sombreadas) e infectados (linhas abertas) incubados com hem\u00e1cias n\u00e3o infectadas (azul) ou hem\u00e1cias infectadas com PbA-GFP (vermelho). O gr\u00e1fico de barras indica a atividade fagoc\u00edtica de MO-DCs, iMOS e MOs. Os resultados s\u00e3o expressos em m\u00e9dia. Diferen\u00e7as estat\u00edsticas foram consideradas significantes entre infectados e n\u00e3o infectados (**, p>0.01) ap\u00f3s two-way ANOVA.\n5.2.2\tA mal\u00e1ria induz a express\u00e3o de CCR5+CXCL9+CXCL10+ em MO-DCs\nPara a caracteriza\u00e7\u00e3o g\u00eanica de MO-DCs, lisados de c\u00e9lulas purificadas (Figura 17B) foram obtidos e os transcritos do gene analisados para 547 genes relacionados ao sistema imune, mais 14 genes constitutivos (housekeeping genes) utilizando o kit comercial de sondas Nanostring. Observou-se um aumento na express\u00e3o de 18% dos genes analizados. Dentre eles, o aumento maior foi observado na express\u00e3o de CXCL9 (24 vezes) e CXCL10 (19 vezes). Al\u00e9m disso, da fam\u00edlia de receptores de quimiocinas, a express\u00e3o de CCR5 foi aumentada seis vezes (Figura 18A). Como CXCL9 e CXCL10 tem demonstrado um importante papel na mal\u00e1ria cerebral no modelo experimental75,81, foi investigada a express\u00e3o dessas quimiocinas no ba\u00e7o de animais infectados com PbA. Para isso, foi utilizado o animal transg\u00eanico REX3 (reporting the expression of CXCR3 ligants), que expressa prote\u00edna fluorescente vermelha (red fluorescence protein - RFP) e prote\u00edna fluorescente azul (blue fluorescence protein - BFP) como genes reporter sob os promotores dos genes CXCL9 e CXCL10 respectivamente. Foram encontradas grandes quantidades de c\u00e9lulas duplo positivas RFP+BFP+ em MO-DCs, enquanto iMOs foram RFPBFP (Figuras 18B e 18C). Da mesma forma, aproximadamente 80% de MO-DCs s\u00e3o CCR2+CCR5+, sendo iMOs CCR2+, por\u00e9m CCR5- (Figura 18D).\nCD11c+CD11b+ F4/80+ DC-SIGN+MHC IIhi8h\nCXCL10\nF4/80\nCXCL9\nF4/80\nCXCL9\nCXCL10\nF4080\nCXCL10\nCDllc\nCXCL9\nCDllc\nCXCL9\nCXCL10\nCDllc\nCXCL9 / CXCL10 / CDllc\nCXCL9 / CXCL10 / F4/80\nInfectado\nN\u00e3o infectado\n0.047\nio4 io5 CXCL10 io5-j\n5.59\n77.6\n10 10 10\nMHC II\n\u00edo3 io4 ios\nCD11c\nio3 io4\nCD11b\nto\n<U \"O\nCD11b+ F4/80+ MHC II+ CD11c+\nCCR2+ CCR5+\n80-|\n60-\n40-\n20-\n0-\n**\nN\u00e3o\tInfectado\ninfectado\t(dia 6)\nD\nFigura 18. Express\u00e3o de CXCL9 e CXCL10 por MO-DCs de animais infectados com PbA. Esplen\u00f3citos foram coletados no sexto dia ap\u00f3s, a infec\u00e7\u00e3o com PbA, marcados com anticorpos fluorescentes e CD11c+CD11b+F4/80+DC-SIGN+MHCIIhigh MO-DCs purificadas por citometria de fluxo (Figura 1B) e analisadas para A. express\u00e3o de RNA de genes relacionados ao sistema imune utilizando o sistema de an\u00e1lise nCounter. Os resultados indicam um aumento na express\u00e3o g\u00eanica, quando comparado MO-DCs de tr\u00eas animais infectados por tr\u00eas controles. B. Microscopia confocal de ba\u00e7o um animal REX3 infectado. Pain\u00e9is superiores indicam marca\u00e7\u00f5es para F4/80+ (APC convertido em verde), CXCL9-RFP e CXCL10-BFP. Setas indicam c\u00e9lulas duplo e triplo positivas respectivamente. C. Animais REX3 infectados foram sacrificados no sexto dia ap\u00f3s infec\u00e7\u00e3o e MO-DCs do ba\u00e7o foram avaliadas quanto a express\u00e3o de CXCL9 e CXCL10. Janela primeiramente em c\u00e9lulas do ba\u00e7o duplo positivas para CXCL9 e CXCL10 e em seguida em c\u00e9lulas F4/80+CD11b+ e DC-SIGN+MHCII+. Todas as c\u00e9lulas CXCL9+CXCL10+F4/80+CD11b+DC-SIGN+MHCII+ s\u00e3o positivas para CDllc. D. C\u00e9lulas do ba\u00e7o foram coletadas no sexto dia ap\u00f3s a infec\u00e7\u00e3o e uma janela de exclus\u00e3o foi feita para selecionar c\u00e9lulas F4/80+CD11b+ e posteriormente em c\u00e9lulas CD11c+MHCII+. A maioria de MO-DCs de animais controle e animais infectados com PbA s\u00e3o CCR2+CCR5- e CCR2+CCR5+ respectivamente. Os dados s\u00e3o representativos de tr\u00eas experimentos independentes com tr\u00eas animais por grupo que reproduziram resultados similares.\n5.2.3\tC\u00e9lulas MO-DCs CCR5+CXCL9+CXCL10+ s\u00e3o encontradas no sistema nervoso central de animais infectados com PbA.\nPosteriormente, c\u00e9lulas MO-DCs foram avaliadas no sistema nervoso central (SNC) de animais com MCE. Para analisar a presen\u00e7a de MO-DCs no SNC de animais infectados com PbA, c\u00e9lulas mononucleares do c\u00e9rebro (CMNC) foram discriminadas em hematopoi\u00e9ticas CD45high e micr\u00f3glias (CD45interm). Uma vez que o infiltrado celular na MCE \u00e9 enriquecido por c\u00e9lulas T CD8+, foi feita uma sele\u00e7\u00e3o na janela da popula\u00e7\u00e3o celular CD45highCD8-. As c\u00e9lulas MO-DCs surgem no quinto dia ap\u00f3s infec\u00e7\u00e3o com PbA obtendo um pico no dia 7, o que coincide com a express\u00e3o de CXCL9 e CXCL10 e outros mediadores inflamat\u00f3rios no SNC (Figura 19A). Al\u00e9m disso, foi analisada a express\u00e3o de CXCL9, CXCL10 e CCR5 em c\u00e9lulas CMNC de animais infectados com PbA. Entretanto, n\u00e3o foi observado o aumento da express\u00e3o de CXCL9 e CXCL10 em animais REX3 controle (Figura 19B). Em animais REX3 infectados, c\u00e9lulas BFP+RFP+ s\u00e3o CD45high. As c\u00e9lulas CD45highCD8+ s\u00e3o BFP-RFP-, enquanto aproximadamente 60% de c\u00e9lulas CD45highCD8- s\u00e3o BFP+RFP+ (Figura 19C). C\u00e9lulas CD45interm como tamb\u00e9m CD45-, provavelmente microglia, neuronios/c\u00e9lulas gliais respectivamente, s\u00e3o ambas BFP e RFP negativas. Por fim, avaliamos a express\u00e3o de CCR2 e CCR5 em MO-DCs do SNC de animais infectados. Os resultados mostrados na figura 19D indicam que aproximadamente 60% de c\u00e9lulas MO-DCs do c\u00e9rebro de animais infectados, mas n\u00e3o de animais controle, s\u00e3o duplo positivas para CCR2 e CCR5.\nA\nB\nC\nD\nC\u00e9rebro\nCD45high CD11b* Ly6c* IVIHCIP CD11c* DC SIGN*\nDias$ap\u00f3s$infec\u00e7\u00e3o$\nCD45h\u00abh\n\u00b0CD8\nCD45hlghCD8\u2018\ncXCl\u00cdo\nCD45l\u00b0\u201c/\"eS\tCQ45low/neg CDg-\nCD8\tCXCL10\nCMNC\nCD45 (IFM)\nCD45|ow/nee\nCD8-\n96.1\nCD45I\u00b0\u00bb/\"<!S CD8-\nCD8\nFigura 19. Aumento da frequ\u00eancia de MO-DCs no c\u00e9rebro de animais infectados com PbA. A. MO-DCs (CD45highCD8'CD3'F480+Ly6C+DC-SIGN+) foram quantificados por citometria de fluxo em CMNC isoladas nos dias 0, 6 e 8 ap\u00f3s Infec\u00e7\u00e3o com PbA. B. CMNC de animais REX3 foram analisadas por citometria de fluxo nos dias 0 e 7 ap\u00f3s a .infec\u00e7\u00e3o. Em MO-DCs, foi feita uma janela em c\u00e9lulas CD45highCD8-. Aproximadamente 70% de c\u00e9lulas CD45high CD8- de animais infectados, mas n\u00e3o de controles, s\u00e3o duplo positivas para CXCL9 e CXCL10, RFP e BFP respectivamente. Oito por cento de c\u00e9lulas CD45highCD8-cXcL9+CXCL10+ s\u00e3o positivas para CDIIb, Ly6C, CDIIc e MHCII. CMNC, que s\u00e3o negativas ou expressam .n\u00edveis baixos de CD45, s\u00e3o negativas para CD8, RFP e BFP. Resultados representativos da sele\u00e7\u00e3o de CD45high pela citometria de fluxo s\u00e3o mostrados. C. CMNC foram coletadas de animais WT nos dias 0 e 7 ap\u00f3s infec\u00e7\u00e3o com PbA e a express\u00e3o de CCR2 e CCR5 foi avaliada em MO-DCs (c\u00e9lulas CD45highCD8-CD3-Ly6C+CD11b+) por citometria de fluxo. Dados representam a m\u00e9dia de tr\u00eas ou quatro animais por grupo e os resultados s\u00e3o representativos de tr\u00eas experimentos independentes. Diferen\u00e7as foram consideradas estatisticamente significativas quando *, p<0,05, e **, p<0,01 como indicado pelo teste t student.\n5.2.4\tIFNy induz a express\u00e3o de CXCL9 e CXCL10 em MO-DCs\nEstudos recentes tem desmonstrado que IFNy \u00e9 um importante mediador na diferencia\u00e7\u00e3o de MO-DCs87. Al\u00e9m disso, ambos IFNy e IFN do tipo I (IFNa/p) est\u00e3o relacionados com a express\u00e3o de CXCL9 e CXCL10 em macr\u00f3fagos. Com isso, utilizamos animais IFNy-/-, o REX3IFNyR-/-, infectados com PbA. Primeiramente, foi avaliado o perfil da express\u00e3o g\u00eanica em MO-DCs purificadas de animais C57BL/6 e IFNy-/- infectados. De 98 genes que a express\u00e3o foi induzida por PbA, 58 (60%) s\u00e3o dependentes de IFNy end\u00f3geno. A express\u00e3o de mRNA de CXCL9 e CXCL10 induzida pela infec\u00e7\u00e3o por PbA foi totalmente ausente em MO-DCs de animais IFNy-/-, enquanto o aumento da express\u00e3o de outros genes, como por exemplo CCR5, CCL7 e CCL8 foi independente de IFNy end\u00f3geno (Figura 20A). Coerentemente, MO-DCs de REX3, mas n\u00e3o animais REX3IFNyR-/-, expressaram elevados n\u00edveis de RFP e BFP (Figuras 20B e 20C). Avaliou-se tamb\u00e9m se IFNy \u00e9 necess\u00e1rio para a diferencia\u00e7\u00e3o de MO-DCs. Foi observado um ac\u00famulo de iMOs e uma redu\u00e7\u00e3o da frequ\u00eancia de MO-DCs em REX3/IFNyR-/- relativo aos animais REX3 e C57BL/6 infectados com PbA respectivamente (Figuras 20B e 20C). Estes resultados indicam que a diferencia\u00e7\u00e3o do precursor iMOs em MO-DCs \u00e9 afetada em animais quando o gene IFNyR n\u00e3o \u00e9 funcional.\nA\nCD11c+CD11b+ F4/80+ DC-SIGN+MHC iih\u00a1sh\nB\nAnimal REX3 Transg\u00e9nico\nCD11b\tMHC II\tCXCL10\nAnimal REX3 Transg\u00e9nico IFNyR/-\nCD11b\tMHC II\tCXCL10\nCD11b+ F4/80+\nG1- CD11b+ F4/80+ DC-SIGN + MHC+\nG2 - CD11b+ F4/80+ DC-SIGNint MHC-\n50-\n40-\n30-w\n20-\n10-\n0-\nG3 - CD11b+F480+ DC-SIGN- MHC II-\nCD11b+F480+DC-SIGN+\nMHC II+CXCL9+CXCL10+\nN\u00e3o infectado\tInfectado\tN\u00e3o infectado\tInfectado\tN\u00e3o infectado\tInfectado\n(dia 6)\t(d\u00eda 6)\t(dia 6)\nC\nFigura 20. Express\u00e3o de CXCL9 e CXCL10 por MO-DCs de animais infectados com PbA \u00e9 dependente de IFNy. Animais C57BL/6, IFNy-7' ou REX3/IFNyR-/- foram infectados e seus ba\u00e7os coletados no sexto dia ap\u00f3s infec\u00e7\u00e3o. A. A express\u00e3o g\u00eanica foi analisada pelo sistema de an\u00e1lise nCounter, em RNA total extra\u00eddo de MO-DCs altamente purificadas (aproximadamente 98% de pureza) do ba\u00e7o de animais C57BL/6 e IFNy-/- infectados. Dados s\u00e3o representados por m\u00e9dia da express\u00e3o g\u00eanica de tr\u00eas animais por grupo. B. Resultados representativos de citometria de fluxo s\u00e3o referentes a MO-DCs de ba\u00e7o de animais REX3 e REX3IFNyR-/-. Primeiramente foi feito uma janela incluindo c\u00e9lulas F4/80+CD11b+ (pain\u00e9is da esquerda) e depois c\u00e9lulas DC-SIGN+MHCIIhigh (painel do meio), e CXCL9 e CXCL10 duplo positivas (painel da direita), respectivamente. As porcentagens de MO-DCs (janela 1, F4/80+CD11b+DC-SIGN+MHCII+), iMOs (janela 2, F4/80+CD11b+DC-SIGN+MHCII-), MOs (janela 3, F4/80+CD11b+DC-SIGN-MHCII-) e CXCL9+ CXCL10+ MO-DCs est\u00e3o indicadas. C. Frequ\u00eancia das subpopula\u00e7\u00f5es de CD11b+F4/80+ no ba\u00e7o de animais REX3 e REX3IFNyR-/- infectados. A m\u00e9dia e desvio padr\u00e3o s\u00e3o representativos de experimentos distintos com tr\u00eas ou quatro animais por grupo. Diferen\u00e7as significativas foram consideradas estatisticamente quando **, p<0.01; and ****, p<0.0001 como indicado pela an\u00e1lise two-way ANOVA.\n5.2.5\tTLRs induzem a express\u00e3o de CXCL9 e CXCL10 em MO-DCs\nCheong et aP6. demonstrou que o LPS induz a diferencia\u00e7\u00e3o de iMOS para MO-DCs. Sabe-se tamb\u00e9m que a infec\u00e7\u00e3o por Plasmodium ativa o sistema imune inato primeiramente pela ativa\u00e7\u00e3o de TLR9 e outros receptores intracelulares que reconhecem \u00e1cidos nucl\u00e9icos42,57,82,83. A ativa\u00e7\u00e3o de TLR9 durante a infec\u00e7\u00e3o por PbA induz a produ\u00e7\u00e3o de IL-12 por DCs, culminando na produ\u00e7\u00e3o de IFNy primeiramente por linf\u00f3citos T. Por conseguinte, avaliamos se a infec\u00e7\u00e3o por PbA induzia a diferencia\u00e7\u00e3o de MO-DCs via ativa\u00e7\u00e3o de TLR. Para tanto, foi utilizado o E6446, um antagonista que previne a ativa\u00e7\u00e3o de TLR7 e TLR9 por ssRNA e DNA. Os dados mostrados na Figura 21A e 21B mostram que o tratamento com o E6446 inibe a express\u00e3o de mRNA de IFNy por esplen\u00f3citos e resulta na diminui\u00e7\u00e3o de n\u00edveis circulantes de IFNy no soro de animais no quinto dia ap\u00f3s infec\u00e7\u00e3o com PbA. Ademais, no quinto dia ap\u00f3s infec\u00e7\u00e3o, a propor\u00e7\u00e3o de linf\u00f3citos T CD4+ e T CD8+ (CD44high/CD62Ll0W) aumentou para 55.5% e 39.9% em animais infectados, quando comparado com 14.7% e 12.2% ou 27.8% e 10.2% em animais controles ou infectados e tratados com E6446, respectivamente (Figura 21C).\nA porcentagem de c\u00e9lulas T n\u00e3o ativadas (CD44loW/CD62Lhigh) foi inversalmente proporcional a c\u00e9lulas ativadas e observou-se uma redu\u00e7\u00e3o de 32.9% de linf\u00f3citos T CD4+ e 37.3% de linf\u00f3citos T CD8+ em animais infectados, quando comparado com 77.7% e 78.1% dos controles e 59.6% e 64% em animais infectados e tratados com E6446, respectivamente. Da mesma forma, o E6446 inibiu a express\u00e3o de IFNy tanto por linf\u00f3citos T CD4+ quanto por linf\u00f3citos T CD8+ de animais infectados. Os resultados apresentados na Figura 21D foram obtidos usando o camundongo GREAT que expressa o gene YFP no promotor IFNy. A express\u00e3o de YFP por linf\u00f3citos T CD4+ e linf\u00f3citos T CD8+ aumentou, respectivamente, de 2.16% para\n8.99% e 3.94% para 14.4%, quando comparado animais controle com infectados. Nos animais GREAT infectados com PbA e tratados com E6446 somente 3.05% e 4.60% de linf\u00f3citos T CD4+ e linf\u00f3citos T CD8+ expressaram YFP, respectivamente. Para avaliar a contribui\u00e7\u00e3o de c\u00e9lulas NK para a diferencia\u00e7\u00e3o de MO-DCs, foi utilizado animais RAG-/-, o qual \u00e9 deficiente em linf\u00f3citos T. Foi observado em animais RAG-/- infectados, que iMOS n\u00e3o se diferenciaram em MO-DCs. Estes resultados indicam que IFNy e/ou outros sinais provenientes de c\u00e9lulas NK n\u00e3o s\u00e3o o suficiente para promover a diferencia\u00e7\u00e3o de MO-DCs (Figura 21E). Como consequ\u00eancia da inibi\u00e7\u00e3o da produ\u00e7\u00e3o de IFNy por linf\u00f3citos T, o tratamento com E6446 tamb\u00e9m inibiu a express\u00e3o de mRNA de CXCL9 e CXCL10 (Figura 21F) bem como RFP (CXCL9) e BFP (CXCL10) por MO-DCs de animais REX3 infectados (Figura 21G).\n\nIFNy RT-PCR (ba\u00e7o)\nIFNy CBA (soro)\nE6446\n_______ infectado\nN\u00e3o infectado Ve\u00edculo\nD\nRAG-/- Controle RAG-/- Infectado\nCD11b+F4/80+CD11c+MHC IIhlgh DCs\nCXCL10\n0\nInfectado\nO~j 20\n1\u00b0\no\nWT Controle WT Infectado\nFigura 21. Tratamento com E6446 inibe a express\u00e3o de IFNy por linf\u00f3citos T bem como de CXCL9 e CXCL10 em MO-DCs. Animais C57BL/6, GREAT, e REX3 foram infectados com PbA e tratados com E6446 (120 mg/Kg/dia) ou ve\u00edculo do dia -1 a 3 ap\u00f3s infec\u00e7\u00e3o. A. Ba\u00e7os foram coletados de animais WT nos dias indicados, o RNA total foi extra\u00eddo e os n\u00edveis de express\u00e3o de mRNA de IFNy foram analisado por qPCR. Resultados foram normalizados pela express\u00e3o de RNA de p2 microblobulina. B. Soro de animais C57BL/6 infectados foi coletado em diferentes tempos ap\u00f3s infec\u00e7\u00e3o e usado para medir IFNy por CBA. O efeito inibit\u00f3rio de E6446 em n\u00edveis circulantes de IFNy foi avaliado no sexto dia ap\u00f3s infec\u00e7\u00e3o (painel da direita). C. Animais C57BL/6 foram tratados ou n\u00e3o com E6446 e os ba\u00e7os foram coletados no quinto dia ap\u00f3s infec\u00e7\u00e3o. Gr\u00e1fico de barras correspondem a porcentagem de c\u00e9lulas naive (CD62LhighCD44l0W) por c\u00e9lulas efetoras ativadas (CD62Ll0WCD44high) CD4+ T (pan\u00e9is superiores) e CD8+ T (pain\u00e9is inferiores). D. Esplen\u00f3citos de animais GREAT infectados foram estimulados com PMA (50 ng/mL) e ionomicina (500 ng/mL) por quatro horas em cultura contendo brefeldina A e em seguida, submetidos a citometria de fluxo. C\u00e9lulas YFP positivas foram consideradas como produtoras de IFNy em c\u00e9lulas T CD4+ (painel superior) e c\u00e9lulas T CD8+ (painel inferior). E. Ba\u00e7os de animais WT e RAG'/_ infectados com PbA ou n\u00e3o foram coletados e a frequ\u00eancia de MO-DCs foi analisada .por citometria de fluxo. Pain\u00e9is da direita e esquerda mostram a frequ\u00eancia de F4/80+ CD11b+ DC-SIGN+ MHCIIhigh e a express\u00e3o de CDIIc em MO-DCs respectivamente. F. qRT-PCR e G. an\u00e1lise por citometria de fluxo revelaram que o tratamento com E6446 inibe da express\u00e3o de mRNA de CXCL9 e CXCL10 no ba\u00e7o, assim como na express\u00e3o de prote\u00ednas RFP (CXCL9) e BFP (CXCL10) em MO-DCs do ba\u00e7o de animais infectados com PbA C57BL/6 e REX3 respectivamente. Resultados apresentados nos pain\u00e9is C,D,E e F s\u00e3o representativos de experimentos distintos com tr\u00eas ou cinco animais por grupo. Diferen\u00e7as foram consideradas estatisticamente significativas quando *, p<0,05; **, p<0,01; ***, p<0,001 como indicado pelo teste t student.\n5.2.6\tO recrutamento de MO-DCs para o SNC em animais infectados com PbA \u00e9 dependente de IFNy\nOs resultados apresentados nas figuras 22A e 22B mostram que a express\u00e3o de mRNA relacionado a CCL2, CCL3, CCL4, CCL5, CXCL9, CXCL10 e IFNy n\u00e3o \u00e9 observada ou \u00e9 reduzida no c\u00e9rebro de animais IFNy-/- infectados com PbA ou animais C57BL/6 infectados com PbA e tratados com E6446. Uma vez que MO-DCs expressam CCR2 (receptor para CCL2) e CCR5 (receptor para CCL3, CCL4 e CCL5), avaliou-se o surgimento de MO-DCs no c\u00e9rebro de animais IFNy-/-infectados com PbA bem como animais C57BL/6 tratados com E6446. Foi observado que, a migra\u00e7\u00e3o de MO-DCs para o c\u00e9rebro de animais IFNy-/- infectados e C57BL/6 tratados com E6446 foi afetada (Figura 23C). Consistente com a import\u00e2ncia de MO-DCs no recrutamento de linf\u00f3citos T CD8+ e o desenvolvimento da MCE, o n\u00famero de linf\u00f3citos T CD8+ foi reduzido, mas n\u00e3o foi ausente no SNC de animais IFNy-/- ou C57BL/6 tratados com E6446, ambos infectados com PbA.\nA\nB\n0.06-1\nCCL4\n0.020-1 CC|\n0.015-\n:L3\n0.010-\n0.005-\n0.000-\nT\n0.0004-1\n0.04-\n0.0002-\n0.02-\nr 0.0001-\n0.0000-\nC\nI.\nCD45high\nCD40-\nCD40+\nCD40-\nCD40+\nDia 7\nCD45\n10 10\"\nCD11b\nX Q CL &lt;O -'O i/i\n000\nO U\nT\n0.004\u2014*\nCMNC\nCD4 96.1\t0-\tCD40+ 3.24\n-io3\t103 104 105\nCD43-\tCD40+\t105-\t03.0\t\t\t10S-\n88.4 |\t11.6\tio4.\t\t,#\u25a0.\t\tio4- &lt;\u201c3: io2-\n\t\t\t8.06 \u25a1\t\t\t\n\t\t0&lt;\t\t\t\t0 l\nCXCL10\nWT Infectado (E6446) (dia 7)\nInfectado\n\u25a0 11 CD45highCD3-CD8-CD11b+ CD11c+DC-SIGNhighLy6C+\n\u25a1 CD45high CD3+ CD8+\n-I\nIFNy-/-\nInfect ado\n-I\nI\nFigura 22. Express\u00e3o de quimiocinas e o surgimento de c\u00e9lulas hematopoi\u00e9ticas CD45high para o SNC de animais infectad os com PbA \u00e9 dependente de IFNy. A express\u00e3o de mRNA de CCL2, CCL3, CCL4, CCL5, CXCL9, CXCL10 e IFNy foi analisada no c\u00e9rebro de animais controles ou infectados com PbA. A. An\u00e1lise g\u00eanica em animais IFNy-/- e C57BL/6 controles ou infectados com PbA (7 dias ap\u00f3s a infec\u00e7\u00e3o). B. Animais C57BL/6 controles, infectados (7 dias ap\u00f3s a infec\u00e7\u00e3o), tratados com E6446 (120 mg/kg/dia) ou ve\u00edculo. O RNA total foi extra\u00eddo e os n\u00edveis de express\u00e3o de mRNA foram analisado por qPCR. Resultados foram normalizados pela express\u00e3o de RNA de p2 microblobulina. C. An\u00e1lise por citometria de fluxo de MO-DCs do c\u00e9rebro (CD45highCD3-CD8-CD11b+Ly6C+CD11c+DC-SIGN+) de animais controles ou infectados com PbA, IFNy-/- ou C57BL/6 tratados ou n\u00e3o com E6446. Diferen\u00e7as foram consideradas estatisticamente significativas quando *, p<0,05; **, p<0,01; ***, p<0,001 como indicado pela an\u00e1lise two-way ANOVA.\n5.2.7\tO recrutamento de MO-DCs para o SNC em animais infectados com PbA \u00e9 dependente de CCR5\nHipotetizou-se que CCL2, CCL3, CCL4 e CCL5 s\u00e3o respons\u00e1veis pelo recrutamento de MO-DCs para o SNC de animais infectados com PbA. Nos resultados apresentados na Figura 23A, indicam que MO-DCs migram atrav\u00e9s de ambos gradiante de CCL2 ou CCL5, embora CCL5 mostrou-se mais eficiente. Tamb\u00e9m foi observado um efeito aditivo das duas quimiocinas. Como CCL2 e CCR2 s\u00e3o importantes no recrutamento de iMOS durante a infec\u00e7\u00e3o com Toxoplasma gondii and P. chabaudi77,85, avaliou-se o papel de CCR2 no desenvolvimento da MCE. O n\u00famero de MO-DCs no SNC de animais CCR2-/- infectados com PbA, foi marginalmente reduzido (Figura 23B). Al\u00e9m disso, a frequ\u00eancia e o n\u00famero de MO-DCs no SNC de animais CCR5-/- infectados com PbA foram drasticamente reduzidos (Figura 23C). Consistente com o n\u00famero de MO-DCs no SNC, animais CCR5-/-, mas n\u00e3o CCR2-/-, foram mais resistentes ao desenvolvimento da MCE que os animais WT infectados com PbA (Figura 23D). Mais de 80% de MO-DCs no SNC de animais C57BL/6 infectados expressaram CCR5. Entretanto, menos de 10% de linf\u00f3citos T CD4+ e linf\u00f3citos T CD8+ expressaram CCR5, enquanto mais de 90% expressaram CXCR3 (Figuras 24A e 24B). Consequentemente, hipotetizou-se que CCR5 \u00e9 um receptor chave para o recrutamento de MO-DCs para o SNC enquanto CXCR3 e seus ligantes CXCL9 e CXCL10 s\u00e3o respons\u00e1veis por atrair linf\u00f3citos T. Por fim, foram realizado experimentos in vivo para avaliar o papel de CCR5 no recrutamento de MO-DCs para o SNC. C\u00e9lulas MO-DCs purificados de ba\u00e7os de animais WT ou CCR5-/- infectados com PbA foram transferidas para animais WT no quinto dia ap\u00f3s a infec\u00e7\u00e3o e a migra\u00e7\u00e3o de MO-DCs marcadas com CFSE foi avaliada por 15 a 60 min ap\u00f3s a transfer\u00eancia celular. Foi observado um aumento na frequ\u00eancia de\n101 c\u00e9lulas MO-DCs de animais WT na microvasculatura e no par\u00eanquima do SNC. C\u00e9lulas MO-DCs de animais CCR5-/- infectados com PbA foram menos eficientes na migra\u00e7\u00e3o para o SNC de animais WT infectados. Nenhuma migra\u00e7\u00e3o de MO-DCs foi observada para o SNC de animais controles ou n\u00e3o infectados (Figura 24C).\no 1o3 104 1o5\nCD45\n-io3o 1o3\t104 1o5\nDC-SIGN\nCD45h'eh DC-SIGN+\nMHC-II+\nWT N\u00e3o infectado\n\u2014 CCR2-/- Infectado (dia 7)\n\u2014\u25a0 WT infectado (dia 7)\nCD3\nCD11b\n_ N\u00e3o infectado C57BL/6\n\u2014 Infectado C57BL/6 Infectad o CCR57/7\nns\nE\n4\nCD45+ CD3- CD8- CDllb+ Ly6c+\nCD11c\tDC-SIGN\nO\n+-\u00bb _3\nO\nin _Q\nCU\n2\nCU\nE o\n8x1Q03-\n6X1O03-\n4x1O03-\n2X1O03-\n0\nT\n2*\nh\ni\nFigura 23. Aumento da resistencia de animais CCR5-/- ao desenvolvimento da MCE. A. Migra\u00e7\u00e3o in vitro de c\u00e9lulas MO-DCs para diferentes concentra\u00e7\u00f5es de CCL2, CCL5 ou a combina\u00e7\u00e3o de ambos. B. An\u00e1lise por significativa na frequ\u00eancia e n\u00famero absoluto de CD45highCD11c+CD1lb+DC-SIGN+MHCII+F480+Ly6C+ no c\u00e9rebro de animais CCR2-/- infectados com PbA. C. An\u00e1lise por citometria de fluxo de MO-DCs no SNC em animais WT e CCR5-/- infectados com PbA. A frequ\u00eancia de CD45hlghCD8-CD3-CD11c+CD11b+DC-SIGN+Ly6C+ \u00e9 significantemente menor no c\u00e9rebro de animais CCR5-/- infectados com PbA. Resultados representativos da citometria de fluxo s\u00e3o apresentados ap\u00f3s a janela em CD45high para leuc\u00f3citos, excluindo c\u00e9lulas CD46interm e CD45-. D. Curva de sobreviv\u00eancia de animais C57BL/6, CCR2-/- e CCR5-/- infectados com PbA. Os resultados s\u00e3o representativos de dois experimentos independentes com tr\u00eas a cinco animais por grupo. Diferen\u00e7as foram consideradas estatisticamente significativas quando * p<0,01 como indicado pelo teste t student. A curva de sobreviv\u00eancia foi analisada pelo teste log-rank e animais CCR5-/- apresentaram-se mais resistente a infec\u00e7\u00e3o por PbA, quando comparado com animais CCR2\u2019/_ ou WT (p<0,01).\nA\nB\nC\nMO-DCs\nCD11b\nCXCR3+CCR5+\nCXCR3-CCR5-\nCXCR3+CCR5-\nMHCII\nCXCR3-CCR5+\nLinfocito T CD3+ CD4+\nLinfocito T CD3+ CD8+\nCD11c\n*\nFigura 24. Migra\u00e7\u00e3o de c\u00e9lulas MO-DCs para o SNC de animais infectados com PbA \u00e9 dependente de CCR5. A. An\u00e1lise por citometria de fluxo de c\u00e9lulas MO-DCs e linf\u00f3citos T expressando CXCR3 bem como CCR5 no SNC de animais infectados com PbA. CMNC de animais infectados com PbA obtidas na janela inicial CD45high e ent\u00e3o CD3+CD8+ ou CD3+CD4+ e analisadas quanto a express\u00e3o de CXCR3 e CCR5. C\u00e9lulas CD45high foram selecionadas em CD11b+Ly6C+MHCII+CD11c+ e logo ap\u00f3s analisadas quanto a express\u00e3o de CCR5. B. Gr\u00e1ficos superiores mostram a frequ\u00eancia de linf\u00f3citos T CD4+, linf\u00f3citos T CD8+ bem como MO-DCs no c\u00e9rebro de animais C57BL/6 em diferentes tempos ap\u00f3s infec\u00e7\u00e3o com PbA. Pain\u00e9is inferiores mostram a frequ\u00eancia de linf\u00f3citos T CD4+ e linf\u00f3citos T CD8+ expressando CXCR3 e CCR5, e tamb\u00e9m MO-DCs expressando CCR5. C. Imagens in vivo de MO-DCs no SNC de animais infectados com PbA. C\u00e9lulas MO-DCs enriquecidas foram obtidas de animais WT e CCR5-/- no quinto dia ap\u00f3s infec\u00e7\u00e3o, coradas com CFSE e transferidas para animais WT infectados e controles. A presen\u00e7a de c\u00e9lulas marcadas com CFSE foi detectada na microvasculatura e no par\u00e9nquima cerebral por microscopia confocal entre 15 a 60 min ap\u00f3s o in\u00f3culo das c\u00e9lulas pelo plexo orbital. Os resultados s\u00e3o representativos de quatro experimentos independentes. Diferen\u00e7as foram consideradas estatisticamente significativas quando * p<0,01 como indicado pelo teste t student.\n6 DISCUSS\u00c3O\n6 DISCUSS\u00c3O\nA mal\u00e1ria \u00e9 uma das doen\u00e7as mais importantes do mundo, e afeta aproximadamente 200 milh\u00f5es de pessoas por ano, causando altas taxas de morbidade e mortalidade em aproximadamente meio milh\u00e3o de crian\u00e7as anualmente O paroxismo, uma das principais respostas fisiopatologicas a infec\u00e7\u00e3o por Plasmodium, \u00e9 caracterizado por ciclos agudos de febre alta acompanhada por calafrios, que coincidem com a ruptura sincronizada de gl\u00f3bulos vermelhos (hem\u00e1cias) e a libera\u00e7\u00e3o de parasitas. Embora a febre possa ajudar na defesa, retardando o crescimento de agentes patog\u00eanicos, ela tamb\u00e9m est\u00e1 associada a diversos processos patol\u00f3gicos, tais como sintomas associados a sepse como cefaleia, mialgia, letargia, assim como insufici\u00eancia respirat\u00f3ria e manifesta\u00e7\u00f5es neurol\u00f3gicas que causam morbidade e mortalidade na mal\u00e1ria20.\nO objetivo geral desta tese foi o de estudar os mecanismos pelos quais a infec\u00e7\u00e3o com Plasmodium ativa o sistema imune inato, levando a inflama\u00e7\u00e3o sist\u00eamica e tecidual, que causam muitos dos sintomas e sinais da mal\u00e1ria. Em primeiro lugar, utilizando amostras de pacientes com mal\u00e1ria, interrogamos sobre o papel pr\u00f3-inflamat\u00f3rio de ICs durante mal\u00e1ria. Em um segundo cap\u00edtulo, estudamos a diferencia\u00e7\u00e3o e o papel de c\u00e9lulas MO-DCs na mal\u00e1ria cerebral murina. De uma maneira geral nossos estudos indicam que a ativa\u00e7\u00e3o de mon\u00f3citos e DCs por IFNy end\u00f3geno e \u00e1cido nucleicos do parasita tem um importante papel na ativa\u00e7\u00e3o do sistema imune inato e na patog\u00eanese da mal\u00e1ria.\nOs ICs s\u00e3o considerados parte da defesa imunit\u00e1ria contra ant\u00edgenos sol\u00faveis. Sua forma\u00e7\u00e3o se d\u00e1 quando anticorpos policlonais se ligam a ant\u00edgenos polivalentes gerando um amplo complexo ant\u00edgeno-anticorpo. S\u00e3o consequ\u00eancias inevit\u00e1veis de uma resposta imune efetiva, no intuito de eliminar patog\u00eanos. Em alguns casos, a forma\u00e7\u00e3o excessiva de leva a sua deposi\u00e7\u00e3o em tecidos com sequelas devido a atividade pro-inflamat\u00f3ria dos ICs. A elimina\u00e7\u00e3o de ICs \u00e9 um processo delicado, e sua reten\u00e7\u00e3o nos tecidos est\u00e1 associada a uma variedade de doen\u00e7as de cunho inflamat\u00f3rio, devido a fixa\u00e7\u00e3o de complemento e ativa\u00e7\u00e3o de c\u00e9lulas do sistema imune inato atrav\u00e9s de receptores Fcy49,51.\nLES \u00e9 considerado uma doen\u00e7a autoimune que apresenta altos n\u00edveis de ICs circulantes, principalmente contra ant\u00edgenos nucleares pr\u00f3prios, tais como histonas e \u00e1cidos nucl\u00e9icos, principalmente DNA de cadeia dupla (dsDNA). Estes ICs s\u00e3o depositados em org\u00e3os, mantendo uma resposta inflamat\u00f3ria, o que leva a sintomatologia da doen\u00e7a48.\nTendo em vista a import\u00e2ncia de \u00e1cidos nucl\u00e9icos na forma\u00e7\u00e3o de ICs e na ativa\u00e7\u00e3o de c\u00e9lulas da imunidade inata, torna-se importante o estudo do papel deste agregado molecular na patog\u00eanese da mal\u00e1ria. O DNA e o RNA derivado do Plasmodium estimulam TLRs e receptores citos\u00f3licos que ativam TBK1, STING e via IRF3, al\u00e9m de induzirem a forma\u00e7\u00e3o de plataformas multiprot\u00e9icas, os inflamassomas. Como conseq\u00fc\u00eancia, eles ativam tanto a via de transcri\u00e7\u00e3o NF-k\u00f3 quanto IFN do tipo l44,58\\ Contudo, como os \u00e1cidos nucl\u00e9icos do parasita se tornam acess\u00edveis a receptores intracelulares da imunidade inata ainda n\u00e3o \u00e9 bem compreendido.\nEstudos recentes demonstram que a hemozo\u00edna, um pol\u00edmero da mol\u00e9cula heme, formada durante a degrada\u00e7\u00e3o da hemoglobina pelo parasito e liberada na ruptura de gl\u00f3bulos vermelhos, tem um papel importante no transporte de DNA para o meio intracelular. A hemozo\u00edna nativa se liga ao DNA do Plasmodium carreando para o fagolisosoma de c\u00e9lulas fagoc\u00edticas, quando \u00e9 fagocitada por mon\u00f3citos, macr\u00f3fagos e c\u00e9lulas dendr\u00edticas. Deste modo, ao atingir o compartimento endossomal o DNA do parasita ativa o TLR9. Al\u00e9m disso, os cristais de hemozo\u00edna desestabilizam a membrana do fagolisossomo, liberando o seu conte\u00fado, que inclui \u00e1cidos nucl\u00e9icos do parasito, para o citosol da c\u00e9lula do hospedeiro, culminando na forma\u00e7\u00e3o de inflamassomas e ativando outros receptores citos\u00f3licos que reconhecem DNA e RNA42,43.\nAl\u00e9m disto, a fagocitose de gl\u00f3bulos vermelhos infectados tamb\u00e9m pode resultar na libera\u00e7\u00e3o de hemozo\u00edna e \u00e1cidos n\u00facleicos do parasito no fagolisossomo e, consequentemente, culminando da ativa\u00e7\u00e3o dos TLRs e receptores da imunidade inata citos\u00f3licos. Portanto, a opsoniza\u00e7\u00e3o por IgG, que medeia com efic\u00e1cia a fagocitose de gl\u00f3bulos vermelhos infectados bem como componentes do parasito, deve contribuir para a ativa\u00e7\u00e3o da imunidade inata durante a mal\u00e1ria. O papel dos anticorpos como carreadores de componentes do parasita para o interior de c\u00e9lulas fagoc\u00edticas, quer seja atrav\u00e9s forma\u00e7\u00e3o de ICs ou opsoniza\u00e7\u00e3o de gl\u00f3bulos vermelhos infectados parecem ser especialmente relevantes na infec\u00e7\u00e3o com P. vivax, uma vez que na infec\u00e7\u00e3o com esta esp\u00e9cie do Plasmodium a parasitemia e o n\u00edvel de dep\u00f3sitos de hemozo\u00edna s\u00e3o bem menores que na infec\u00e7\u00e3o com P. falciparum43.\nOs resultados apresentados nesta tese, indicam como previamente descrito para o LES48,67,68, que ICs presentes na circula\u00e7\u00e3o de pacientes com mal\u00e1ria cont\u00e9m\nDNA, do parasita, e estimulam mon\u00f3citos a expressar uma assinatura transcricional induzida pelo fator de transcri\u00e7\u00e3o NF-Kb. Al\u00e9m disso, observamos que os ICs isolados do soro de pacientes com mal\u00e1ria causada por P. vivax ou P. falciparum induzem a produ\u00e7\u00e3o de citocinas pr\u00f3-inflamat\u00f3rias por mon\u00f3citos inflamat\u00f3rios. Neste estudo, tamb\u00e9m observamos que ICs, purificados de pacientes com mal\u00e1ria, induzem a forma\u00e7\u00e3o de inflamassomas contendo NLRP3 e ASC bem como AIM2 e ASC em mon\u00f3citos humanos. Sendo assim, hipotetizamos que ICs dos pacientes com mal\u00e1ria se ligam a receptores Fcy e s\u00e3o internalizados, liberando DNA do parasito no fagolisossomos e posteriormente no citosol de mon\u00f3citos, onde eles ativam TLRs endossomais e AIM2, respectivamente. A indu\u00e7\u00e3o e a forma\u00e7\u00e3o de inflamassomas e a ativa\u00e7\u00e3o de caspase-1 requer a ativa\u00e7\u00e3o da via NF-kB, por exemplo, por agonistas de TLR ou citocinas, que levam a express\u00e3o dos componentes do inflamassoma (NLRs, pr\u00f3-caspase-1 e pr\u00f3-ILip) Acreditamos que, de forma an\u00e1loga a hemozo\u00edna, os ICs circulantes em pacientes com mal\u00e1ria transportam DNA do Plasmodium, ir\u00e1 ativar os TLRs endosomais, tais como TLR7, TLR8 e TLR9, servindo como primeiro sinal para a indu\u00e7\u00e3o de inflamassomas. Simulataneamente, os ICs induzem instabilidade na membrana de fagolisossomos e liberam seus componentes no citosol da c\u00e9lulas, induzindo a forma\u00e7\u00e3o de inflamassomas como NLPR3 e AIM2 em mon\u00f3citos humanos.\nDesestabiliza\u00e7\u00e3o fagossomal e libera\u00e7\u00e3o de catepsina\nCNBP? SKIV2L2?\nFigura 25. Ativa\u00e7\u00e3o de receptores da imunidade inata por hemozo\u00edna (Hz) ou imunocomplexos (ICs). Internaliza\u00e7\u00e3o de Hz ou ICs resulta na libera\u00e7\u00e3o de DNA do parasito no fagolisossomo, onde haver\u00e1 a ativa\u00e7\u00e3o de TLR9. Hz e ICs desestabilizam a membrana do fagolisossomo liberando o seu conte\u00fado. No citosol de c\u00e9lulas hospedeiras, os cristais de Hz e ICs ativam NLRP3, enquanto o DNA do parasito ativa AIM2 e cGAS. A ativa\u00e7\u00e3o desdes receptores da imunidade inata resulta na express\u00e3o de genes que codificam IFN do tipo I e de outras citocinas pro-inflamat\u00f3rias (IL-1 p, IL-18 e TNF -a). A ativa\u00e7\u00e3o destas vias da imunidade inata \u00e9 a base da inflama\u00e7\u00e3o sist\u00eamica, sintomas e sinais da mal\u00e1ria.\nOs mon\u00f3citos constituem uma popula\u00e7\u00e3o de c\u00e9lulas heterog\u00eaneas, constituindo a primeira linha de defesa contra microrganismos. Estas c\u00e9lulas podem ser distinguidas pela express\u00e3o de CD1424. Diferentes membros da fam\u00edlia dos receptores Fcy podem estar com a express\u00e3o aumentada ou diminu\u00edda durante os processos infecciosos. Por exemplo, a ativa\u00e7\u00e3o de FCyRIIIA (CD16a) ou FCyRI (CD64) promove uma resposta pro-inflamat\u00f3ria, aumentando a capacidade de endocitose e fagocitose de ICs, enquanto FCyRIIB (CD32) leva a uma resposta anti-\ninflamat\u00f3ria. Sendo assim, a sinaliza\u00e7\u00e3o simult\u00e2nea de ativa\u00e7\u00e3o e inibi\u00e7\u00e3o de receptores Fcy define um limiar para a ativa\u00e7\u00e3o celular impedindo uma resposta inflamat\u00f3ria excessiva. De acordo com os resultados encontrados, ap\u00f3s estimulo com ICs, mon\u00f3citos CD14+ FCyRI(CD64)+ CD16(FcYRIIIA)+ CD32(FcYRIIB)l0W s\u00e3o as principais fontes de citocinas pr\u00f3-inflamat\u00f3rias em c\u00e9lulas mononucleares de sangue perif\u00e9rico de pacientes com mal\u00e1ria49,51. Deste modo, o aumento da express\u00e3o de FcyRI e FcyRIIIA associada a uma diminui\u00e7\u00e3o da express\u00e3o de FcYRIIB+ em mon\u00f3citos de pacientes com mal\u00e1ria parece tender a uma produ\u00e7\u00e3o excessiva de citocinas e a uma resposta inflamat\u00f3ria sist\u00eamica.\nAl\u00e9m disso, as citocinas s\u00e3o tamb\u00e9m de grande import\u00e2ncia para determinar a capacidade de ICs de estimular respostas pro-inflamat\u00f3rias ou anti-inflamat\u00f3rias49. Por exemplo, dependendo da forma cl\u00ednica da doen\u00e7a, a infec\u00e7\u00e3o com Leishmania induz uma resposta pr\u00f3-inflamat\u00f3ria ou anti-inflamat\u00f3ria caracterizadas por produ\u00e7\u00e3o elevada de TNFa/IFNY ou IL-10, respectivamente70. Observamos que em pacientes com mal\u00e1ria na fase aguda, ICs induzem mon\u00f3citos a produzirem altos n\u00edveis de TNFa e IL-1 p e baixos n\u00edveis de IL-10. Este padr\u00e3o na produ\u00e7\u00e3o de citocinas muda para anti-inflamat\u00f3rio ap\u00f3s o tratamento e cura parasitol\u00f3gica do indiv\u00edduo. Da mesma forma, mon\u00f3citos de doadores saud\u00e1veis estimulados com ICs produzem elevados n\u00edveis de IL-10 e baixos n\u00edveis de TNFa e IL-ip, enquanto ap\u00f3s a sensibiliza\u00e7\u00e3o com IFNy, a produ\u00e7\u00e3o de citocinas pr\u00f3-inflamat\u00f3rias se torna dominante. Como demonstrado em nossos estudos, a citocina IFNy promove a express\u00e3o de CD64, enquanto inibe a express\u00e3o de CD32. Al\u00e9m disto, a um aumento na frequ\u00eancia dos mon\u00f3citos CD16+ na circula\u00e7\u00e3o de pacientes com mal\u00e1ria aguda, explicando em parte a mudan\u00e7a funcional destas c\u00e9lulas durante a\nmal\u00e1ria.\n\u00c9 importante mencionar que em estudos pr\u00e9vios, observou-se que crian\u00e7as africanas com mal\u00e1ria grave, infectadas com P. falciparum, apresentaram n\u00edveis elevados de ICs circulante, quando comparado com adultos ou crian\u00e7as com a doen\u00e7a moderada71. Al\u00e9m disso, trabalho mostram que adultos sintom\u00e1ticos bem como crian\u00e7as africanas infectadas com P. falciparum s\u00e3o hiper responsivos a agonistas de TLR, como por exemplo CpG23,72. Por outro lado, indiv\u00edduos imunes na \u00c1frica, que est\u00e3o continuamente expostos ao P. falciparum, s\u00e3o mais tolerantes a 73\ndoen\u00e7a e menos responsivos a agonistas de TLR9, e portanto, devem ser menos responsivos a ICs contendo DNA que est\u00e3o em altos n\u00edveis na circula\u00e7\u00e3o de pacientes com mal\u00e1ria. Concluindo, muitos sinais e sintomas da mal\u00e1ria s\u00e3o resultado da ativa\u00e7\u00e3o excessiva de c\u00e9lulas da imunidade inata. Nossos dados fornecem evid\u00eancias que ICs s\u00e3o de grande import\u00e2ncia neste processo.\nApesar das diferentes manifesta\u00e7\u00f5es cl\u00ednicas e etiologia, existem similaridades entre a mal\u00e1ria e o l\u00fapus eritematoso sist\u00eamico (LES). Em ambas as doen\u00e7as, DNA e RNA s\u00e3o respons\u00e1veis por ativar receptores da imunidade inata e induzir inflama\u00e7\u00e3o sist\u00eamica42,43,44. A ativa\u00e7\u00e3o de sensores de \u00e1cidos nucl\u00e9icos via TLRs pode ser patog\u00eanica ou conferir prote\u00e7\u00e3o, tanto no LES quanto na mal\u00e1ria45. Da mesma forma, o TNFa, citocina induzida pela ativa\u00e7\u00e3o de TLRs pode mediar resist\u00eancia ou patog\u00eanese, seja no LES, seja na mal\u00e1ria46,47. Curiosamente, por muitas d\u00e9cadas, diferentes medicamentos contra a mal\u00e1ria t\u00eam sido utilizados regularmente no tratamento do LES, como por exemplo a cloroquina. O mecanismo de a\u00e7\u00e3o destas drogas caracteriza-se por elevar o pH de lisossomas e, por conseguinte, previne a ativa\u00e7\u00e3o de TLRs endossomais, isto \u00e9 TLR7, TLR8 e TLR946. \u00c9 de grande import\u00e2ncia a compreens\u00e3o de como os \u00e1cidos nucl\u00e9icos t\u00eam acesso aos TLRs endossomais para o entendimento da patog\u00eanese do LES e da mal\u00e1ria.\nNo LES, imunocomplexos (ICs) contendo anticorpos patog\u00eanicos anti-DNA de dupla fita podem ser importantes transportadores de DNA e RNA humano para o compartimento intracelular de c\u00e9lulas B e fag\u00f3citos, onde ativam TLRs endossomais e outros sensores citos\u00f3licos de DNA. \u00c9 importante ressaltar que elevados n\u00edveis de ICs, tamb\u00e9m s\u00e3o encontrados em pacientes com mal\u00e1ria36,45,48. Contudo, a import\u00e2ncia de ICs contendo DNA na ativa\u00e7\u00e3o de c\u00e9lulas da imunidade inata e patog\u00eanese da mal\u00e1ria \u00e9 desconhecida.\nA fam\u00edlia de receptores Fcy pode ser classificada de acordo com a homologia estrutural, afinidade e especificidade \u00e0s subclasses de IgG, express\u00e3o nas c\u00e9lulas e fun\u00e7\u00f5es biol\u00f3gicas, obtendo um papel importante na internaliza\u00e7\u00e3o de ICs por c\u00e9lulas do sistema imune inato. Uma vez ligado \u00e0 por\u00e7\u00e3o Fc de IgGs, estes receptores podem ser classificados como receptores de ativa\u00e7\u00e3o (FcyRI - CD64, FcyRIII - CD16) ou de inibi\u00e7\u00e3o (FcyRII - CD32). Isso resulta na sua capacidade de estimular ou inibir fun\u00e7\u00f5es como fagocitose, citotoxicidade, degranula\u00e7\u00e3o, apresenta\u00e7\u00e3o de ant\u00edgenos e produ\u00e7\u00e3o de citocinas via ITAM (do ingl\u00eas, immunoreceptor tyrosine-based activation motif) ou ITIM (do ingl\u00eas, immunoreceptor tyrosine-based inhibition motif)49.\nDe acordo com as fun\u00e7\u00f5es biol\u00f3gicas e localiza\u00e7\u00e3o no cromossomo, os receptores Fcy podem estar relacionados \u00e0 suscetibilidade ao LES. Um grande n\u00famero de polimorfismos tem sido descrito entre as sequ\u00eancias g\u00eanicas que codificam os receptores FcyRIIa, llb e lllb. Al\u00e9m do mais, polimorfismos de um \u00fanico nucleot\u00eddeo (SNP, do ingl\u00e9s, single nucleotide polymorphism) observados nestes genes apresentam fun\u00e7\u00f5es biol\u00f3gicas diferentes entre os gen\u00f3tipos encontrados49,50.\nA incid\u00eancia de LES \u00e9, em m\u00e9dia, tr\u00eas vezes maior em popula\u00e7\u00f5es africanas ou asi\u00e1ticas que em caucasianos. Nestas popula\u00e7\u00f5es observa-se uma maior\nfrequ\u00eancia de homozigose associada a FcyRIIB7232. Essa altera\u00e7\u00e3o \u00e9 comumente encontrada em regi\u00f5es end\u00eamicas de mal\u00e1ria. Uma disfun\u00e7\u00e3o em FcyRIIB pode resultar numa vantagem para a sobreviv\u00eancia contra a doen\u00e7a. Em humanos, a express\u00e3o de FcyRIIB7232 aumenta a fagocitose de eritr\u00f3citos infectados com P. falciparum opsonizados por macr\u00f3fagos in vitro. Al\u00e9m disso, a homozigose para FcyRIIB7232 est\u00e1 associada a uma prote\u00e7\u00e3o consider\u00e1vel contra a mal\u00e1ria grave em crian\u00e7as do K\u00eania. Portanto, a perda da fun\u00e7\u00e3o do polimorfismo no gene que codifica o FcyRIIB, protege contra a mal\u00e1ria por\u00e9m, aumenta a suscetibilidade ao LES51. Contudo, estudos sugerem que os ICs parecem ter um importante papel na patog\u00eanese da mal\u00e1ria.\n6.2\tPapel de mon\u00f3citos e DCs durante a mal\u00e1ria\nAs DCs e iMOS desempenham pap\u00e9is importantes na resist\u00eancia ao Plasmodium e patog\u00eanese da mal\u00e1ria. De fato, h\u00e1 uma distribui\u00e7\u00e3o din\u00e2mica dos iMOS e subpopula\u00e7\u00f5es de DCs no ba\u00e7o de animais com infec\u00e7\u00e3o aguda, que varia de acordo com o tempo de infec\u00e7\u00e3o, esp\u00e9cie do Plasmodium e sua virul\u00eancia63. iMOS e DCs podem internalizar e destruir os gl\u00f3bulos vermelhos infectados no ba\u00e7o e mediar a resist\u00eancia \u00e0 infec\u00e7\u00e3o P. chabaudi em camundongos. Al\u00e9m disso, as DCs durante a fase eritroc\u00edtica na infec\u00e7\u00e3o por P. chabaudi s\u00e3o capazes de produzir elevados n\u00edveis de IL-12 que induzem a produ\u00e7\u00e3o de IFNy por linf\u00f3citos 7 e c\u00e9lulas NK. Por sua vez, IFNy ativa os macr\u00f3fagos, e estes produzem metab\u00f3litos potencialmente t\u00f3xicos, tais como esp\u00e9cie reativa de oxig\u00eanio (ROS) e nitrog\u00eanio (RNS), que mediam a resist\u00eancia do hospedeiro \u00e0 infec\u00e7\u00e3o por Plasmodium em camundogos74.\nOs iMOS e DCs tamb\u00e9m desempenham um papel fundamental na resposta inflamat\u00f3ria delet\u00e9ria e patog\u00eanese da mal\u00e1ria em roedores. As DCs promovem o aumento de citocinas no sangue e perda de peso em animais infectados com P. chabaudF5. Tanto iMOS quanto DCs s\u00e3o necess\u00e1rias para o recrutamento de c\u00e9lulas T CD8+ e o desenvolvimento da neuroinflama\u00e7\u00e3o observada na mal\u00e1ria murina65,75,76. No modelo da MCE, observamos que a maioria das c\u00e9lulas CD11c+ MHCIIhigh no ba\u00e7o de animais infectados com PbA, tamb\u00e9m \u00e9 DC-SIGNhighCD11b+F4/80+, consistente com o fen\u00f3tipo de MO-DCs. Em estudos pr\u00e9vios utilizando o modelo murino com P. chabaudi, observou-se em iMOS, a baixa express\u00e3o de CD11c, bem como uma redu\u00e7\u00e3o na frequ\u00eancia de c\u00e9lulas CD11c+ que s\u00e3o CD11b+F4/80+77,78. Os resultados apresentados nesta tese sugerem que em animais infectados com PbA, iMOS e MOs espl\u00eanicos s\u00e3o progenitores das MO-DCs. Ao passo que a frequ\u00eancia e o n\u00famero de MO-DCs est\u00e3o aumentadas significativamente, os mesmo par\u00e2metros para iMOS e MOs est\u00e3o diminu\u00eddos, entre as c\u00e9lulas CD11b+F4/80+ do ba\u00e7o de animais infectados com PbA. Ademais, a popula\u00e7\u00e3o de c\u00e9lulas MO-DCs apresentam varia\u00e7\u00f5es na express\u00e3o de Ly6C. Enquanto iMOS s\u00e3o classicamente Ly6Chigh, propomos que c\u00e9lulas Ly6Chigh MO-DCs s\u00e3o recentemente diferenciadas, enquanto Ly6Cl0W MO-DCs s\u00e3o totalmente diferenciadas. Notavelmente, determinamos que c\u00e9lulas MO-DCs induzidas pela mal\u00e1ria, e n\u00e3o iMOS ou MOs, expressam elevados n\u00edveis de CCR5, CXCL9 e CXCL10 que s\u00e3o de grande relev\u00e2ncia para o desenvolvimento MCE.\nAp\u00f3s est\u00edmulo microbiano por meio de TLRs ou citocinas, iMOS podem se diferenciar em macrofagos ou MO-DCs, migrando para org\u00e3os linf\u00f3ides e n\u00e3o linf\u00f3ides67,79. O IFNy tem um papel fundamental na resist\u00eancia do hospedeiro a infec\u00e7\u00e3o por Plasmodium. Al\u00e9m disso, \u00e9 um importante mediador na patog\u00eanese da\nmal\u00e1ria. O aumento de IFNy circulante durante a infec\u00e7\u00e3o por Plasmodium, leva a uma sensibiliza\u00e7\u00e3o pr\u00f3 inflamatoria que promove a inflama\u00e7\u00e3o sist\u00eamica20. No caso da MCE, o tratamento com anticorpos neutralizantes anti-IFNy ou a infec\u00e7\u00e3o em camundongos IFNy-/- com PbA impede a neuroinflama\u00e7\u00e3o e consequentemente a letalidade. Diferentes fun\u00e7\u00f5es s\u00e3o atribu\u00eddas para o IFNy no desenvolvimento de MCE, que inclui o aumento na produ\u00e7\u00e3o de citocinas pr\u00f3-inflamat\u00f3rias e quimiocinas, bem como o aumento da express\u00e3o de mol\u00e9culas de ades\u00e3o em c\u00e9lulas endoteliais da vasculature cerebral80. Muito importante para este estudo, animais CXCL9-/-, CXCL10-/- e CXCR3-/- apresentam um infiltrado menos intenso de c\u00e9lulas T CD8+ no SNC e s\u00e3o mais resistentes ao desenvolvimento de MCE81. De acordo com os nossos resultados, a diferencia\u00e7\u00e3o de MO-DCs \u00e9 prejudicada e a express\u00e3o de CXCL9 e CXCL10 \u00e9 abolida em animais IFNy7' ou IFNyR'1'. J\u00e1 a express\u00e3o de CCR5 por MO-DCs parece ocorrer independente da produ\u00e7\u00e3o de IFNy.\nDiferentes estudos sugerem que TLR7 e TLR9 s\u00e3o importantes receptores que est\u00e3o envolvidos na ativa\u00e7\u00e3o de DCs e na produ\u00e7\u00e3o de IL-12 e consequentemente de IFNy, tanto na mal\u00e1ria humana, quanto no modelo murino experimental42,55,82,83. No presente estudo observamos que o composto lisossomo-tr\u00f3pico (E6446), que se liga ao RNA e DNA e bloqueia a ativa\u00e7\u00e3o dos receptores TLR7 e TLR9, previne o desenvolvimento da MCE. Quando administrado durante os primeiros tr\u00eas dias de infec\u00e7\u00e3o, o tratamento com E6446 inibe a ativa\u00e7\u00e3o e a produ\u00e7\u00e3o de IFNy por ambas as c\u00e9lulas T CD4+ e T CD8+. Como consequ\u00eancia, a express\u00e3o de CXCL9 e CXCL10 por MO-DC n\u00e3o foi induzida em animais infectados com PbA e tratados com E6446. Estes resultados corroboram estudo anterior que mostra que IFNy produzido pelas c\u00e9lulas T CD4+ induz a express\u00e3o de CXCL9 e\nCXCL10 e promove o recrutamento de c\u00e9lulas T CD8+ patog\u00eanicas para o c\u00e9rebro\n75 de animais infectados com PbA75.\nNo nosso trabalho tamb\u00e9m observamos o surgimento de MO-DCs CXCL9+ CXCL10+ no c\u00e9rebro de animais infectados com PbA. C\u00e9lulas hematopoi\u00e9ticas (CD3-CD8-CD45high) apresentaram-se em n\u00famero elevado, sendo que, a maior parte delas, expressa CDIIb, F4/80, DC-SIGN, Ly6C, MHC II e CDIIc. O aumento da frequ\u00eancia de MO-DCs CCR5+CXCL9+ CXCL10+ coincidiu com o aumento na express\u00e3o de mRNA de CXCL9 e CXCL10 no SNC de animais infectados com PbA. Tamb\u00e9m foi observado que MO-DCs CD45high s\u00e3o as principais fontes de CXCL9 e CXCL10 (c\u00e9lulas RFP+ BFP+) no c\u00e9rebro de animais REX3 infectados com PbA. Sendo assim, MO-DCs CCR5+CXCL9+CXCL10+ parecem desempenhar um papel fundamental no recrutamento e ativa\u00e7\u00e3o de c\u00e9lulas T CD4+ e T CD8+ durante a MCE.\nUm quest\u00e3o importante gerada pelos nossos resultados \u00e9 se MO-DCs diferenciam de iMOS recrutados para o SNC ou se s\u00e3o diretamente recrutados do ba\u00e7o a partir de MO-DCs espl\u00eanicos CCR5+ CXCL9+ CXCL10+. Com base na literatura, salienta-se que tanto iMOS quanto MO-DCs expressam CCR2. Demonstra-se que CCL2 e CCR2 s\u00e3o importantes no egresso de iMOS da medula \u00f3ssea, ba\u00e7o e na migra\u00e7\u00e3o para o local da infec\u00e7\u00e3o e na resist\u00eancia do hospedeiro aos protozo\u00e1rios P. chabaudi e Toxoplasma gondii84,85. Contudo, observamos que a frequ\u00eancia de MO-DCs no c\u00e9rebro de animais CCR2-/- infectados com PbA foi marginalmente afetada e a suscetibilidade a MCE n\u00e3o se alterou. \u00c9 importante ressaltar que, como dito anteriormente, o n\u00famero total de iMOS no ba\u00e7o foi consideravelmente reduzido em animais CCR2-/- infectados com PbA. De acordo com nossos dados, observamos um aumento na popula\u00e7\u00e3o de MOs (CD11c-MHCII-\nDC-SIGN-) que se tornaram Ly6Chigh dentro de esplen\u00f3citos que s\u00e3o CDIIb e F4/80 positivos em animais CCR2-/- infectados com PbA. Com isso propomos que em animais CCR2-/- infectados, MOs Ly6Chigh s\u00e3o os principais precursores de MO-DCs.\nEm nosso trabalho tamb\u00e9m observamos que as MO-DCs induzidas pela mal\u00e1ria experimental expressam elevados n\u00edveis de CCR5. O mesmo n\u00e3o foi observado em iMOS. Animais CCR5-/- apresentam mais resist\u00eancia a infec\u00e7\u00e3o por PbA por\u00e9m, o mecanismo pelo qual o CCR5 medeia a MCE n\u00e3o \u00e9 bem definido. A aus\u00eancia de CCR5 n\u00e3o teve impacto na diferencia\u00e7\u00e3o de MO-DCs no ba\u00e7o, mas afetou claramente o surgimento de MO-DCs no c\u00e9rebro de animais infectados com PbA. 7odos os agonistas de CCR5 (CCL2, CCL3 e CCL5) s\u00e3o expressos no c\u00e9rebro de animais infectados com PbA e podem agir em conjunto para recrutar MO-DCs CCR5+ CXCL9+ CXCL10+. Embora c\u00e9lulas 7 CD8+ CXCR3+ n\u00e3o expressem CCR5, sua migra\u00e7\u00e3o para o c\u00e9rebro tamb\u00e9m foi comprometida em animais CCR5-/-infectados. Estes resultados s\u00e3o consistentes com a hip\u00f3tese de um circuito de amplifica\u00e7\u00e3o entre MO-DCs (fonte importante de ligantes ao CXCR3) e linf\u00f3citos 7 CD8+ (fonte importante de ligantes CCR5) no recrutamento durante a MCE, como foi recentemente proposto para c\u00e9lulas monoc\u00edticas Ly6C+ e c\u00e9lulas 7 CD8+.\nCXCR3\nDisfun\u00e7\u00e3o endotelial\nCXCR3\nTNFa\nDCs Convencionais\nEritrocitos infectados\nMon\u00f3citos Inflamat\u00f3rios\n\u00cdF\u00d1y/TNFa IH\u201d\n\u2019\u2019\u2019^J\u2019jFNy'\"\u2018j\nCD8 T '\nTNFa\npcrr\t/W 1\nCCR5+CXCL9/10 MO-DC !\n! ) W\u00ca\u00bb \u2022\t!\n&lt;!\nFigura 26. C\u00e9lulas dendr\u00edticas derivadas de mon\u00f3citos (MO-DCs) na mal\u00e1ria cerebral experimental. A infec\u00e7\u00e3o com PbA leva a ativa\u00e7\u00e3o de DC convencionais e induz a diferencia\u00e7\u00e3o de mon\u00f3citos inflamat\u00f3rios (\u00a1MOS) por meio de IFNy para MO-DCs do ba\u00e7o que expressam altos n\u00edveis de CCR5, CXCL9 e CXCL10 (MO-DCs CCR5+ CXCL9+ CxCl10+). Hipotetizamos que ap\u00f3s a diferencia\u00e7\u00e3o , MO-DCs CCR5+ CXCL9+ CXCL10+ migram para 0 sistema nervoso central em resposta aos ligantes de CCR5 (CCL3, CCL4 e CCL5) amplificando 0 recrutamento de linf\u00f3citos T CD8+, iniciado por c\u00e9lulas endoteliais expressando CXCL10 e promovendo 0 desenvolvimento de MCE.\nConcluindo, como ilustrado na figura 26 nossos dados s\u00e3o consistentes com o modelo de mal\u00e1ria cerebral onde a infec\u00e7\u00e3o com PbA induz uma diferencia\u00e7\u00e3o massiva de MO-DCs no ba\u00e7o, o qual posteriormente emerge no SNC mediando a MCE. A diferencia\u00e7\u00e3o e a ativa\u00e7\u00e3o de MO-DCs no ba\u00e7o \u00e9 mediada por IFNy e receptores de \u00e1cidos nucl\u00e9icos. Estas c\u00e9lulas ent\u00e3o, migram para o c\u00e9rebro, de uma forma dependente da express\u00e3o de CCR5, levando a um aumento da express\u00e3o de CXCL9 e CXCL10 e o recrutamento de linf\u00f3citos T patog\u00eanicos CXCR3+CD8+, no\nSNC de animais infectados com PbA.\n7 CONCLUS\u00c3O\n7 CONCLUS\u00c3O\nComo conclus\u00e3o, muitos dos sinais e sintomas da mal\u00e1ria s\u00e3o resultado da ativa\u00e7\u00e3o excessiva das c\u00e9lulas da imunidade inata. O presente trabalho fornece evid\u00eancias de que ICs s\u00e3o importantes nesse processo. Baseado em nossos resultados, ICs parecem transportar DNA do parasito ao compartimento interior de c\u00e9lulas do hospedeiro, tornando-os acess\u00edveis aos sensores intracelulares da imunidade inata, incluindo a ativa\u00e7\u00e3o de inflammasomas e libera\u00e7\u00e3o de IL-1 p.\nAl\u00e9m disso, ap\u00f3s se diferenciarem no ba\u00e7o, MO-DCs migram para o c\u00e9rebro de uma maneira dependente de CCR5 e independente de CCR2, amplificando o influxo de linf\u00f3citos T CD8+ contribuindo para a patog\u00eanese da mal\u00e1ria, levando a inflama\u00e7\u00e3o neurol\u00f3gica letal.\nREFER\u00caNCIAS\nREFER\u00caNCIAS\n1.\tKrafts, Hempelmann. Bad air, amulets and mosquitoes: 2,000 years of changing perspectives on malaria. Malaria Journal 12, 232-245 (2013).\n2.\tCunha, B.A., Cunha C.B. Brief history of the clinical diagnosis of malaria: from Hippocrates to Osler. J. Vector Borne Dis. 45, 194-199 (2008).\n3.\tCenters for disease control and prevention. The history of malaria, an ancient disease. Dispon\u00edvel em: http://www.cdc.gov/malaria/about/history. Acesso em: 16 mar 2016.\n4.\tCox, FE. History of the discovery of the malaria parasites and their vectors. Cox Parasites &amp; Vectors 3, 5-14 (2010).\n5.\tNobel prize. The nobel prize in physiology or medicine 1907.\nDispon\u00edvel em: http://www.nobelprize.org/nobel prizes/medicine/laureates/\n1907. Acesso em: 16 mar 2016.\n6.\tGolgi, C. On the cycle of development of malarial parasites in tertian fever: differential diagnosis between the intracellular parasites of tertian and quartant fever. Archivio per le Scienza Mediche 13, 173-196 (1889).\n7.\tWagner, J., Bruetsch, W. L. The history of the malaria treatment of general paralysis. Am. J. Psychiatry 102, 577-582 (1946).\n8.\tNobel prize. The treatment of dementia paralytica by malaria inoculation.\nDispon\u00edvel em:&lt;http://www.nobelprize.org/nobel prizes/medicine/laureates/ 1927/wagner-jauregg-lecture.html> Acesso em: 16 mar 2016.\n9.\tNobel prize. The nobel prize in physiology or medicine 1902.\nDispon\u00edvel em:&lt;http://www.nobelprize.org/nobel prizes/medicine/laureates/\n1902. Acesso em: 16 mar 2016.\n10.\tNobel prize. Dichloro-Diphenyl-Trichloroethane and newer insecticides. http://www.nobelprize.org/nobel_prizes/medicine/laureates/1948/mullerlecture.html. Acesso em: 16 mar 2016.\n11.\tYouyou Tu. The discovery of artemisinan (qinghaosu) and gifts from Chinese medicine. Nature Medicine 17, 1217-1220 (2011).\n12.\tNobel prize. A novel therapy against malaria.\tDispon\u00edvel em:\n<http://www.nobelprize.org/nobel prizes/medicine/laureates/2015/tu-facts.html> Acesso em: 16 mar 2016.\n13.\tAlonso, P. Tanner, M. Public health challenges and prospects for malaria control and elimination. Nature Medicine 19, 150-155.\n14.\tWorld Health Organization: Malaria. WHO, 2015.\n15.\tMinist\u00e9rio da Sa\u00fade. Situa\u00e7\u00e3o Epidemiol\u00f3gica da Mal\u00e1ria no Brasil, ano de 2015. Dispon\u00edvel em:&lt;www.saude.gov.br/svs>. Acesso em 10 fev 2016.\n16.\tOliveira-Ferreira, J. et al. Malaria in Brazil: an overview. Malaria Journal 9, 115130.\n17.\tSilva-Nunes, M. et al.. Amazonian malaria: Asymptomatic human reservoirs, diagnoctic challenges, environmentally driven changes in mosquito vector populations, and the mandate for sustainable control strategies. Acta Tropica 121, 281-291 (2012).\n18.\tMINIST\u00c9RIO DA SA\u00daDE. Manual de diagn\u00f3stico laboratorial da mal\u00e1ria. Bras\u00edlia, 2005. 118p.\n19.\tRenaud, F., Michalakis, Y. Evolution in vector control. Nature 462, 298-300 (2009).\n20.\tGazzinelli, R.T., Kalantari, P., Fitzgerald, K.A. &amp; Golenbock, D.T. Innate sensing of malaria parasites. Nature rev. Immunol. 14, 744-757 (2014).\n21.\tDrakeley, C. et al. Asymptomatic malaria infections: detectability, transmissibility and public health relevance. Nature rev. Microbiol. 12, 833-840 (2014).\n22.\tAnstey, N. et al. The pathophysiology of vivax malaria. Trends in Parasitology\n25,\t220-227 (2009).\n23.\tFranklin, B. et al. Malaria primes the innate immune response due to interferongamma induced enhancement of toll-like receptor expression and function. Proceedings of the National Academy of Sciences of the United States of America 106, 5789-5794 (2009).\n24.\tAntonelli, L.R., et al. The CD14+CD16+ inflammatory monocyte subset displays increased mitochondrial activity and effector function during acute Plasmodium vivax malaria. Plos Pathog. 10, e1004393 (2014).\n25.\tAnstey, N. M. et al. Plasmodium vivax: clinical spectrum, risk factors and pathogenesis. Adv. Parasitol. 80, 151-201 (2012).\n26.\tMiller, L. et al. Malaria biology and disease pathogenesis: insights for new treatments. Nature Medicine 19, 156-168 (2013).\n27.\tClark, I. et al. Human malarial disease: a consequence of inflammatory cytokine release. Malaria Journal 5, 85-117 (2006).\n28.\tChang, K., Stevenson, M. Malarial anaemia: mechanisms and implications of insufficient erythropoiesis during blood-stage malaria. Int. J. Parasitol 34, 1501-1516 (2004).\n29.\tAwandare, G. et al. Mechanisms of erythropoiesis inhibition by malarial pigment and malaria-induced proinflammatory mediators in an in vitro model. Am. J. Hematol. 86, 155-162 (2011).\n30.\tBuffet, P. et al. The pathogeneses of Plasmodium falciparum malaria in humans: insights from splenic physiology. Blood 117, 381-394 (2011).\n31.\tScherf, A., Lopez-Rubio, J. Riviere, L. Antigenic variation in Plasmodium falciparum. Annu. Rev. Microbiol. 62, 445-470 (2008).\n32.\tIdro, R., Jenkins, N. Newton, C. Pathogenesis, clinical features, and neurological outcome of cerebral malaria. Lancet Neurol. 4, 827-840 (2005)\n33.\tRogerson, S. et al. Malaria in pregnancy: pathogenesis and immunity. Lancet Infect. Dis. 7, 105-117 (2007).\n34.\tTakeuchi, O, Akira, S. Pattern recognition receptors and inflammation. Cell 140, 805-820 (2010).\n35.\tO'Neil, L., Golenbock, D. Bowie, A. The history of Toll-like receptors - redefining innate immunity. Nature rev. Immunol. 13, 453-460 (2013).\n36.\tBarbalat, R. et al. Nucleic acid recognition by the innate immune system. Annu. Rev. Immunol. 29, 185-214 (2011).\n37.\tSchroder, K. Tschopp, J. The inflammasomes. Cell 140, 821-832 (2010).\n38.\tMantel, P. Marti, M. The role of extracellular vesicles in Plasmodium and other protozoan parasite. Cell. Microbiol. 16, 344-354 (2014).\n39.\tOrengo, J. et al. Plasmodium-induced inflammation by uric acid. Plos Pathog. 4, e1000013 (2008).\n40.\tFerreira, A. et al. Sickle hemoglobin confers tolerance to Plasmodium infection. Cell 145, 398-409 (2011).\n41.\tDurai, P., Govindaraj, R., Choi, S. Structure and dynamic behavior of toll-like receptor 2 subfamily triggered by malarial glycosylphosphatidylinositols of Plasmodium falciparum. FEBS J. 280, 6196-6212 (2013).\n42.\tParroche P. et al. Malaria hemozoin is immunologically inert but radically enhances innate responses by presenting malaria DNA to Toll-like receptor 9. Proceedings of the National Academy of Sciences of the United States of America 104:1919-1924 (2007).\n43.\tKalantari P., et al. Dual engagement of the NLRP3 and AIM2 inflammasomes by plasmodium-derived hemozoin and DNA during malaria. Cell Reports 6, 196-210 (2014).\n44.\tSharma, S., et al. Innate immune recognition of an AT-rich stem-loop DNA motif in the Plasmodium falciparum genome. Immunity 35, 194-207 (2011).\n45.\tBarrat, F.J., Coffman, R.L. Development of TLR inhibitors for the treatment of autoimmune diseases. Immunol. Rev. 223, 271-283 (2008).\n46.\tRonnblom, L., Elkon, K. Cytokines as therapeutic targets in SLE. Nature rev. Rheumatology 6, 339-347 (2010).\n47.\tGrau, G. et al.Tumor necrosis factor (cachectin) as an essential mediator in murine cerebral malaria. Science 237,1210-1212 (1987).\n48.\tMeans T. et al. Human lupus autoantibody-DNA complexes activate DCs through cooperation of CD32 and TlR9. J. Clin. Invest. 115, 407-4l7 (2005).\n49.\tNimmerjahn, F., Ravetch, J. Fcgamma receptors as regulators of immune responses. Nature rev. Immunol. 8, 34-47 (2008).\n50.\tPierre, B. et al. Specificity and affinity of human Fcg receptors and their polymorphic variants for human IgG subclasses. Blood 113, 3716-3725 (2008).\n51.\tKenneth, G. Smith, K., Clatworthy, M. FcgRIlB in autoimmunity and infection: evolutionary and therapeutic implications. Nature rev. Immunol. 10, 328-343 (2010).\n54.\tFranke-Fayard, B. et al. Sequestration and tissue accumulation of human malaria parasites: can we learn anything from rodent models of malaria ? Plos Pathog 6, e1001032 (2010).\n55.\tFranklin, B.S., et al. MyD88-dependent activation of dendritic cells and CD4(+) T lymphocytes mediates symptoms, but is not required for the immunological control of parasites during rodent malaria. Microbes and Infection / Institut Pasteur 9, 881-890 (2007).\n56.\tAdachi, K. et al. Plasmodium berghei infection in mice induces liver injury by an IL-12- and toll-like receptor/myeloid differentiation factor 88-dependent mechanism. J. Immunol. 167, 5928-5934 (2001).\n57.\tFranklin, B.S., et al. Therapeutical targeting of nucleic acid-sensing Toll-like receptors prevents experimental cerebral malaria. Proceedings of the National Academy of Sciences of the United States of America 108, 3689-3694 (2011).\n58.\tLiehl, P. et al. Host-cell sensors for Plasmodium activate innate immunity against liver-stage infection. Nature Medicine 20, 47-55 (2014).\n59.\tMiller, J. et al. Interferon-mediated innate immune responses against malaria parasite liver stages. Cell Reports 7, 436-447 (2014).\n60.\tGeissmann, F., et al. Development of monocytes, macrophages, and dendritic cells. Science 327, 656-661 (2010).\n61.\tDavies, L.C., Jenkins, S.J., Allen, J.E. &amp; Taylor, P.R. Tissue-resident macrophages. Nature Immunol. 14, 986-995 (2013).\n62.\tGordon, S., Pluddemann, A. &amp; Martinez Estrada, F. Macrophage heterogeneity in tissues: phenotypic diversity and functions. Immunol Rev 262, 36-55 (2014).\n63.\tWykes, M.N. &amp; Good, M.F. What really happens to dendritic cells during malaria? Nature rev. Microbiol. 6, 864-870 (2008).\n64.\tdeWalick, S., et al. Cutting edge: conventional dendritic cells are the critical APC required for the induction of experimental cerebral malaria. J. Immunol. 178, 60336037 (2007).\n65.\tPai, S., et al. Real-time imagining reveals the dynamics of leukocyte behaviour during experimental cerebral malaria pathogenesis. Plos Pathog. 10, e1004236 (2014).\n66.\tMurray, C. J. et al. Global malaria mortality between 1980 and 2010: a systematic analysis. Lancet 379, 413-431 (2012).\n67.\tCros, J. et al. Human CD14dim monocytes patrol and sense nuclei acids and viruses via TLR7 and TLR8 receptors. Immunity 33, 375-386 (2010).\n68.\tDean, J. A. et al. Control of Toll-like receptor 7 expression is essencial to restrict autoimmunity and dendritic cell proliferation. Immunity 27, 801-810 (2007).\n69.\tAtaide, M. A. et al. Malaria-induced NLRP12/NLRP3-dependent caspase-1 activation mediates inflammation and hypersensibility to bacterial superinfection. Plos Pathog. 10, e1003885 (2014).\n70.\tElshafie, A. L. et al. Circulating immune complexes (IC) and IC-induced levels of GM-CSF are increased in Sudanese patients with acute visceral Leishmania donovani infection undergoing sodium stibogluconate treatment: implications for disease pathogenesis. J. Immunol. 178, 5383-5389 (2007).\n71.\tThomas, B. et al. Circulating immune complex levels are associated with disease severity and seasonality in children with malaria from Mali. Biomark Insights 7, 81-86 (2012).\n72.\tHartgers, F. C. et al. Enhanced Toll-like receptor responsiveness associated with mitogen-activated protein kinase activation in Plasmodium falciparum-infected children. Infect Immun. 76, 5149-5157 (2008).\n73.\tCrompton, P. D. et al. The TLR9 ligand CpG promotes the acquisition of Plasmodium falciparumspecific memory B cells in malaria-naive individuals. J. Immunol. 182, 3318-3326 (2009).\n74.\tIng, R., et al. Interaction of mouse dendritic cells and malaria-infected erythrocytes: uptake, maturation, and antigen presentation. J. Immunol. 176, 441-450 (2006).\n75.\tCampanella, G.S., et al. Chemokine receptor CXCR3 and its ligands CXCL9 and CXCL10 are required for the development of murine cerebral malaria. Proceedings of\nthe National Academy of Sciences of the United States of America 105, 4814-4819 (2008).\n76.\tdeWalick, S., et al. Cutting edge: conventional dendritic cells are the critical APC required for the induction of experimental cerebral malaria. J. Immunol. 178, 60336037 (2007).\n77.\tSponaas, A.M., et al. Migrating monocytes recruited to the spleen play an important role in control of blood stage malaria. Blood 114, 5522-5531 (2009).\n78.\tBorges da Silva, H., et al. In vivo approaches reveal a key role for DCs in CD4+ T cell activation and parasite clearance during the acute phase of experimental bloodstage malaria. Plos Pathog. 11, e1004598 (2015).\n79.\tBogunovic, M., et al. Origin of the lamina propria dendritic cell network. Immunity 31, 513-525 (2009).\n80.\tVillegas-Mendez, A., et al. IFN-gamma-producing CD4+ T cells promote experimental cerebral malaria by modulating CD8+ T cell accumulation within the brain. J. Immunol. 189, 968-979 (2012).\n81.\tNie, C.Q., et al. IP-10-mediated T cell homing promotes cerebral inflammation over splenic immunity to malaria infection. Plos Pathog. 5, e1000369 (2009).\n82.\tGowda, N.M., Wu, X. &amp; Gowda, D.C. TLR9 and MyD88 are crucial for the development of protective immunity to malaria. J. Immunol. 188, 5073-5085 (2012).\n83.\tGuermonprez, P., et al. Inflammatory Flt3l is essential to mobilize dendritic cells and for T cell responses during Plasmodium infection. Nature Medicine 19, 730-738 (2013).\n84.\tSponaas, A.M., et al. Migrating monocytes recruited to the spleen play an important role in control of blood stage malaria. Blood 114, 5522-5531 (2009).\n85.\tDunay, I.R., et al. Gr1(+) inflammatory monocytes are required for mucosal resistance to the pathogen Toxoplasma gondii. Immunity 29, 306-317 (2008).\n86.\tCheong, C., et al. Microbial stimulation fully differentiates monocytes to DC-SIGN/CD209(+) dendritic cells for immune T cell areas. Cell 143, 416-429 (2010).\n87.\tGoldszmid, R.S., et al. NK cell-derived interferon-gamma orchestrates cellular dynamics and the differentiation of monocytes into dendritic cells at the site of infection. Immunity 36, 1047-1059 (2012).\nANEXO\nRf S\u00ed ARCH ARTICLE\n(g)^\nDNA-Containing Immunocomplexes Promote Inflammasome Assembly and Release of Pyrogenic Cytokines by CD14+ CD16+ CD64hl8*\u2019 CD3210* Inflammatory Monocytes from Malaria Patients\nIsabala C. Hlrako,\" Carohna Gall-ago-Mann?* Marco A. Ata*fe.*'d Warrtson A. Andrade.*b Humberto Gravlna? Bruno C. Rocha,wd Rosan\u00bb B. do Otoralra? Dhollo B. Parara.* Joseph Vtnrtz,' Betty Diamond,\u00bb Sanjay Ram? Douglas T. Golanbodt,*-\u2018> Ricardo T. Gaaatnolb**\u00bb\nCentra 3a RasqiBa ftrc Sbcrou F indopo DsaMdo Crac Sic Horscnu. Mnas Gras, Bran t DMbon&lt;r stocacus Oseaos ano lorninotaay. Urnrarslty tf Massachusetts Vadea Schoo. WoKodsr. Vasar-usrtts USA* Centra rroracKrJ de Encaramadoe rnaaaacxnas MedcasCXeM CaA Coontsa Lcpatamarn: de \u00edoi.r, ,; rn.-oozu raijo da Otoca BcHqcas J-\u00edvsri\u00bb:S\u00f3e Fahral X Vras Laras MMMnBRMUIGnh :>--f Cann: de trac rasa am UecScru Tropea. Podo Ato R\u00f3ndense Braa \u2022 Sr boa&lt;3 Madero. UrMnty 3 CaBbrnta San Daao San Daoo. CMSorrsa USA1, Canear lor Auearrmm a\u201cd Musnfoaactal Lbasws The raSTdss'i nstluls fbr Msdcal ibssasch Marfiasaef New Vtrt, USA\"\nILHmdCG U,mdD.TGmi RJG, aytMr rsvVrfcUai Io Ita aoA.\n8\n9\n5\n6\nI z\nI\n5\n\u00e1\nDespite different etiologies and dinical manifestations, there are many parallels between malaria and systemic lupus erythematosus (SLE). In both diseases, nucleic adds are thought to be responsible for activating innate immune sensors and promoting systemic inflammation (1-41. Activation of nudoc-acidsensing Toll-lie receptors (NAS-TLRs) may be either pathogenic or protective in both SLE (5-81 and malaria (9-12). Likewise, tumor necrosis factor alpha (TNF-w), a cytokine induced by TLR activa-\nbon. can either mediate resistance or enhance the pathogenesis of either disease (13-16). Intriguingly, far many decades effective antimalarial drugs have been rued to treat SLE patients. These drags accumulate in lysosomes, where they raise the pH. and are thought to mitigate the symptoms of SLE by preventing activation of endosomal TLIls (17).\nHow nucleic adds gain access to intracellular innate immune receptors is an important question in understanding the patho-\ngenesis of SLE and malaria (7). In SLE. immunocompieses I ICs) containing pathogenic anti-DNA/BNA antibodies are thought to be important carriers of human nucleic adds to the intracellular compartments of B cdls and phagocytes, where they can activate the endosomal TLBs and possibly transit In the cytoplasm, where other DNA sensors can be engaged (4,7,8,18,19). Importantly, high levds of IQ are also found in both human and rodent malaria (20-22). However, the importance of DN A-con taming IQ in activation of innate immune cells and pathogenesis of malaria is unknown.\nThe IgC Fc receptors have an important role in internalization of IQ by innate immune cells. Once bound to the Fc portion of IgC. Fc receptors can inhibit (eg.. FcyRIlB) or activate (e.g, FcyRIlIA and FcyRl) monocyte functions (23). Indeed, a loss-of-function polymorphism in the gene encoding the deactivating FcyfUIB protects against malaria but enhances susceptibility to SLE (24-28).\nIn this study, we report that IQ containing Pfesnodiion DNA activate intracellular DNA sensors. Our data indicate a previously undescribed roie of the protnflammatory activity of ICs by dan onstrating their ability to induce inflammasome assembly, caspase-1 activation, and interlesiinlp (1L-10) secretion, primarily via CDI4- CD16 (FcyRUIA)* CD64 (FcyRl)\u00bb1* CD32 (FcyRJIB)*\u2019* monocytes. Our findings have important implications for understanding the role of ICs and monocyte subsets in malaria pathogenesis and, more broadly, for understanding other infectious and autoimmune diseases.\nRESULTS\nIncreased levels of cytokines and circulating IQ in sera of maLaria patients. The levels of IL-6, IL-8,and IL-10 in the plasma of malaria patients used in th is study (see Fig. SI in the supplemental material) are consistent with our prior data (29.30). To evaluate the immune-stimulatory properties of sera from malaria patients, we incubated peripheral blood mononudear cells {PSMQ) from healthy donors with RPM1 medium containing 20% sera from either Plasmodium vriax-or Piasnodium fofapiirwn-infected subjects. We found that only sera from malaria patients, not those from healthy controls, triggered TNF-w production (Kg IA). The TNF-o levels were undetectable in samtlariy diluted (20%) patient sera (data not shown), ensuring that it was released from monocytes and not presented a priori in the tissue culture medium.\nWe hypothesized that circulating IQ were responsible for stimulating monocytes. Indeed, we detected high levels of IQ in sera of the same patients with acute untreated malaria I Fig IB). The levels of IQ were also measured in sera from P. sriuz- infected patients before and after chemotherapy and compared with healthy donors as baseline controls. We found high levels of IQ in sera from patients during acute P muz episodes (mean. -16.1 isg-equivalents Ipg-eqVml) compared to healthy donors I mean. -23 /i geq-'ml). The 1C lends in the sera of treated patients were intermediate (mean. -12.1 pg-eq/ml) and differed significantly from patient serum pretreatment and healthy controls ( Fig. IC). We found no correlation between the level of IQ and parasitemia.\n\n\n\nrr\u00e0\u00bb mbia.wm.stg 3\nI>NA in a highly sensitive and Pkasnodrarrt species-spectric man ncT. We observed increased levels of both human and parasite DNA in the plasma of P vivox malaria patients before treatment Circulating human DNA persisted, although at lower levels, wheresu parasite DNA was not detectable in plasma following an timalarial chemotherapy (Fig. 3A). Stmiarly. parasite DNA was detected in purified ICs from P vrsux malaria patients before and (at much lower levels) after treatment Human DNA was detected at very low levels in IC preparations from the same patients (Fig. 3B i. Bentonase treatment degraded DNA and confirmed the presence of DNA in ICs from malaria patients I Fig. 3C).\nAn NF-kB transcriptional signature in monocytes stimulated with IC*. We next profiled mllN A expression of highly enriched monocytes {over 999t purity) collected from four healthy donors (Fig. 4). A custom code set for NanoString analyas was designed for 96 genes rdated to inflammatory responses. Gena were divided into six groups: NOD like receptor signaling pathway, TLR signaling pathway NF-kB signaling pathway, cytolunes and cytokine receptors; adhsion molecules, chemokina, and chemokine receptors: and interferon i IFNI stimulated genes Of these. 27 genes had augmented expression upon IC stimulation (fold change, > 1.8; P value.&lt;0.05) (see Table SI in the supplemental material). Of the 27 differentially expressed genes, five were from the NF-kB family, and most of the genes with enhanced expression were proinflammatory cytokines and chemokines known to be induced by NF-kB I Fig. 4).\nICs derived from malaria patients induce cytokine prodnc tion by human monocytes. We then examined if ICs from malaria\nanti daDNA Igdf M\nyetaos\nV \u2022 \u2022>\n\u2022 \u2022\u2022\nF1C3 H^lrvtlser turnanand psradti DNA tn ptaona aod tCsoTI*. matan* patlrnu, IA and El Quanntacw RCR tn \u00f3ssmtm kvds o\u00ed hucm CYCU.VD1 (OCA'Di anl P. omSSMM &lt;183 han rRNAl pacs e plasma trena P. \u00abwxpact\u00e9is \u00edn - 24) beftrr and 30 to 43 days z*.rr tnatment as wit aatnlan\u2014y iliai<rs(\u00bb - SKAladDNAtxndadnompmlMICseunP. wms matar\u00eda mtacnts\u00eda- 8) bcrtxcasd 30 k>43 daysaftrr triarme: as wtl n tiextry donen&lt;n - 5) (B)-(C) Q-o-rn catire o\u00ed rota DNAenradul ten portnsd icsRom P mu malaria potxnts (a - 4 ) txAxc and altar Bmzcnass triatmmt mi dinerales an Indfcaaed \u00abrttti P ratas mtag a parad rtasL\n------1----------------->--------1-------\u25a0\t\u25a0------ \u2122----------------------I'.vir\nFIC 2 rtqp kvm of urcnladng anti dtf)NA In pattens endegetng amir agtotfos of ft \u00bbn\u00abz nd ft Unpmuv matrix Uvds ar ctailattag aU-taDNA IgC(tcp) and IgM bcixm meanrrd by ELISA In sera Rm patents \u00ab\u25a0naaittepkodncrp.wwslv- SI)mdP.>dhgwwv(i<- 2Simatartaand xnnlsomt loony. IndMluals 30 tn 45 days after antimalxlal scrapy Sera tram mteltcted Iwaktry doom icontrol; \u25a0 - 28) anl \u25a0epus padenb I\u00ab - It) wet used as nqptrvc and posatvv xntrdx rcsccdlwfy Sytihcan: dthn \u25a0xn ar Indicated with P nluesusrig the Maan Whtney U mt. NS. rondg rrArant.\nCirculating ICs from malaria patients contain Plasmodium DNA. We next measured the levds of IgM and IgC specific for double-stranded DNA (dsDNA) and single-stranded DNA (ss-DNAI in the \u00abra of P. vrvux- and P. faldpanm- infected patterns. As in SLE patients, the levels of antidsDNA IgC and IgM were significantly increased in the sera of acutely infected patients over those tn sera from healthy donors (Fig 21. Anti-dsDNA IgC per sisted at least 30 to 40 days after treatment and parasitological cure in either P. vrrax- or P. fekiparww-infected individuals. In contrast, anti ssDNA IgC and IgM levels in malaria patients did not differ from the corresponding levels measured in healthy donors I data not shown).\nThe levels of human and parasite DNA present in ICs and total plasma from malaria patients wse determined by quantitative PCR using CCND/- and SSL'rRNA specifsc primers. CCNDI > a single-copy gene optimized to quantify human DNA Ihap-'i' www.rtprimsdb.org, primer ID 36(b). SSUrRNA is a multicopy gene from P. vhux. which allows amplification and quantitation of\nDNA levels in plasma\nns\ng-bOMr\nDNA levels in plasma\nduced high levels of IL-Ip and TNF\u00ab. but not IL-IO. upon stim-dation with ICs (Fig. 6A). As shown in Rg. 6B. and in Fig. S4 in the supplemental material (and previously reported/, the frequency of CD 14* CD 16 (FcyftlllA) * cells is increased in patients with acute P. sfvux infection and drops tn levds seen in healthy individuals 30 to tO days postlreatment!34.35). Furthermore, we defined CDI4* CD16* cells as the primary source of cytokins among different monocytes from malaria patients (Fig. 6CL\nwhich coincided with the lower frequency of CD144 CDI6* ceils in convalescent patients. Importantly, while expression of the deactivating FcyRIIB (CD32) was unchanged. CD64 mean\nCD64(F\u00abj^\nL.\nC016 (FiyRIIIA)\nI\nWWW //////\nJ\n*-=\u2022\nR&lt;bM\nprotein 3 (NLRP3) or absent in mdinama 2 (AJM2) inftim muome specks. respectively, while NLRC4 iNLR family, CARD domain containing 4) specks were not detected (Fig. 7A). In addition, apcptods-assxiated gieck-likc protein containing a caspase recruitment domain (ASC) colocalized with either NLRP3 or AIM? inflammasome specks Our results also show that procaspase-1 was asatodeaved into mature caspase-1 (plO subunit) after monocyte stimulation with ICs (Rg 7B |. Importantly, we how that monocytes purified from PB.MCs from patisits undergoing acute episodes of P. rowr malaria esprss NLRP3 * ASC* or AIM2* ASC* specks [Rg. 7C| as wel as acthe caspase-1 (34). These findings suggest that ICs stimulate inflammasoene assembly, caspase-1 activation, and IL- IB secretion in vm> during acute malaria infection.\nKswwrri\u2014'Dwwnta. jots Voknw S to\u00bb * \u00abCiaos IS\nrrft|p mtatiwnag S\na\n\u2022<r\n\u2666O\u2019\n\u2666&amp;*1\nQ u\u2019en'rod\n\u2022 IFNr-pnmed\n\u2022\u00ab\u00bf\u00bfJi *\nDISCUSSION\nMalaria is a devastating disease, infecting - 200 million people and killing dose to I million children every year (36,37}. Paroiysm, a main pathophysiological response to Pknnodium infection, is characterized by cycles of sharp peaks of high fever accompanied by chAs and rigors, which coincide with synchronized release of parasites from red blood cdls i RDCs' . While fever may aid in host defense, delaying the growth of pathogens, it is also associated with various pathological processes, such as respiratory distress, anemia, and neurological manifestations that cause morbidity and mortality in malaria. These clinical manifestations are associated with a systemic production of pyrogenic cytokines, such as TNF-\u00ab and IL- 10. However, many of the basic details of malaria-\n\u20190*\nMedium IFN-f\nIC1\nICIHFNy IC2\nIC2*IFNy\nCO\u201916|CR3,i\n.\t\u00ab> W\t\u00ab\u2022\nCOM&lt;f cKlAI\ns\nJ.\nV .\t\u00ab\u2022 V if\nC0>S|CIM|\nFIG S Mcoocy\u00bb in thz nuln sounre ar cytokUK, tn PEMCi mmulhnl wth ICi dkrtwd \u00bbom mxirti panera. (A) PEMCi ackttad (me bcatlhy damn were MwrmigrNMdarpMd wthIN1 mini . \u25a0ItWjdalwkBliljiyUiliFiridiMttlir F ' r\u00bbf Jdn| i n n \u25a0NwNgNhnliH i iiiillm tow town, maared 24 titas. I El CO14' mcnocyus wire poOMv atochal ftonPlMCicf dan heathy daicr\u00bb.Taul puEad tna\u00bbcyUs.rnaiocyre dip total PEMCi. ml :aa PBMCs were a-ixr uncrfcMd ar pruned with tFN y (100 ng.mi > xd fltmttaal with M a? ml a Id from mixta pattorcs. TNF-a. IL lfl. aid IUIC \u25a0Nft mavar al try CBA 241 a\\r ermitn Ilasiu we -zpraarauw&lt;k one ok st Eree eErrtmxti KJ PEMCs were dSer tepruned a primal with IX ng a IFN 7 cwcml^ arid sfcmiuc with Kirar24bl.\u00abi3aniy\u00ab was pelxrnsl with gamymcbll \u25a0 casBmdrvaeatlngEa towtorfaprewkxi :MFi;.crCT>lAa\u00bb2. CD64, CD1 lh. a CD3S. HoufeKown sinprosczvi orone an or threeczpetocnu. Frahm mown tn pawl A wire artzrmtxd by i pibal &lt;tea.\n\n\n\n\n\n\n1 \u00ab\u25a0 \u00a3 . J:\t\t\n\t\t\n- ftdl\u00e0-ot\u00ed ty mtto aon o\u00abg\n!*l\t*\t\u2022*\n-\t\t*\n8 1- i\t* \u2022* \u2014_\t- \u00abi\ti;\nFIC7 lntammascme speds cmsiaing NUU>3 andA1M2 after tomuiaticriotinizccyus webICX(A)CaifbcdanrplsdctadadASC(greenJ.NLKP3(red), and AIM*1 Mi specks In GDI 4 mcnocr-B smmlafcd wan j of ICs for 14 b. We aso ased zdfbodlcs to dried N ULC4 nflammatr~.es. ten the rents were rsaptfrt. ReacUon with scccodxy arctodrs In *r absrrxe at penury \u25a0ndbedy yteklsd nrgatbi rcsc-ts an aredxsl zuf yss. The bar ^aptu stw Sm iraqnaidBcf spedrsInmaiocytesdisrvedfrMhrakhy Sanaa 24h after sbmittlcowtmdOpgofKXiB:'Westen txatasay shearing procazuse I and acme tagtas 1 (p 101 levee t> erfoxd sonacyta heathy Sancrs srtirelaUd with W /ig'ml oi ICs for 24 It (C DodSe positive NUtPJfASC and AIM2/ASC E^ammasome seeds ze found m drcUailng nsenocns derived from F. max ruiarta patterns ret nd from healths danert\n\u25a1f malaria pzients carry Rasmodrum DNA and activate intracellular NAS-Tills, most likdy TLR8 and TLR9. which may serve as the first signal for inflammasome activation. IC-induced instability of phagolysoso mes and release of their contents tn to the cytosol may trigger the formation ofNLRP3 inflammasomes. In addition, AIM2. a DNA sensor, is activated by Plasmodium DNA tn mouse cdls and may also provide the second signal for assembly of \u25a0>-flammaserne platforms during malaria (3). Hence, the results presented here indicate that circulating ICs from malaria patients trigger the assembly of NLRP3\"/ASC\" and AIM2\"/A5C\" inhuman monocytes.\nMonocytes are a heterogeneous population. which reflects different developmental stages or activation status with distinct physiological roles, such as migration to lesions or entry to normal tissues. production of proinflammatory or anti- inflammatory cytokines. and antimicrobial effector functions (43). These mono\ncyte subsets can be distinguished based on expression of CDI4 and different members of the FcyR family that may up- or downregu-late ceil responsiveness to ICs. For example, activation of FcyRIlIA (CDItia? or FcyRI (CD64) promotes a proinflammatory response, whereas FcyRIIB (CD 32) triggers an anti-inflammatory response (23, 44). Interestingly, the frequency of a single\nnucleotide polymorphism in the FcyRIIB (CD32) gene that Aro gates the receptor function is augmented in populations from areas of mdonkity. suggesting a survival advantage against malaria This same polymorphism is associated with susceptibility to SLE. further suggesting that CD32 is a negative regulator of the proinflammatory response and protects against this autoimmune disease Thus, the simultaneous signaling of activating versus inhibitory Fey receptors sets the threshold for cellular activation and prevents an excessive inflammatory response. .Another important finding of our study is that upon 1C stimulation, CDI4\" CDI6 (FcyRIlIA) \u2022 CD32 I FcyRIIB)\"* monocytes are the main source of promflammaiory cytokines in PBMCs from malaria patients. Hence, the enhanced expression of FcyRIlIA and/or FcyRI associated with decreased expression of FcyRIlB * in monocytes from malaria patients seems to skew the balance of cytokine production toward a proinflammatory response. Further research is needed to determine whether activation of FcyRIlIA or FcyRI by ICs directly induces cytokine production by monocytes or simply licenses these cels to produce large amounts of proinflammatory cytokines upon activation of intracellular DNA/RNA sensors.\nFurthermore, the cytokine milieu is also an important determinant of the capacity of ICs to stimulate other a pro- or anti-\nHnfeatrf.\ninflammatory response (23.44). This dichotomy is regulated by cytokines, such asIRi-y and TNF-w, which favor cellular activation. or IL-10. which modulates activation of professional phagocytes. For instance, depending on the clinical form of the disease. Leistmmia infection induces a pronounced proinflamnutory response (45). In contrast, induction of IL-10 by ICs promotes an anti-inflammatory response leading to establishment of Leakma ma parasitism and disease (46). We found that in clinically il patients undergoing acute malaria episodes, ICs trigger monocytes to produce high levels ofTNF-a and IL- IB and low levels of IL-10. This pattern of cytokine production changes to an antiinflammatory one after treatmint and parasitological cure of malaria patients. Likewise, monocytes from healthy donors stimulated with ICs produce high IL-lOlevds and low TNF-w and IL-10 feeds, whereas after IFN-y priming the production of the prom flammatory cytokines becomes dominant. These findings are likdy to be relevant to the cytokine storm during malaria; a hallmark of this inflammatory response is IFN-y-indtaced priming, of innate immune cdls (30.34).\nIt is noteworthy that our studies were conducted in Brazil, where malaria is an occupational disease and affects mainly adults. In addition, both P. vrrax and P. falciparum farms of malaria m Brazil are not as severe as those in Africa, where mostly children&lt;5 years of age develop the disease. Hence, significant differences are likdy to be found among populations from different geographic regions and different age groups as well as in pregnant women. It is notable that different studies described TLR9 polymorphisms associated with severity of disease in both P. vrraxand P. faiapanm malaria patients from Brazil and Africa, respectively (47-491. Furthermore, higher levels of circulating ICs were found in African children with severe malaria than in adults and children with moderate dinical symptoms (50). Moreover, studies have diewn that symptomatic adults in Brazil as wdl as African children infected with P. faldpanim are hyperresponsrve to TLR agonists, including oligonucleotides containing unmethylated CpC motifs (30.51). Hence, as reported here for adult mdaria patients, children infected with P. Jbkiparum are likely to be more region live to IC stimtdation. In contrast, immune individuals in Africa, who are continuously exposed to P. fakipanm. are more tolerant to disease and less responsive to a TLR9 agonist and may be less responsive to malaria-end need ICs (52.53).\nIn conclusion, many of the signs and symptoms of malaria are a result of the excessive activation of innate immune edit. This study provides evidence that ICs are important players in this process. ICs from malaria patients appear to carry parasite DN'As to the inner compartment of host cdls, making them accessible to the intraceHular innate immune sensors, including NAS-TLRs and AJM2 inflammasomes. Furthermore, our results suggest that the ratio of FcyRI and FcyfUlLA I stimulatory I expression to FcyfUIB (inhibitory I expression influences the magnitude of cytokine response by IC-activated monocytes. Hence, the IgC respense during the early stage of malaria has an important role in the activation of the innate immune response and the pathogen esis of malaria.\nMATERIALS AND METHODS\nElhacs statement. The protocols and consent forms were approved by the tnotmatlonal ReMew Baud of the University of Massachsecs Medtal School (IRB-UMMS H-I02MI and the Ethical Committees on Human Experimentation from Centro de Pesquis em Medldna Tropical (CEP-\nCEPLM WV2tX\u00bb> ini Centro de Prsqulax llene \u00a1tach\u00f3n- fundado Os wide Cruz I CEP-CPcRR 20041. as well as by the National Ethical Com-mttxee IOONEP 15452) hum the Mtaktiy of Health, Brazil\nPatients. Individuas were between IB and 6C years old. Mitina patients Infected wkh ether P. smox ser Tape 92 tn the supplemental matertail or P. falaparam (see Table S3) were diagnosed by a thick blood smear and confirmed by PCR. The dlnlcal rranlfestatxxis of malaria were fever, myalgia, ch\u00a3s, nausea, vomiting and/or diarrhea, but no patient had compkated malaria requiring txnpttaltaauon Patsems Infected with P. iaktpanuK received a fixed dose of the artemether 120-mg? and kune fantrtne 1 120-mgi combination two times a day (filar tablets each dose! for 3 days followed by a single dose of primaquine (45 mgl on the last day of treatment Patients Infected with P river were treated with chloroqplne (ISO mgl every 8 h for 3 days and a stn0e dose per day of primaquine (15 mgl for 2 weeks. The treatinent schedule. dose, and dray described above have been tested and ire recommended by the Brazilian Ministry of Health. Healthy donors as well as patterns before and after chemotherapy had SOto too ml of total btood collected using EDTA anticoagulant tubes Pansttermc cure was documented by PCR. Exchasxxiary criteria tnduded any patient who had a malaria eptsode tn the last 6 months, severe anemia (defined as a hematocrit of&lt;351, severe disease I requiring admtsskn to the hospital .any comorbidity, recent or ccocnrTent treatment, wlh anti inflammatory or Immunosuppressive dray, or pregnancy.\nIC quantitation. The MicroVue CIC-Clq enzyme Immunoassay \"imH. Tin rftrgr. **** mr will In ipstorify rkntliltiqt In human serum according to the manufacturer's instradlons. Serum samples were diluted 1:90 and tetied in dxxpAcate Results were obtained In reference to the standard curve and were expressed as microgram-equlvierns per ml llltter.\nAnti dsDNA and anti ssDNA antibody ELISA. Anti-dsDNA antibody levels tit sera of patients and healthy controls were determined as previously described 1541. Briefly, Custar 96-well half-area piares \u00a1Com-tng Inc, New Yotk, NY I were dry coated overnight al 37\"C with 25 gaym: of sonicated calf thymus DNA I Sigma-Aldrich. St louts. MOI hat had been file red using a 045-gxni Mlllei HA filter (Millpore. Cermanyi to remove ssDNA Plata were blocked and then Incubated with serum samples (1:90 and 1:100 dilutions, 25 gilfwell. IgC* or tgM* antl-dsDNA xntlbodles were detected using alkaline phosphatase I API-labeled antihuman IgC or anti-human IgM antibody '.Southern Btotechndogy, Bit minium. AL) and developed with 50 gxl/wdl AP substrate (Stpoa-Aldrkhl. The optical densky at 405 nm (OD*\u00bb! was measured byustng a Victor micropate reader (PerktnElmer, Witham, MAI. The enzyme-linked immunosorbent assy (EUSA) to determine the levels of anti ssDNA antibodies was performed exactly as described above, except that the plates were ccuted wth 25 gqpml ssDNA (Sfgma-Aldndi I.\nIC purification- ICs from ptisma were purified using the Afh-Cel protein A MAPS II kit IBIo-Rad, Heredes. CA) Plasma fl nil was thawed, homogenized, and diluted 1:1 using a filtered rinding riafler at pH 9.0 (Blo-Radl. An Bcuno-Cohtmn chromatography column 11 by 10 an) was packed with 1 ml of Afh-Cel protein A agarose and equilibrated with 5 bed volumes of binding buffer. The diluted ample was applied, and the column was washed wtth 15 bed volumes of binding buffer. IgC was exiled wth 5 bed volumes of an elution buffer I pH 3-0). neutralized Immedlatdy after ekiticn by he addition of I M Tris-H<3 (pH 9AI, and quantified In a Nano Drop spectrophotometer\nQuantitative PCR. DNA samples were extracted freer plasma or ICs using the QLAamp circulating nucleic add kit (Qtagyn. Germantown. MDI according to the manufacturer's tnstiuchons. Reverse transcripclcm-quan trjttve PCIls &lt;qltT- PCRs) were per\u00edo rmed to a ti na volume of 20 gal. containing I gil DNA. 0.15 gal primera (10 gaM Initial concentration; 0075 gaM final concentration), lOgal SYBR green PCR am reagents (Applied Blosystems), and ST gal strrtle water. Primer sequences for the tn-OUB CVCUN DI ICCNDl gene were GCTCCTCCTCAACAACCrCAA (F) and TTCGAGAOGAACTCTTCAATGAAA (R). and those for the P. max IBS from rRNA (SSUrRNA) gene were ACGATCACATAOCCTCC\n5\nI\nI\nI\n3\n8\n&amp;\n\u00cd\n9\nI\n\u00cd\n8\nc*\ni\ni \u25a0?\ni\n3\ni\nTCGTAAT&lt;Fl and CAATCTAAGAATAAACTCOGAAGAGAAA (R>. A standard curve was construcled by diluting each gene (from 10* to 1(F). Rei -time monaortng of FCR amplification was performed using a 7500 Head-Time PCR system. and results were artayzed wr.h 7500 software, v2jO.S The temperature profile was 9S9C for 10 mln foftowed by 40 cydes of denaturattc at 95X for 15 s and anneadng/extenskm z \u00abTC for I mln.\nPBMC and morsocyte asxayx Blood from patients or healthy donors was dinted 1:1 tn petsphate-buffered saline (PBS), tayered onto Hcod-Paque gradients with a density of 1.078 g\u2018rrt ICE Healtfxare. Unted Kingdom), and centrifuged far IS mm at BOO x g.The mononuclear cels at the Interface were aspkated. washed, and resuspended at 3 x 10* cells.1 well m compete RPM: medium containing :0*> feta calf serum (ICSI. CD14- cells were purified using the FasYSep positive sdectfon tat according to the manufacturer s protocol (StemCell Technologies, Canada). Cels werestatned wth anti CD 14 laUcphycocyanln I APC11 (eBioscience. San Diego.CA I and antl-CDI6 cphyurerythrtn | PEI I (Becton. Dtcktrscn, Funclm Lakes, NJ Land purty was checked by fluorescence-actuated cell sexting (FACS).\nNanostrtng anaiy SC After stimulation with 60 yag/nft of purified KX human monocytes were lysed In RLTbnfier c Qiagen I supplemented with B-mercaptoethanoL and used tn determine mRNA abundance by Nano-Strtng technology as prevltxidy described (53). in brief, lysates were hy-bndlzed with capture and reporter probes overnight X 69*C and loaded onto the nComxer preparation station. Partfied targeVprobe complexes were etxed and immcblltred tn the cartridge for data coCeolon and quantification fry the nCouncer digital anahraer Fee side-by-side cnmpar-Iscns of nCcunter experiments, data were ncrmaltaed far small varta tar ns user g Internal positive controls and seven housekeeping genes included In the CcdeSeL The heat map was cnnstrocled usng the Tiger Multi Experiment Viewer software, version 43.1.\nCytokine assays Levelsofbuman TNF-w.IL- IB,tl.-6.IL-Aand 11,10 were measured m PBMC culture supernatant or plasma by the cytometric bead array ICBAI human inflammatory cytokine tat (Bedton. Dkftln-son) and ELISA for IL-13 (RAD Systems. Mmneapoin, MN).\nFlow cytometry. For IntracehdaT measurement of cytosines, ?BMCs were isolated and cultured for 8 h tn the presence of IO 160 ysgjml I and brrfedtn AI GogtPkag; Becton, Dickinson I. Surface markers were stained with xnU-CDI th, -CD32. -CD35. -CD64. and -CD 14 (eBioscience, San \u25a1lego. CA) at aotl-CDI6 (Becton, IMrfrtmnnl. fixed and permeabtltzed with Cytnfix (Becton. Dickinson), and Incubated with phraervthrtn-antl-TNF -a or -antltL 13 ( Becton, Dickinson 1 Subsecuerrjy, c a Is were washed andaruyzed by flew cytometry on a FACScan cytometer) Becton, Dickinson).\nImmunoblotting assays for caspase I Radlotmmunoprrclpttatlon assay (HIPA) buffer (250 nil pkis protease trfofotor was added 10 a peter containing 1 x 10* sUmuated PBMCs. After 15 mtn on Ice. lysates were centrifuged at 13,000 x g far 20 mln at 4*C. Supernatants were separated on a 15% acrytamfoe SDS-PACE ged and transferred onto ntrcceluOse membranes The membranes were incubated with pro-caqiase-1- or caspase-1-specific antftxtals and visualized with HRP-ctmJqpted antibody and the ECL system {Amenham, 3ocb, United Kingdom)\nConfocal anthrax Monocytes obtained from either hea-foy dononor malarta pahents were anahnted ex vise er after lr Hire stlmula tiro wrdi ICs for 24 h. Mcnocyteswere filed wth 4% paraformaldehyde, permeablltaed uffigTrtton X-100.and stained wtthantl-NLRP) Ifiocrescetn Bochkxya-nale |HTC| or Texas Red). antl-NLRC4 ITexas Red), or \u00abXI-AIM2 (Texas Bed) (al from Abeam | tinted Kmgdosnl) and antlASC (HTCI I Santa Cruz, Dallas. TXI.: mages were acquired iking an LSM5 ID mkcru-sccpe I Zeiss, Germany) and anayzed by Image; software (National Institutes of Health). LXaal-mlor Images were acquired by consecutive scan ntng with orty one laser line acme per scan to arc id cross-excitatton.\nStatistical an aty d x All data were analyzed using CraphPad InStat 60 software. Comparisons were performed using a one-way analysts of variance IANOVAI and Student's t test. The paired 1 test was used tn expert-\nrrklo mbs&amp;Mm-esg \u2022\nmeans where we compared foe same patients before and after treatment Mann-Whkney D testing was med far nonparametnc analysis when data did not fit a Gaussian dlKrtuticro\nSUPPLEMENTAL MATERIAL\nsapptOTOital uzerlal hr this antae may be tuna z ttapji'ieiaoasm.a'p' lockup, supp t1 dd: 1D. 112S.'m3 0 J1605-1 s,1 .\u2019DCSuppknwmaL HpireSt.TTFtlk.t3 MB. figure S2.TTF Me. 1 3 MB.\nHpire S3.TIF tad. )3 MB.\nFigure S4.TTF Ike. 13 MB. fl pire S5.TTF tic, 13 MB. Tatar St. DOCX Ike 03 MB. Tatas 52. DOCX Ik. 0.1 MB. Tatar S3. DOCX Me. 0.1 MB.\nWe are grateful to Mebme Trombly far critically reviewing the marc scncc.\nThis werk was supported by the C.S. National Institutes of Health (AI079293I, foe National institute of Science and Technology fix Vaccines ICNPq and FAPEMBC). and the Rede Minelra de Btatnofocuias (Fapemlgl. R.T.G. D.T.G.. MAA, and BGJt. received felknntnps fiom CNFq. I.C.H. resowed a fellowship from CAPES. The funders had no role tn Rudy design, data czMedtan and analysis, decision to puNtfo. or preparation of the manuscript.\nLCJL, MAA B.D., SJL, D.TXL, and R_TG. conceived and designed the experiments. J.V. provided samples. I.C.H.. CG.-M. MAA, HG, WAA. BG.R, R.B.DjO.and D-B.P. performed the experiments. LC.H, BJ>. SR, J.V., D.T.G, and R.T.G analyzrd the data. l.C-H, D.T.G, and R.TG. wrote the paper.\n1.\tParnxhe P, Lane FN. Contagny N. Lata E, Masks BG. Vian Un A. HXnen KA, Larr-cfiler M. Olivier M, Barthdomes DC. Gazztselll RT. Gtaobock DT. 2007. Maiarta harooMM k BiManotagkZIy hurt tnt rauall\u00bb MtaHM Inrcc; -cs>\u2019n\u00ab > press-c-g malari; UN ft Ij Hi like receptor 9. Proc Natl Acad Sd US A I04CI9I9I524- httpe/i dx.^xcaTO.t\u00abZ3mnKMK745IO4.\n2.\tSurma i DeOlbetra R. Kalantart P. Parrocbe P, Ccntagny N. Aaag Z. Chas L Barthacmen D. Latrw F. Hall I. Barber G, Caaalnell R. FtUuyrald K. Goteabas D. 2011. Innate tanrarn rn riy\u00f1llrw of a AT rkh stem loop DNA motar tn the Ptasnoltum tiudparum aenamc. lm munky 3&amp;1M-2H7. http:Adutol.C4BriO.10l6fl.knrTnwi.2011.0SBI6.\n3.\tKalantirt P. DeOlhetra R. Qian I. Cotbelt ir. RaUUnam V. Statz A. Lat\u00ed E, cazzlneui R. Colatxxx D. Fttzaerald K. 2014. Deal sgagcunt ofdicNLRPfzul AIMLmnammascrt\u00e1byclasusxEun dcrrol hoo arar and DNA durmg ma-xta. Cat Rep 6:156-110. http.li<tr.xirrp ld.lOI6flxaep.20lS.12bl4.\n4.\tBarbaJal R. Evald SE. Mruchea ML Bart\u2122 GM. 2011. Nuclac sell recognmce by the Innalt Immure system. Anrra Rev yinol 25: 105-214. httpj'.'dudsKoqy 10.1 tatVaratrev Immenol 031210-101340.\n5.\tHilen M. Fkltayama H. McGaha TU Aderan A, Revets JV. 3X6. TLiS'MyDM slanaitna Is required for class swtehng to pzbegeue SgC2a and 2h mtcontlbodles In SLE. I Exp MM \u00bb3tSS3-S6l. http.1/&lt;ta.doLocgTO.tt\u00ab4fl\u00abm20C6243B.\n6.\tDeme >A, Ptsnkun P. Barrett RS, Fetaentuim L Town T. Ward L FlanH RA. Btalaad 5.2007. Control oTTotl Hta rtezpix 7 apreMoe Is cwoittal io restr.cl anrxmmxtitvzcd dmtttk cell proirrrattxc mrrrn nlty 27301 810. hRJcMxataLeegf IA10l\u00abpnamiL2007J>9009.\n7.\tIsenberg DA Mansen 11. Dirmstein MR, Maa A 2007. Hfty yean c&lt;anti 4s DMA antltnoec art wr approaching fooracy's ctkP Rhemuta ogy lOshnd) 46:1052 1066. Hfoj?duiolxxpT0.\u00cd093/naanattaagy>\n8.\tSacral Ft, Cafoa RL 2:OS. Dtvtiocvncrr. of TLR mhlMors ftr Ok IreatmE-. a aulotumune meases. Immtml lev 223371-33. Mtptf/ dLdoLayiO.t 11 tfl.t6004165Xj:\u00abjX630x\n5. CtMn C, MU KI. UemaM S, Aaisue N. Sain S. Tauaolo M. Kart T. TaXencM O. Hlsaeda H. Horn T. Akira S. 2007. PaUKtoglcal rote of\n* Bi\tR R 3\tS\tU\nda ddddd Bi d\nti\tti\ttiti\n\nHirako et al. - Figure SI\nA\n\u2022n1\u2019\niz.\n*T\n10\nio -\u2022\n\u2022J\n3J tj\u2019i\n2\ni j \u25a0\no<ooooi\npO.0353\np'0&amp;)C1\np^c.caj4\npOOOCI\nP'OOOC 1\nTable S1 - Genes with augmented expression in monocytes stimulated with ICs\nGon# Momo\tCommon Gone Romo (o)\tFold Chongo\tStarter\nAT\u00dc\tTumor mcnan Mctx ofpfio^tA/a^\t.1\t3OJ\t\nCCU\tCftomofcrw i C-C mrt'j Wyn-rt .1\t10M\t\u2022*\nCCl.4\tC/MmcArw |'C-C\tM^rrd 4\t9\u00bb\t\nCtXS\tC<HmcA*W I C-C \u00abt\u00faf,\td 5\t2.11\t**\nCCL0\tCMmctano iC-C OKflf, taHd \u00e1\tS.M\t\u2022\nGCW\tcuoiiK of rwwWiv ac'\t221\t\u2022\nZXCifO\tGAomoiane fC-X C mc\u00fc\u00bbl tyani 10\t3 42\t\u2022\nGBPf\tGuon^wo\tiroMoi 1\t344\t*\nxcx\t\u00bbv\u00bb~\u00bbctxp<vm- G\u00bbr xnj w\t229\t\u2022*\nJGAi/r\tWwrxtkv adTiwatn motecu* 1\tW 2.?1\t\n\t.U\u2019XXur of mmm V<\tu*\u201d* wtotw i9 fl-tute\t2224\t\nILtt\te.Mrtaw\u00bb&lt;Ti\t3JB7\t*\u2022\nILM\tmMBuMfl ?4K>hfl\t929\t*\u2022\nMB\tAi^^jtvi \u2666 teta\t1010\t\n\tMotioufc* f Note mcopto'\t741\t*\n110\t.W\u00f1t\u00bb>*vi C\tM>\t\u25a0n\nIII\t\t17\u00bb\t\n\tiVuraOn* iterar at Jutppu OjW patfpBfOtia gano nrmanaar ai ftoaCa 1\t240\t\u2022*\nNF&amp;B2\tRUchor (Kfix ofu^fjo\tpQtywMi t>\u00bbw avUttur r>fl- aA* 2 QMfeplKJ\t2 44\t*\u2022\n\tMuctoor A*tA> \u00fct fufioo \u00bb\u00a1/v u>A.<v*tl\u00fa gwnd i^iuiut* Ai\t.\u00ab\u00abMfrk*. oJfckA-w\t445\t\nPSTPfPi\t/=re\u00edna oence \u00a1fincado jito^iofwe /vfe<\u00bbc0ni \u00a3\u00bbx4ex: 2\t2 J\u00bb\t\u2022\nPTGS?\tPrsiitQimr*\t5/\u00ab-<hase 2\t5.97\t\u2022\u2019\n\tRooGCFrfwnotn ><r\u00bb>y nfmOer fB\t3 4>\t\u2022\n5VCS3\t\u2022S WT4W-r of .-/V**\u00bbO pjr\u00bbv>9 J\t4 JOI\t\u2022ra\nTUV\tWAl\u00bb mmpOx 2\t700\t\u2022*\n\tIvtnv SAavrwM .\u2018 ncVz-wxw\tT41\t\u2666\nAsterisks indicate that differences are significant, as determined by student t test \u20220.01 > p &lt;0.05. \"0.001 >p<0.01. \"7x0.001. \u201d\"p<0.001).\nTable S2 - Plasmodium vivax malaria patients\nCharacteristics\tMalaria Before Treatment\tMalaria After Treatment\nGender. MaleiFemate\t15/65\t10/44\nMean Age. Years (range)\t345 (18-60)\t345 (18-60)\nMalaria Episodes, n (%)*\t\t\n1\u201c\t10 (125)\t-\n<5\t31 (38.7)\t-\n*5\t39(48.7)\t\nParasitemia.\t\t\nparasites/\u00bb L of Mood, n (%)\t\t\nTNc* smear positive\"\t17\t\n200-300\t4 (6.3)\t-\n301-500\t21 (333)\t-\n501-10,000\t29(46i\t-\n>10,000\t9 (14.2)\t\u2022\nSymptoms, n (%)\t\t\nFever\t\t\n>36\t8(10)\t\n36 - 37.9\t47 (58.71\t\n>37.9\t25 (312)\t\nRigor\t61 (762)\t\nHeadache\t68(85)\t\nMyalgia\t72(90)\t\nMauses\t45 (562'1\t\nVoming\t32(40)\t\nCNIS\t70 (875)\t\nDiarrhea\t21 (262)\t\nHematological Records\t\t\nHemogioMn levels a\u00abL (Median)\t13.45\t14\nRed Blood Cells xlOihim3 (Median)\t4.82\t4.85\nWhite Blood Cels xio\u2019/mm5 iMedao\t5\t5.6\nPlatelets x 1 o\u2019/mn? (Median)\t8C.5\t237\n* The number of maiara episodes for each patient was determined according to individual history and detaied anamnesis.\n\u201d Parasitemia s not avatable.\nTable S3 - Plasmodium falciparum malaria patients\nCharacteristics\tMalaria Before Treatment\tMalaria After Treatment\nGender. Mai e/F emate\t256\t2116\nMean Age. Years (range)\t34(18-60)\t34(18-60)\nMalarta Episodes, n (%)\u2022\t\t\nNA\t4\t\nl\u201c\t4 (14.8)\t-\n\u00ab5\t16 (592)\t-\n\u00ab5\t7(25.9)\t\nParasitemia.\t\t\nparasttee^L or Mood, n (%)\t\t\nTNc* smear postve\u201d\t5\t\n2D0-30C\t1 (38)\t-\n3C1-50C\t14 (53.8)\t-\n501-10.000\t11 (42.3)\t-\n>10.000\t0(0)\t\u2022\nSymptoms, n (%)\t\t\nFever\t\t\n'NA\t6\t\n<36\t2(8)\t\n36-37.9\t13(52)\t\n>379\t10(40)\t\nRigor\t27(87)\t\nHeadacre\t27(87)\t\nMyalgia\t29 (93.5)\t\nNausea\t15 (48.31\t\nVorrHng\t9(28)\t\nCtws\t24(75)\t\nDarrhea\t11 (34.3)\t\nHematological Records\t\t\nHemogioMn e.ets VdL i Median)\t14\t14.2\nRed Blood Cels x lOiTnn? (Medan)\t4.81\t4.74\nwrite Blood Cels x lo\u2019.'mm5 iMediah;\t5\t7\nPlatelets xio\u2019ffnm\u2019 (Median)\t150\t199\n* The number of malana episodes for each patient was determined according to individual h story and detaied anamnesis.\n\"Parasitemia is not available.\nSplenic differentiation and emergence of CCR5*CXCL9+CXCL10+ monocyte-derived dendritic cells in the brain during cerebral malaria\nIsabella C. Hirako1,25. Marco A. Ataide1,3,5, Lucas Faustino2.\nElizabeth W. Sorensen2. Hisashi Ueta2, Natalia M. Ara\u00fajo1,3.\nGustavo B. Menezes3, Andrew D. Luster2,5,\nand Ricardo T. Gazzinelli1,3,4,5\nCentro de Pesquisas Ren\u00e9 Rachou - Funda\u00e7\u00e3o Oswaldo Cruz, Belo Horizonte. Minas Gerais. Brazil1; Center for Immunology and Inflammatory Diseases. Division of Rheumatology. Allergy, and Immunology. Massachusetts General Hospital.\nHarvard Medical School. Boston. Massachusetts. USA2; Department of Biochemistry and Immunology and Department of Morphology - Universidade Federal of Minas Gerais, Belo Horizonte. Minas Gerais. Brazil3; and Division of Infectious Diseases and Immunology - University of Massachusetts Medical School.\nWorcester. Massachusetts. USA4\ns \u00ea These authors contributed equally to this work.\nCorrespondence should be addressed to R.T.G. (ricardo.gazzinelli@umassmed.edu) or A.D.L. (aluster@mgh.harvard.edu).\nDendritic cells play an important role in immune surveillance. After being exposed to microbial components, they migrate to secondary lymphoid organs and activate T lymphocytes. Here we report that during rodent malaria splenic inflammatory monocytes differentiate into monocyte-derived dendritic cells (MO-DCs), which are CD11b*F4,'80*CD11c*MHC ll**DC-SIGNh*\"\u2018Ly6c* and express high levels of CCR5, CXCL9 and CXCL10 (CCR5*CXCL9/10* MO-DCs). We propose that malaria-induced splenic MO-DCs take a reverse migratory route. After differentiation in the spleen, CCR5*CXCL9/10* MO-DCs traffic to the brain in a CCR2-independent, CCR5-dependent manner where they amplify the influx of CD8* T lymphocytes, leading to a lethal neuropathological syndrome.\nIntroduction\nMonocytes (MOs), macrophages and dendritic cells (DCs) are heterogeneous cell populations that have critical roles in tissue repair, sensing the presence of invasive microorganisms and initiating protective immune responses. These cell subsets have overlapping functions. DCs are more specialized in antigen presentation and shaping T cell mediated immunity, whereas macrophages primarily act as a source of pro-inflammatory cytokines and phagocytic cells that effectively destroy pathogens. MOs are less specialized cells that contribute to 1he overall production of inflammatory cytokines, anti-microbial effector functions, and are the main progenitors for DCs and macrophages 1 .\nDCs. MOs and macrophages are thought to play an important role in host resistance to both rodent and human malaria . During malaria, DCs are activated through Toll-Like Receptors (TLRs), primarily TLR9 . and serve as important source of IL-12. IL-12 activates NK cells to produce IFNyand promotes differentiation of Th1 lymphocytes that orchestrate the acquired protective immunity against Plasmodium infection 1M. Importantly, uptake of infected erythrocytes seems to inhibit maturation and function of human DCs *7, and depletion of circulating DCs is associated with impairment of antigen-specific T cell responses in symptomatic patients infected with either P. falciparum or P. vivax, suggesting their role in resistance to human disease . In addition, inflammatory monocytes (iMOs) in rodents (CCR2*Ly\u20acc* and F4Z80*) and humans (CD14<CD16H*1) as well as DCs are important sources of inflammatory cytokines and reactive nitrogen and oxygen intermediates that effectively destroy Plasmodium parasites within phagocytized infected red blood cells 11,1\t.\nDCs also contribute to the pathogenesis of rodent malaria. Blockade of T cell and DC interaction prevents an overwhelming response associated with wasting syndrome and hypothermia in P. chabaudi infected mice . DCs are also required for the development of experimental cerebral malaria (ECM) . In addition, a subset of Ly6c* monocytic cells is critical for recruiting CD8* T cells to the central nervous system (CNS) and development of ECM . Furthermore, a high proportion of iMOs and DCs express inflammasomes and upon a secondary microbial stimuli release deleterious levels of IL-1P, both in rodent and human malaria 2S.\nWhile at homeostasis the progenitors of most DCs that enter peripheral tissues are not monocytes, different studies have demonstrated that in response to infection or inflammation, monocytes can be induced to differentiate and provide important DC functions 2S_ . The monocyte-derived dendritic cells (MO-DCs) have many of morphological and functional characteristics of conventional DCs, including a powerful capacity for capturing antigens and presenting them to CD4* T lymphocytes as well cross-presenting antigen to CD8* T lymphocytes. Monocytes are far more abundant than DCs in blood and bone marrow, and the m vivo mobilization of this monocyte reservoir to generate potent antigen-presenting DCs is of central importance when the organism is threatened by microbial infections 3V34JS.\nRecent studies have defined various markers that allow the distinction of conventional DCs and iMOs from MO-DCs. However the role of MO-DCs in rodent\nmalaria as well as in neuroinflammation observed during ECM has not been explored. Here we report that MO-DCs emerge as a main splenic DC population during early stages of P. bergher ANKA (PbA) infection in mice. These MO-DCs are unique in that they express high levels of the chemokine receptor CCR5 as well as the interferon-inducible CXCR3 chemokine ligands CXCL0 and CXCL10 (CCR5*CXCL0/1O* MO-DCs). CCR5*CXCL9/10* MO-DCs were the main DC subset found in the CNS of mice undergoing cerebral malaria. Importantly, emergence of MO-DCs in the CNS and development of ECM was dependent on MO-DC CCR5 expression and independent of CCR2 expression. Our results reveal a previously unappreciated role of MO-DCs in PbA induced neuroinflammation as well as the mechanism by which CCR5 mediates the development of ECM.\nResults\nMalaria infection induces MO-DCs\nRecent studies have demonstrated that in vivo microbial challenge signal iMOs to differentiate into MO-DCs35'38. Here, we evaluated whether MO-DCs emerge during rodent malaria by searching for CD11c*MHC llhl\u00b0f'CD11b*F4/8O*DC-SIGN,\u20180*\u2019 cells in the spleen, a main site of phagocytic cell interaction with Plasmodium infected red blood cells. For this purpose, we gated double positive CD11b and F4/80 spleen cells for MHC llw*'DC-SIGN*CD11c* 3S. The results presented in Figure 1A indicate that the frequency of MO-DCs in total CD11b*F4/80* splenic cells was increased from 18% in uninfected to 74% in PbA-infected mice. In addition, the level of expression, as indicated by MFI. of DC-SIGN and MHC II in MO-DCs from infected mice increased three-fold. A fraction of these cells also expressed different levels of Lytic. In contrast the frequency of CD11b*F4/80*DC-SIGNlmMHC ll\u2018CD 1IcLytic'\u2019*' cells (iMOs) decreased from 19% to 4.4%, suggesting that iMOs were converted into MO-DCs. After infection, most MOs (Gate 3. CD11b*F4/80*DC-SIGN'MHC II\u2019 CD11c') became Lytic1\u2019*\u2019, but as a whole the difference in number of cells was not statistically significant when comparing uninfected with infected WT mice. We also performed the initial gating on CD11c*MHC II1\u20191*\u2019 cells and then on the DC-SIGN*LYtic* population and confirmed that over 89% of these cells in PbA-infected mice were CD11b*F4/80* (Supplementary Figure 1A). In addition, our analysis indicated that the frequency of CD11c*MHC lll*\"CD11b\u2019F4/80\u2019DC\u2019SIGN\u2019Lytic' cells, which correspond to conventional DCs (eDCs), decreased from 48% in uninfected control mice to 20% of total CD11c*MHC II\u2019\u2019**\u2019 in infected mice.\nTo further characterize the MO-DCs. we sorted MO-DCs (95-99% purity) by flow cytometry (Supplementary Figure 2). and analyzed by Giemsa staining and optical and scanning electronic microscopy (SEM) (Figure 1B). The results obtained from SEM show that morphology of MO-DCs is heterogeneous. While a significant proportion of MO-DCs from PbA-infected mice were typical DCs with a smooth surface and dendrites, other cells displayed characteristics of monocytes or transitional morphological phenotypes. Interestingly, we found in the Giemsa staining that a high frequency of MO-DCs purified from infected mice contained hemozoin, which are heme polymers produced by the parasite. To further evaluate the phagocytic capacity of MO-DCs. we incubated spleen cells from uninfected controls and infected mice with erythrocytes infected with a PbA clone that\nexpresses GFP. By flow cytometry, we demonstrated that MO-DCs were highly efficient phagocytic cells, when compared with iMOs and MOs (Figure 1C). In addition, we observed that unlike iMOs and MOs. MO-OCs express very high levels of CD80 and CD86 (Figure 1D and Supplementary Figure 1B). further suggesting that they are highly efficient antigen presenting cells.\nMalaria-induced CCR5*CXCL9/10*MO-DCs\nTo further characterize MO-DCs. lysates of highly purified FACS sorted MO-DCs (Supplementary Figure 2) were obtained and gene transcripts analyzed for 547 immune-related genes plus 14 housekeeping genes using a commercially available set of nanostring probes. We observed an increase in the expression of approximately 18% of the analyzed genes in MO-DCs isolated from the spleens of infected mice compared to uninfected mice. Of note, the induction in the expression of CXCL9 (24-fold increase) and CXCL10 (10-fold increase) stood out In addition, the expression of CCR5 was enhanced 6 fold (Figure 2A). As CXCL9 and CXCL10 have been shown to play an important role on ECM 3l\"35, we farther investigated 1he expression of these chemokines in spleens of PbA-infected mice. The results presented in Supplementary Figure 3A show that expression of CXCL9 and CXCL10 mRNA achieved the highest level from 5 to 7 days post-infection, coinciding with the peak of MO-DCs in the spleen. We also used the Reporting Expression of CXCR3 ligands (REX3) transgenic mice that express the Red Fluorescent Protein (RFP) and Blue Fluorescent Protein (BFP) as reporter genes under the control of the CXCL9 and CXCL10 promoters, respectively 40. We found that a large proportion of the double-positive RFP*BFP* cells from infected mice were MO-OCs (Figures 2B and 2C). Likewise, over 80% of these cells were CCR2*CCR5*. whereas the iMOs and MO-DCs from uninfected mice were CCR2*. but CCR5\u2018 (Figure 2D).\nEmergence of CCR5*CXCL9/10\u2018 MO-DCs in the CNS of PbA-infected mice\nWe next evaluated the presence of MO-DCs in the CNS of mice undergoing ECM. To analyze the presence of MO-DCs in the CNS of PbA-infected mice, we first gated the CD45h'0,' brain mononuclear cells (BMNC) to discriminate hematopoietic cells from microglia (CD45We\u2019\u2019''). Because the cellular infiltrate in ECM is highly enriched for CD8* T cells, we then gated on CD45hw'CD8' cells. MO-DCs emerge at day 5 and peaked at day 7 post-infection with PbA, which coincides with expression of CXCL9 and CXCL10 and other inflammatory mediators in the CNS (Figure 3A and Supplementary Figures 3B and 4A). Importantly, most of CD45*CD11c*MHC II1\u20191\u00ae1 cells in the CNS were also CD11b*F4/80*. which is consistent with the MO-DC phenotype. We further analyzed BMNCs from PbA-infected mice for CXCL9. CXCL10 and CCR5 expression. We found no cells expressing CXCL9 and CXCL10 in uninfected REX3 mice (Figure 3B and Supplementary Figure 4A). In infected REX3 mice. BFP*RFP* cells were CD45r*n. CD45h**CD8* cells were BFP\u2019RFP\", whereas approximately 60% of CD45n\u2018(rCD8\u2019 cells were BFP*RFP* (Figure 3C). Furthermore. 80% of CD45rt\u2018\u00b0r'CD8\u2018BFP*RFP* cells were CD11b*Ly&amp;c*CD11c* MHC llhloft. consistent with the hypothesis that MO-DCs are also a main hematopoietic source of CXCL9 and CXCL10 in the CNS of infected mice (Figure\n3C). CD45rtwr\u2019 as well as CD45\u2019 cells, most likely microglia and neuron or glial cells, respectively, were both BFP and RFP negative. Finally, we evaluated 1he expression of CCR2 and CCR5 in MO-DCs derived from CNS of infected mice. The results shown in Figure 3D demonstrate that approximately 60% of brain MO-DCs from infected, but not from uninfected mice, were double positive for CCR2 and CCR5.\nIFNy-induced expression of CXCL9 and CXCL10 by MO-DCs\nA recent study has demonstrated that IFNy is an important mediator of MO-DC differentiation 3S. In addition, both IFNv and Type I IFN (IFNa/p) have been shown to induce expression of CXCL9 and CXCL10 in macrophages. Hence, we used IFN/*. REX3IFNyR'*' as well as REXSIFNAR* mice infected with PbA. We first evaluated the profile of gene expression in highly purified splenic MO-DCs (Supplementary Figure 2) isolated from infected C57BL/6 and IFNyr mice. From 98 PbA-induced genes. 58 (60%) were dependent on endogenous IFN?. Expression of CXCL9 and CXCL10 mRNA induced by PbA infection was totally absent in MO-DCs from IFN/\u2019\"\u2019 mice, whereas enhanced expression of other genes, such as CCR5, CCL7 and CCL8 was independent of endogenous IFN? (Figure 4A). Consistently. MO-DCs from REX3, but not from REX3IFNfR\",_ mice, expressed high levels of RFP and BFP (Figures 4B and 4C). Unexpectedly, we found no redundancy of IFN? and IFNa/p, and surprisingly, expression of CXCL9 (RFP) and CXCL10 (BFP) were significantly augmented in MO-DCs from PbA-infected REX3IFNAR'?\u2019 mice, when compared to infected REX3 mice (data not shown).\nWe also tested whether IFNv is necessary for differentiation of MO-DCs. We noticed an accumulation of iMOs and decreased frequency of MO-DCs in REX3/IFNyR* and IFNy^ relative to REX3 and C57BL76 mice infected with PbA (Figures 4B, 4C and Supplementary Figure 5). Together, these results indicate that differentiation of precursor iMOs into MO-DCs is impaired in mice lacking either functional IFNy or IFNyR genes.\nTLR-induced expression of CXCL9 and CXCL10 by MO-DCs\nCheong et al.35 demonstrated that LPS induces differentiation of iMOs into MO-DCs. It is also well established that Plasmodium infection activates the innate immune system primarily by activation of TLR96\"9-41 and other nucleic acid sensors 4i43. The activation of TLR9 during PbA infection induces the production of IL-12 by DCs. culminating in the production of IFNy primarily T lymphocytesHence we decided to evaluate whether PbA infection was inducing differentiation of MO-DCs via TLR activation. With this in mind, we used E6446. an antagonist that prevents activation of TLR7 and TLR9 by ssRNA and DNA41'*4. The results presented in Supplementary Figure 6 show that therapy with E6446 prevented lethality when given in the very early days of infection (from day -1 to 3 post-infection).\nThe data presented in Figures 5A and 5B show that treatment with E6446 inhibits the expression of IFNy mRNA by spleen cells and results in decreased circulating levels of IFNy in sera of mice at 6 days post-infection with PbA. In addition, at five days post-infection, the proportion of activated (CD44h*\u00b0,'/CD62L'0*)\nCD4* T and CD8* T lymphocytes was augmented to 55.5% and 39.9%, when compared to 14.7% and 12.2% in uninfected controls or 27.8% and 10.2% in infected mice treated with E6446, respectively (Figure 5C). The percentage of resting T cells (CD44lo\"/CD62Lw') was inversely proportional to activated cells, and decreased to 32.9% of CD4* T and 37.3% of CD8* T lymphocytes in infected mice, as compared to 77.7% and 78.1% in uninfected controls and 59.0% and 64% in infected mice treated mice with E6446, respectively. Likewise. E6446 inhibited expression of IFNy by both CD4* T as well as CD8* T cells from infected mice. The results presented in Figure 5D were obtained by using GREAT mice that express an YFP gene under the IFNy promoter. Expression of YFP by CD4* T and CD8* T cells isolated from controls and infected mice increased from 2.16% to 8.99% and 3.94% to 14.40%, respectively. In GREAT mice infected with PbA and treated with E6446. only 3.05% and 4.60% of CD4* T and CD8* T cells expressed YFP. respectively. These results were confirmed by intracellular staining for IFNy in T lymphocytes from C57BL/6 mice infected with PbA (data not shown). To evaluate the NK cell contribution to MO-DC differentiation we used the RAG* mice, which lack T cells. To our surprise, we observed that iMOs did not differentiated into MO-DCs in RAG ' mice infected with PbA. These results indicate that IFNy and/or other signals provided by NK cells are not sufficient to promote MO-DC differentiation (Figure 5E).\nAs a consequence of inhibition of IFNy production by T lymphocytes, treatment with E6446 also inhibited the expression of CXCL9 and CXCL10 mRNA by spleen cells (Figure 5F) as well as RFP (CXCL9) and BFP (CXCL10) by MO-DCs from infected WT and REX3 mice, respectively (Figure 5G). Immunocytochemistry analysis revealed the inhibitory effect of E6446 treatment on CXCL9 and CXCL10 expression by spleen cells from PbA-infected REX3 mice (Supplementary Figure 6B).\nIFNy-dependent recrurtment of MO-DCs to the CNS of PbA-infected mice\nThe results presented in Supplementary Figure 3B show that expression of IFNy and chemokine genes (/.e, CCL2, CCL3, CCL4, CCL5, CCL8, CXCL9 and CXCL10) is induced and peaks in the brain at 6-7 days post-infection with PbA. Our experiments also demonstrated that expression of these genes is not seen or largely decreased in the brains of PbA-infected IFNy* mice or PbA-infected C57BL/6 mice treated with E6446 (Figures 6A and 6B). Since MO-DCs express both CCR2 (receptor for CCL2) and CCR5 (receptor for CCL3, CCL4 and CCL5). we evaluated the emergence of MO-DCs in the brain of PbA-infected IFNy\" mice as well as infected C57BL/6 mice treated with E6446. We observed that migration of MO-DCs into the brain of infected IFNy* mice or E6446 treated WT mice was also impaired (Figure 6C). Consistent with the importance of MO-DCs in recruitment of CD8* T cells and development of ECM 37*M. the total number of CD8* T lymphocytes was reduced, but not absent in the CNS of either IFNy'' mice or PbA-infected C57BL/6 mice treated with E6446. Based on these results and those published elsewhere , we propose that IFNy is a key cytokine mediating ECM by promoting the expression of chemokines that recruit MO-DCs into the brain and consequently amplifying recruitment of CD8* T cells to the CNS.\nCCR5-dependent recruitment of MO-DCs to the CNS of PbA-infected mice\nWe hypothesized that CCL2. CCL3. CCL4 and CCL5 are largely responsible for recruiting MO-DCs to the CNS of PbA-infected mice. The data presented in Figure 7A provided evidence that isolated MO-DCs (75-85% purity) migrate towards to both CCL2 and CCL5 in vitro, although CCL5 appeared to be a more efficacious chemoattractant for MO-DCs. We also noticed an additive effect of the two chemokines. As CCL2 and CCR2 have been shown to be important for recruitment of iMOs during infection with Toxoplasma gondii and P. chabaudi''4 . we evaluated the role of CCR2 in the development of ECM. As expected, we observed a decreased frequency of MO-DCs in the spleen of both uninfected and PbA-infected CCR2'*\u2019 mice (Supplementary Figures 7A and 7B). However, the number of MO-DCs in the CNS of PbA-infected CCR2'1' mice was only marginally reduced (Figure 7C). In contrast, we observed no difference in the frequency or number of splenic MO-DCs in infected CCR5^\u2019 mice (Supplementary Figures 8A and 8B). Nevertheless, emergence of MO-DCs in the CNS of PbA-infected CCRS^ mice was highly compromised (Figure 7C). Consistent with numbers of MO-DCs in the CNS. CCR5^mice. but CCR2* mice, were more resistant to the development of ECM than PbA-infected WT mice (Figure 7D).\nImportantly, over 80% of MO-DCs in the CNS of infected C57BL/6 mice expressed CCR5. Less than 10% of CD4* T and CD8* T lymphocytes expressed CCR5. whereas over 99% expressed CXCR3 (Figures 8A and 8B). Hence, we hypothesize that CCR5 is a key receptor for MO-DC recruitment to the CNS. whereas CXCR3 and its ligands. CXCL9 and CXCL10. are responsible for attracting T lymphocytes to the CNS. Finally, we performed in vivo imaging experiments to evaluate the role of CCR5 in the recruitment of MO-DCs to the CNS. MO-DCs (7585% purity) from spleens of PbA-infected WT or CCR5'\u2019\u2019 mice were transferred into WT mice five days post-infection. Migration of CSFE-labeled MO-DCs was evaluated from 15 to 60 minutes after cell transfer. We found high frequency of WT MO-DCs. primarily, in the microvasculature. MO-DCs from CCR5^ mice were less efficient in migrating to the CNS of infected mice. No migration of MO-DCs to the CNS of uninfected mice was observed (Figure 8C and Supplementary Videos 1 and 2). Consistent with role of CCR5*CXCL9/10 MO-DCs in recruitment of CCR5\" CXCRS\u2019CDS* T cells, the number of both cell populations was markedly decreased in the CNS of PbA-infected CCR5'*' mice (Figure 8D).\nDiscussion\nWe provide compelling evidence that acute infection with PbA stimulates differentiation of splenic iMOs into MO-DCs in an IFNy-dependent manner. Different from iMOs, malaria-induced MO-DCs possess a strong phagocytic activity, and express high levels of molecules involved in antigen presentation (r.e., MHC II. CD80 and CD86) as well as the IFNv-inducible CXCR3 ligands CXCL9 and CXCL10 and the chemokine receptor CCR5. Hence, splenic CCR5*CXCL9/10* MO-DCs seem to play an important role in activating T lymphocytes and promoting systemic inflammation during acute malaria episodes. We hypothesize that high levels of circulating IFNy produced by splenic T cells induces the expression of\nadhesion molecules and chemokines by endothelial cells and initiates recruitment of leukocytes to the CNS. Furthermore, our data suggest that after differentiation, splenic CCR5\u2019CXCL9/10* MO-DCs migrate to the brain in a CCR5-dependent manner and amplify the recruitment and activation of CXCR3*CD8* T cells, promoting neuroinflammation and ECM.\nDCs and iMOs play important roles in host resistance to malaria. Indeed, there is a very dynamic distribution of iMOs and DC subpopulations in the spleen of acutely infected mice, which changes with the course of infection, parasite virulence and infective Plasmodium spps. For instance, DCs exposed to the erythrocytic stage of P. chabaudi produce high levels of IL-12 and promote the production of IFNy by both T lymphocytes and NK cells1*. This cytokine activates macrophages to produce toxic metabolites, such as reactive nitrogen intermediates (RNI). and promotes Ig switch to the lgG2a/lgG2c. which mediate host resistance to Plasmodium infection in mice11 . In addition, both iMOs and DCs can internalize and destroy infected RBCs in the spleens and mediate resistance to P. chabaudi infection in mice19*1. However, depending on experimental setting, dendritic cells may become refractory or impaired for presenting antigen to CD4* T and CD8* T cells51- . For instance, virulent P. yoelli strains impair DC functions to prevent the induction of host protective immune responses15. iMOs and DCs also play key roles in the deleterious inflammatory response and pathogenesis of rodent malaria. As examples. DCs promotes cytokinemia and wasting syndrome in P. chabaudi infected mice22: and both conventional DCs and iMOs are required for recruitment of CD8\u2019T cells and development of neuroinflammation in the ECM model23-24'38.\nUnexpectedly, we found that most CDIIc\u2019MHC llhlsri cells in the spleen of PbA-infected mice are DC-SIGNhlfltlCD11b\u2019F4/80* consistent with a MO-DC phenotype35,36. Because these cells share various markers with iMOs and conventional myeloid as well as plasmocytoid DCs. some of the existing results in the literature may have missed that a significant proportion of DCs in this rodent malaria model are indeed MO-DCs. Previous studies using the P. chabaudi model identified iMOs that express low levels of CD11c as well as a low frequency of CD11c\u2019cells that were CD11b\u2019F4X80*19-21. Here we provide evidences that in this model, splenic iMOs and MOs are progenrtors of MO-DCs. While the frequency and numbers of MO-DCs cells were markedly increased in the spleen following infection, iMOs and MOs were decreased within the splenic CD11b\u2019F4/80\u2019 population. Furthermore, we noticed a continuous gradient of MO-DCs expressing Lytic, from Ly6cr\u201cflf' to Lytic10*. As iMOs are classically Ly&amp;ch'l,,\u2019. we propose that Lytic^MO-DCs are recently differentiated, whereas Lytic1\"* MO-DCs are fully differentiated. Importantly, we determined here that malaria-induced MO-DCs. but not iMOs or MOs. express high levels of CCR5, CXCL9 and CXCL10. which are highly relevant for the development ECM38-39-53\nUpon TLR or cytokine stimulation. iMOs may differentiate into macrophages or MO-DCs that migrate to lymphoid organs and non-lymphoid tissues26\"36,3*36. IFNy not only has an important role in host resistance to Plasmodium infection, but is also a key mediator of malaria pathogenesis4 The high circulating levels of IFNv elicited during Plasmodium infection lead to pro-inflammatory priming48'54 that promotes systemic inflammation25'48,55. In the case of ECM. treatment with\nneutralizing anti-IFNv antibodies or genetic deficiency of IFNy prevents PbA-mduced neuroinflammation and lethality due ECM46'47\u201996 Different functions are attributed to IFNyin the development of ECM. which includes the enhanced production of pro-inflammatory cytokines and chemokines as well as enhanced expression of adhesion molecules in endothelial cells from brain vasculature S7,a. Important to this study, CXCL9\"\u2019*\u2019. CXCL10\\ and CXCR3 *'mice have a less intense infiltrate of CD8* T cells in the CNS and are more resistant to development of ECM37\u201939. Here, we demonstrate that differentiation of MO-DCs is impaired and expression of CXCL9 and CXCL10 abolished in PbA-infected IFNy'*\u2019 and IFHyR\"*\" mice.\nDifferent studies suggest that TLR7 and TLR9 are important receptors involved in the activation of DCs and initiation of IL-12 and IFNy production during both human and mouse malaria 14-22-sM\u00b0. We found that the lysosomotropic compound (E8446), which binds to RNA and DNA and blocks TLR7 and TLR9 activation, prevents development of ECM41'44 When given in the first three days of infection, treatment with E6448 inhibited CD4\" and CD8\" T cell activation and IFNv production. As consequence expression of CXCL9 and CXCL10 by MO-DCs was not induced. These results are consistent wi1h earlier studies showing that IFNy produced by CD4* T cells induce CXCL9 and CXCL10 expression and promotes the recruitment of pathogenic CD8* T cells to the brain of PbA-infected mice38,39'46'47'81'62. Plasmodium DNA and RNA were also shown to activate other families of cytosolic innate immune receptors. Since E8448 binds and \"inactivates\" DNA and RNA that transit through the lysosomes, it may also prevent activation of other DNA/RNA cytosolic sensors that are inducers of Type I IFN 42\u201943\u20ac2 However, expression of CXCL9 and CXCL10 by MO-DCs was not abolished in infected REX3IFNAR+ mice, demonstrating the Type I IFN is not a physiological inducers of CXCL9 and CXCL10 following PbA infection.\nWe also observed the emergence of CCR5*CXCL9/10* MO-DCs in the brain of PbA-infected mice. Among the CD3'CD8\u2019CD45r,|X' hematopoietic cells, most cells expressed CD 11b. F4/80. DC-SIGN. Ly6c. MHC II and CD 11c 6465 The increased frequency of CCR5*CXCL9/10* MO-DCs coincided with increased expression of CXCL9 and CXCL10 mRNA in the CNS of PbA-infected mice. While we have evidence that endothelial cells are also important source of CXCL10 in the brain, we found that among CD45r\u2018\u00b0h cells. MO-DCs were the major source of both CXCL9 and CXCL10 (RFP*BFP* cells) in the brain of PbA-infected REX3 mice. Hence. CCR5*CXCL9/10* MO-DCs are likely to play an important role in recruiting and activating CD4* T and CD8* T lymphocytes during ECM. Importantly, recent studies have proposed that endothelial cells are able to cross-present malaria antigens6* . However, our data suggest the MO-DCs maybe the key cells presenting malaria antigens to CD8+ T cells in the brain microvasculature and parenchyma.\nA main question raised by these results is whether MO-DCs differentiate in the CNS from recruited iMOs or are being directly recruited from the pool of splenic CCR5*CXCL9/10* MO-DCs. As previously described36, both iMOs and MO-DCs express CCR2. CCL2 and CCR2 play important roles in controlling iMOs egress from the bone marrow and their migration to the spleen or to sites of infection. CCL2 and CCR2 have also been shown to be important for host resistance to P. chabaudi and Toxoplasma gondii'9'*3. However, we found that the frequency of MO-\nDCs in the brain was only marginally affected in CCR2\"\u2019\u2019 mice and susceptibility to ECM was not altered. Importantly, as previously reported (what ref), the total number of iMOs was markedly decreased in spleen in CCR2\u2019\u2018_ mice infected with PbA. Interestingly, we found that MOs (CDUc\u2019MHC ll'DC-SIGN') 1hat become Ly\u20acc\"\u00b0l\u2019were increased within the CD11b*F4Z80* population in PbA-infected CCR2+ mice. Thus, we propose that in infected CCR2* mice, the splenic Ly6cn<,,,MOs are the main precursors of MO-DCs.\nInterestingly, we found that malaria-induced MO-DCs. but not iMOs. express high levels of CCR5. CCR5+ mice have been reported to be more resistant to PbA infection53, but the mechanism by which CCR5 mediates ECM is not known. The deficiency on CCR5 did not impact MO-DCs differentiation in the spleen, but clearly affected their emergence in the brain of PbA-infected mice. All three CCR5 chemokine agonists (i.e.. CCL2. CCL3 and CCL5) are expressed in the brain of PbA-infected mice, and may act together to recruit CCR5*CXCL9/10* MO-DCs. Although most CXCR3',CD8*T cells do not express CCR5, their migration to the CNS is also compromised in infected CCR5'*\" mice. These results are consistent wi1h the hypothesis of an amplification loop involving MO-DCs (important source of CXCR3 ligands) and CD8* T lymphocyte (important source of CCR5 ligands)45,68, resulting in increased CD8* T cell and MO-DC recruitment to the brain in ECM. as recently proposed for Ly&amp;c* monocytic cells and CD8* T cells Our study provides important novel information regarding the pathogenic mechanism responsible for ECM by demonstrating that the vast majority of Ly6c* that emerge in the CNS of PbA infected mice are indeed MO-DCs. We also demonstrate how these cells induce T lymphocyte recruitment to the CNS, as we dearly show that they are an important source of CXCL9 and CXCL10. Finally, we demonstrate that the emergence of these LyfJc* MO-DCs in the CNS is dependent on CCR5. and. surprisingly, independent of CCR2. which is classically involved in iMOs recruitment to lymphoid organs and to site of infection.\nIn conclusion, we propose that immune responses during malaria are initiated by exposure of resident splenic DCs to parasite nucleic adds, which leads to IFNy production by CD4* T and CD8* T lymphocytes and differentiation of iMOs into MO-DCs. The CCR5*CXCL9/10* MO-DCs display a potent phagocytic activity and express high levels of MHC II. CD80 and CD86. indicating a great potential not only to recruit, but also to present antigen and activate T lymphocytes. Importantly, CCR5*CXCL9/10* MO-DCs become the dominant subset of splenic DCs (CD11c*MHC II\"*\u2019) and likely play a key role in activating parasite-specific T cells and promoting systemic inflammation during acute malaria. Finally, our results suggest that MO-DCs are not following the conventional path from non-lymphoid tissues to secondary lymphoid organs. Instead they are being recruited from a pool of splenic MO-DCs to the CNS of PbA-infected mice. Once they reach the brain, the CCR5*CXCL9/10* MO-DCs execute their pathogenic role by recruiting and activating CD8*T cells, which are the effector cells in ECM.\nAcknowledgements.\nThis work was supported by grants from the US National Institutes of Health to A.D.L. R.T.G. laboratory was supported by Rede Mineira de Biomol\u00e9culas from Funda\u00e7\u00e3o de Amparo a Pesquisa de Minas Gerais (Fapemig, RED-00012-14) and Brazilian National Institute of Science and Technology for Vaccines granted by Conselho Nacional de Desenvolvimento Cientifico e Tecnol\u00f3gico (CNPqyFapemig/Minist\u00e9rio da Sa\u00fade (573547/2008-4). R.T.G. was recipient of a Scholar Fellowship from Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de Ensino Superior (CAPES) and the David Rockefeller Center for Latin American Studies at Harvard University. I.C.H.. M.A.A.. and N.M.A are recipient of Science without Borders and Graduate Student fellowships from CNPq and CAPES. R.T.G. and G.B.M. are research fellows from CNPq. We thank Barbara Louzada for her technical assistance in the laboratory.\nMethods\nMethods and any associated references are available in the online version of the paper at http://www.nature.com/natureimmunology/.\nFigure Legends\nFigure 1. Differentiation of splenic MO-DCs (F4/80*CD11b*DC-SIGN\u201c\u00b0hMHC II1-\u00ae** CD11c*Ly6C*) in PbA-infected mice. Spleens were harvested five days after PbA infection. Representative primary flow cytometric dot plots are shown. (A) Splenocytes were first gated for F4/80*CD11b* cells and then for DC-SIGN*MHC Ilh*r' cells. F4/80*CD11b*DC-SIGN,*0,,MHC llr*n cells were also checked for CD11c* and Ly6C* expression. Bar graphs correspond to total number of cells (four mice per group). The data shown are representative of eight independent experiments. (B) Splenocytes were labeled with fluorescent antibodies and CD11c*CD11b*F4/80*DC-SIGNh'*\u2019MHC llhv\u2019 monocyte-derived dendritic cells (MO-DCs) purified by flow cytometry (Supplementary Figure 2) and analyzed by Giemsa staining and optical microscopy as well as scanning electronic microscopy. White arrows indicate hemozoin crystals inside purified MO-DCs. (C) Flow cytometry histograms show the MFI results from spleen cells of uninfected (shaded lines) versus infected (open lines) incubated, at 1:1 ratio, with uninfected red blood cells (RBCs) (blue) or RBCs infected with GFP-expressing PbA (red). The results indicate the phagocytic activity of MO-DCs. iMOs and MOs. as indicated. Bar graphs correspond to the MFI average of three to four mice per group. The data shown are representative of two independent experiments. (D) Expression of costimulatory molecules CD80 and CD86 on cell surface of MOs. iMOS. and MO-DCs. The data shown are representative of two independent experiments. Results are expressed as mean. Differences considered statistically significant when comparing infected and non-infected mice (\u201d. p>0.01) after two-way ANOVA.\nFigure 2. Expression of CXCL9 and CXCL10 by MO-DCs from PbA-infected mice. Splenocytes were harvested at 6 days post PbA infection. CD11c\u2019CD11b*F4/80*DC-SIGNn^MHC llhv\u2019 monocyte-derived dendritic cells (MO-DCs) were purified by flow cytometry (Supplementary Figure 2) and analyzed for (A) RNA expression of immune related genes using a nCounter Analysis System. The results indicate fold increase of gene expression, when comparing MO-DCs isolated from three infected mice compared to three non-infected mice. (B) Confocal microscopy of spleen from an infected REX3 mouse. Top panels shows F4/80* (APC converted in green), CXCL9-RFP and CXCL1D-BFP staining. Bottom panels show CD11c* (APC converted in green). CXCL9-RFP and CXCL10-BFP staining. Arrows and arrowheads show double and triple positive cells, respectively. (C) PbA-infected REX3 mice were sacrificed at day 6 post-infection and splenic MO-DC cells analyzed for CXCL9 and CXCL10 expression. Spleen cells were first gated on double positive CXCL9/CXCL10. and then on F4/80*CD11b* and DC-SIGN*MHC II* cells. All CXCL9*CXCL10*F4/80*CD11b*DC-SIGN*MHC II* cells were CD11c*. (D) Spleen cells harvested 6 days post-infection were first gated on F4/80*CD11b* and then on CD11c*MHC II* cells. The majority of MO-DCs from uninfected and PbA-infected mice were CCR2*CCR5\" and CCR2*CCR5*. respectively. Representative primary flow cytometric dot plots are shown. The data are representative of three experiments wrth three mice per group that yielded similar results. Results are expressed as mean. Difference considered statistically significant when comparing infected and non-infected mice (\u201d. p>0.01) after student t test\nFigure 3. High levels of MO-DCs in the brain from PbA-infected mice. (A) MO-DCs (CD45rtflhCD8'CD3CD11b'Ly6C*MHC ll*DC-SIGNhW\u2019CD11c*) were quantified by flow cytometric analysis within brain mononuclear cells (BMNCs) isolated at 0, 5 and 7 days post-infection with PbA. (B) BMNCs from uninfected REX3 mice were analyzed by flow cytometric analysis. All CD45,,ohCD8' cells were negative for CXCL9 (RFP) and CXCL10 (RFP). (C) Approximately 70% of CD45\"BhCD8\u2019 BMNCs from PbA-infected REX3 mice were double positive for the CXCL9 and CXCL10 reporters. Eighty percent of CD45MCD8'CXCL9*CXCL10* cells were CD11b*Ly6c*CD11c*MHC II*. CD45\u00b0\u201c\u2018ne9-h'CD8\u2019BMNCs were all negative for CXCL9-RFP and CXCL10-BFP. Representative primary flow cytometric dot plots are shown after CD45l*0h gating for leukocytes. (D) BMNCs were harvested from WT mice at 0 and 7 days post-infection and expression of CCR2 and CCR5 analyzed in MO-DCs. Data represent the average of three or four mice per group and results are representative of three independent experiments. Differences were considered statistically significant when p<0.05. and *\u2019. p<0.01 as indicated by two-way ANOVA (A) and student t test analyses (D).\nFigure 4. IF My-de pen dent expression of CXCL9 and CXCL10 by MO-DCs from PbA-infected mice. C57BL/6. IFNy*. REX3 or REX3/IFNyR* mice were infected with PbA and their spleens harvested at 6 days later. (A) Gene expression was analyzed in total RNA extracted from highly purified (over 98% purity) MO-DCs from infected C57BL76 and IFNy\u2019 mice by nCounter Analysis System. Data represent the average of gene expression of three mice per group. (B) Representative primary flow cytometric dot plots are shown for splenic MO-DCs from REX3 and REX3/IFNyR* mice gated on F4/80*CD11b* (left panels), then on DC-SIGNhtf1MHC llhl<r' ceiis (middle panels), and CXCL9 and CXCL10 double positive cells (right panels), respectively. The percentage of MO-DC (Gate 1). iMOs (Gate 2), and MOs (Gate 3). and CXCL9*CXCL10*MO-DCs are indicated. (C) Frequency of splenic CD11b*F4/80* cell subsets in infected REX3 and REX3/IFN-fR',\u2018 mice are shown. The average and SD are representative of two independent experiments with three or four mice per group. Differences were considered statistically significant when \u2019*. p<0.01; and p<0.0001 as indicated by two-way ANOVA analysis.\nFigure 5. Treatment with E6446 inhibits expression of IFNy by T lymphocytes as well as CXCL9 and CXCL10 by MO-DCs. C57BU6, GREAT. RAG* as well as REX3 mice were infected with PbA and treated with either E6446 (120 mg/Kg/day) or vehicle from -1 to 3 days post-infection. (A) Spleens were harvested from WT mice at 0. 5 and 7 post-infection, total RNA extracted, and expression levels of IFNy mRNA analyzed by qPCR. The results were normalized to 02-MICROBULIN. (B) Sera from infected C57BU6 mice were collected at different times post-infection and used to measure the levels of IFNy by Cytometric Bead Analysis. The inhibitory effect of E6446 on the levels of circulating IFNy was evaluated at 6 days postinfection (right panel). (C) Spleens from untreated and E6446-treated C57BL6 mice were harvested 5 days-post infection. Bar graphs correspond to the percentage of naive (CD62Lr\u2018trCD4410\") versus activated effector (CD62L,<wCD44\u2019\"ah) CD4* T (top panels) and CD8* T (bottom panels) cells. (D) Splenocytes from uninfected and\ninfected GREAT mice treated with E6446 or left untreated were stimulated with PMA (50 ng/ml) and ionomycin (500 ng/ml) for 4h in culture containing brefeldin A, and analyzed by flow cytometry. YFP positive cells were considered as IFNy producers CD4* T (top panels) and CD8* T (bottom panels) cells. (E) Spleens were harvested from uninfected and PbA-infected WT and RAG* mice and the frequency of MO-DCs analyzed by flow cytometry. Left and right panels show the frequency of F4/80*CD1 Ib\u2019DC-SIGN^MHC II1** and levels of CD11c expression on MO-DCs, respectively. (F) qRT-PCR (left panels) and (G) flow cytometry analysis revealed that treatment with E6446 resulted in inhibition of CXCL9 and CXCL10 mRNA expression in the spleen and RFP and BFP proteins by splenic MO-DCs from PbA-infected C57BL/6 and REX3 mice, respectively. Representative primary flow cytometry dot plots are shown in panels C. D. E and F. Results are representative of two to three independent experiments with three to five mice per group. Differences considered statistically significant when *. p<0.05; \u201d, p<0.01; p<0.001; *\u201dp<0.0001, as indicated by two-way ANOVA analysis.\nFIGURE 6. IFNy-dependent chemokine expression and emergence of CD451-*1 hematopoietic cells to the CNS of PbA-infected mice. CCL2, CCL3, CCL4, CCL5, CXCL9, CXCL10 and IFNv mRNA expression was analyzed in brain tissue of uninfected or PbA-infected (A) IFNy* and C57BL76 mice, as well as (B) C57BL/6 mice treated from day -1 to 3 post-infection with vehicle or E6446 (120 mg/Kg/day), as indicated. The mRNA levels were analyzed by qPCR and results presented after normalization with either GAPDH (A) or 02-microglobulin (B) mRNA. (C) Flow cytometric analysis of brain MO-DCs (CD45r,\u00b0,,CD3'CD8 CD11b*Ly6C*CD11c*DC-SIGN*) from uninfected and PBA-infected WT, IFNy*, and WT mice treated with E6446 seven days post-infection. The numbers of both CD45hl*\u2019CD8*CD3* and CD45hl\u00b0r'CD8CD3CD11c*CD11b*DC-SIGNr*onLy\u20acc* cells are significantly decreased in the brain of infected IFNy* and EB448-treated mice. Differences considered statistically significant when \", p<0.05; \u201d, p<0.01;\tp<0.001; and '\u201d*,\np<0.0001 as indicated by two-way ANOVA analysis.\nFIGURE 7. Enhanced resistance of CCR5* mice to development of ECM. (A) In vitro migration of enriched MO-DCs towards different concentrations of CCL2, CCL5 or the combination of CCL2 and CCL5. (B) Flow cytometric analysis of MO-DCs in the CNS of WT and CCR2* mice infected with PbA. A lower, but not significant difference in the frequency of CD45r*r'CD11c*CD11b*DC-SIGNh*MHCIIhwiLy6c> is observed in the brain of PbA-infected CCR2*mice. (C) Flow cytometric analysis of MO-DCs in the CNS of WT and CCR5\u2019\u2019\u2019 mice infected with PbA. The numbers of CD45h,\u00b0r'CD8CD3CD11c*CD11 b*DC-SIGNr\u2018BhLy8c* are significantly decreased in the brain of PbA-infected CCR5\u2019\u2019\u2019 mice. Representative primary flow cytometric dot plots are shown after CD45r**' gating for leukocytes. (D) Survival curve of PbA infected C57BU6, CCR2* and CCR5* mice. The results are representative of two independent experiments with three to five mice per group. Differences were considered statistically significant when * p<0.01 as indicated by student t test The survival curves were analyzed by log-rank test and CCR5'1' mice were shown more resistant to PbA infection, when compared to CCR2*or WT mice (p<0.01).\nFIGURE 8. CCR5-dependent migration of MO-DCs to the CNS of PbA-infected mice. (A) Flow cytometric analysis of MO-DCs and T lymphocytes expressing CXCR3 as well as CCR5 in the CNS of PbA-infected mice. Brain mononuclear cells (BMNC) were recovered from PbA-infected mice gated on CD45r*s,'. then on CD3*CD8* or CD3*CD4* and analyzed for CXCR3 and CCR5 expression. Alternatively, CD45h\u20188t' cells were gated on CD3CD8CD11b*Ly6c*MHC iTCDIIc\" and then analyzed for CCR5 expression. (B) Top graph shows the frequency of CD45,,IB,'cells (i.e., MO-DCs, CD4* T and CD8* T cells) in total BMNCs isolated from C57BL/6 mice at different time post-infection. Bottom panel shows the frequency of MO-DCs. CD4* T cells and CD8* T cells expressing CXCR3 and CCR5.&lt;C) In vivo imaging of MO-DCs in the CNS of PbA-infected mice. MO-DC enriched populations were obtained from WT and CCRfT' mice 5 days post-infection and labeled with CSFE transferred i.v. (one million cells/mouse) in the orbital vein into uninfected and PbA-infected WT mice. The presence of CSFE labeled cells were detected in the microvasculature and brain parenchyma by confocal microscopy 15-60 minutes after cell transfer in the orbital vein (Supplementary Videos 1 and 2). (D) Numbers of both CD45'*nCD8\u2019CD3\u2018CCR5*CD11c>CD11b\u2019DC-SIGN\"0hLy6c> and CD45h\u2018sr'CCR5\u2019CXCR3*CD8'\u2019CD3* are significantly decreased in the brain of PbA-infected CCR5* mice. These results are representative of four experiments. Differences were statistically significant (\u25a0 p<0.01) as indicated by student t test.\nREFERENCES\n1.\tGeissmann, F., et al. Development of monocytes, macrophages, and dendritic cells. Science 327, 655-661 (2010).\n2.\tDavies. L.C., Jenkins. S.J., Allen. J.E. &amp; Taylor, P.R. Tissue-resident macrophages. Nature immunology 14. 986-905 (2013).\n3.\tGordon. S.. Pluddemann, A. &amp; Martinez Estrada. F. Macrophage heterogeneity in tissues: phenotypic diversity and functions. Immunol Rev 262. 36-55 (2014).\n4.\tGazzinelli. R.T., Kalantari, P\u201e Fitzgerald. K.A. &amp; Golenbock. D.T. Innate sensing of malaria parasites. Nature reviews. Immunology 14. 744-757 (2014).\n5.\tWykes. M.N. &amp; Good. M.F. What really happens to dendritic cells during malaria? Nat Rev Microbiol 6. 864-870 (2008).\n6.\tGowda. N.M.. Wu. X. &amp; Gowda. D.C. TLR9 and MyD88 are crucial for the development of protective immunity to malaria. Journal of immunology 188. 5073-5085 (2012).\n7.\tParroche. P., et al. Malaria hemozoin is immunologically inert but radically enhances innate responses by presenting malaria DNA to Toll-like receptor 9. Proceedings of the National Academy of Sciences of the United States of America 104, 1919-1924 (2007).\n8.\tPichyangkul. S., et al. Malaria blood stage parasites activate human plasmacytoid dendritic cells and murine dendritic cells through a Toll-like receptor 9-dependent pathway. Journal of immunology 172, 4926-4933 (2004).\n9.\tGuermonprez. P., et al. Inflammatory Flt3l is essential to mobilize dendritic cells and for T cell responses during Plasmodium infection. Nature medicine 19. 730-738 (2013).\n10.\tSedegah, M.. Finkelman. F. &amp; Hoffman. S.L. Interleukin 12 induction of interferon gamma-dependent protection against malaria. Proceedings of the National Academy of Sciences of the United States of America 91, 1070010702(1994).\n11.\tStevenson. M.M.. Tam. M.F., Wolf. S.F. &amp; Sher. A. IL-12-induced protection against blood-stage Plasmodium chabaudi AS requires IFN-gamma and TNF-alpha and occurs via a nitric oxide-dependent mechanism. Journal of immunology 155, 2545-2556 (1995).\n12.\tArtavanis-Tsakonas. K. &amp; Riley. E.M. Innate immune response to malaria: rapid induction of IFN-gamma from human NK cells by live Plasmodium falciparum-infected erythrocytes. Journal of immunology 169, 2956-2963 (2002).\n13.\tJung. S., et al. In vivo depletion of CD11c+ dendritic cells abrogates priming of CD8+ T cells by exogenous cell-associated antigens. Immunity 17. 211220 (2002).\n14.\tIng. R., Segura. M.. Thawani, N.. Tam. M. &amp; Stevenson. M.M. Interaction of mouse dendritic cells and malaria-infected erythrocytes: uptake, maturation, and antigen presentation. Journal of immunology 176, 441-450 (2006).\n15.\tWykes. M.N., et al. Plasmodium strain determines dendritic cell function essential for survival from malaria. PLoS pathogens 3, e06 (2007).\n16.\tHaque. A., et al. Type I IFN signaling in CD8- DCs impairs Th1-dependent malaria immunity. The Journal of clinical investigation 124. 2483-2496 (2014).\n17.\tUrban. B.C., et al. Plasmodium falciparum-infected erythrocytes modulate the maturation of dendritic cells. Nature 400. 73-77 (1999).\n18.\tPinzon-Charry, A., etal. Apoptosis and dysfunction of blood dendritic cells in patients with falciparum and vivax malaria. The Journal of experimental medicine 210. 1635-1646 (2013).\n19.\tSponaas. A.M., et al. Migrating monocytes recruited to the spleen play an important role in control of blood stage malaria. Blood 114, 5522-5531 (2009).\n20.\tAntonelli. L.R., et al. The CD14+CD16+ inflammatory monocyte subset displays increased mitochondrial activity and effector function during acute Plasmodium vivax malaria. PLoS pathogens 10. e1004393 (2014).\n21.\tBorges da Silva. H., et al. In vivo approaches reveal a key role for DCs in CD4+ T cell activation and parasite clearance during the acute phase of experimental blood-stage malaria. PLoS pathogens 11. e1004598 (2015).\n22.\tFranklin. B.S., et al. MyD88-dependent activation of dendritic cells and CD4(+) T lymphocytes mediates symptoms, but is not required for the immunological control of parasites during rodent malaria. Microbes and infection / Institut Pasteur 9. 881-890 (2007).\n23.\tdeWalick. S., etal. Cutting edge: conventional dendritic cells are the critical APC required for the induction of experimental cerebral malaria. Journal of immunology 178, 6033-6037 (2007).\n24.\tPai. S., et al. Real-time imaging reveals the dynamics of leukocyte behaviour during experimental cerebral malaria pathogenesis. PLoS pathogens 10,\ne 1004236 (2014).\n25.\tAtaide. M.A., et al. Malaria-induced NLRP12/NLRP3-dependent caspase-1 activation mediates inflammation and hypersensitivity to bacterial superinfection. PLoS pathogens 10. e1003885 (2014).\n26.\tRomani. N., etal. Proliferating dendritic cell progenitors in human blood. The Journal of experimental medicine 180, 83-93 (1994).\n27.\tSallusto. F. &amp; Lanzavecchia. A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. The Journal of experimental medicine 179, 1109-1118 (1994).\n28.\tJakubzick. C., et al. Blood monocyte subsets differentially give rise to CD103+ and CD103- pulmonary dendritic cell populations. Journal of immunology 180, 3019-3027 (2008).\n29.\tBogunovic, M.r et al. Origin of the lamina propria dendritic cell network. Immunity 31. 513-525 (2009).\n30.\tCros. J., etal. Human CD14dim monocytes patrol and sense nucleic acids and viruses via TLR7 and TLR8 receptors. Immunity 33. 375-386 (2010).\n31.\tLeon. B.. Lopez-Bravo, M. &amp; Ardavin. C. Monocyte-derived dendritic cells formed at the infection site control the induction of protective T helper 1 responses against Leishmania. Immunity 26. 519-531 (2007).\n32.\tNakano. H., etal. Blood-derived inflammatory dendritic cells in lymph nodes stimulate acute T helper type 1 immune responses. Nature immunology 10. 394-402 (2009).\n33.\tSerbina. N.V.. Salazar-Mather, T.P.. Biron. C.A., Kuziel, W.A. &amp; Pamer, E.G. TNF/iNOS-producing dendritic cells mediate innate immune defense against bacterial infection. Immunity 19. 59-70 (2003).\n34.\tSiddiqui. K.R.. Laffbnt. S. &amp; Powrie. F. E-cadherin marks a subset of inflammatory dendritic cells that promote T cell-mediated colitis. Immunity 32. 557-507 (2010).\n35.\tCheong, C., et al. Microbial stimulation fully differentiates monocytes to DC-SIGN/CD209(+) dendritic cells for immune T cell areas. Ceff 143. 416-429 (2010).\n36.\tGoldszmid, R.S., et al. NK cell-derived interferon-gamma orchestrates cellular dynamics and the differentiation of monocytes into dendritic cells at the site of infection. Immunity 36, 1047-1059 (2012).\n37.\tHansen. D.S.. Bernard. N.J.. Nie. C.Q. &amp; Schofield. L NK cells stimulate recruitment of CXCR3+ T cells to the brain during Plasmodium berghei-mediated cerebral malaria. Journal of immunology 178, 5779-5788 (2007).\n38.\tCampanella. G.S., et al. Chemokine receptor CXCR3 and its ligands CXCL9 and CXCL10 are required for the development of murine cerebral malaria. Proceedings of the National Academy of Sciences of the United States of America 105, 4814-4819 (2008).\n39.\tNie, C.Q., etal. IP-10-mediated T cell homing promotes cerebral inflammation over splenic immunity to malaria infection. PLoS pathogens 5. e 1000369 (2009).\n40.\tGroom. J.R., et al. CXCR3 chemokine receptor-ligand interactions in the lymph node optimize CD4+ T helper 1 cell differentiation. Immunity 37, 10911103 (2012).\n41.\tFranklin. B.S., et al. Therapeutical targeting of nucleic acid-sensing Toll-like receptors prevents experimental cerebral malaria. Proceedings of the National Academy of Sciences of the United States of America 108. 36893694 (2011).\n42.\tKalantari. P., et al. Dual engagement of the NLRP3 and AIM2 inflammasomes by plasmodium-derived hemozoin and DNA during malaria. Cell reports 6. 196-210(2014).\n43.\tSharma. S., etal. Innate immune recognition of an AT-rich stem-loop DNA motif in the Plasmodium falciparum genome. Immunity 35. 194-207 (2011).\n44.\tLamphier, M_, etal. Novel small molecule inhibitors ofTLR7 and TLR9: mechanism of action and efficacy in vivo. Molecular pharmacology 85. 429440 (2014).\n45.\tGriffith, J.W.. Sokol. C.L. &amp; Luster, A.D. Chemokines and chemokine receptors: positioning cells for host defense and immunity. Annual review of immunology 32. 659-702 (2014).\n46- Belnoue. E., et al. Control of pathogenic CD8+ T cell migration to the brain by IFN-gamma during experimental cerebral malaria. Parasite immunology 30. 544-553 (2008).\n47.\tVillegas-Mendez, A., et al. IFN-gamma-producing CD4+ T cells promote experimental cerebral malaria by modulating CD8+ T cell accumulation within the brain. Journal of immunology 189. 968-979 (2012).\n48.\tFranklin. B.S., et al. Malaria primes the innate immune response due to interferon-gamma induced enhancement of toll-like receptor expression and function. Proceedings of the National Academy of Sciences of the United States of America 106. 5789-5794 (2009).\n49.\tDunay. I.R., etal Gr1(+) inflammatory monocytes are required for mucosal resistance to the pathogen Toxoplasma gondii. Immunity 29. 306-317 (2008).\n50.\tSu, Z. &amp; Stevenson. M.M. IL-12 is required for antibody-mediated protective immunity against blood-stage Plasmodium chabaudi AS malaria infection in mice. Journal of immunology 168. 1348-1355 (2002).\n51.\tPerry. J.A., Olver, C.S., Burnett. R.C. &amp; Avery. A.C. Cutting edge: the acquisition of TLR tolerance during malaria infection impacts T cell activation. J Immunol 174, 5921-5925 (2005).\n52.\tWilson. N.S., et al. Systemic activation of dendritic cells by Toll-like receptor ligands or malaria infection impairs cross-presentation and antiviral immunity. Nature immunology 7. 165-172 (2006).\n53.\tBelnoue. E., etal. CCR5 deficiency decreases susceptibility to experimental cerebral malaria. Blood 101,4253-4259 (2003).\n54.\tMcCall. M.B., et al. Plasmodium falciparum infection causes proinflammatory priming of human TLR responses. Journal of immunology 179, 162-171 (2007).\n55.\tda Silva. H.B., etal. IFN-gamma-induced priming maintains long-term straintranscending immunity against blood-stage Plasmodium chabaudi malaria. Journal of immunology 191. 5160-5169 (2013).\n56.\tGrau. G.E., et al. Monoclonal antibody against interferon gamma can prevent experimental cerebral malaria and its associated overproduction of tumor necrosis factor. Proceedings of the National Academy of Sciences of the United States of America 86. 5572-5574 (1989).\n57.\tMiu. J.. Hunt. N.H. &amp; Ball. H.J. Predominance of interferon-related responses in the brain during murine malaria, as identified by microarray analysis. Infection and immunity 76. 1812-1824 (2008).\n58.\tMiu. J., et al. Chemokine gene expression during fatal murine cerebral malaria and protection due to CXCR3 deficiency. Journal of immunology 180, 1217-1230 (2008).\n59.\tCoban. C., et al. Toll-like receptor 9 mediates innate immune activation by the malaria pigment hemozoin. The Journal of experimental medicine 201, 19-25 (2005).\n60.\tBaccarella, A., Fontana, M.F.. Chen. E.C. &amp; Kim. C.C. Toll-like receptor 7 mediates early innate immune responses to malaria. Infection and immunity 81,4431-4442 (2013).\n61.\tBelnoue. E., etal On the pathogenic role of brain-sequestered alphabeta CD8+ T cells in experimental cerebral malaria. Journal of immunology 169, 6369-6375 (2002).\n62.\tPoh, C.M.. Howland. S.W., Grotenbreg, G.M. &amp; Renia, L. Damage to the blood-brain barrier during experimental cerebral malaria results from synergistic effects of CD8+ T cells with different specificities. Infection and immunity 82. 4854-4864 (2014).\n63.\tWu, J., et al. Strain-specific innate immune signaling pathways determine malaria parasitemia dynamics and host mortality. Proceedings of the National Academy of Sciences of the United States of America 111. E511 -520 (2014).\n64.\tFischer. H.G. &amp; Reichmann. G. Brain dendritic cells and macrophages/microgiia in central nervous system inflammation. Journal of immunology 166. 2717-2726 (2001).\n65.\tJohn. B., et al. Analysis of behavior and trafficicing of dendritic cells within the brain during toxoplasmic encephalitis. PLoS pathogens 7. e 1002246 (2011).\n66.\tHowland, S.W., et al. Brain microvessel cross-presentation is a hallmark of experimental cerebral malaria. EMBO molecular medicine 5. 916-931 (2013).\n67.\tHowland, S.W.. Poh. C.M. &amp; Renia. L. Activated Brain Endothelial Cells Cross-Present Malaria Antigen. PLoS pathogens 11. e 1004963 (2015).\n68.\tCocchi. F., etal. Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells. Science 270. 1811-1815 (1995).\nSUPPLEMENTARY MATERIAL\nMice All animals used in this work were 8- to 12-week-old mice. C57BL/6 mioe were obtained from either Animal Facility of the UFMG or Jackson Laboratories. The REX3, REX.3tFNa.pR\" and REX3/FNyR\"' ' were generated by AD.L. at Massachusetts General Hospital (MGH). The GREAT mice (IFNy GFP-reporter), the CCR2*\\ CCRtf', RAG1' and /FWy\u201dmioe were originally purchased from Jackson Laboratories and housed under spectric-pa*.bogen-free conditions at MGH or at Oswaldo Cruz Foundation (Fiocruz). All procedures were approved by the MGH Subcommittee on Research and Animal Care and Harvard Committee on Microbiological Safety (IACUC# 2OO5NOOO176); as well as the Institutional Ethical Committee for Animal Experimentation at Fiocruz (CEUA# LW15-14).\nInfection. The PbA or GFP transgenic PbA (GFP-PbA) kept in liquid nitrogen were thawed and maintained into C57BU6 mice for up to 12 passages. For experimental infection, PbA-infected red blood cells (iRBCs) were collected from donors in heparinized tubes and 1x10s iRBCs injected i.p. into naive mice. These mice were observed daily, and parasitemia was estimated by counting Giemsa-stained thin blood smears. ECM signs were evaluated by two independent observers using different parameters that included ruffled fur. abnormal postural responses, reduced reflexes, reduced grip strength, coma, and convulsions. Mice that demonstrated complete disability in all parameters or died between days 7 and 9 postinfection were considered as having ECM .\nFlow Cytometry. Brains were removed after intracardial perfusion with 30 mi of PBS; they were minced and the cells were passed through a 70 p.m cell strainer and centrifuged on a 45% Percol for 30 min at 800 x g. The cells were washed, diluted 1:1 PBS. counted and stained for flow cytometry 3. Spleens were removed, passed through a 70 pm strainer, RBCs lysed, splenocytes counted by using a hemocytometer For flow cytometry analysis, cells were stained with antibodies specific for mouse CD11b (PE-Cy7, done: MI/70. e-Biosoence). F4/80 (PE-Cy5, done: BM8. e-Bioscience), CD11c (Alexa 700. done: N418, e-Biosoence). MHC II (PE. done: AF6-120.1. BD). DC-SIGN (APC e-fluor 660, done: MMD3, e-Biosoence). Ly6C (e-fluor 450, clone: HK1.4. e-Bosciences), CD80 (FITC, done: 16-1 DAI. BD). CD86 (FITC, clone: GL1, BD). CDS (APC Cy7. done: 53-6.7, Biolegend) or (PerCP-Cy 5.5. done: 53-6.7. e-Biosdence), CD3 (Percep Cy5.5, done: 145-2C11. e-Bioscience), CD31 (PE. done: 390. eBioscience). CD45 (V500. done: 30-F11. BD). CD62L (PE-Cy7. done: MEL-14. BD). CD44 (Pacific Blue, done: IM7. Biolegend) CD4 (APC. done: RM4-5. Biolegend) at RT for 20 min. In REX3 mice, endogenous RFP (CXCL9) and BFP (CXCL10) were read in PE and Padfic Blue channels, respectively. Cytofluorometry was performed by using a Fortessa Cytometer (Becton-Dickinson) and analyzed with Flowjo software.\nPhagocytosis assay by flow cytometry. Blood (2 mL) from GFP-PbA-mfected and noninfected mice were collected in heparinized tubes. The enrichment of iRBCs was performed using a positive selection kit according to the manufacturer's protocol (Miltenyi Biotec. Bergisch Gladbach. DE). Uninfected RBCs were used as a negative control. The purity was determined by Giemsa-stained thin blood smears. Total splenocytes (5x10s) from infected (6 days) and non-infected mice were incubated with iRBCs (5x10s) or RBCs (5x10\u00a3) for 1 hour at 37*C (1:1). Cells were washed and stained with the antibodies specific for mouse CD11b (PE-Cy7). F4/80 (PE-Cy5). CD11c (Alexa 700), MHC II (PE). DC-SIGN (APC e-fluor 660). Ly6C (e-fluor 450) at RT for 20 min. Flow Cytometry was performed by using a Fortessa Cytometer (Becton-Dickinson) and analyzed with Flowjo software.\nCell sorting. Spleens from the C57BL/6 and IFNy^' control uninfected and infected mioe, at 7 day post-infection, were harvested and splenocytes stained with CD11b (PE-Cy7). F4/80 (PE-Cy5). CD11c (Alexa 700), MHC II (PE). DC-SIGN (APC e-fluor 660) and then submitted to purification by using a cell sorting ARIA (BD). These cells were first gated on FSC-H/FSC-A in order tn .avoid dnuhlets Mert we fimt nxrted on CD11 h\u2019F4.'flfl* .and then no MHC-II^DC-\nSIGNN\u00aeh The gated ceils were sorted, collected into fresh new tubes, confirmed to be CD11c\u2019 and then frozen in small aliquots of 10.000 cells for used for gene expression analysis using the nanostring technology. Alternatively, cells were submitted to cytospin, stained with Giemsa for morphological analysis using corrected optics 40x and 100x (oil) in an optical microscope (Olympus. GXML3200B).\nScanning Electronic Microscopy (SEM). After cell sorting aliquots of MO-DCs were fixed in 2.5% buffered glutaraldehyde solution. 0.1 M. Ph 7.2, 6 h. 8\u2018C. Cells were then washed with the same buffer and fixed in a mixture of 1% osmium tetroxide and 1.5% (w/v) potassium ferrocyanide, dehydrated in a graded series of ethanol, infiltrated, and embedded in Araldite 502 I Electron Microscopy Sciences. Hatfield, PA. USA). Sections were stained with 2% uranyl acetate and Reynolds lead citrate and then analyzed using SEM (DSM 060 A).\nConfocal. Spleens were harvested into PLP buffer [0.05 M phosphate buffer containing 0.2M L-lysine (pH 7.4), 2 mg, ml NalO*. 10 mg/ml paraformaldehyde], fixed for 5-12 hr. and dehydrated in 30% sucrose prior to embedding in OCT freezing media (Sakura Fineteck). Ten mm frozen sections were cut on a CM3050S cryostat (Leica). Sections were dried for 2h. acetone fixed for 10 min. rehydrated, fixed with formaIdehyde-calcium solution and washed with PBS. Sectons were blocked in PBS containing American Hamster or Rat gamma globulin (100pg/mL). stained in PBS, F4/80 (APC) or CO11c (APC) and embedded in prolong gold. Images were acquired on a LSM510 confocal microscope (Cart Zeiss Mircoimaging).\nIntravital confocal microscopy. MO-DCs were purified from spleens of PbA-infected from four mice by consecutive positive selection of CD11b\u2019 (cat 130-007-142) and then CD11c\u2019 (cat 130-052-001) cells using lhe MicroBeads kit (Miltenyi Biotec, Bergtsch Gladbach. DE. CD11b). The cells were then incubated with CFSE (2 uM / 1x10^ cells in 100 pl) for 8 min and washed. The vasculature was stained using 10 pL of a PE-coupled anti-CD31 antibody stock solution (0.2 mg/ml). Infected mice (5 days post-infection) were anesthetized intraperitoneally (100 pl for each animal) with a mixture of ketamine (37.5 mg/ml. final concentration) and xytazine (2.5 mg/ml. final concentration). After anesthetized, one million of CFSE-stained CD1 lb\u2019CDI 1c\u2019 cells and anti-CD31 were injected intravenously and a cranial window (2 x 2 mm) was drilled above the parietal cortex leaving the dura mater intact to exposed and visualize the brain vasculature. Mouse was immobilized using the stereotaxis apparatus and CD11b* CD11c\u2019 cells and endothelium were observed using a confocal microscope (Nikon, ECLIPSE 50i, 20x objective lens) outfitted with a fluorescent light source (epi-illumination at 510-560 nm. using a 590 nm emission filter). The number of migrating cells was determined offline during the video playback analyses. In each animal, a field was recorded and analyzed to determine the total number of cells. Quantitative image analysis was performed by using the software Voloaty (Version 6.3).\nDendritic cell migration assay. Splenic CD11b\u2019CD11c\u2019 cells from uninfected and 6 days post-inflection mice were purified using a positive selection kit. as described in the intravital confocal microscopy section (Miltenyi Biotec. Bergisch Gladbach. DE). Cells were stained with anti-CD11b (PE-Cy7. done: M1/70, e-B\u00abscience) and anti-CD11c (Alexa 700, clone: N418. e-Biosoenoe). and purity checked by FACS. CD11b\u2018CD11c\u2019 cells were suspended in RPMI medium plus 10% FBS at 1x10s cells/ml To assess the migratory capacities of MO-DCs cells, we used a 12 well-T ran swell microplate (Coming, Amboise. FR) with 5-pm membrane pore size that forbade the passive diffusion, but allowed the active migration of MO-DCs. For each condition tested, lower chambers of the transwell were filled with 600 pL in the absence or presence of 0.1. 1 or 10 ng/mL CCL2 (Brolegend) and/or CCL5 (e-broscience). MO-DCs (1x10s in 100 pL) were deposited in the upper chamber of the transwell and were allowed to migrate for 3 hours at 37\u00b0C Migrating DCs were harvested from lhe lower chamber and were counted using Neubauer camara Enumerations were performed twice to assess the reliability of the method.\nCytokine assays. The levels of IFNy were measured in sera of control and infected mice by using the Cytometric Bead Array (CBA) Mouse Th1/Th2/Th17 Cytokines Kit (BD Becton-Dickinson. cat 560485)4.\nQuantitative PCR. Total RNA from spleens and brains from uninfected or PbA infected mice was extracted by using TRtzol and cDNA prepared using Multiscribe RT (Applied Biosystems). qPCR was performed with SYBR Green Master Mix (Applied Biosystems) using a Realplex2 mastercycler (Eppendorf) 1. Primer sequences for measuring /FWyand chemokine gene expression were: CXCL9, 5-AATGCACGATGCTCCTGCA-3\u2019 and 5-AGGTCTTTGAGGGATTTGTAGTGG-3'; CXCL10. 5- GCCGTCATTTTCTGCCTCA-3' and 5-CGTCCTTGCGAGAGGGATC-3'; ffTVy. 5'-AACGCTACACACTGCATCTTGG-3' and 5-GCCGTGGCAGTAACAGCC -3\u2018; CD8. 5-GACGAAGCTGACTGTGGTTGA-3' and 5-GCAGGCTGAGGGTGGTAAG-3', CCL2, 5-- TGGCTCAGCCAGATGCAGT -3\" and 5-TTGGGATCATCTTGCTGGTG -3': CGL3. 5-- CCAAGTCTTCTCAGCGCCAT-3\u2019 and 5-TCCGGCTGTAGGAGAAGCAG -3\u2018; CCL4, 5\u2019-TCTTGCTCGTGGCTGCCT-3' and 5-GGGAGGGTCAGAGCCCA-3\u2019; and CCL5. 5-CAAGTGCTCCAATCTTGCAGTC-3' and 5-TTCTCTGGGTTGGCACACAC-3'. All samples were normalized using (32-M1CROGLOBULIN or GAPDH expression employing either 5\u2019-CCGAACATACTGAACTGCTACGTAA-3' and 5'-CCCGTTCTTCAGCATTTGGA-3' or 5-GTGGTGAAGCAGGCATCTGA-3' and 5-GGGAGTCACTGTTGAAGTCGC-3' primers, respectively.\nQuantification of RNA Expression by Nanostring Purified MO-DCs from C57BL/6 and tFNf infected with PbA were analyzed by NanoString methodology. Briefly. 10.000 cells were resuspended in 1 ml of Qiagen RLT lysis buffer and hybridized to the target specific code set on 65 *C. The code set contained probes against a panel of 561 genes encoding relevant innate immunity proteins (nCountei\u00ae Mouse Immunology) After incubation, samples (three animals per group) were loaded onto the NanoString Prep station for excess reporter removal, binding to cartridge surface, and probe scanning After scanning and data collection onto a digital analyzer, data normalization was performed against positive and negative control oligonucletides and fourteen housekeeping genes Normalized results are represented as the relative mRNA level. The fold change was defined by rate of mRNAs numbers of copies of the infected by non-infected mice. The software Multiple Experiment Viewer (MeV) was used to generate the heat maps. Differences in gene expression were considered significant if p<0.05 as defined by unpaired t test\nDrug and Treatment TLR7/8 antagonist (E6446, Eisai Pharmaceuticals) was dissolved in water and mice were treated 120 mg'Kg'day from a day before infection to the indicated day post-infection, given in 100 jd through oral gavage once daily 2. Mice treated with vehicle (water) were used as a control.\nStatistical Analysis. All data were analyzed using Graphpad Prism 6.0 Software Two-tailed Student's t tests were used for data analysis and generation of p values. Mann-Whitney testing was used for nonparametric analysis when data did not fit a Gaussian distribution. AN OVA via post-tukey test for multiple comparisons was used for comparing more than two samples. A p &lt;0.05 value was considered statistically significant. All data are represented as mean with individual data points representing individual samples. Bar graph data show standard deviation error (SD) bars.\nREFERENCES\n1.\tGroom, J.R., et al CXCR3 chemokine receptor-ligand interactions in the lymph node optimize CD4+ T helper 1 cell differentiation. Immunity 37, 1091-1103 (2012).\n2.\tFranklin. B.S., et al. Therapeutical targeting of nucleic acid-sensing Toll-like receptors prevents experimental cerebral malaria. Proceedings of the National Academy of Sciences of the United States of America 108, 3689-3694 (2011).\n3.\tLaFrance-Corey, R.G. &amp; Howe. C.L Isolation of brain-infiltrating leukocytes. Journal of visualized experiments: JoVE (2011).\n4.\tFranklin, B.S., et al MyD88-dependent activation of dendritic cells and CD4(+) lymphocytes mediates symptoms, but is not required for the immunological control\nparasites during rodent malaria. Microbes and infection / Institut Pasteur 9, 881-890 (2007).\n9,-1\nSUPPLEMENTARY FIGURES\nA\nInfected\nCDUb\nVOOB\n\u25a0\nMHCil\n.MOS\nCDM\nCDM\nCOM\nB\nSupplementary Figure 1. knmunophenotyping of MO-DCs. Splenocy.es were harvested from control and infected mice at five days post-infection. (A) Splenocytes were first gated for CD11c*MHC II1** cells and then for DC-SIGNr*r and LyOc\u2019 cells. Over 90% of CD1 Ic\u2019MHC II^DC-SIGN^LyOc* cells were CD11b\"F4/80* Bar graphs correspond to total number of cells (four mice per group). Results are expressed as mean. Differences considered statistically significant between infected and non-infected, when \u2019 p<0.05 or \" p<0.01 after two-way ANOVA. The data shown are representative of five independent experiments. (B) Levels of CD80 and CD86 expression in iMOs (CD11b,F4/80,DC-SIGN\u2019c*MHCir) and MO-DCs (CD11b\u2018F4t'80\u2018DC-SIGNh'*\u2018MHCIIN9h)from control and infected mice. Representative results of four mice per group of control versus infected mice.\nSupplementary Figure 2. Purity of MO-DCs isolated by cell sorting. Spleens were harvested at six days a'ter infection with PbA. Mo-DCs were labeled with F4.'80\u2019CD11b*DC-SIGNN9,\u2019MHC II'*0* cells and submitted to sorting by flow cytometry. We obtained over 88.2% purity of cells that were also CD11c*. The data shown are representative of MO-DCs purified from at least ten mice and used for analysis by optical and scanning electronic microscopy (Figure 1) as well as gene expression by nanostring (Figures 2 and 4).\nSupplementary Figure 4. CCR5 expression by splenic MO-DCs from C57BL6 mice infected with PbA. (A) Representative primary flow cytometric dot plots of spleens from uninfected control mice are shown. The percentage of MO-DCs (Gate 1. F4/807CD11b*DC-SIGN\u2019MHC II*). Gate 2 (F4/807CD11b*DC-SIGN*MHC IF), and Gate 3 (F4/807CD11b*DC-SIGN'MHC ip expressing CXCR2 and CXCR5 are indicated. (B) C57BU6 mice were inoculated with PbA. and spleens harvested 6 days later. Representative primary low cytometiic dot plots of spleens from infected mice are shown. The percentage of MO-DCs (Gate 1. F4/8CT/CD11b\u2019DC-SIGN'MHC II*) expressing CXCR2 and CXCR5 are indicated. C. Frequency of splenic MO-DCs and other cell populations in controls and infected C57BL/6 are shown in bar graphs. The average and SD are one representative of three independent experiments with three or four mice per group. \u2019* indicates that p<0.01 as determined by twoway ANOVA analysis.\nSupplementary Figure 5. Frequency of splenic MO-DCs is reduced in IFNy4' mice infected with PbA. C57BL/6 and IFNy4' mice were inoculated with PbA. and spleens harvested 6 days later. (A) Representative primary flow cytometric dot plots of spleens from infected mice are shown. The percentage of MO-DCs (Gate 1. F4/80*/CD11b*DC-SIGN*MHC ll\u2018). Gate 2 (F4/80*/CO11 b\u2018DC-SIGN*MHC IQ. and Gate 3 (F4/80\u2018/CD11b\u2019DC-SIGN'MHC F) are indicated (B) Frequency of splenic MO-DCs and other cell populations in controls and infected C57BL/6 and fFN-f4' mice are shown in bar graphs. The average and SD are one representative of two independent experiments with three or four mice per group. Differences were considered statistically significant when p<0.05; \", p<0.01;\tp<0.0001 as indicated\nby two-way ANOVA analysis.\nSupplementary Figure 7. Frequency and total numbers of MO-DCs in spleens from CCR74' mice infected with PbA. C57BL/6 and CCRZ* mice were infected with PbA and spleens harvested at 0, 5 and 7 days later. Splenocytes were gated on CO11b and F4/S0 and then analyzed for DC-SIGN and MHC II expression. Average and standard deviation of (A) total number and (B) frequency of MO-DCs (Gate 1. F4/80*/CD11b*DC-SIGN*MHC II*), Gate 2 (F4/80*/CD11b*DC-SIGN*MHC IF). and Gate 3 (F4/80*/CO11b*DC-SIGN MHC II ) within CD11b*F4/80* cells are shown. The presented data are representative of one out of two experiments. Differences were considered statistically significant when * p<0.05,*'p<0.01 and \u2022\u201dp<0.001 as indicated by two-way ANOVA analysis.\nB i \u2022 I\t\ty\t\t\t\tfilXlV\n\tBe\tCCRS' MO-DCs\t\t\tae cere' IMOs\t\tae cots-' MOs\nSupplementary Figure 8. Frequency and total number of splenic MO-DCs is not affected in CCR5\u201d mice infected with PbA. C57BL/6 and CCR5*' mice were inoculated with PbA. and spleens harvested 0. 5 and 7 days later. Splenocytes were gated on CD11b and F4/80 and then analyzed for DC-SIGN and MHC II expression. Average and standard deviation of (A) total number and (B) frequency of MO-OCs (Gate 1. F4/80\u2019/CD11b\u2019DC-SIGN\u2019MHC II*). Gate 2 (F4/80\u2018/CD11 b\u2019DC-SIGN*MHC II\u2019). and Gate 3 (F4/80*/CD11b\u2018DC-SJGhTMHC II ) wrthin CD11b*F4Z8O* cells are shown. The presented data are representative of one out of two experiments. Differences were considered statistically significant when \u2019 p<0.05,\"p<0.01 and \u201d\u2019p<0.001 as indicated by two-way ANOVA analysis.\nSupplementary Videos 1A and 1B. In vivo imaging of CCR5J'MO-DCs in the brain of C57BL/6 mice infected with PbA. MO-DC enriched populations were obtained from CCR54' mice at 5 days post-infection labeled with CSFE and transferred i.v. (one million cells/mouse) to PbA-infected WT mice. The presence of CSFE labeled cells were detected in the microvasculature and brain parenchyma by confocal microscopy 15-30 minutes after cell transfer m the orbital vein.\nSupplementary Videos 2A and 2B. In vivo imaging of WT MO-DCs in the brain of CR7BL/6mice infected with PbA. MO-DC enriched populations were obtained from C57BL/ mice 5 days post-infection labeled with CSFE and transferred i.v. (one milion cels/mouse) to PbA-infected WT mice. The presence of CSFE labeled cells were detected in the microvasculature and brain parenchyma by confocal microscopy 15-30 minutes after cell transfer in the orbital vein.\nMASSACHUSETTS GENERAL HOSPITAL\nHARVARD MEDICAL SCHOOL\nAndrew D. Luster, MD, PhD Guef Dtvekh o/JWifbPtroiogi.\nandbmunolo^\nDrtcxrr. CaitaJbrhmtnoiog^\nDrvmoti of Rheumatology Alergy and Immunology Center for Immunology and Inflammatory Diseases 149 Diittenft Street Fjxxn 8301\nCharlestown. MA 02129\nTeL S17.736.57ia Fax 617.736.5651\nPazz. QrmandMaiawB.\nHartan Prqfkzor erf Muscat Harvard X\u00edt\u00bfa\u00a1i School\nOctober 29,2013\nConselho Nacional de Desenvolvnnemo Ciennfico e Tecnologico - CNPq\nMinistry for Science and Technology of Brazil\nTo whom it may concern:\nThis letter is to confinn that Isabella Hirako joined my laboratory on October 21,2013 with an award from CNPq to evaluate the role of TLR9 in mediating inflammation and development of cerebral malaria in mire\nSincerely,"}]}}}